<SEC-DOCUMENT>0000950123-18-002913.txt : 20180501
<SEC-HEADER>0000950123-18-002913.hdr.sgml : 20180501
<ACCEPTANCE-DATETIME>20180309171250
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-18-002913
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		8
FILED AS OF DATE:		20180309
<PUBLIC-REL-DATE>20180501
DATE AS OF CHANGE:		20180322

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Iterum Therapeutics Ltd
		CENTRAL INDEX KEY:			0001659323
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L2
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-01913
		FILM NUMBER:		18680995

	BUSINESS ADDRESS:	
		STREET 1:		25-28 NORTH WALL QUAY
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			1
		BUSINESS PHONE:		(872) 225-6077

	MAIL ADDRESS:	
		STREET 1:		25-28 NORTH WALL QUAY
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			1
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>As confidentially submitted with the U.S. Securities and Exchange Commission on
March&nbsp;9, 2018 </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>Iterum Therapeutics Limited </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Its Charter) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Ireland</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">98-1283148</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other Jurisdiction of<BR>Incorporation or Organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Primary Standard Industrial<BR>Classification Code Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer<BR>Identification Number)</B></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Block 2 Floor 3, Harcourt Centre, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Harcourt Street, </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Dublin 2,
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Ireland </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>+353 1
903 8920 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#146;s Principal Executive Offices)
</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Corey Fishman </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>President
and Chief Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>200 West Monroe St., Suite 1575 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Chicago, IL 60606 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(312) <FONT
STYLE="white-space:nowrap">778-6070</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent
for Service) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Charles S. Kim<BR>Alan D. Hambelton<BR>Cooley LLP<BR>4401 Eastgate Mall<BR>San Diego, CA 92121<BR>(858) <FONT STYLE="white-space:nowrap">550-6049</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Sophia Hudson</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Richard D. Truesdell, Jr.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Davis Polk&nbsp;&amp; Wardwell LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>450 Lexington Avenue</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>New
York, NY 10017</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">450-4000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective
date of this registration statement. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or
continuous basis pursuant to Rule&nbsp;415 under the Securities Act of 1933 check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">If this Form is
filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting
company&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging growth company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9746; </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF
REGISTRATION FEE </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of Each Class&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Securities to be Registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Maximum</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate<BR>Offering&nbsp;Price<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount of<BR>Registration&nbsp;Fee</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Ordinary shares,
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;par value per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Estimated solely for the purpose of calculating the amount of the registration fee in accordance with Rule&nbsp;457(o) under the Securities Act. Includes the offering price of shares that the underwriters have the
over-allotment option to purchase. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman"><B>The Registrant
hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment that specifically states that this registration statement shall thereafter become
effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine.
</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#cc062a"><B>The information in this preliminary prospectus is not complete and may be changed.
These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any
jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#cc062a"><B>SUBJECT TO COMPLETION, DATED MARCH 9, 2018 </B></FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g522368g73n73.jpg" ALT="LOGO">
 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp; Ordinary Shares </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This is our initial public offering. We are
offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of our ordinary shares. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior
to this offering, there has been no public market for our ordinary shares. We expect the initial public offering price to be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. We have applied to list our ordinary shares on the Nasdaq Global Select Market under the symbol &#147;ITRM.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as that term is used in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. See
&#147;Prospectus Summary&#151;Emerging Growth Company Status.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>You should consider the risks we have described in &#147;<A HREF="#toc522368_2">Risk
 Factors</A>&#148; beginning on page&nbsp;10. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission
has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and
commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">We refer you to &#147;Underwriting&#148; beginning on page 167 of this prospectus for additional information regarding underwriting compensation. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted the underwriters an over-allotment option to purchase up to an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares on the same terms and conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
underwriters expect to deliver the ordinary shares on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top"><B>Leerink Partners</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>RBC Capital Markets</B></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Guggenheim Securities </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Needham&nbsp;&amp; Company </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc522368_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc522368_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc522368_3">Special Note Regarding Forward-Looking Statements and Industry
Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc522368_4">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc522368_5">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc522368_6">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc522368_7">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc522368_8">Selected Consolidated Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc522368_9">Management&#146;s Discussion and Analysis of Financial Condition and Results of
 Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc522368_10">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc522368_11">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc522368_12">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc522368_13">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc522368_14">Principal Shareholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc522368_15">Description of Share Capital</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc522368_16">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc522368_17">Taxation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc522368_18">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc522368_19">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc522368_20">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc522368_21">Where You Can Find Additional Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc522368_22">Index to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>We are responsible for the information contained in this prospectus and in any free writing prospectus we prepare and authorize. Neither we
nor any of the underwriters have authorized anyone to provide you with different information, and we take no responsibility for any other information others may give you. Neither we nor the underwriters are making an offer to sell these securities
in any jurisdiction where such offer and sale is not permitted. You should not assume that the information contained in this prospectus is accurate as of any date other than the date on the cover of this prospectus. Our business, financial
condition, results of operations, and future growth prospects may have changed since that date. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Persons who
come into possession of this prospectus and any applicable free writing prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this
prospectus and any such free writing prospectus applicable to that jurisdiction. </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc522368_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained in other parts of this prospectus. Because it is only a summary, it does not contain all of
the information that you should consider before investing in our ordinary shares and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere in this prospectus. You should read
the entire prospectus carefully, especially &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our consolidated financial statements and the related notes, before
deciding to buy our ordinary shares. Unless the context requires otherwise, references in this prospectus to &#147;Iterum,&#148; the &#147;company,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148; refer to Iterum Therapeutics Limited and
its wholly owned subsidiaries.</I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a pharmaceutical company dedicated to developing and commercializing sulopenem to be potentially the first and only oral and intravenous
(IV)&nbsp;branded penem available globally. Penems, including thiopenems and carbapenems, belong to a class of antibiotics more broadly defined as &szlig;-lactam antibiotics, the original example of which was penicillin, but which now also includes
cephalosporins. Sulopenem, which we licensed from Pfizer Inc. (Pfizer) in November 2015, is a potent, targeted gram-negative spectrum thiopenem delivered intravenously. Pfizer also developed an oral prodrug, sulopenem etzadroxil, which we further
enhanced with the addition of probenecid and combined into a single bilayer tablet, which we refer to as oral sulopenem. Both oral sulopenem and sulopenem have the potential to be important new treatment alternatives to address growing concerns
related to antibacterial resistance without the known toxicities of some of the most widely-used antibiotics, specifically fluoroquinolones. We believe there are two distinct opportunities for our sulopenem program: patients at elevated risk for
treatment failure in the community setting suffering from uncomplicated urinary tract infections (uUTI), and hospitalized patients suffering from complicated, antibiotic-resistant infections. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to initiate a Phase 3 clinical program in the second half of 2018 for the treatment of adults in three indications: uUTI, complicated
urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). We designed one Phase 3 clinical trial in each indication based on our end of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) as well as feedback
from the European Medicines Agency (EMA). We intend to conduct the Phase 3 clinical trials under Special Protocol Assessment (SPA) agreements from the FDA. We expect to complete enrollment and produce topline data for all three clinical trials in
the second half of 2019 and to file our new drug applications (NDAs) with the FDA by the end of 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g522368g20i14.jpg" ALT="LOGO">
 </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Medical Need </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are approximately 13.5 million emergency room and office visits for symptoms of urinary tract infections (UTIs) and approximately 21
million uUTIs in the United States annually. There are also approximately 3.6 million patients with cUTI and approximately 350,000 patients with cIAI that receive antibiotic therapy every year in the United States. The treatment of urinary tract and
intra-abdominal infections has become more challenging because of the development of resistance by pathogens responsible for these diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on market research, physicians estimated that approximately 35% of uUTI patients are at elevated risk for treatment failure. Proper
antibiotic treatment of resistant infections in this group is particularly important due to the risks associated with treatment failure. Elevated risk patients were defined in the research as patients with recurrent UTIs, elderly patients, those who
have a suspected or confirmed drug-resistant infection, patients with comorbidities (e.g., Diabetes mellitus) or that are immunocompromised, patients that have had a recent hospitalization, patients with a history of prior antibiotic failure and
patients in a long-term care setting. Treatment failures pose significant clinical and economic challenges to the healthcare system. In addition, the Infectious Diseases Society of America and European Society for Microbiology and Infectious
Diseases recommend against empiric use, or prescribing without results from a bacterial culture, of fluoroquinolones for uUTIs in their 2010 Update to the International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis
and Pyelonephritis in Women. Similarly, the FDA in its November 2015 Advisory Committee meeting stated that the risk of serious side effects caused by fluoroquinolones generally outweighs the benefits for patients with uUTIs and other uncomplicated
infections. Serious side effects associated with fluoroquinolones include tendon rupture, tendinitis, and worsening symptoms of myasthenia gravis and peripheral neuropathy. Subsequently, the FDA mandated labeling modifications for quinolone
antibiotics directing healthcare professionals to reserve fluoroquinolones for patients with no other treatment alternatives. The combination of growing prevalence of bacterial resistance and <FONT STYLE="white-space:nowrap">FDA-mandated</FONT>
safety label changes for fluoroquinolones have left physicians in search of new oral treatment alternatives to safely and effectively treat their uUTI patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Solution: Sulopenem Program </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. Sulopenem has <I>in vitro</I> activity against gram-negative organisms with resistance to one or more
established antibiotics and can be delivered in an oral formulation. In November 2015, we acquired an exclusive, worldwide license under certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT> to develop and commercialize sulopenem and
its oral prodrug, sulopenem etzadroxil, from Pfizer. Pfizer conducted Phase 1 and Phase 2 clinical trials of sulopenem delivered intravenously in Japan in over 1,450 patients with a variety of hospital and community acquired infections. Adverse
event data from these trials documented a safety profile of sulopenem similar to that of the marketed carbapenems. Pfizer subsequently developed sulopenem into a prodrug formulation, sulopenem etzadroxil, to enable oral delivery. We have further
enhanced this prodrug formulation with the addition of probenecid to extend sulopenem&#146;s half-life and enhance its antibacterial potential. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the most commonly used oral antibiotics for treatment of uUTIs were initially approved by the FDA within the last two decades.&nbsp;We
believe oral sulopenem will be an important empiric treatment option for elevated risk uUTI patients because of its potency against resistant pathogens, as well as its spectrum of antibacterial activity.&nbsp;In addition, oral sulopenem will allow
patients who develop an infection with a resistant pathogen, but are stable enough to be treated in the community, to avoid the need for an IV catheter and even hospitalization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the hospital setting, the lack of effective oral stepdown options results in the potential for lengthy hospital stays or insertion of a
peripherally inserted central catheter (PICC) to facilitate administration of IV antibiotics, </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
even for some patients with relatively straightforward infections. Our sulopenem program may enable faster discharges, providing cost-saving advantages for the hospital and mitigating the risk of
catheter-related infection for patients. Based on potency, safety and formulation advantages, we believe our sulopenem program is uniquely positioned to address unmet medical needs for patients suffering from uncomplicated and complicated infections
in both the community and hospital settings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sulopenem etzadroxil has an issued composition of matter patent in the United States (which
we have exclusively licensed from Pfizer) that is scheduled to expire in 2029, subject to potential extension to 2034 under the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). In addition, the FDA has
designated sulopenem and oral sulopenem as Qualified Infectious Disease Products (QIDP) for the indications of uUTI, cUTI and cIAI pursuant to the Generating Antibiotic Incentives Now Act (the GAIN Act), which provides the potential for a more rapid
NDA review cycle and which could add five years to any regulatory exclusivity period that we may be granted. None of the licensed patents cover the IV formulation of sulopenem. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Commercialization Plan </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the
FDA approves oral sulopenem and sulopenem, we plan to build a targeted commercial infrastructure to launch both product candidates in the United States. Data from a study we commissioned in 2017 to quantify zip code level quinolone resistance, in
addition to data from our clinical trials and available prescriber data, will inform our initial targeted sales force as to where the medical need for a new, effective therapy for UTIs is highest in the community and hospital settings. Outside of
the United States, we are evaluating our options to maximize the value of our sulopenem program. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to employ a dual sourcing
strategy for critical elements of our sulopenem supply chain. We expect to register and validate two suppliers for the manufacture of the active pharmaceutical ingredient (API) at the time of our planned regulatory filings in the United States by
the end of 2019. Also, given the importance of oral sulopenem to our potential commercial results, we plan to utilize two sites to manufacture sulopenem tablets: one third-party facility registered and validated to supply product for our launch and
an Iterum-operated facility registered and validated within one year of product launch. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Management Team and Investors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were founded in June 2015 by former executives of Durata Therapeutics,&nbsp;Inc. (Durata), a biopharmaceutical company, which developed
dalbavancin, another antibiotic from the Pfizer portfolio, and successfully obtained FDA approval, launched the product in the United States and submitted a marketing authorization application (MAA) to the EMA (approval was received in 2015). Durata
was acquired by Allergan, Plc (Allergan, formerly Actavis, Inc.) in late 2014. To date, we have raised approximately $120&nbsp;million to develop our sulopenem program from a leading investor group including Advent Life Sciences LLP (Advent Life
Sciences), Arix Bioscience plc (Arix Bioscience), Bay City Capital LLC (Bay City Capital), Canaan Partners, Domain Associates, L.L.C. (Domain Associates), Frazier Healthcare Partners, New Leaf Venture Partners, Pivotal bioVenture Partners and
Sofinnova Ventures, Inc. (Sofinnova Ventures), as well as our founders. Pfizer is also one of our shareholders. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy is to develop and commercialize our sulopenem program for multiple indications, and in the long term to build a market-leading
anti-infective business. The key elements of this strategy include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">complete sulopenem clinical development in three initial indications; </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain regulatory approval for oral sulopenem and sulopenem in the United States and subsequently in the European Union; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maximize commercial potential of sulopenem program; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pursue the development of oral sulopenem and sulopenem in additional indications; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">build a portfolio of differentiated anti-infective products. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to a number of risks of which you should be aware before making a decision to invest in our ordinary shares. These
risks are discussed more fully in the section titled &#147;Risk Factors&#148; and include, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have incurred net losses in each year since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of the sulopenem program. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If clinical trials of oral sulopenem, sulopenem or any other product candidate that we may advance to clinical trials fail to demonstrate safety and efficacy or do not otherwise produce favorable results, we may incur
additional costs or experience delays in completing, or ultimately may be unable to complete, the development and commercialization of oral sulopenem, sulopenem or any other product candidate. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We face substantial competition from other pharmaceutical and biotechnology companies and our business may suffer if we fail to compete effectively. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If we fail to comply with our obligations in our agreement with Pfizer, we could lose valuable intellectual property rights that are necessary to our development and commercialization of oral sulopenem and sulopenem.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our principal shareholders and management own a significant percentage of our ordinary shares and will be able to exert significant control over matters subject to shareholder approval. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our product candidates may never achieve the market acceptance by physicians, patients, hospitals, third-party payors and others in the medical community that is necessary for commercial success, and the market
opportunity may be smaller than we estimate. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Delays or issues with the manufacture of preclinical, clinical or commercial supplies of oral sulopenem and sulopenem could negatively impact our development and commercialization plans. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company Status </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an
&#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act (the JOBS Act), enacted in April 2012; therefore, we intend to take advantage of certain exemptions from various public company reporting requirements,
including not being required to have our internal control over financial reporting audited by an independent registered public accounting firm pursuant to Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations
regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments not previously approved. We may take
advantage of these exemptions for up to five years or until we are no longer an &#147;emerging growth company,&#148; whichever occurs earlier. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The JOBS Act permits an emerging growth company to take advantage of an extended transition
period to comply with new or revised accounting standards applicable to public companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on
the relevant dates on which adoption of such standards is required for <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Iterum
Therapeutics Limited was incorporated in Ireland in June 2015. Our principal executive offices are located at Block 2 Floor 3, Harcourt Centre, Harcourt Street, Dublin 2, Ireland, and our telephone number is +353&nbsp;1 903 8920. Our U.S.
headquarters are located at 200 West Monroe Street, Suite 1575, Chicago, IL 60606, and our telephone number is (312) <FONT STYLE="white-space:nowrap">778-6070.</FONT> Our corporate website address is www.iterumtx.com. Information contained on or
accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Iterum, our logo and our other registered or common law trademarks, trade names or service marks appearing in this prospectus are owned by us.
We do not intend our use or display of other companies&#146; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Ordinary shares offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Ordinary shares to be outstanding after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Over-allotment option to purchase additional shares </P></TD>
<TD>We have granted the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> over-allotment option to purchase up to an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds to us from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise
their over-allotment option in full, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting the
estimated underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds from this offering to fund our Phase 3 clinical trials of oral sulopenem and sulopenem, for payments to Pfizer pursuant
to the exclusive license agreement we have entered into with Pfizer, to establish an Iterum-operated facility in Dublin as a second source supplier to produce oral sulopenem bilayer tablets, and for working capital and other general corporate
purposes, which may include regulatory, manufacturing, clinical supply and related costs. See &#147;Use of Proceeds&#148; for additional information. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Proposed Nasdaq Global Select Market symbol </P></TD>
<TD>&#147;ITRM&#148; </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk Factors </P></TD>
<TD>You should carefully read the section titled &#147;Risk Factors&#148; and other information included in this prospectus for a discussion of factors that you should consider before deciding to invest in our ordinary shares. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of ordinary shares to be outstanding after this offering is based on 95,827,720 ordinary shares outstanding as of December&nbsp;31,
2017 plus the ordinary shares issuable upon the conversion of 26,858,743 Series&nbsp;B-2 preferred shares we issued and sold in February 2018, and excludes: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">3,898,334 ordinary shares issuable upon the exercise of outstanding stock options as of December&nbsp;31, 2017, with a weighted-average exercise price of $0.21 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">3,061,666 ordinary shares reserved for future issuance under our 2015 Equity Incentive Plan as of December&nbsp;31, 2017; all shares reserved for future issuance and not subject to an outstanding stock option will cease
to be available for issuance at the time our 2018 Equity Incentive Plan becomes effective in connection with this offering; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares reserved for future issuance under our 2018 Equity Incentive Plan, as well as any automatic increases in the number of ordinary
shares reserved for future issuance under this plan, which will become effective upon the execution of the underwriting agreement for this offering. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, unless we specifically state otherwise, all information in this prospectus
assumes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our <FONT STYLE="white-space:nowrap">re-registration</FONT> as a public limited company and the filing and effectiveness of our amended and restated constitution in connection with the closing of this offering;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the conversion of all outstanding preferred shares into an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares immediately prior to the closing of this offering, which
includes the conversion of 26,858,743 <FONT STYLE="white-space:nowrap">Series&nbsp;B-2</FONT> preferred shares we issued and sold in February 2018; </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reverse stock split of our ordinary shares, effective as
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise of outstanding stock options; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise by the underwriters of their over-allotment option to purchase up to an additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares from us. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary Financial Data </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize our consolidated financial and other data. We have derived the summary consolidated statements of operations
data for the years ended December&nbsp;31, 2016 and 2017 from our audited consolidated financial statements included elsewhere in this prospectus. The consolidated statements of operations data for the years ended December&nbsp;31, 2016 and 2017 and
the consolidated balance sheet data as of December&nbsp;31, 2017 are derived from our audited consolidated financial statements included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that may be
expected in any future period. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this data together with our consolidated financial statements and related notes
included elsewhere in this prospectus and the sections titled &#147;Selected Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>per&nbsp;share&nbsp;data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,464</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,963</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,455</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,351</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,962</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,464</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to ordinary shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,464</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36.21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average ordinary shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">371,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,704,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average ordinary shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Net loss per share, basic and diluted, is the same due to our net loss. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma</B><br><B>As&nbsp;Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The pro forma column reflects (a)&nbsp;the issuance and sale of 26,858,743 Series B-2 preferred shares and the receipt of $32.2 million of gross proceeds, (b) the conversion of all outstanding preferred shares
into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of our ordinary shares immediately prior to the closing of this offering and (c)&nbsp;the filing and effectiveness of our amended and restated constitution upon the closing
of this offering. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The pro forma as adjusted column reflects the sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares in this offering at an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by
us. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Each $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus,
would increase (decrease) each of cash and cash equivalents, working capital, total assets, and total shareholders&#146; equity on a pro forma as adjusted basis by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of
shares offered by us, as set forth on the cover page of this prospectus remains the same, after deducting the estimated underwriting discounts and commissions and the estimated offering expenses payable by us. Similarly, each increase (decrease) by
1,000,000 shares in the number of shares offered by us would increase (decrease) each of cash and cash equivalents, working capital, total assets, and total shareholders&#146; equity on a pro forma as adjusted basis by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the assumed initial public offering price remains the same, after deducting the estimated underwriting discounts and commissions. The pro forma as adjusted information discussed
above is illustrative only and will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Working capital is equal to current assets minus current liabilities. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc522368_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our ordinary shares involves a high degree of risk. You should carefully consider the risks described below, together with the
other information contained in this prospectus, including our consolidated financial statements and the related notes appearing at the end of this prospectus, before making your decision to invest in our ordinary shares. We cannot assure you that
any of the events discussed in the risk factors below will not occur. These risks could have a material and adverse impact on our business, results of operations, financial condition and cash flows, and if so our future prospects would likely be
materially and adversely affected. If any of such events were to happen, the trading price of our ordinary shares could decline, and you could lose all or part of your investment.</I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Position and Capital Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred net losses in each year since our inception and anticipate that we will continue to incur significant losses for the foreseeable future.
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage pharmaceutical company with a limited operating history. We have not generated any revenue and have
incurred net losses in each year since our inception in 2015. As of December&nbsp;31, 2017, we had an accumulated deficit of $29.4&nbsp;million. Our product candidates, oral sulopenem and sulopenem (together, the sulopenem program), are in clinical
development, have not been approved for sale and we may never have our product candidates approved for commercialization. We have financed our operations through private placements of our preferred shares. We have devoted substantially all of our
financial resources and efforts to research and development, including preclinical and clinical development, for our sulopenem program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future as we conduct planned clinical
trials of oral sulopenem and sulopenem, seek marketing approval for such product candidates if clinical trials are successful, and pursue the development of our sulopenem program in additional indications through preclinical and clinical
development. Our expenses will also increase substantially if and as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conduct additional clinical trials for oral sulopenem and sulopenem, which include our planned Phase 1 clinical trials, which we expect will occur in 2018 and 2019, and our three planned pivotal Phase 3 clinical trials
which we plan to initiate in the second half of 2018; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">initiate other studies as part of our sulopenem program, some of which may be required for regulatory approval of our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish a sales, marketing and distribution infrastructure to commercialize oral sulopenem and sulopenem in the United States if we obtain marketing approval from the U.S. Food and Drug Administration (FDA);
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish manufacturing and supply chain capacity sufficient to provide commercial quantities of oral sulopenem and sulopenem, if we obtain marketing approval; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pursue the development of our sulopenem program in additional indications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain, expand, defend and protect our intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">hire additional clinical, scientific and commercial personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts, as well as to support our transition to a
public reporting company; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates or technologies. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are substantially dependent on the success of our two product candidates, oral sulopenem and
sulopenem, and if we are unable to achieve and sustain profitability, the market value of our ordinary shares will likely decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to become and remain profitable depends on our ability to generate revenue. To date, we have invested substantially all of our
efforts and financial resources in the development of oral sulopenem and sulopenem, which are currently our two product candidates in development. Our prospects, including our ability to finance our operations and generate revenue from product
sales, will currently depend entirely on the development and commercialization of our sulopenem program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not expect to generate
significant revenue unless and until we obtain marketing approval for, and commercialize, oral sulopenem and sulopenem. Our ability to generate future revenue from product sales will require us to be successful in a range of challenging clinical and
commercial activities, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">commencing, enrolling and successfully completing Phase 3 clinical trials of our sulopenem program in our three initial indications; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">applying for and obtaining marketing approval for oral sulopenem and sulopenem; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">protecting and maintaining our rights to our intellectual property portfolio related to our sulopenem program; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing and maintaining supply and manufacturing relationships with third parties that can support clinical development and can provide adequate commercial quantities of oral sulopenem and sulopenem, if approved;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing sales, marketing and distribution capabilities to effectively market and sell oral sulopenem and sulopenem; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining market acceptance of oral sulopenem and sulopenem as viable treatment options. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with developing pharmaceutical products, we are unable to predict the extent of any
future losses or when, or if, we will become profitable. We may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is significant or large enough to achieve profitability. Our expenses could
increase if we are required by the FDA, the European Medicines Agency (the EMA), or any comparable foreign regulatory authority, to perform different studies or studies in addition to those currently expected, or if there are any delays in
completing our clinical trials, including delays or expense associated with increasing the sample size of any study, or the development of our sulopenem program or any future product candidates. Even if oral sulopenem or sulopenem are approved for
commercial sale, we anticipate incurring significant costs associated with the commercial launch of oral sulopenem and sulopenem. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of
our company could cause you to lose all or part of your investment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will require additional capital to fund our operations, and if we fail to
obtain necessary financing, we may not be able to complete the development and commercialization of our sulopenem program. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Developing pharmaceutical products is a time-consuming, expensive and uncertain process that takes years to complete. We expect that our
expenses will increase substantially as we commence and advance our planned clinical trials of oral sulopenem and sulopenem, seek marketing approval for such product candidates if clinical trials are successful, and pursue the development of our
sulopenem program in additional indications through preclinical and clinical development. If we obtain marketing approval for oral sulopenem, sulopenem or any future product candidate, we expect to incur significant commercialization expenses
related to product sales, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
marketing, distribution and manufacturing. Some of these expenses may be incurred in advance of marketing approval, and could be substantial. Accordingly, we will be required to obtain further
funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as
and when needed would have a negative effect on our financial condition and our ability to develop and commercialize our sulopenem program and otherwise pursue our business strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will enable us to fund our
operating expenses and capital expenditure requirements through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . Our cash forecasts are based on assumptions that may prove to
be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances could cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more than currently
expected because of circumstances beyond our control. Our future funding requirements, both short-term and long-term, will depend on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and costs of our planned clinical trials of oral sulopenem and sulopenem; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the initiation, progress, timing, costs and results of preclinical studies and clinical trials of other potential product candidates and of our current product candidates in additional indications; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount of funding that we receive under government awards that we have applied for or may apply for in the future; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and characteristics of product candidates that we pursue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the outcome, timing and costs of seeking regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of commercialization activities for oral sulopenem and sulopenem and other product candidates if we receive marketing approval, including the costs and timing of establishing product sales, marketing,
distribution and manufacturing capabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the receipt of marketing approval and revenue received from any potential commercial sales of oral sulopenem and sulopenem; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and timing of any future collaborations, licensing or other arrangements that we may establish; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property
rights, including milestone and royalty payments and patent prosecution fees that we are obligated to pay pursuant to an exclusive license agreement with Pfizer (the Pfizer License) or other future license agreements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against any intellectual property related claims; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of operating as a public company; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire other products and technologies. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, <FONT STYLE="white-space:nowrap">our&nbsp;non-dilutive&nbsp;source</FONT> of funding is expected to be a
sub-award from&nbsp;the Trustees of Boston University under the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator <FONT STYLE="white-space:nowrap">(CARB-X)</FONT> program (the <FONT STYLE="white-space:nowrap">CARB-X</FONT>
Award). The <FONT STYLE="white-space:nowrap">CARB-X</FONT> Award supports preclinical and clinical trials in support of our potential regulatory filings for oral sulopenem and sulopenem, along with chemistry, manufacturing and controls optimization
and development of our commercial bilayer tablet. The <FONT STYLE="white-space:nowrap">CARB-X</FONT> Award is structured as a cost reimbursement arrangement. In June <FONT STYLE="white-space:nowrap">2017,&nbsp;CARB-X&nbsp;awarded</FONT> funds of up
to $1.5&nbsp;million to advance the development of our sulopenem program.&nbsp;The <FONT STYLE="white-space:nowrap">CARB-X&nbsp;Award</FONT> is subject to termination by the Trustees of Boston University with 30 days written notice, and to the
availability of federal government and <FONT STYLE="white-space:nowrap">non-government</FONT> funding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a limited operating history and no history of commercializing pharmaceutical products, which
may make it difficult to evaluate the prospects for our future viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We began operations in November 2015. Since our
inception, we have devoted substantially all of our financial resources and efforts to organizing and staffing our company, business planning, raising capital, planning for potential commercialization, and research and development, including
preclinical and clinical development, for our sulopenem program. While the members of the development team have successfully developed and registered other antibiotics, as Iterum we have limited experience and have not yet demonstrated an ability to
successfully complete a large-scale, pivotal clinical trial, obtain marketing approval, manufacture a commercial scale product (or arrange for a third party to do so on our behalf), or conduct sales and marketing activities necessary for successful
product commercialization. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing pharmaceutical
products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming we obtain marketing approval for oral sulopenem and sulopenem, we will need to transition from a company with a
research and development focus to a company capable of supporting commercial activities. We may encounter unforeseen expenses, difficulties, complications and delays, and may not be successful in such a transition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our shareholders, including purchasers of ordinary shares in this offering, restrict our operations or
require us to relinquish rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless and until we can generate a substantial amount
of revenue from our sulopenem program or future product candidates, we expect to finance our future cash needs through equity offerings, debt financings, collaboration agreements, other third-party funding, strategic alliances, licensing
arrangements, marketing and distribution arrangements or government funding. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current
or future operating plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our issuance of additional securities, whether equity or debt, or the possibility of such issuance, may cause
the market price of our ordinary shares to decline, and our shareholders may not agree with our financing plans or the terms of such financings. To the extent that we raise additional capital through the sale of ordinary shares, convertible
securities or other equity securities, your ownership interest may be materially diluted, and the terms of these securities could include liquidation or other preferences and anti-dilution protections that could adversely affect your rights as an
ordinary shareholder. In addition, debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring
additional debt, making capital expenditures or declaring dividends, which could adversely affect our ability to conduct our business. In addition, securing additional financing would require a substantial amount of time and attention from our
management and may divert a disproportionate amount of their attention away <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">from&nbsp;day-to-day&nbsp;activities,</FONT></FONT> which may adversely affect our management&#146;s
ability to oversee the development of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise additional funds through collaborations, strategic alliances or
marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications
that may be more profitable or for which there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have limited financial resources, we
intend to focus on developing our sulopenem program for the specific indications of uUTI, cUTI and cIAI, all of which are focused on the most pressing near-term medical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
needs, in terms of both their potential for marketing approval and commercialization. As a result, we may forego or delay pursuit of opportunities with other potential product candidates or
developing our sulopenem program other indications that may prove to have greater commercial potential. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our resource allocation decisions
may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially
viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty
arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to the product candidate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Clinical Development and Commercialization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are heavily dependent on the success of our sulopenem program, and our ability to develop, obtain marketing approval for and successfully
commercialize oral sulopenem and sulopenem. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no products approved for sale and have invested substantially all of
our efforts and financial resources in the development of our sulopenem program as the first and only oral and intravenous (IV)&nbsp;branded penem available globally. Our near-term prospects are substantially dependent on our ability to develop,
obtain marketing approval for and successfully commercialize oral sulopenem and sulopenem. The success of our sulopenem program will depend on several factors, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successful enrollment in, and completion of, clinical trials, including our three planned pivotal Phase 3 clinical trials of oral sulopenem and sulopenem, which we plan to initiate in the second half of 2018;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical trial results with safety, tolerability and efficacy profiles that are satisfactory to the FDA or any comparable foreign regulatory authority; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">timely completion of any additional clinical trials and <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies conducted to support the filing for regulatory approvals of our sulopenem program, if required by the
FDA or any comparable foreign regulatory authority; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receipt of marketing approvals from applicable regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishment and maintenance of arrangements with third-party manufacturers to obtain commercial supply at a scale sufficient to meet anticipated demand and at a cost appropriate for our commercialization;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acquisition and maintenance of patent, trade secret and other intellectual property protection and regulatory exclusivity, both in the United States and internationally, including our ability to maintain our license
agreement with Pfizer Inc. (Pfizer); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">protection of our rights in our intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launch of commercial sales of oral sulopenem and sulopenem, if approved, whether alone or in collaboration with others; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our own or any future collaborators&#146; marketing, sales and distribution strategy and operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance of oral sulopenem and sulopenem, if approved, by patients, physicians and the medical community at large; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain and sustain an adequate level of reimbursement by third-party payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence, frequency and severity of adverse side effects of oral sulopenem and sulopenem; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability, perceived advantages, relative cost and relative efficacy of alternative and competing therapies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a continued acceptable safety profile of oral sulopenem and sulopenem following approval. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of these factors are beyond our control, including clinical development, the regulatory submission process, potential threats to our
intellectual property rights, manufacturing and the impact of competition. If we are unable to develop, receive marketing approval for, or successfully commercialize oral sulopenem and sulopenem, or if we experience delays as a result of any of
these factors or otherwise, our business could be materially harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As Iterum, we have no experience in obtaining regulatory approval for a drug.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As Iterum, we have never obtained regulatory approval for, or commercialized, a drug. We must complete extensive preclinical and
clinical trials to demonstrate the safety and efficacy of our product candidates in humans before we will be able to obtain these approvals. To gain approval to market a product candidate, we must provide the FDA and foreign regulatory authorities
with <FONT STYLE="white-space:nowrap">non-clinical,</FONT> clinical and chemistry, manufacturing, and controls (CMC) data that adequately demonstrates the safety and efficacy of the product for the intended indication applied for in the NDA or other
respective regulatory filing. It is possible that the FDA may refuse to accept any or all of our planned NDAs for substantive review or may conclude after review of our data that our application is insufficient to obtain regulatory approval for any
current or future product candidates. If the FDA does not approve any of our planned NDAs, it may require that we conduct additional costly clinical, nonclinical or manufacturing validation studies before it will reconsider our applications.
Depending on the extent of these or any <FONT STYLE="white-space:nowrap">other&nbsp;FDA-required&nbsp;studies,</FONT> approval of any NDA or other application that we submit may be significantly delayed, possibly for several years, or may require us
to expend more resources than we have available. Any failure or delay in obtaining regulatory approvals would prevent us from commercializing oral sulopenem and sulopenem, generating revenues and achieving and sustaining profitability. It is also
possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve any NDA or other application that we submit. If any of these outcomes occur, we may be forced to abandon the development of our
product candidates, which would materially adversely affect our business and could potentially cause us to cease operations. We face similar risks for our applications in foreign jurisdictions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If clinical trials of oral sulopenem, sulopenem or any other product candidate that we may advance to clinical trials fail to demonstrate safety and
efficacy to the satisfaction of the FDA or comparable foreign regulatory authorities or do not otherwise produce favorable results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the
development and commercialization of oral sulopenem, sulopenem or any other product candidate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not commercialize, market,
promote, or sell any product candidate in the United States without obtaining marketing approval from the FDA or in other countries without obtaining approvals from comparable foreign regulatory authorities, such as the EMA, and we may never receive
such approvals. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. We have not previously submitted an NDA to the FDA or similar applications to comparable
foreign regulatory authorities for any of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business currently depends entirely on the successful development,
regulatory approval and commercialization of our sulopenem program. The clinical development of our sulopenem program is susceptible to the risk of failure inherent at any stage of drug development, including failure to demonstrate efficacy in a
clinical trial or across a broad population of patients, the occurrence of severe adverse events, failure to comply with protocols or applicable regulatory requirements, and determination by the FDA or any comparable foreign regulatory authority
that a drug product is not approvable. A number of companies in the pharmaceutical </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">industry, including biotechnology companies, have suffered significant
setbacks in clinical trials, even after </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
promising results in earlier nonclinical studies or clinical trials. The results of preclinical and other nonclinical studies and/or early clinical trials of our product candidates may not be
predictive of the results of later-stage clinical trials. Notwithstanding any promising results in early nonclinical studies or clinical trials, we cannot be certain that we will not face similar setbacks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, we present data from clinical trials conducted by Pfizer Japan in the 1990s.&nbsp;The data from those clinical trials is not
directly comparable to data from clinical trials that would be conducted today or the data that we anticipate from our Phase 3 program for a variety of reasons, including that protocols were designed for different purposes and as a consequence had
different enrollment and efficacy evaluation criteria.&nbsp;For example, while a subjective investigator assessment of outcome is typically included in all cUTI protocols and was performed in the Japanese program, more structured endpoints are
required as part of current FDA guidelines for registrational trials. Current FDA guidelines define the primary efficacy outcome based on both clinical and microbiological success, while EMA guidelines recommend microbiologic outcome. The structured
endpoint in the Japanese program assessed outcome based on resolution of pyuria and microbiologic outcome. In addition, the pathogens isolated in the course of a clinical trial will vary depending on the types of patients enrolled, the geographic
location of the sites that contribute to the study and the year in which the study is performed. While the organisms seen in the Japanese study are similar to those we anticipate in the Phase&nbsp;3 program, we expect the frequency distribution of
these pathogens may be different. Furthermore, adverse event reports can vary by geographic region and we may see a different adverse event rate and different types of events, in patients that we study in the Phase 3 program relative to the
experience in Japan. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical development of oral sulopenem, sulopenem and other product candidates is susceptible to the risk
of failure inherent at any stage of drug development, including failure to achieve efficacy in a clinical trial or across a broad population of patients, the occurrence of severe adverse events, failure to comply with protocols or applicable
regulatory requirements, and determination by the FDA or any comparable foreign regulatory authority that a drug product is not approvable. The outcome of preclinical studies and early clinical trials may not be predictive of the success of later
clinical trials, and interim results of a clinical trial do not necessarily predict final results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, preclinical and clinical
data are often susceptible to varying interpretations and analyses. Although data from Phase 1 and Phase 2 clinical trials of oral sulopenem and sulopenem provides support for the overall safety profile of the product candidates, many companies that
believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for the product candidates. Even if we believe that the results of our clinical trials warrant
marketing approval, the FDA or comparable foreign regulatory authorities may disagree and may not grant marketing approval of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some instances, there can be significant variability in safety and/or efficacy results between different clinical trials of the same
product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, adherence to the dosing regimen and other trial protocols and the rate of dropout
among clinical trial participants, among others. It is possible that even if one or more of our product candidates has a beneficial effect, that effect will not be detected during clinical evaluation as a result of one of the factors listed or
otherwise. Conversely, as a result of the same factors, our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any. Similarly, in our clinical trials, we may fail to
detect toxicity of or intolerability of our product candidates or may determine that our product candidates are toxic or not well tolerated when that is not in fact the case. In the case of our clinical trials, results may differ on the basis of the
type of bacteria with which patients are infected. We cannot assure you that any Phase&nbsp;3 or other clinical trials that we may conduct will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to market our
product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may encounter unforeseen events prior to, during, or as a result of, clinical trials that
could delay or prevent us from obtaining regulatory approval for oral sulopenem, sulopenem or any of our other product candidates, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">although we expect to conduct our Phase 3 clinical trials pursuant to Special Protocol Assessment (SPA) agreements, the FDA or other comparable foreign regulatory authorities may ultimately disagree as to the design or
implementation of our Phase 3 clinical trials or other clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not reach agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly
among different CROs and trial sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical trials of our product candidates may produce unfavorable or inconclusive results; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our third-party contractors, including those manufacturing our product candidates or conducting clinical trials on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us
in a timely manner, or at all; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA, the local National Health Authorities or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may have to suspend or terminate clinical trials of a product candidate for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable
health risks, undesirable side effects or other unexpected characteristics of the product candidate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we enter into agreement for clinical and commercial supplies;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are required to conduct additional clinical trials or other testing of oral sulopenem, sulopenem or any other product candidate beyond
the clinical trials and testing that we contemplate, if we are unable to successfully complete clinical trials or other testing of our product candidates, if the results of these clinical trials or tests are unfavorable or are only modestly
favorable or if there are safety concerns associated with oral sulopenem, sulopenem or any other product candidate, we may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">incur additional unplanned costs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be delayed in obtaining marketing approval for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not obtain marketing approval at all; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain approval for indications or patient populations that are not as broad as intended or desired; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain approval with labeling that includes significant use or distribution restrictions or significant safety warnings, including boxed warnings; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be subject to additional post-marketing testing or other requirements; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be required to remove the product from the market after obtaining marketing approval. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
failure to successfully initiate and complete clinical trials of our product candidates and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market any of our product candidates would significantly harm our business.
We cannot assure you that our clinical trials will begin as planned or be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
completed on schedule, if at all, or that we will not need to restructure our clinical trials after they have begun. Significant clinical trial delays also could shorten any periods during which
we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates, which may harm our business and
results of operations. In addition, many of the factors that cause, or lead to, delays of clinical trials may ultimately lead to the denial of regulatory approval of oral sulopenem, sulopenem or any other product candidate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we experience delays or difficulties in the enrollment of patients in clinical trials, clinical development activities could be delayed or otherwise
adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timely completion of clinical trials in accordance with their protocols depends, among other things, on
our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may not be able to initiate, continue or complete clinical trials of oral sulopenem, sulopenem or any other product candidate that we develop if
we are unable to locate and enroll a sufficient number of eligible patients to participate in clinical trials as required by the FDA or comparable foreign regulatory authorities, such as the EMA. Patient enrollment is a significant factor in the
timing of clinical trials, and is affected by many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the size and nature of the patient population; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the severity of the disease under investigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the proximity of patients to clinical sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the eligibility criteria for participation in the clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of sites at which we conduct the trial and the speed at which we are able to open such sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence of antibiotic resistance to pathogens where we conduct the clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the accuracy of certain estimates and assumptions upon which the design of the protocols are predicated; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to recruit clinical trial investigators with appropriate experience; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competing clinical trials and clinicians&#146; and patients&#146; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new
drugs that may be approved for the indications that we are investigating; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain and maintain patient consents; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risk that patients enrolled in clinical trials will drop out of the clinical trials before completion. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The inclusion and exclusion criteria for our contemplated Phase 3 clinical trials of oral sulopenem and sulopenem may adversely affect our
enrollment rates for patients in these clinical trials. In addition, we may face competition in enrolling suitable patients as a result of other companies conducting clinical trials for antibiotic product candidates that are intended to treat
similar infections, resulting in slower than anticipated enrollment in our clinical trials. Enrollment delays in our clinical trials may result in increased development costs for oral sulopenem and sulopenem, or slow down or halt our product
development for oral sulopenem and sulopenem. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our inability to enroll a sufficient number of patients for our clinical trials would
result in significant delays or might require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, slow down or halt our product
candidate development and approval process and jeopardize our ability to seek and obtain the marketing approval required to commence product sales and generate revenue, which would cause the value of our company to decline and limit our ability to
obtain additional financing if needed. Furthermore, we rely on and expect to continue to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials, and we will have limited influence over their performance.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Success in <FONT STYLE="white-space:nowrap">non-clinical</FONT> testing and early clinical trials does
not ensure that later clinical trials will be successful, and we cannot assure you that any of our current clinical trials, planned Phase 3 clinical trials or any other clinical trials that we may conduct will demonstrate consistent or adequate
efficacy and safety to obtain regulatory approval to market our sulopenem program in any indication. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our planned pivotal Phase 3
clinical trials of oral sulopenem and sulopenem are subject to a number of specific risks arising from our clinical program and the design of such clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not previously conducted Phase 3 clinical trials of oral sulopenem or sulopenem in the indications, uUTI, cUTI and cIAI, and we have
not documented to the satisfaction of regulators that these treatments are effective in treating uUTIs, cUTIs or cIAIs in humans. Although we believe that oral sulopenem and sulopenem have the potential to treat uUTIs, cUTIs, and cIAIs in humans
based on the results of prior preclinical studies and clinical trials, the results of these preclinical studies and clinical trials are not necessarily predictive of the results of our planned clinical trials and we cannot guarantee that oral
sulopenem will demonstrate the expected efficacy in our planned pivotal Phase 3 clinical trial patients. We also cannot guarantee that the projections made from the pharmacokinetic and pharmacodynamic models that we developed from nonclinical and
clinical oral sulopenem and sulopenem studies will be validated in our planned pivotal Phase 3 clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other companies in the
pharmaceutical industry have frequently suffered significant setbacks in later clinical trials, even after achieving promising results in earlier nonclinical studies or clinical trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Serious adverse events or undesirable side effects or other unexpected properties of oral sulopenem, sulopenem or any other product candidate may be
identified during development or after approval that could delay, prevent or cause the withdrawal of regulatory approval, limit the commercial potential, or result in significant negative consequences following marketing approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Serious adverse events or undesirable side effects caused by, or other unexpected properties of, our product candidates could cause us, an
institutional review board, or regulatory authorities to interrupt, delay or halt our clinical trials and could result in a more restrictive label, the imposition of distribution or use restrictions or the delay or denial of regulatory approval by
the FDA or comparable foreign regulatory authorities. If oral sulopenem, sulopenem or any of our other product candidates is associated with serious or unexpected adverse events or undesirable side effects, the FDA or the IRBs at the institutions in
which our studies are conducted, could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted
indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the clinical trial or result in potential product liability claims. Any of these occurrences may harm our business,
financial condition and prospects significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the active pharmaceutical ingredient in the bilayer tablet is sulopenem
etzadroxil, the combination product with probenecid has not yet been tested extensively in patients. There may be unforeseen serious adverse events or side effects that differ from those seen in Phase 1 normal healthy volunteers with oral sulopenem
or the prior post-marketing experience with probenecid. There may also be unexpected adverse events associated with probenecid that have not been seen to date. We may see higher rates of adverse events than were reported in the clinical trials
Pfizer conducted in Japan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, sulopenem and sulopenem etzadroxil have generally been well tolerated in clinical trials conducted in
healthy subjects and patients. During the development of oral sulopenem and sulopenem, patients have experienced drug-related side effects including diarrhea, temporary increases in hepatic enzymes, allergic reactions, and rash. In the Japanese
program, one patient reported a serious adverse event related to sulopenem of a transient elevation in liver function tests. The patient died due to metastatic lung cancer. Other serious adverse events recorded in patients receiving sulopenem in the
Japanese program, which were not considered by the investigator to be related to sulopenem, included myocardial infarction with respiratory failure and progression </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of underlying ovarian carcinoma, in both cases resulting in death. For each of these patients, sulopenem was not determined to be the cause of death. If unexpected adverse events occur in any of
our planned clinical trials, we may need to abandon development of our product candidates, or limit development to lower doses or to certain uses or subpopulations in which the undesirable side effects or other unfavorable characteristics are less
prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds that initially showed promise in clinical or earlier stage testing are later found to cause undesirable or unexpected side effects that prevented further
development of the compound. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Undesirable side effects or other unexpected adverse events or properties of oral sulopenem, sulopenem or
any of our other product candidates could arise or become known either during clinical development or, if approved, after the approved product has been marketed. If such an event occurs during development, our clinical trials could be suspended or
terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of, or could deny approval of, oral sulopenem, sulopenem or our other product candidates. If such an event occurs after such product
candidates are approved, a number of potentially significant negative consequences may result, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may withdraw the approval of such product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to recall a product or change the way such product is administered to patients; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require additional warnings on the label or impose distribution or use restrictions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require one or more post-market studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require the addition of a &#147;black box&#148; warning; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to implement a REMS including the creation of a medication guide outlining the risks of such side effects for distribution to patients; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we could be sued and held liable for harm caused to patients; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our product may become less competitive; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reputation may suffer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining
market acceptance of the affected product candidate, if approved, or could substantially increase commercialization costs and expenses, which could delay or prevent us from generating revenue from the sale of our products and harm our business and
results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if a product candidate does obtain regulatory approval, it may never achieve the market acceptance by physicians,
patients, hospitals, third-party payors and others in the medical community that is necessary for commercial success, and the market opportunity may be smaller than we estimate. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we obtain FDA or other regulatory approvals and are able to launch oral sulopenem, sulopenem or any other product candidate
commercially, the product candidate may not achieve market acceptance among physicians, patients, hospitals (including pharmacy directors) and third-party payors and, ultimately, may not be commercially successful. For example, physicians are often
reluctant to switch their patients from existing therapies even when new and potentially more effective or convenient treatments enter the market. Moreover, many antibiotics currently exist for the pathogens underlying uUTI, cUTI and cIAI. While
many of those pathogens are resistant to certain drugs in the market, the selection is broad, and individual physicians&#146; prescribing patterns vary widely and are affected by resistance rates in their geographies, whether their patients are at
elevated risk, the ability of patients to afford branded drugs and concerns regarding generating resistance with specific classes of antibiotics. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to educate the medical community and third-party payors on the benefits of our
product candidates may require significant resources and may not be successful. If oral sulopenem, sulopenem or any other product candidate that we develop does not achieve an adequate level of market acceptance, we may not generate significant
product revenues and, therefore, we may not become profitable. Market acceptance of any product candidate for which we receive approval depends on a number of factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the efficacy and safety of the product candidate as demonstrated in clinical trials as compared to alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential and perceived advantages and disadvantages of the product candidates, including cost and clinical benefit relative to alternative treatments; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">relative convenience and ease of administration; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the clinical indications for which the product candidate is approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the willingness of physicians to prescribe the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the willingness of hospital pharmacy directors to purchase the product for their formularies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance by physicians, patients, operators of hospitals and treatment facilities and parties responsible for coverage and reimbursement of the product; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of coverage and adequate reimbursement by third-party payors and government authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our sales and marketing efforts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the strength of marketing and distribution support; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations or warnings, including distribution or use restrictions, contained in the product&#146;s approved labeling or an approved risk evaluation and mitigation strategy; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy for particular infections; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the approval of other new products for the same indications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of market introduction of the approved product as well as competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse publicity about the product or favorable publicity about competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the emergence of bacterial resistance to the product; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rate at which resistance to other drugs in the target infections grows. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the
potential market opportunity for oral sulopenem and sulopenem is difficult to estimate. Our estimates of the potential market opportunity are predicated on several key assumptions such as industry knowledge and publications, third-party research
reports and other surveys. While we believe that our internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are inherently uncertain and the reasonableness of these
assumptions has not been assessed by an independent source. If any of the assumptions proves to be inaccurate, then the actual market for oral sulopenem and sulopenem could be smaller than our estimates of the potential market opportunity. If the
actual market for oral sulopenem and sulopenem is smaller than we expect, or if the product fails to achieve an adequate level of acceptance by physicians, health care payors and patients, our product revenue may be limited and it may be more
difficult for us to achieve or maintain profitability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We currently have no commercial organization. If we are unable to establish sales, marketing and
distribution capabilities or enter into sales, marketing and distribution agreements with third parties, we may not be successful in commercializing oral sulopenem, sulopenem or any other product candidate if such product candidate is approved.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to establish sales, marketing and distribution capabilities or enter into sales, marketing and distribution
agreements with third parties, we may not be successful in commercializing oral sulopenem, sulopenem or any other product candidate if such product candidate is approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently do not have a sales, marketing or distribution infrastructure and we have no experience in the sales, marketing or distribution
of pharmaceutical products. To achieve commercial success for any approved product, we must either build our marketing, sales, distribution, managerial and other <FONT STYLE="white-space:nowrap">non-technical</FONT> capabilities, or make
arrangements to outsource those functions to third parties. If oral sulopenem and sulopenem receive regulatory approval, we intend to build a commercial organization in the United States and recruit a targeted sales force with technical expertise,
an internal marketing and health resource group, as well as a managed markets group focused on reimbursement activities with third-party payors and a specialty distribution team to ensure pharmacy-level stocking. The development of sales, marketing
and distribution capabilities will require substantial resources, will be time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing and distribution
capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization costs. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and
marketing personnel. In addition, we may not be able to hire a sales force in the United States that is sufficient in size or has adequate expertise in the medical markets that we intend to target. If we are unable to establish a sales force and
marketing and distribution capabilities, our operating results may be adversely affected. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of our
product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors that may inhibit our efforts to commercialize our products on our own include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to recruit and retain adequate numbers of effective sales and marketing personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to identify the best territories to target based on resistance statistics and prescribers within those territories; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability of sales personnel to obtain access to educate physicians regarding the attributes of our future products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unforeseen costs and expenses associated with creating an independent sales and marketing organization. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focusing our initial commercial efforts on the United States market, which we believe represents the largest market opportunity for our
sulopenem program. We are currently evaluating our commercialization strategy outside the United States. For those countries in which we choose not to commercialize directly ourselves, we intend to use collaborators that have direct sales forces and
established distribution systems to assist with the commercialization of oral sulopenem, sulopenem and any other product candidate. As a result of entering into arrangements with third parties to perform sales, marketing and distribution services,
our product revenues or the profitability of these product revenues to us would likely be lower than if we were to directly market and sell products in those markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, we may be unsuccessful in entering into the necessary arrangements with third parties or may be unable to do so on terms that are
favorable to us. In addition, we likely would have little control over such third parties, and any of them might fail to devote the necessary resources and attention to sell and market our products effectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do not establish sales and marketing capabilities successfully, either on our own or
in collaboration with third parties, we will not be successful in commercializing our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We intend to establish our own facility
to produce oral sulopenem tablets, if approved, on a commercial scale. We do not have experience in manufacturing products on a commercial scale and we have limited resources for such <FONT STYLE="white-space:nowrap">build-out.</FONT> If, due to our
lack of manufacturing experience and resources, we cannot produce our tablets on a commercial scale successfully or produce sufficient tablets to meet our expected commercial requirements, our business may be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently contract with third parties for the manufacture of oral sulopenem and sulopenem. We plan to continue contracting with third
parties in the future but also contemplate leasing our own tableting facility in Ireland, as a secondary source of producing oral sulopenem bilayer tablets. We do not have experience in manufacturing products on a commercial scale and we have
limited personnel to devote to the <FONT STYLE="white-space:nowrap">build-out</FONT> of the potential new facility. If we do not have sufficient revenues to cover the costs of the tableting facility, we may need to shut down the facility at a loss
or borrow or raise funds to maintain the facility until sufficient revenues can be generated. Before we can begin to commercially produce oral sulopenem tablets in&nbsp;our own facility, we must obtain regulatory approval from the FDA and from the
Health Products Regulatory Authority in Ireland for our manufacturing process and facility. If we decided to commercialize in Europe as well, manufacturing authorization must also be obtained from the appropriate European Union regulatory
authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we are successful, our manufacturing capabilities could be affected by cost-overruns, unexpected delays, equipment
failures, lack of capacity, labor shortages, natural disasters, power failures and numerous other factors that could prevent us from realizing the intended benefits of our manufacturing strategy and have a material adverse effect on our business.
These difficulties could delay the <FONT STYLE="white-space:nowrap">build-out</FONT> and equipping of a commercial tableting facility, increase our costs, cause production delays or result in us not producing sufficient product to meet our expected
commercial requirements, any of which could damage our reputation and hurt our profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face substantial competition from other
pharmaceutical and biotechnology companies and our business may suffer if we fail to compete effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development and
commercialization of new drug products is highly competitive. We face competition from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide with respect to oral sulopenem, sulopenem and our other
product candidates that we may seek to develop and commercialize in the future. There are a number of pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates for the
treatment of resistant infections. Potential competitors also include academic institutions, government agencies and other public and private research organizations. Our competitors may succeed in developing, acquiring or licensing technologies and
drug products that are more effective or less costly than oral sulopenem, sulopenem or any other product candidates that we may develop, which could render our product candidates obsolete and noncompetitive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are a variety of available oral therapies marketed for the treatment of multi-drug resistant infections that we would expect would
compete with oral sulopenem and sulopenem, such as levofloxacin, ciprofloxacin, nitrofurantoin, fosfomycin, amoxicillin-clavulanate, cephalexin and trimethoprim-sulfamethoxazole. Many of the available therapies are well established and widely
accepted by physicians, patients and third-party payors. Insurers and other third-party payors may also encourage the use of generic products, for example in the fluoroquinolone class. If oral sulopenem or sulopenem is approved, the pricing may be
at a significant premium over other competitive products that are generic. This may make it difficult for oral sulopenem or sulopenem to compete with these products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are also a number of oral product candidates in clinical development by third parties that are intended to treat UTIs. <FONT
STYLE="white-space:nowrap">Some&nbsp;mid-&nbsp;to</FONT> late-stage product candidates include&nbsp;ceftibuten clavulanate&nbsp;from Achaogen, Inc., </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
tebipenem pivoxil from Spero Therapeutics, Inc., delafloxacin from Melinta Therapeutics and omadacycline from Paratek Pharmaceuticals, Inc. If our competitors obtain marketing approval from the
FDA or comparable foreign regulatory authorities for their product candidates more rapidly than us, it could result in our competitors establishing a strong market position before we are able to enter the market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are several <FONT STYLE="white-space:nowrap">IV-administered</FONT> products marketed for the treatment of infections resistant to
first-line therapy for gram-negative infections, including Avycaz from Allergan plc and Pfizer Inc., Vabomere from Melinta Therapeutics, and Zerbaxa from Merck&nbsp;&amp; Co. There are also a number of
<FONT STYLE="white-space:nowrap">IV-administered</FONT> product candidates in late-stage clinical development that are intended to treat resistant gram-negative infections, including plazomicin from Achaogen, Inc., cefiderocol from
Shionogi&nbsp;&amp; Co. Ltd., and imipenem-relabactam from Merck&nbsp;&amp; Co. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our competitors have significantly greater
financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical
and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well
as in acquiring technologies complementary to, or necessary for, our programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2012, the Food and Drug Administration Safety and
Innovation Act was passed, which included the Generating Antibiotics Incentives Now Act, or the GAIN Act. The GAIN Act is intended to provide incentives for the development of new, qualified infectious disease products (QIDP). One such incentive is
that, once a product receives QIDP designation and completes the necessary clinical trials and is approved by the FDA, it will be given an additional five years of market exclusivity regardless of whether it is protected by a patent, provided that
it is already eligible for another type of regulatory exclusivity. In December 2016, the Cures Act was passed, providing additional support for the development of new infectious disease products. These incentives may result in more competition in
the market for new antibiotics, and may cause pharmaceutical and biotechnology companies with more resources than we have to shift their efforts towards the development of product candidates that could be competitive with oral sulopenem, sulopenem
and our other product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we are able to commercialize oral sulopenem, sulopenem or any other product candidate, the product may
become subject to unfavorable pricing regulations, or third-party payor coverage and reimbursement policies that could harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Some countries require
approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains
subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of
the product, possibly for lengthy time periods, which may negatively affect the revenues that we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or
more product candidates, even if our product candidates obtain marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently expect that oral sulopenem will be used
in the community setting. The commercial success of oral sulopenem will depend substantially, both domestically and abroad, on the extent to which adequate coverage and reimbursement for this product and related treatments are available from
government health programs, private health insurers and other third-party payors. If coverage is not available, or reimbursement is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limited, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish
or maintain pricing sufficient to realize a sufficient return on our investments. Government authorities and third-party payors, such as health insurers and managed care organizations, publish formularies that identify the medications they will
cover and the related payment levels. The healthcare industry is focused on cost containment, both in the United States and elsewhere. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount
of reimbursement for particular medications, which could affect our ability to sell our product candidates profitably. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United
States, sales of our product candidates will depend, in part, on the availability and extent of coverage and reimbursement by third-party payors, such as government health programs, including Medicare and Medicaid, commercial insurance and managed
healthcare organizations. There is no uniform coverage and reimbursement policy among third-party payors; however, private third-party payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates.
Obtaining coverage and reimbursement approval for a product candidate from third-party payors is a time-consuming and costly process that may require the provision of supporting scientific, clinical and cost effectiveness data for the use of product
candidate to the third-party payor. There may be significant delays in obtaining such coverage and reimbursement for newly approved products, and coverage may be more limited than the purposes for which the product candidate is approved by the FDA.
Moreover, eligibility for coverage and reimbursement does not imply that a product candidate will be paid for in all cases or at a rate that covers operating costs, including research, development, intellectual property, manufacture, sale and
distribution expenses. Reimbursement rates may vary according to the use of the product candidate and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost products and may be incorporated into
existing payments for other services. It is difficult to predict what third-party payors will decide with respect to coverage and reimbursement for our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently expect that sulopenem IV, if approved, will be administered in a hospital setting, and oral sulopenem, if approved, will be used
in a community setting and possibly be administered in a hospital inpatient setting as well. In the United States, third-party payors generally reimburse hospitals a single bundled payment established on a prospective basis intended to cover all
items and services provided to the patient during a single hospitalization. Hospitals bill third-party payors for all or a portion of the fees associated with the patient&#146;s hospitalization and bill patients for any deductibles <FONT
STYLE="white-space:nowrap">or&nbsp;co-payments.&nbsp;Because</FONT> there is typically no separate reimbursement for drugs administered in a hospital inpatient setting, some of our target customers may be unwilling to adopt our product candidates in
light of the additional associated cost. If we are forced to lower the price we charge for our product candidates, if approved, our gross margins may decrease, which would adversely affect our ability to invest in and grow our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An inability to promptly obtain coverage and adequate payment rates from third-party payors for any approved product candidates that we
develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We cannot predict whether bacteria may develop resistance to oral sulopenem or sulopenem, which could affect their revenue potential. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing oral sulopenem and sulopenem to treat drug-resistant bacterial infections. The bacteria responsible for these infections
evolve quickly and readily transfer their resistance mechanisms within and between species. We cannot predict whether or when bacterial resistance to oral sulopenem and sulopenem may develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As with some commercially available carbapenems, oral sulopenem and sulopenem are not active against organisms expressing a resistance
mechanism mediated by enzymes known as carbapenemases. Although occurrence of this resistance mechanism is currently uncommon, we cannot predict whether carbapenemase-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
mediated resistance will become widespread in regions where we intend to market sulopenem if it is approved. The use of carbapenems or penems in areas with drug resistant infections or in
countries with poor public health infrastructures, or the potentially extensive use of oral sulopenem or sulopenem outside of controlled hospital settings or in the community, could contribute to the rise of resistance. In addition, prescribers may
be less likely to prescribe oral sulopenem and sulopenem if they are concerned about contributing to the rise of antibiotic resistance. If resistance to oral sulopenem or sulopenem becomes prevalent, or concerns about such resistance are strong, our
ability to generate revenue from oral sulopenem and sulopenem could suffer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to costly product liability claims related to our
clinical trials and product candidates and, if we are unable to obtain adequate insurance or are required to pay for liabilities resulting from a claim excluded from, or beyond the limits of our insurance coverage, a material liability claim could
adversely affect our financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we conduct clinical trials with human patients, we face the risk that the use of
our product candidates may result in adverse side effects to patients in our clinical trials. We face even greater risks upon any commercialization of our product candidates. Although we have product liability insurance, which covers our clinical
trials for up to $10&nbsp;million, our insurance may be insufficient to reimburse us for any expenses or losses we may suffer, and we will be required to increase our product liability insurance coverage for our advanced clinical trials that we plan
to initiate. We will need to increase our insurance coverage if and when we receive marketing approval for and begin selling oral sulopenem, sulopenem or any other product candidate. We do not know whether we will be able to continue to obtain
product liability coverage and obtain expanded coverage if we require it, on acceptable terms, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not have sufficient
resources to pay for any liabilities resulting from a claim excluded from, or beyond the limits of, our insurance coverage. Where we have provided indemnities in favor of third parties under our agreements with them, there is also a risk that these
third parties could incur liability and bring a claim under such indemnities. An individual may bring a product liability claim against us alleging that one of our product candidates or products causes, or is claimed to have caused, an injury or is
found to be unsuitable for consumer use. Any product liability claim brought against us, with or without merit, could result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal of clinical trial volunteers, investigators, patients or trial sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to commercialize our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decreased demand for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory investigations that could require costly recalls or product modifications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">loss of revenue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">substantial costs of litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">liabilities that substantially exceed our product liability insurance, which we would then be required to pay ourselves; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase in our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, if at all; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the diversion of management&#146;s attention from our business; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">damage to our reputation and the reputation of our products. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our operations, including our use of
hazardous materials, chemicals, bacteria and viruses, require us to comply with regulatory requirements and expose us to significant potential liabilities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations involve the use of hazardous materials, including chemicals, and may produce dangerous waste products. Accordingly, we, along
with the third parties that conduct clinical trials and manufacture our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
products and product candidates on our behalf, are subject to federal, state, local and foreign laws and regulations that govern the use, manufacture, distribution, storage, handling, exposure,
disposal and recordkeeping with respect to these materials. We are also subject to a variety of environmental and occupational health and safety laws. Compliance with current or future laws and regulations can require significant costs and we could
be subject to substantial fines and penalties in the event of noncompliance. In addition, the risk of contamination or injury from these materials cannot be completely eliminated. In such event, we could be held liable for substantial civil damages
or costs associated with the cleanup of hazardous materials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we experience a significant disruption in our information technology systems or
breaches of data security, our business could be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on information technology systems to keep financial
records, capture laboratory data, maintain clinical trial data and corporate records, communicate with staff and external parties and operate other critical functions. Our information technology systems are potentially vulnerable to disruption due
to breakdown, malicious intrusion and computer viruses or other disruptive events including but not limited to natural disaster. If we were to experience a prolonged system disruption in our information technology systems or those of certain of our
vendors, it could delay or negatively impact the development and commercialization of our sulopenem program and any future product candidates or technology, which could adversely impact our business. Although we maintain offsite <FONT
STYLE="white-space:nowrap">back-ups</FONT> of our data, if operations at our facilities were disrupted, it may cause a material disruption in our business if we are not capable of restoring function on an acceptable timeframe. In addition, our
information technology systems are potentially vulnerable to data security breaches&#151;whether by employees or others&#151;which may expose sensitive data to unauthorized persons. Such data security breaches could lead to the loss of trade secrets
or other intellectual property, or could lead to the public exposure of personal information (including sensitive personal information) of our employees, customers and others, any of which could have a material adverse effect on our business,
financial condition and results of operations. Moreover, a security breach or privacy violation that leads to disclosure or modification of, personally identifiable information, could harm our reputation, compel us to comply with applicable Irish,
and United States federal and/or state, breach notification laws, subject us to mandatory corrective action, require us to verify the correctness of database contents and otherwise subject us to litigation and liability under laws and regulations
that protect personal data, resulting in increased costs or loss of revenue. In addition, a data security breach could result in loss of clinical trial data or damage to the integrity of that data. If we are unable to prevent such security breaches
or privacy violations or implement satisfactory remedial measures, our operations could be disrupted, and we may suffer loss of reputation, financial loss and other negative consequences because of lost or misappropriated information. In addition,
these breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Dependence on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations in our agreement with Pfizer, we could lose such rights that are important to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely heavily on the Pfizer License pursuant to which we exclusively <FONT STYLE="white-space:nowrap">in-license</FONT> certain patents and <FONT
STYLE="white-space:nowrap">know-how</FONT> related to sulopenem etzadroxil and certain <FONT STYLE="white-space:nowrap">know-how</FONT> related to the IV formulation of sulopenem. The Pfizer License imposes, and we may enter into additional
agreements, including license agreements, with other parties in the future that impose diligence, development and commercialization timelines, milestone payments, royalties, insurance and other obligations on us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Pfizer License gives us exclusive worldwide rights to develop, manufacture, and commercialize sulopenem etzadroxil and sulopenem, or any
other prodrug of sulopenum previously identified by Pfizer as well as the right to use relevant information and regulatory documentation developed by Pfizer to support any regulatory filings worldwide. In exchange for those rights, we are obligated
to satisfy diligence requirements, including using commercially reasonable efforts to develop, obtain regulatory approval for and commercialize </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sulopenem etzadroxil and sulopenem by implementing a specified development plan and providing an update on progress on an annual basis. Under the Pfizer License, we paid Pfizer a <FONT
STYLE="white-space:nowrap">one-time</FONT> nonrefundable upfront fee of $5.0&nbsp;million and are obligated to pay Pfizer milestone payments upon the achievement of specified clinical, regulatory and sales milestones as well as royalties ranging
from a single-digit to <FONT STYLE="white-space:nowrap">mid-teens</FONT> percentage based on the amount of marginal net sales of each licensed product. Pfizer also received six million of our Series A preferred shares as additional payment for the
licensed rights. For a more detailed summary of the Pfizer License, please see the section titled &#147;Business&#151;Pfizer License Agreement.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with our obligations to Pfizer under the Pfizer License, Pfizer may have the right to terminate the Pfizer License, in
which event we would not be able to develop, obtain regulatory approval for, manufacture or market any product candidate that is covered by the Pfizer License, including sulopenem etzadroxil and sulopenem, which would materially harm our business,
financial condition, results of operations and growth prospects. Any termination of the Pfizer License or reduction or elimination of our rights thereunder may result in our having to negotiate new or reinstated agreements with less favorable terms.
Any termination of the Pfizer License would cause us to lose our rights to important intellectual property or technology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to depend on
collaborations with third parties for the development and commercialization of oral sulopenem and sulopenem in certain territories. Our prospects with respect to those product candidates will depend in part on the success of those collaborations.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we are focusing our initial commercial efforts on the United States market, which we believe represents the largest
market opportunity for our sulopenem program, we are also evaluating our commercialization strategy outside the United States. For those countries in which we choose not to commercialize directly ourselves, we intend to seek to commercialize for
oral sulopenem and sulopenem through collaboration arrangements. In addition, we may seek third-party collaborators for development and commercialization of other product candidates. Our likely collaborators for any marketing, distribution,
development, licensing or broader collaboration arrangements include large and <FONT STYLE="white-space:nowrap">mid-size</FONT> pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. We are not
currently party to any such arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may derive revenue from research and development fees, license fees, milestone payments and
royalties under any collaborative arrangement into which we enter. Our ability to generate revenue from these arrangements will depend on our collaborators&#146; abilities to successfully perform the functions assigned to them in these arrangements.
In addition, our collaborators may have the right to abandon research or development projects and terminate applicable agreements, including funding obligations, prior to or upon the expiration of the agreed upon terms. As a result, we can expect to
relinquish some or all of the control over the future success of a product candidate that we license to a third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face
significant competition in seeking and obtaining appropriate collaborators. Collaborations involving our product candidates may pose a number of risks, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not perform their obligations as expected; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the
collaborators&#146; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new
formulation of a product candidate for clinical testing; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the
commercialization of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or
commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not properly maintain, defend or enforce our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our
intellectual property or proprietary information or expose us to potential litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may infringe, misappropriate or otherwise violate the intellectual property rights of third parties, which may expose us to litigation and potential liability; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a
collaborator of ours is involved in a business combination, it could decide to delay, diminish or terminate the development or commercialization of any product candidate licensed to it by us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to conduct our preclinical studies and our clinical trials. If these third parties do not successfully carry out their
contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or commercialize any of our product candidates. If they do not perform satisfactorily, our business may be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not independently conduct nonclinical studies that comply with good laboratory practice (GLP) requirements. We also do not have the
ability to independently conduct clinical trials of any of our product candidates. We rely on third parties, such as contract research organizations (CROs), clinical data management organizations, medical institutions, and clinical investigators, to
conduct our clinical trials of oral sulopenem and sulopenem and expect to rely on these third parties to conduct clinical trials of any potential product candidates. Any of these third parties may terminate their engagements with us at any time. If
we need to enter into alternative arrangements, it would delay our product development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our reliance on these third parties
for clinical development activities limits our control over these activities but we remain responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards. For
example, notwithstanding the obligations of a contract research organization for a clinical trial of one of our product candidates, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general
investigational plan and protocols for the clinical trial. While we will have agreements governing their activities, we control only certain aspects of their activities and have limited influence over their actual performance. The third parties with
whom we contract for execution of our GLP studies and our clinical trials play a significant role in the conduct of these studies and clinical trials and the subsequent collection and analysis of data. Although we rely on these third parties to
conduct <FONT STYLE="white-space:nowrap">our&nbsp;GLP-compliant&nbsp;nonclinical</FONT> studies and clinical trials, we remain responsible for ensuring that each of our nonclinical studies and clinical trials are conducted in accordance with
applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities. The FDA and regulatory authorities in other jurisdictions also require us to comply with standards, commonly referred to as good
clinical practices (GCPs), for conducting, monitoring, recording and reporting the results of clinical trials to assure that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
data and reported results are accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. The FDA enforces these GCPs through periodic
inspections of trial sponsors, principal investigators, clinical trial sites and institutional review boards. If we or our third-party contractors fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed
unreliable and the FDA may require us to perform additional clinical trials before approving our product candidates, which would delay the regulatory approval process. We cannot assure you that, upon inspection, the FDA will determine that any of
our clinical trials comply with GCPs. We are also required to register clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result
in fines, adverse publicity and civil and criminal sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the third parties conducting clinical trials on our behalf are
not our employees, and except for remedies available to us under our agreements with such contractors, we cannot control whether or not they devote sufficient time and resources to our ongoing development programs. These contractors may also have
relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could impede their ability to devote appropriate time to our clinical programs.
If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we may not be able to obtain, or may be delayed
in obtaining, marketing approvals for our product candidates. If that occurs, we may not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. In such an event, our financial results and the commercial
prospects for oral sulopenem, sulopenem or other product candidates could be harmed, our costs could increase and our ability to generate revenue could be delayed, impaired or foreclosed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our
distributors could delay clinical development or marketing approval of our product candidates or commercialization of any resulting products, producing additional losses and depriving us of potential product revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We contract with third parties for the manufacture of preclinical and clinical supplies of oral sulopenem and sulopenem and expect to continue to do so
in connection with any future commercialization and for any future clinical trials and commercialization of our other product candidates and potential product candidates. This reliance on third parties increases the risk that we will not have
sufficient quantities of our product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have the internal infrastructure or capability to manufacture oral sulopenem and sulopenem for use in the conduct of our preclinical
research or clinical trials, however we do have plans to lease our own tableting facility able to release commercial supplies after FDA approval. We rely on third-party contract manufacturers to manufacture supplies of oral sulopenem and sulopenem,
and we expect to rely on third-party contract manufacturers to manufacture commercial quantities of any product candidate that we commercialize following approval for marketing by applicable regulatory authorities, if any. Reliance on third-party
manufacturers entails risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacturing delays if our third-party manufacturers give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreement
between us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possible breach of the manufacturing agreement by the third party; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the failure of the third-party manufacturer to comply with applicable regulatory requirements; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possible misappropriation of our proprietary information, including our trade secrets and <FONT STYLE="white-space:nowrap">know-how.</FONT> </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently rely on a small number of third-party contract manufacturers for all of our required raw materials, drug substance and finished
product for our preclinical research and clinical trials. We do not have long-term agreements with any of these third parties. We also do not have any current contractual relationships for the manufacture of commercial supplies of any of our product
candidates. If any of our existing manufacturers should become unavailable to us for any reason, we may incur delays in identifying or qualifying replacements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to lease our own tableting facility in Ireland. In addition, we will enter into agreements with third-party contract manufacturers
for the commercial production of those products. This process is difficult and time consuming and we may face competition for access to manufacturing facilities as there are a limited number of contract manufacturers operating under cGMPs that are
capable of manufacturing our product candidates. Consequently, we may not be able to reach agreement with third-party manufacturers on satisfactory terms, which could delay our commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party manufacturers are required to comply with cGMPs and similar regulatory requirements outside the United States. Facilities used by
our third-party manufacturers must be approved by the FDA after we submit an NDA and before potential approval of the product candidate. Similar regulations apply to manufacturers of our product candidates for use or sale in foreign countries. We
have no direct control over the ability of our third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel, and are completely dependent on our third-party manufacturers for compliance with the
applicable regulatory requirements for the manufacture of our product candidates. If our manufacturers cannot successfully manufacture material that conforms to the strict regulatory requirements of the FDA and any applicable foreign regulatory
authority, they will not be able to secure the applicable approval for their manufacturing facilities. If these facilities are not approved for commercial manufacture, we may need to find alternative manufacturing facilities, which could result in
delays in obtaining approval for the applicable product candidate. In addition, our manufacturers are subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies for compliance with cGMPs and similar
regulatory requirements. Failure by any of our manufacturers to comply with applicable cGMPs or other regulatory requirements could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspensions or
withdrawals of approvals, operating restrictions, interruptions in supply and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates and have a material adverse effect on our business,
financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our <FONT STYLE="white-space:nowrap">third-party</FONT> suppliers also continue to
refine and improve the manufacturing process, certain aspects of which are complex and unique, and we may encounter difficulties with new or existing processes, particularly as we seek to significantly increase our capacity to commercialize oral
sulopenem and sulopenem. Our reliance on contract manufacturers also exposes us to the possibility that they, or third parties with access to their facilities, will have access to and may appropriate our trade secrets or other proprietary
information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As drug candidates are developed through <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies to <FONT
STYLE="white-space:nowrap">late-stage</FONT> clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, methods of making drug formulations, and drug
formulations, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our drug candidates to perform differently and
affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. Such changes may also require additional testing, FDA notification or FDA approval. This could delay completion of clinical trials,
require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our drug candidates and jeopardize our ability to commence sales and generate revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current and anticipated future dependence upon others for the manufacture of oral
sulopenem and sulopenem and our other product candidates and potential product candidates may adversely affect our future profit margins and our ability to commercialize any products for which we receive marketing approval on a timely and
competitive basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely heavily on the Pfizer License for the patent rights and <FONT STYLE="white-space:nowrap">know-how</FONT> required to develop and commercialize
oral sulopenem and the <FONT STYLE="white-space:nowrap">know-how</FONT> required to develop the IV formulation of sulopenem. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
currently do not own any patents or patent applications and rely heavily on the Pfizer License for intellectual property rights that are important or necessary for the development of oral sulopenem and sulopenem. We do not own or license any patent
rights that cover the IV formulation of sulopenem. In addition, all patents directed to the compound sulopenem expired prior to us entering into the Pfizer License. Licenses to additional third-party intellectual property, technology and materials
that may be required for the development and commercialization of our sulopenem program or any other product candidates or technology may not be available at all or on commercially reasonable terms. In that event, we may be required to expend
significant time and resources to redesign our sulopenem program and any other product candidates or technology we may obtain in the future or to develop or license replacement technology, all of which may not be feasible on a technical or
commercial basis. If we are unable to do so, we may be unable to develop or commercialize oral sulopenem or sulopenem or other future product candidates or technologies, which could materially harm our business, financial condition, results of
operations and growth prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Pfizer License, and we expect under certain of our future license agreements, we are
responsible for prosecution and maintenance of the licensed patents and for bringing any actions against any third party for infringing on such patents. In addition, the Pfizer License requires, and we expect certain of our future license agreements
would also require, us to meet certain development thresholds to maintain the license, including establishing a set timeline for developing and commercializing products. In addition, such license agreements are complex, and certain provisions in
such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology,
or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. Disputes may
arise regarding intellectual property subject to the Pfizer License or any of our future license agreements, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope of rights granted under the license agreement and other interpretation-related issues; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which our technology and processes infringe, misappropriate or otherwise violate any intellectual property of the licensor that is not subject to the licensing agreement; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the sublicensing of patent and other rights under the license agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the priority of invention of patented technology. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In spite of our best efforts, Pfizer and
any potential future licensors might conclude that we have materially breached our license agreements and might therefore terminate the relevant license agreements, thereby removing our ability develop and commercialize products and technology
covered by such license agreements. If any of our inbound license agreements are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market,
products identical to ours. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations and growth prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain and maintain patent protection or other intellectual property rights for
oral sulopenem or our other technology and product candidates, or if the scope of the patent protection or intellectual property rights we obtain is not sufficiently broad, we may not be able to successfully develop or commercialize oral sulopenem
or any other product candidates or technology or otherwise compete effectively in our markets. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely upon a combination of
patents, trademarks, trade secret protection, confidentiality agreements and other proprietary rights to protect the intellectual property related to our development programs and product candidates. Our success depends, in part, on obtaining and
maintaining patent protection and successfully enforcing these patents and defending them against third-party challenges in the United States and other countries. If we or our licensors are unable to obtain or maintain patent protection with respect
to oral sulopenem or any other product candidates or technology we develop, our business, financial condition, results of operations and prospects could be materially harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have sought to protect our proprietary position by <FONT STYLE="white-space:nowrap">in-licensing</FONT> patents in the United States and
abroad related to oral sulopenem and sulopenem. The patent prosecution process is expensive and time-consuming, and we and our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in
a timely manner or in all jurisdictions. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, although we control prosecution of the
patents we have licensed from Pfizer related to our sulopenem program, we may not always have the right to control the preparation, filing and prosecution of patent applications, or to maintain, enforce or defend the patents, covering technology
that we may license from third parties. Therefore, these patents and patent applications may not be prosecuted, maintained, enforced or defended in a manner consistent with the best interests of our business. The patent applications that we may own
in the future or <FONT STYLE="white-space:nowrap">in-license</FONT> may fail to result in issued patents with claims that cover our current and future product candidates in the United States or in foreign countries. Patent applications cannot be
enforced against third parties practicing the technology claimed in such applications unless, and until, a patent issues from such applications, and then only to the extent the issued claims cover the technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any patent applications we may <FONT STYLE="white-space:nowrap">in-license</FONT> in the future with respect to our development programs or
product candidates fail to issue, if their breadth or strength of protection is threatened or if they fail to provide meaningful exclusivity for our current and future product candidates, it could dissuade companies from collaborating with us to
develop product candidates and threaten our ability to commercialize products. Any such outcome could materially harm our competitive position, business, financial conditions, results of operations and growth prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent
years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, EU patent law restricts the patentability of methods of treatment of
the human body more than U.S. law does. In addition, publications of discoveries in scientific literature often lag behind the actual discoveries, patent applications in the United States and other jurisdictions remain confidential for a period
after filing, and some remain so until issued. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in the patents or pending patent applications we currently license or may own or license in the future,
or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. There is no assurance that all potentially
relevant prior art relating to our patent rights has been found, and such prior art could potentially invalidate one or more of the patents we currently license or may own or license in the future or prevent a patent from issuing from a one or more
of the pending patent applications we currently license or may own or license in the future. There is also no assurance that prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim in our patent
rights, may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. Even if patents do successfully issue and even if such patents cover our current and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
future product candidates, third parties may challenge their ownership, validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable,
which could allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Any
successful opposition to these patents or any other patents owned by us in the future or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Furthermore, even if
they are unchallenged, our patents rights may not adequately protect our product candidates and technology, provide exclusivity for our product candidates, prevent others from designing around our claims or provide us with a competitive advantage.
Any of these outcomes could impair our ability to prevent competition from third parties. Changes in either the patent laws or interpretation of the patent laws in the United States or other countries may diminish the value of our patent rights or
narrow the scope of our patent protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot offer any assurances about whether any issued patents will be found invalid and
unenforceable or will be challenged by third parties. Any successful challenge or opposition to patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may
develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, our patent rights may be subject to a reservation of rights by one or more third parties. For example, certain research we
conducted was funded in part by the U.S. government. As a result, the U.S. government may have certain <FONT STYLE="white-space:nowrap">march-in</FONT> rights to patents and technology arising out of such research, if any. When new technologies are
developed with government funding, the government generally obtains certain rights in any resulting patents, including a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license authorizing the government to use the invention for <FONT
STYLE="white-space:nowrap">non-commercial</FONT> purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise <FONT STYLE="white-space:nowrap">march-in</FONT> rights to use or allow third
parties to use our licensed technology. The government can exercise its <FONT STYLE="white-space:nowrap">march-in</FONT> rights if it determines that action is necessary because we fail to achieve practical application of the government-funded
technology, to alleviate health or safety needs, to meet requirements of federal regulations or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying
such inventions in the United States. Any exercise by the government of such rights could harm our competitive position, business, financial condition, results of operations and growth prospects. For example, under the
<FONT STYLE="white-space:nowrap">CARB-X</FONT> grant funding program, the U.S. Department of Health and Human Services (HHS) awarded us a grant in connection with research to reduce the threat to human health from antimicrobial resistance and we
granted the U.S. government a nonexclusive, nontransferable, irrevocable, <FONT STYLE="white-space:nowrap">paid-up</FONT> license to practice or have practiced for or on behalf of the U.S. government any inventions arising out of our research
globally for <FONT STYLE="white-space:nowrap">non-commercial</FONT> purposes. In addition, under such agreement, if we or our licensees do not use commercially reasonable efforts to exploit or further the development of any intellectual property
rights we have generated out of such research within five years of the end date of our research project, Wellcome Trust Limited has the option to take responsibility for the commercialization and exploitation of such intellectual property rights,
including by way of sale, assignment and license of such intellectual property rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not identify relevant third party patents or may
incorrectly interpret the relevance, scope or expiration of a third party patent which might adversely affect our ability to develop and market our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot guarantee that any of our or our licensors&#146; patent searches or analyses, including but not limited to the identification of
relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third party patent and pending application in the United States and abroad
that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. For example, U.S. applications filed before November&nbsp;29, 2000 and certain U.S. applications filed after that date that will not be filed
outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date
being commonly referred to as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the priority date. Therefore, patent applications covering our product candidates could have been filed by others without our knowledge. Additionally, pending patent applications that have been
published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our product candidates. The scope of a patent claim is determined by an interpretation of the law, the written
disclosure in a patent and the patent&#146;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates. We
may incorrectly determine that our product candidates are not covered by a third party patent or may incorrectly predict whether a third party&#146;s pending application will issue with claims of relevant scope. Our determination of the expiration
date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents may
negatively impact our ability to develop and market our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The patent protection for our product candidates may expire before we
are able to maximize their commercial value which may subject us to increased competition and reduce or eliminate our opportunity to generate product revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally
20 years from its earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. The patents for our product candidates
have varying expiration dates and, if these patents expire, we may be subject to increased competition and we may not be able to recover our development costs. For example, our licensed U.S. patent claim for a composition of matter patent for oral
sulopenem is due to expire in 2029, subject to potential extension to 2034 under the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Given the amount of time required for the development, testing and regulatory
review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our patent rights may not provide us with sufficient rights to exclude others
from commercializing product candidates similar or identical to ours. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA designated sulopenem and oral sulopenem as QIDPs for
the indications of uUTI, cUTI and cIAI, however that does not guarantee that we will receive any regulatory exclusivity extensions or that any such extensions will be for a period sufficient to provide us with any commercial advantage. Moreover, we
do not own or license any patent directed to the compound sulopenem. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and conditions of FDA
marketing approval of our product candidates, one or more of the U.S. patents we currently license may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of&nbsp;1984, referred to as the
Hatch-Waxman Amendments, and similar legislation in the European Union. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during
product development and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims
covering the approved drug, a method for using it or a method for manufacturing it may be extended. We may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of the relevant patents or
otherwise fail to satisfy applicable requirements and the length of the extension could be less than we request. To the extent we wish to pursue patent term extension based on a patent that we <FONT STYLE="white-space:nowrap">in-license</FONT> from
Pfizer or another third party, we would need the cooperation of Pfizer or the third party. Moreover, similar extensions may be available in some of the larger economic territories, such as Europe, but may not be available in all of our markets of
interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to obtain patent term extension/restoration or some other exclusivity, or the term of any such extension is
less than we request, the period during which we can enforce our exclusive rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
result, we could be subject to increased competition and our opportunity to establish or maintain product revenue could be substantially reduced or eliminated. Furthermore, we may not have
sufficient time to recover our development costs prior to the expiration of our U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent rights. Further, if this occurs, our competitors may take advantage of our investment in development and
trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case. Any of the foregoing would materially harm our business, financial conditions, results of operations and growth prospects.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential threats to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once granted, patents may remain open to opposition, interference, <FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review,
<I>inter partes</I> review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such grant. In the
course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether. In addition,
the degree of future protection afforded by our intellectual property rights is uncertain because even granted intellectual property rights have limitations, and may not adequately protect our business. The following examples are illustrative: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">others may be able to make compounds, or formulations that are similar to oral sulopenem and sulopenem compounds or formulations but that are not covered by the claims of our patent rights; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the patents of third parties may have an adverse effect on our business; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we or our licensors or any future strategic partners might not have been the first to conceive or reduce to practice the inventions covered by the issued patent or pending patent application that we own or have
exclusively licensed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we or our licensors or any future strategic partners might not have been the first to file patent applications covering certain of our inventions; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">it is possible any future pending patent applications will not lead to issued patents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issued patents that we may own in the future or have exclusively licensed may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our
major commercial markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">third parties performing manufacturing or testing for us using our product candidates or technologies could use the intellectual property of others without obtaining a proper license </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not develop additional proprietary technologies that are patentable; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the patents of others may have an adverse effect on our business. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these events
occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in patent laws
or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining
and enforcing patents in the pharmaceutical industry involve both </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
technological complexity and legal complexity. Therefore, obtaining and enforcing pharmaceutical patents is costly, time-consuming and inherently uncertain. In addition, the America Invents Act,
or the AIA, was signed into law on September&nbsp;16, 2011, and many of its substantive changes became effective on March&nbsp;16, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An important change introduced by the AIA is that, as of March&nbsp;16, 2013, the United States transitioned to a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same
invention. A third party that files a patent application in the U.S. Patent and Trademark Office, or USPTO, after that date but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it
was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and
providing opportunities for third parties to challenge any issued patent in the USPTO, including through post-issuance patent review procedures such as <I>inter partes</I> review, post-grant review and covered business methods. This applies to all
U.S. patents, including those issued before March&nbsp;16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party
could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third
party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. The AIA and its implementation could increase the
uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
USPTO has developed in the last few years regulations and procedures to govern administration of the AIA, and many of the substantive changes to patent law associated with the AIA, and, in particular, the first to file provisions, only became
effective on March&nbsp;16, 2013. Accordingly, it is not clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of
our or our licensors&#146; or collaboration partners&#146; patent applications and the enforcement or defense of our or our licensors&#146; or collaboration partners&#146; issued patents, all of which could have an adverse effect on our business and
financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the standards that the USPTO and foreign patent offices use to grant patents are not always applied
predictably or uniformly and can change. Consequently, any patents we currently license or may own or license in the future may have a shorter patent term than expected or may not contain claims that will permit us to stop competitors from using our
technology or similar technology or from copying our products. Similarly, the standards that courts use to interpret patents are not always applied predictably or uniformly and may evolve, particularly as new technologies develop. In addition,
changes to patent laws in the United States or other countries may be applied retroactively to affect the ownership, validity, enforceability or term of patents we currently license or may own or license in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, the U.S. Supreme Court&#146;s rulings on several patent cases in recent years, such as <I>Association for Molecular Pathology v.
Myriad Genetics, Inc. </I>(Myriad I), <I>Mayo Collaborative Services v. Prometheus Laboratories, Inc.</I>, and <I>Alice Corporation Pty. Ltd. v. CLS Bank International</I>, either narrow the scope of patent protection available in certain
circumstances or weaken the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value
of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce
our existing patents and patents that we might obtain in the future. Similarly, the complexity and uncertainty of European patent laws has also increased in recent years. In addition, the EP patent system is relatively stringent in the type of
amendments </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that are allowed during prosecution. These changes could limit our ability to obtain new patents in the future that may be important for our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and
unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe, misappropriate or otherwise violate our patents, trademarks, copyrights or other
intellectual property, or those of our licensors. To counter infringement, misappropriation, unauthorized use or other violations, we may be required to file legal claims, which can be expensive and time consuming and divert the time and attention
of our management and scientific personnel. We may not be able to prevent, alone or with our licensors, infringement, misappropriation or other violations of our intellectual property rights, particularly in countries where the laws may not protect
those rights as fully as in the United States. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents. In addition, in a patent infringement
proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even
if the validity of such patents is upheld, the court will construe the patent&#146;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patents do not cover the
invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making
and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine
that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such
trademarks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any infringement, misappropriation or other intellectual property litigation, any award of monetary damages we receive may
not be commercially valuable. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure
during litigation. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in
such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property
rights, the outcome of which would be uncertain and could have a negative impact on the success of our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial
success depends, in part, upon our ability, and the ability of our future collaborators, to develop, manufacture, market and sell oral sulopenem, sulopenem and any future product candidates, if approved, and use our proprietary technologies without
alleged or actual infringement, misappropriation or other violation of the patents and other intellectual property rights of third parties. There have been many lawsuits and other proceedings involving patent and other intellectual property rights
in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and reexamination proceedings before the USPTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents
and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex
intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us. As the
biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the intellectual property rights of third parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may in the future become party to, or be threatened with, adversarial proceedings or
litigation regarding intellectual property rights with respect to oral sulopenem and sulopenem and any future product candidates and technology, including interference or derivation proceedings, post grant review and <I>inter partes</I> review
before the USPTO or similar adversarial proceedings or litigation in other jurisdictions. Similarly, we or our licensors or collaborators may initiate such proceedings or litigation against third parties, e.g., to challenge the validity or scope of
intellectual property rights controlled by third parties. In order to successfully challenge the validity of any U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present
clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court would invalidate the claims of any such U.S. patent. Moreover, third parties may assert infringement claims against us based on
existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we
believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our ability to commercialize such
product candidate unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Similarly, if any third-party patents were held by a court of competent jurisdiction
to cover aspects of our compositions, formulations, or methods of treatment, prevention or use, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a
license or until such patent expires or is finally determined to be invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms, or at all. Even if we were able to obtain a license, it could be <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research
or allow, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In such an event, we would be unable to further practice our technologies or develop and
commercialize any of our product candidates at issue, which could harm our business significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against us may
obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates, if approved. Defense of these claims, regardless of their merit, would involve
substantial litigation expense and would be a substantial diversion of management and employee time and resources from our business. Third parties making such claims may have the ability to dedicate substantially greater resources to these legal
actions than we or our licensors or collaborators can. In the event of a successful claim of infringement, misappropriation or other violation against us, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for
willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical and
biotechnology industries. In addition to infringement claims against us, we may become a party to other patent litigation and other adversarial proceedings such as proceedings before the PTAB and opposition proceedings in the European Patent Office,
regarding intellectual property rights with respect to our products and technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patent litigation and other proceedings may also
absorb significant management time. The cost to us of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. During the course of any patent or other intellectual property litigation or other proceeding,
there could be public announcements of the results of hearings, rulings on motions, and other interim proceedings or developments and if securities analysts or investors regard these announcements as negative, the perceived value of our product
candidates or intellectual property could be diminished. Accordingly, the market price of our ordinary shares may decline. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material
adverse effect on our business, ability to compete in the marketplace, financial condition, results of operations and growth prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property rights globally, which could negatively impact
our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents covering oral sulopenem, sulopenem and any future product candidates
globally would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect
intellectual property rights to the same extent as federal and state laws in the United States. Further, licensing partners may not prosecute patents in certain jurisdictions in which we may obtain commercial rights, thereby precluding the
possibility of later obtaining patent protection in these countries. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made
using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to
territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or
sufficient to prevent them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual
property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those
relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign
jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and any future patent
applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly,
our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Furthermore, while we intend to protect our
intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to
protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the requirements for patentability may differ in certain countries, particularly developing countries. For example, unlike other
countries, China has a heightened requirement for patentability, and specifically requires a detailed description of medical uses of a claimed drug. In India, unlike the United States, there is no link between regulatory approval of a drug and its
patent status. Furthermore, generic or biosimilar drug manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors&#146; patents, requiring us or our licensors to engage in complex, lengthy and
costly litigation or other proceedings. Generic or biosimilar drug manufacturers may develop, seek approval for, and launch biosimilar versions of our products. In addition, certain countries in Europe and developing countries, including China and
India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled
to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our and our licensors&#146; efforts to enforce intellectual property rights around
the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that we or our employees, consultants, contractors or advisors have
infringed, misappropriated or otherwise violated the intellectual property of a third party, or claiming ownership of what we regard as our own intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or
potential competitors. Although we try to ensure that our employees do not use the intellectual property and other proprietary information, <FONT STYLE="white-space:nowrap">know-how</FONT> or trade secrets of others in their work for us, we may be
subject to claims that we or these employees have used or disclosed such intellectual property or other proprietary information. Litigation may be necessary to defend against these claims. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while we typically require our employees, consultants and contractors who may be involved in the development of intellectual
property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. To the extent that we fail to
obtain such assignments, such assignments do not contain a self-executing assignment of intellectual property rights or such assignments are breached, we may be forced to bring claims against third parties, or defend claims they may bring against
us, to determine the ownership of what we regard as our intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Such
intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms or
at all. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and scientific personnel. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims challenging the inventorship of our patents and other intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may in the future be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other
intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> While it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute
agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. For example, the assignment of
intellectual property rights may not be self-executing or the assignment agreements may be breached, or we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product
candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property
rights, such as exclusive ownership of, or right to use, valuable intellectual property. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other
requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over
the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent
lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in
partial or complete loss of patent rights in the relevant jurisdiction. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> events that could result in abandonment or lapse of a patent or patent application include failure to respond to official
actions within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents. If we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or our licensors fail to maintain the patents covering our products, our competitors might be able to enter the market, which would have a material adverse effect on our business, financial
conditions, results of operations and growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our trade secrets, the value of our
technology could be materially adversely affected and our business would be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to seeking patents for some of our
technology and products, we also rely on trade secrets, including <FONT STYLE="white-space:nowrap">unpatented&nbsp;know-how,&nbsp;technology</FONT> and other proprietary information, in seeking to develop and maintain a competitive position. We seek
to protect these trade secrets, in part, by entering <FONT STYLE="white-space:nowrap">into&nbsp;non-disclosure&nbsp;and</FONT> confidentiality agreements with parties who have access to them, such as our employees, consultants, independent
contractors, advisors, corporate collaborators, outside scientific collaborators, contract manufacturers, suppliers and other third parties. We, as well as our licensors, also enter into confidentiality and invention or patent assignment agreements
with employees and certain consultants. We also seek to preserve the integrity and confidentiality of our data, trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> by maintaining physical security of our premises and physical and
electronic security of our information technology systems. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. We cannot guarantee
that our trade secrets and other proprietary and confidential information will not be disclosed or that competitors will not otherwise gain access to our trade secrets. Any party with whom we have executed such an agreement may breach that agreement
and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive
and time-consuming, and the outcome is unpredictable. In addition, some courts both within and outside the United States may be less willing or unwilling to protect trade secrets. Further, if any of our trade secrets were to be lawfully obtained or
independently developed by a competitor, we would have no right to prevent such third party, or those to whom they communicate such technology or information, from using that technology or information to compete with us. If any of our trade secrets
were to be disclosed to or independently developed by a competitor, our business and competitive position could be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Trade secrets
and <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect as trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> will over time be disseminated within the industry through independent development, the
publication of journal articles, and the movement of personnel skilled in the art from company to company or academic to industry scientific positions. If we fail to prevent material disclosure of the
<FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets and other intellectual property related to our technologies to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially
adversely affect our business, results of operations and financial condition. Even if we are able to adequately protect our trade secrets and proprietary information, our trade secrets could otherwise become known or could be independently
discovered by our competitors. For example, competitors could purchase our products and attempt to replicate some or all of the competitive advantages we derive from our development efforts, design around our protected technology or develop their
own competitive technologies that fall outside of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, in the absence of patent protection, we would have no right to
prevent them, or those to whom they communicate, from using that technology or information to compete with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to
prevent misappropriation of our intellectual property, trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States. Furthermore, because of the substantial amount
of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have not yet registered our trademarks in certain jurisdictions. Failure to secure those
registrations could adversely affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have pending applications for the trademark &#147;Iterum&#148; in Japan and
Canada, and we have registered trademarks for &#147;Iterum&#148; in the United States and European Union. If we are unable to secure registrations for our trademarks in other countries, we may encounter more difficulty in enforcing them against
third parties than we otherwise would, which could adversely affect our business. We have also not yet registered trademarks for any of our product candidates in any jurisdiction. Any trademark applications we may file for our product candidates are
not guaranteed to be allowed for registration, and even if they are, we may fail to maintain or enforce such registered trademarks. During trademark registration proceedings in the United States and foreign jurisdictions, we may receive rejections.
We are given an opportunity to respond to those rejections, but we may not be able to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose
pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, any proprietary name we propose to use with oral sulopenem, sulopenem or any other product candidate in the United States must be
approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names.
If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable trademark laws, not
infringe, misappropriate or otherwise violate the existing rights of third parties and be acceptable to the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the long term, if
we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to
trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our business, financial conditions, results of
operations and growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Regulatory Approval and Other Legal Compliance Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize oral sulopenem,
sulopenem or other future product candidates, and our ability to generate revenue will be materially impaired. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product
candidates, oral sulopenem and sulopenem, and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion,
sale and distribution, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable foreign regulatory authorities, with regulations differing from country to country. Failure to obtain
marketing approval for a product candidate will prevent us from commercializing the product candidate. We currently do not have any products approved for sale in any jurisdiction. We have only limited experience in filing and supporting the
applications necessary to gain marketing approvals and expect to rely on third-party contract research organizations to assist us in this process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we have QIDP status for sulopenem and oral sulopenem for the indications of uUTI, cUTI and cIAI which may provide for a more rapid
new drug application review cycle, the time required to obtain approval, if any, by the FDA and comparable foreign authorities is unpredictable and typically takes many years following the commencement of clinical trials and depends upon numerous
factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#146;s
clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that none of our existing product candidates or any product candidates we may seek
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to develop in the future will ever obtain regulatory approval. Neither we nor any future collaborator is permitted to market any of our product candidates in the United States until we or they
receive regulatory approval of an NDA from the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to obtain approval to commercialize a product candidate in the United States
or abroad, we or our collaborators must demonstrate to the satisfaction of the FDA or foreign regulatory agencies, that such product candidates are safe and effective for their intended uses. Results from nonclinical studies and clinical trials can
be interpreted in different ways. Even if we believe that the nonclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. Although we expect
to conduct our Phase 3 clinical trials pursuant to SPA agreements, the FDA may still require us to conduct additional nonclinical studies or clinical trials for our product candidates either prior to or post-approval, and it may otherwise object to
elements of our clinical development program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not submitted an NDA for any of our product candidates. An NDA must include
extensive preclinical and clinical data and supporting information to establish the product candidate&#146;s safety and efficacy for each desired indication. The NDA must also include significant information regarding the chemistry, manufacturing
and controls for the product candidate. Obtaining approval of an NDA is a lengthy, expensive and uncertain process. The FDA has substantial discretion in the review and approval process and may refuse to accept for filing any application or may
decide that our data are insufficient for approval and require additional nonclinical, clinical or other studies. Foreign regulatory authorities have differing requirements for approval of drugs with which we must comply prior to marketing.
Obtaining marketing approval for marketing of a product candidate in one country does not ensure that we will be able to obtain marketing approval in other countries, but the failure to obtain marketing approval in one jurisdiction could negatively
affect our ability to obtain marketing approval in other jurisdictions. The FDA or any foreign regulatory bodies can delay, limit or deny approval of our product candidates or require us to conduct additional nonclinical or clinical testing or
abandon a program for many reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">although we expect to conduct our Phase 3 clinical trials pursuant to SPA agreements, the FDA or the applicable foreign regulatory agency&#146;s disagreement with the design or implementation of our clinical trials;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">negative or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the FDA or comparable foreign regulatory agencies for approval; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to demonstrate to the satisfaction of the FDA or the applicable foreign regulatory body that our product candidates are safe and effective for the proposed indication; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s or the applicable foreign regulatory agency&#146;s disagreement with the interpretation of data from nonclinical studies or clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to demonstrate the clinical and other benefits of our product candidates outweigh any safety or other perceived risks; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s or the applicable foreign regulatory agency&#146;s requirement for additional nonclinical studies or clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s or the applicable foreign regulatory agency&#146;s disagreement regarding the formulation, labeling and/or the specifications for our product candidates; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential for approval policies or regulations of the FDA or the applicable foreign regulatory agencies to significantly change in a manner rendering our clinical data insufficient for approval. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of the large number of drugs in development, only a small percentage complete the FDA or foreign regulatory approval processes and are
successfully commercialized. The lengthy review process as well as the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unpredictability of future clinical trial results may result in our failing to obtain regulatory approval, which would significantly harm our business, financial condition, results of operations
and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we eventually receive approval of an NDA or foreign marketing application for our product candidates, the FDA or
the applicable foreign regulatory agency may grant approval contingent on the performance of costly additional clinical trials, often referred to as Phase 4 clinical trials, and the FDA may require the implementation of a Risk Evaluation and
Mitigation Strategy, or REMS, which may be required to ensure safe use of the drug after approval. The FDA or the applicable foreign regulatory agency also may approve a product candidate for a more limited indication or patient population than we
originally requested, and the FDA or applicable foreign regulatory agency may not approve the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to
obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future legislation, and/or regulations and policies adopted by the FDA, the EMA or similar regulatory authorities may increase the time and cost
required for us to conduct and complete clinical trials of oral sulopenem, sulopenem and other potential product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
FDA has established regulations to govern the drug development and approval process, as have foreign regulatory authorities. The policies of the FDA and other regulatory authorities may change and additional laws may be enacted or government
regulations may be promulgated that could prevent, limit, delay but also accelerate regulatory review of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable
to obtain marketing approval in international jurisdictions, we will not be able to market our product candidates abroad. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order
to market and sell oral sulopenem, sulopenem or our other future product candidates in the European Union and many other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements.
Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or
jurisdictions or by the FDA. The approval procedure varies among countries and can involve additional testing. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. The time required
to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many
countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We may not obtain approvals from regulatory authorities outside the United States on a
timely basis or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently evaluating our commercialization strategy outside the United States, but believe that Europe
represents a significant market opportunity because of rising rates of extended spectrum beta-lactamases (ESBL) resistance. On June&nbsp;23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union, commonly referred
to as&nbsp;Brexit. On March&nbsp;29, 2017, the country formally notified the European Union of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty. Since a significant proportion of the regulatory framework in the United Kingdom is
derived from European Union directives and regulations, the referendum could materially impact the regulatory regime with respect to the approval of our product candidates in the United Kingdom or the European Union. Any delay in obtaining, or an
inability to obtain, any regulatory approvals, as a result of&nbsp;Brexit&nbsp;or otherwise, would prevent us from commercializing our product candidates in the United Kingdom and/or the European Union and restrict our ability to generate revenue
and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom and/or European Union for our product candidates, which could significantly and
materially harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> regulatory authorities may require us to conduct
additional clinical trials or nonclinical studies to accommodate submission for the cUTI indication. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We obtained scientific advice
from the EMA for each of the Phase 3 clinical trials in the uUTI, cUTI and cIAI indications, as well as to gain alignment on nonclinical supportive information required for EMA submission. We are not in alignment with regard to the comparator agent
selected for the cUTI clinical trial and are considering other options to accommodate a European filing for this indication. The EMA may request that we conduct one or more additional clinical trials or nonclinical studies to support potential
approval for oral sulopenem and sulopenem for the cUTI indication. We cannot predict how the EMA will interpret the data and results from our Phase 3 clinical trial and other elements of our development program, or whether oral sulopenem or
sulopenem will receive any regulatory approvals in the EU. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we receive regulatory approval for any product candidate we will be subject to
ongoing obligations and continuing regulatory review, which may result in significant additional expense. Our product candidates, including oral sulopenem and sulopenem, if approved, could be subject to restrictions or withdrawal from the market,
and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if approved. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product candidate, including oral sulopenem and sulopenem, for which we obtain marketing approval will also be subject to ongoing
regulatory requirements for labeling, packaging, storage, distribution, advertising, promotion, record-keeping and submission of safety and other post-market information. For example, approved products, manufacturers and manufacturers&#146;
facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to current Good Manufacturing Practicing (cGMPs). As such, we and our contract manufacturers will be
subject to continual review and periodic inspections to assess compliance with cGMPs. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing,
production and quality control. We will also be required to report certain adverse reactions and production problems, if any, to the FDA and to comply with requirements concerning advertising and promotion for our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses
for which the product may be marketed, may be subject to significant conditions of approval or may impose requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. The FDA may also require a
REMS as a condition of approval of our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries
and other risk minimization tools. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure that drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling and
regulatory requirements. The FDA also imposes stringent restrictions on manufacturers&#146; communications <FONT STYLE="white-space:nowrap">regarding&nbsp;off-label&nbsp;use</FONT> and if we do not restrict the marketing of our products only to
their approved indications, we may be subject to enforcement action <FONT STYLE="white-space:nowrap">for&nbsp;off-label&nbsp;marketing.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or
problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, it may impose restrictions on that product or us. In addition, if any product fails to comply with applicable
regulatory requirements, a regulatory agency may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue fines, warning letters, untitled letters or impose holds on clinical trials if any are still <FONT STYLE="white-space:nowrap">on-going;</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">mandate modifications to promotional materials or require provision of corrective information to healthcare practitioners; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impose restrictions on the product or its manufacturers or manufacturing processes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impose restrictions on the labeling or marketing of the product; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impose restrictions on product distribution or use; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require post-marketing clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require withdrawal of the product from the market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refuse to approve pending applications or supplements to approved applications that we submit; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require recall of the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require entry into a consent decree, which can include imposition of various fines (including restitution or disgorgement of profits or revenue), reimbursements for inspection costs, required due dates for specific
actions and penalties for noncompliance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend or withdraw marketing approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refuse to permit the import or export of the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seize or detain supplies of the product; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue injunctions or impose civil or criminal penalties. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with federal and state
healthcare laws, including fraud and abuse and health information privacy and security laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a pharmaceutical company, even though we do not provide healthcare services or receive payments directly from or bill directly to Medicare,
Medicaid or other third-party payors for our products, certain federal and state healthcare laws and regulations pertaining to fraud and abuse, patients&#146; rights and other healthcare laws and regulations, are applicable to our business. We are
subject to healthcare laws and regulations by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal Anti-Kickback Statute which prohibits, among other things, any person or entity, from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or
rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for either the referral of an individual, or the purchase, lease, furnishing, prescribing, ordering or recommendation of an item, good, facility or
service reimbursable by a federally funded healthcare program, such as the Medicare or Medicaid program. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers and
formulary managers on the other hand. The term &#147;remuneration&#148; has been interpreted broadly and may constrain our marketing practices, educational programs, pricing policies and relationships with healthcare providers or other entities,
among other activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal civil and criminal false claims laws, including the federal False Claims Act, and false statement laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from
knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other government payors that are false or fraudulent or making any materially false statement in connection with the delivery or payment for
healthcare benefits, items or services. Pharmaceutical manufacturers can be held liable under the False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#147;cause&#148; the submission of false or
fraudulent claims; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Health Insurance Portability and Accountability Act of 1996, or HIPAA, which, among other things, imposes
criminal liability for executing or attempting to execute a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully
obstructing a criminal investigation of a healthcare offense, and creates federal criminal laws that prohibit knowingly and willfully falsifying, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
concealing or covering up a material fact or making any materially false, fictitious or fraudulent statements or representations, or making or using any false writing or document knowing the same
to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of, or payment for, benefits, items or services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, including the final omnibus rule published on
January&nbsp;25, 2013, mandates, among other things, the adoption of uniform standards for the electronic exchange of information in common healthcare transactions, as well as standards relating to the privacy, security, transmission and breach
reporting of individually identifiable health information, upon health plans, healthcare clearinghouses and healthcare providers and their respective business associates that perform services for them involve individually identifiable health
information, which require the adoption of administrative, physical and technical safeguards to protect such information. Among other things, HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal
penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs
associated with pursuing federal civil actions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal physician payment transparency requirements, sometimes referred to as the &#147;Physician Payments Sunshine Act,&#148; and its implementing regulations, which imposes annual disclosure requirements to the
United States Department of Health and Human Services, or HHS, on certain manufacturers of drugs, biologics, devices and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with
certain exceptions), of certain payments or other transfers of value made to physicians and teaching hospitals, as well as ownership or investment interests held by physicians and their immediate family members; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers,
which may impose similar or more prohibitive restrictions; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating
compliance efforts; state, local and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government,
obtain pharmaceutical agent licensure, and/or otherwise restrict payments that may be made to healthcare providers; and state, local and foreign laws that require drug manufacturers to report information related to payments and other transfers of
value to other healthcare providers or entities or marketing expenditures. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the
narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and
subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between
healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Additionally, the Patient Protection and Affordable Care Act (as amended by the Health
Care and Education Reconciliation Act), enacted in 2010, or ACA, among other things, amended the intent requirement of the federal Anti-Kickback Statute and criminal health care fraud statutes, so that a person or entity no longer needs to have
actual knowledge of the statute or specific intent to violate it. In addition, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitute a
false or fraudulent claim for purposes of the False Claims Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recently, several pharmaceutical and other healthcare companies have been prosecuted under
the federal false claims laws for allegedly inflating drug prices they report to pricing services, which in turn are used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with
the expectation that the customers would bill federal programs for the product. In addition, certain marketing practices, including <FONT STYLE="white-space:nowrap">off-label</FONT> promotion, may also violate false claims laws. To the extent that
any product we make is sold in a foreign country, we may be subject to similar foreign laws and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The risks of complying with
these laws cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#146;s attention from the operation
of our business. Moreover, achieving and sustaining compliance with applicable federal and state privacy, security, fraud and transparency laws is time consuming and costly. If our past or present operations, or those of our distributors are found
to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to sanctions, including civil, criminal and administrative penalties, fines, damages, disgorgement, exclusion from
participation in U.S. federal or state health care programs, individual imprisonment, additional reporting obligations and oversight if subject to a corporate integrity agreement or other agreement to resolve allegations of <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with these laws, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could materially adversely affect our ability to
operate our business and our financial results. Similarly, if healthcare providers, distributors or other entities with whom we do business are found to be out of compliance with applicable laws and regulations, they may be subject to sanctions,
which could also have a negative impact on us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to various laws protecting the confidentiality of certain patient health information,
and our failure to comply could result in penalties and reputational damage. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain countries in which we operate have, or are
developing, laws protecting the confidentiality of certain patient health information. EU member states and other jurisdictions have adopted data protection laws and regulations, which impose significant compliance obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, the EU Data Protection Directive, as implemented into national laws by the EU member states, imposes strict obligations and
restrictions on the ability to collect, analyze and transfer personal data, including health data from clinical trials and adverse event reporting. Data protection authorities from different EU member states may interpret the EU Data Protection
Directive and national laws differently, which adds to the complexity of processing personal data in the EU, and guidance on implementation and compliance practices are often updated or otherwise revised. The EU Data Protection Directive prohibits
the transfer of personal data to countries outside of the EU member states that are not considered by the European Commission to provide an adequate level of data protection, and transfers of personal data to such countries can only be made in
certain circumstances&#151;for example, where the transfer is required by law or the data subject (i.e. the individual to whom the personal data relates) has given his or her consent to the transfer. We have policies and practices that we believe
make us compliant with applicable privacy regulations. Nevertheless, any failure to comply with the rules arising from the EU Data Protection Directive and related national laws of EU member states, as well as privacy laws in other countries in
which we operate, could lead to government enforcement actions and significant sanctions or penalties against us, adversely impact our results of operations and subject us to negative publicity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The EU Data Protection Regulation, which will replace the current EU Data Protection Directive, was adopted in 2016 and will become
enforceable on May&nbsp;25, 2018. The EU Data Protection Regulation will introduce new data protection requirements in the EU and substantial fines for breaches of the data protection rules, may increase our responsibility and liability in relation
to personal data that we process and may require us to put in place additional mechanisms to ensure compliance with the new EU data protection rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare legislative reform measures may have a material adverse effect on our business and results
of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, there have been and continue to be a number of legislative and regulatory changes, and
proposed changes, that could affect the future results of our business and operations. In particular, there have been and continue to be a number of initiatives at the federal and states levels that seek to reduce healthcare costs. For example, in
March 2010 ACA was enacted, which has substantially changed the way health care is financed by both governmental and private insurers, and significantly impacted the U.S.&nbsp;pharmaceutical industry. Among the provisions of the ACA of greatest
importance to the pharmaceutical and biotechnology industry are the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some
government healthcare programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped
the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, that are inhaled, infused, instilled, implanted or injected;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extension of manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals
with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#146; Medicaid rebate liability; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated
prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of the entities eligible for discounts under the Public Health program; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishment of a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">implementation of the federal physician payment transparency requirements, sometimes referred to as the &#147;Physician Payments Sunshine Act.&#148; </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the provisions of the ACA have yet to be fully implemented, and there have been legal and political challenges to certain aspects of
the ACA. Since January 2017, President Trump has signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the ACA. Concurrently, Congress has considered legislation that would repeal
or repeal and replace all or part of the ACA. Additionally, President Trump signed The Tax Cuts and Jobs Act of 2017 on December&nbsp;22, 2017, which includes a provision repealing, effective January&nbsp;1, 2019, the
<FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year, that is commonly referred to as the &#147;individual
mandate.&#148; We continue to evaluate how the ACA and recent efforts to repeal and replace or limit the implementation of the ACA will impact our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted in the United States
since the ACA was enacted. On August&nbsp;2, 2011, the Budget Control Act of 2011 among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit
reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of Medicare
payments to providers of 2&nbsp;percent per fiscal year. These reductions went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, including the Bipartisan Budget Act of 2015, will remain in effect through
2025 unless additional Congressional action is taken. Moreover, in January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers, including
hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, there has been heightened governmental scrutiny in the United States of the manner in which manufacturers set prices for their
marketed products in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more
transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the federal level, Congress and the Trump Administration have
each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical
and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation
from other countries and bulk purchasing. These new laws and initiatives may result in additional reductions in Medicare and other healthcare funding, as well as limit the amounts that federal and state governments will pay for healthcare products
and services, which could result in reduced demand for our product candidates or additional pricing pressures, all of which could have a material adverse effect on our future customers and accordingly, our financial operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, principal investigators, contract research organizations, consultants or vendors may engage in misconduct or
other improper activities, including noncompliance with regulatory standards and requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk that our
employees, independent contractors, principal investigators, contract research organizations, consultants or vendors may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent
conduct or disclosure of unauthorized activities to us that violates: FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA; manufacturing standards; federal and state healthcare fraud
and abuse laws and regulations; or laws that require the true, complete and accurate reporting of financial information or data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and
regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive
programs and other business arrangements. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical
trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent this
activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations.
Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those
actions could have a significant impact on our business, including the imposition of civil, criminal and administrative </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual imprisonment, additional reporting
obligations and oversight if subject to a corporate integrity agreement or other agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, curtailment of our operations, contractual damages,
reputational harm, and diminished potential profits and future earnings, any of which could adversely affect our business, financial condition, results of operations or prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Employee Matters and Managing Growth </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to retain our Chief Executive Officer and other key executives and to attract, retain and motivate qualified
personnel. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our industry has experienced a high rate of turnover of management personnel in recent years. We are highly dependent
on the development, regulatory, commercialization and business development expertise of Corey N. Fishman, our Chief Executive Officer, and Michael Dunne, M.D., our Chief Scientific Officer, as well as the other principal members of our management,
scientific and clinical team. Although we have formal employment agreements with our executive officers, these agreements do not prevent them from terminating their employment with us at any time. We do not maintain &#147;key man&#148; insurance
with respect to any of our executive officers or key employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we lose one or more of our executive officers or key employees, our
ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in
our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize product candidates successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train,
retain or motivate these additional key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical
personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our
consultants and advisors may be engaged by entities other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high
quality personnel, our ability to develop and commercialize product candidates will be limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to grow our organization, and as a
result, we may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to experience
significant growth in the number of our employees and the scope of our operations, particularly in the areas of product clinical manufacturing development, regulatory affairs, sales, marketing and health resources. Our management may need to divert
a disproportionate amount of its attention away from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">our&nbsp;day-to-day&nbsp;activities</FONT></FONT> to devote time to managing these growth activities. To manage these growth
activities, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited
experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. Our inability to effectively manage
the expansion of our operations may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could
require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage our expected growth, our expenses may
increase more than expected, our potential ability to generate revenue could be reduced and we may not be able to implement our business strategy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If foreign approvals are obtained, we will be subject to additional risks in conducting business in
international markets. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we are able to obtain approval for commercialization of a product candidate in a foreign country,
we will be subject to additional risks related to international business operations, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potentially reduced protection for intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential for <FONT STYLE="white-space:nowrap">so-called</FONT> parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from a foreign market (with
low or lower prices) rather than buying them locally; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unexpected changes in tariffs, trade barriers and regulatory requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">economic weakness, including inflation, or political instability in particular foreign economies and markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">workforce uncertainty in countries where labor unrest is more common than in the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">production shortages resulting from any events affecting a product candidate and/or finished drug product supply or manufacturing capabilities abroad; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business interruptions resulting from <FONT STYLE="white-space:nowrap">geo-political</FONT> actions, including war and terrorism, or natural disasters, including earthquakes, hurricanes, typhoons, floods and fires; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to comply with Office of Foreign Asset Control rules and regulations and the Foreign Corrupt Practices Act. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other risks may materially adversely affect our ability to attain or sustain revenue from international markets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may engage in acquisitions that could disrupt our business, cause dilution to our shareholders or reduce our financial resources. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, we may enter into transactions to acquire other businesses, products or technologies. If we do identify suitable candidates, we
may not be able to make such acquisitions on favorable terms, or at all. Any acquisitions we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in
connection with an acquisition or issue our ordinary shares or other equity securities to the shareholders of the acquired company, which would reduce the percentage ownership of our existing shareholders. We could incur losses resulting from
undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our
existing business in an effective, timely and nondisruptive manner. Acquisitions may also divert management attention <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">from&nbsp;day-to-day</FONT></FONT> responsibilities, increase our
expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or the effect that any such transactions might have on our operating results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Taxation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have been a passive
foreign investment company for U.S. federal income tax purposes in the past and we could be a passive foreign investment company in the future, which could subject U.S. Holders to adverse U.S. federal income tax consequences. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were a passive foreign investment company, or a PFIC, for U.S. federal income tax purposes for our taxable year ended December&nbsp;31,
2017. We do not expect to be a PFIC for our current taxable year or in the future; however, our status as a PFIC is determined annually and subject to change. We will be a PFIC in any taxable year if at least (i)&nbsp;75% of our gross income is
&#147;passive income&#148; or (ii)&nbsp;50% of the average gross value of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our assets, determined on a quarterly basis is attributable to assets that produce, or are held for the production of, passive income. We refer to the passive income test as the &#147;PFIC Income
Test&#148; and the asset test as the &#147;PFIC Asset Test.&#148; The proceeds from this offering will be a passive asset under these rules and could cause us to meet the PFIC Asset Test for our taxable year that includes this offering. If we are a
PFIC in any taxable year in which you hold shares and you are a &#147;U.S. Holder&#148; (as described in the section of this prospectus titled &#147;Taxation&#151;Material U.S. Federal Income Tax Consequences to U.S. Holders&#148;), we always will
be a PFIC with respect to your shares. If we are a PFIC and you are a U.S. Holder and do not make a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election (discussed below) with respect to our
ordinary shares, you may be subject to adverse tax consequences, including deferred tax and interest charges with respect to certain distributions on our ordinary shares, any gain realized on a disposition of our ordinary shares and certain other
events. The effect of these adverse tax consequences could be materially adverse to you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a U.S. Holder and make a valid,
timely <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election with respect to our ordinary shares, you will recognize as ordinary income or loss in each year that we meet the PFIC Income Test or PFIC
Asset Test an amount equal to the difference between your basis in our ordinary shares and the fair market value of the ordinary shares, thus also possibly giving rise to phantom income and a potential <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> tax liability. Ordinary loss generally is recognized only to the extent of net <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> gains previously
included in income. U.S. Holders should also be aware that the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election generally will not be available with respect to any of our subsidiaries that is a
PFIC and that gain recognized on the sale of our ordinary shares that is attributable to a subsidiary that is a PFIC may result in such gain being subject to deferred tax and interest charges. See the section of this prospectus titled
&#147;Taxation&#151;Material U.S. Federal Income Tax Consequences to U.S. Holders&#151;Passive Foreign Investment Company Consequences&#148; for a discussion of the PFIC and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not expect to provide U.S.
Holders with the information necessary for a U.S. Holder to make a qualified electing fund, or &#147;QEF election,&#148; the U.S. federal income tax laws, and prospective investors should assume that a QEF election will not be available. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the IRS determines that we are not a PFIC, and you previously paid taxes pursuant to a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election, you may have paid more taxes than you legally owed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the U.S.
Internal Revenue Service, or IRS, makes a determination that we were not a PFIC in a prior taxable year and you previously paid taxes pursuant to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT>
election, then you may have paid more taxes than you legally owed due to such election. If you do not, or are not able to, file a refund claim before the expiration of the applicable statute of limitations, you will not be able to claim a refund for
those taxes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes to U.S. federal income tax laws could have material consequences for us and U.S. Holders of our ordinary shares. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;22, 2017, U.S. President Donald Trump signed into law a bill that enacts comprehensive changes to the U.S. federal income tax
system. This law and related future legislation, regulations and rulings could affect the U.S. federal income tax treatment of us and U.S. Holders of our ordinary shares. You should consult your tax advisors regarding such changes and their
potential impact related to an investment in our ordinary shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A future transfer of your ordinary shares, other than one effected by means of
the transfer of book entry interests in DTC, may be subject to Irish stamp duty. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Transfers of our ordinary shares effected by
means of the transfer of book entry interests in the Depository Trust Company, or DTC, should not be subject to Irish stamp duty. However, if you hold your ordinary shares directly rather than beneficially through DTC, any transfer of your ordinary
shares could be subject to Irish stamp duty (currently at the rate of 1% of the higher of the price paid or the market value of the shares acquired). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Payment of Irish stamp duty is generally a legal obligation of the transferee. The potential for stamp duty to arise could adversely affect the price of our ordinary shares. See &#147;Irish Tax
Considerations&#151;Stamp Duty&#148; for more information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends paid by us may be subject to Irish dividend withholding tax. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As noted elsewhere in this prospectus, we do not expect to pay dividends for the foreseeable future. To the extent that we do make dividend
payments (or other returns to shareholders that are treated as &#147;distributions&#148; for Irish tax purposes), it should be noted that, in certain limited circumstances, dividend withholding tax (currently at a rate of 20%) may arise in respect
of dividends paid on our ordinary shares. A number of exemptions from dividend withholding tax exist, such that shareholders resident in EU member states (other than Ireland) or other countries with which Ireland has signed a double tax treaty,
which would include the United States, should generally be entitled to exemptions from dividend withholding tax provided that the appropriate documentation is in place. See the section titled &#147;Irish Tax Considerations&#151;Withholding Tax on
Dividends Paid on Our Ordinary Shares&#148; for more information and, in particular, please note the requirement to complete certain dividend withholding tax forms in order to qualify for many of the exemptions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends received by Irish residents and certain other shareholders may be subject to Irish income tax. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As noted elsewhere in this prospectus, we do not expect to pay dividends for the foreseeable future. To the extent that we do make dividend
payments (or other returns to shareholders that are treated as &#147;distributions&#148; for Irish tax purposes), it should be noted that shareholders who are entitled to an exemption from Irish dividend withholding tax on dividends received from us
will not be subject to Irish income tax in respect of those dividends, unless they have some connection with Ireland other than their shareholding in Iterum (for example, they are resident in Ireland). Shareholders who are not resident nor
ordinarily resident in Ireland but who are not entitled to an exemption from Irish dividend withholding tax will generally have no further liability to Irish income tax on those dividends which suffer dividend withholding tax. See the section titled
&#147;Irish Tax Considerations&#151;Income Tax on Dividends Paid on Our Ordinary Shares.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ordinary shares received by means of a gift or
inheritance could be subject to Irish capital acquisitions tax. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Irish capital acquisitions tax (CAT) could apply to a gift or
inheritance of our ordinary shares irrespective of the place of residence, ordinary residence or domicile of the parties. This is because our ordinary shares will be regarded as property situated in Ireland. The person who receives the gift or
inheritance has primary liability for CAT. Gifts and inheritances passing between spouses are exempt from CAT. Children have a <FONT STYLE="white-space:nowrap">tax-free</FONT> threshold of &#128;310,000 in respect of taxable gifts or inheritances
received from their parents. See the section titled &#147;Irish Tax Considerations&#151;Capital Acquisitions Tax&#148; for more information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks
Related to this Offering and Our Ordinary Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No active market for our ordinary shares exists or may develop, and you may not be able to
resell your ordinary shares at or above the initial public offering price. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market
for our ordinary shares, and an active public market for our ordinary shares may not develop or be sustained after this offering. We and the representatives of the underwriters have determined the initial public offering price of our ordinary shares
by <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> negotiations, and the initial public offering price does not necessarily reflect the price at which investors in the market will be willing to buy and sell our ordinary shares following
this offering. In addition, an active trading market may not develop following completion of this offering or, if it is developed, may not be sustained. The lack of an active market may impair your ability to sell your ordinary shares at the time
you wish to sell them or at a price that you consider reasonable. The lack of an active market may also adversely affect our ability to raise capital by selling securities in the future, or impair our ability to
<FONT STYLE="white-space:nowrap">in-license</FONT> or acquire other product candidates, businesses or technologies using our ordinary shares as consideration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The price of our ordinary shares could be subject to volatility related or unrelated to our operations
and your investment in us could suffer a decline in value. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a market for our ordinary shares develops following this offering,
the trading price of our ordinary shares could be subject to wide fluctuations in response to various factors, some of which are beyond our control. These factors include those discussed elsewhere in this &#147;Risk Factors&#148; section of this
prospectus and others, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">results from, and any delays in, our current and future clinical trials, in particular our Phase 3 clinical trials related to oral sulopenem and sulopenem; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements of regulatory approval or disapproval of oral sulopenem and sulopenem or future product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in the commercialization of oral sulopenem and sulopenem or any future product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacturing and supply issues related to our development programs and commercialization of oral sulopenem and sulopenem or any of our future product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">quarterly variations in our results of operations or those of our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in our earnings estimates or recommendations by securities analysts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements by us or our competitors of new product candidates, significant contracts, commercial relationships, acquisitions or capital commitments; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements relating to future development or license agreements including termination of such agreements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse developments with respect to our intellectual property rights or those of our principal collaborators; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">commencement of litigation involving us or our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in our board of directors or management; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">new legislation in the United States relating to the prescription, sale, distribution or pricing of drugs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product liability claims, other litigation or public concern about the safety of oral sulopenem or sulopenem or future products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">market conditions in the healthcare market in general, or in the antibiotics segment in particular, including performance of our competitors; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general economic conditions in the United States and abroad. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the stock market in
general, or the market for equity securities in our industry or industries related to our industry, may experience extreme volatility unrelated to our operating performance. These broad market fluctuations may adversely affect the trading price or
liquidity of our ordinary shares. Any sudden decline in the market price of our ordinary shares could trigger securities class-action lawsuits against us. If any of our shareholders were to bring such a lawsuit against us, we could incur substantial
costs defending the lawsuit and the time and attention of our management would be diverted from our business and operations. We also could be subject to damages claims if we are found to be at fault in connection with a decline in our share price.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or reports about our company, or if they issue adverse or misleading opinions regarding
us or our ordinary shares, our share price and trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently have research coverage by
securities and industry analysts, and if no significant coverage is initiated or maintained following this offering, the market price for our ordinary shares may be adversely affected. Our share price also may decline if any analyst who covers us
issues an adverse or misleading </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
opinion regarding us, our business model, our intellectual property or our share performance, or if our pivotal safety and efficacy studies and operating results fail to meet analysts&#146;
expectations. If one or more analysts cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline and possibly adversely affect
our ability to engage in future financings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our principal shareholders and management own a significant percentage of our ordinary shares and will
be able to exert significant control over matters subject to shareholder approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, based on
shares outstanding as of December&nbsp;31, 2017, our executive officers, directors, holders of five percent or more of our ordinary shares and their respective affiliates will beneficially own in the aggregate
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding ordinary shares. The ownership percentage disclosed above does not reflect the purchase of any ordinary shares in this offering by these holders. As a result of their share ownership,
these holders may have the ability to influence our management and policies and will be able to significantly affect the outcome of matters requiring shareholder approval such as elections of directors, amendments of our organizational documents or
approvals of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our ordinary shares that you may feel are in your best interest as one of our shareholders.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will have broad discretion regarding use of the net proceeds from this offering, and we may use them in ways that do not enhance our operating
results or the market price of our ordinary shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion regarding the use of the net
proceeds from this offering, and we could spend the net proceeds in ways our shareholders may not agree with or that do not yield a favorable return, if at all. We intend to use the net proceeds from this offering to initiate, complete enrollment,
and produce <FONT STYLE="white-space:nowrap">top-line</FONT> results relating to our three Phase 3 clinical trials. We intend to use the remainder of the net proceeds from this offering for working capital and other general corporate purposes. We
may also use a portion of the net proceeds to procure equipment for a tableting facility operated by us in a leased space in Ireland or to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> additional product candidates or complementary
assets or businesses; however, we currently have no agreements, commitments or understandings to complete any such transaction. Our actual use of these proceeds may differ substantially from our current intentions. If we do not invest or apply the
proceeds from this offering in ways that improve our operating results or our prospects, our share price could decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Purchasers in this offering
will experience immediate and substantial dilution in the book value of their investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial public offering price of our
ordinary shares is substantially higher than the pro forma net tangible book value per ordinary share before giving effect to this offering. Accordingly, if you purchase our ordinary shares in this offering, based on the midpoint range set forth on
the cover of this prospectus and the issuance of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares in this offering, we estimate that you will incur immediate dilution of approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, representing the difference between the price per share you pay for our ordinary shares and our pro forma as adjusted net tangible book value per ordinary share as of
December&nbsp;31, 2017. Furthermore, if the underwriters exercise their option to purchase additional shares, if outstanding stock options are exercised, if we issue awards to our employees under our equity incentive plans, or if we otherwise issue
additional ordinary shares, you could experience further dilution. See the section titled &#147;Dilution&#148; for additional information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we
raise additional capital in the future, your level of ownership in us could be diluted or require us to relinquish rights. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
issuance of securities we may undertake in the future to raise additional capital could cause the price of our ordinary shares to decline, or require us to issue shares at a price that is lower than that paid by holders of our ordinary shares in the
past, which would result in those newly issued shares being dilutive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, if we obtain funds through a debt financing or through the issuance of debt or
preference securities, these securities would likely have rights senior to your rights as an ordinary shareholder, which could impair the value of our ordinary shares. Any debt financing we enter into may include covenants that limit our flexibility
in conducting our business. We also could be required to seek funds through arrangements with collaborators or others, which might require us to relinquish valuable rights to our intellectual property or product candidates that we would have
otherwise retained. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of a substantial number of our ordinary shares in the public market could cause our share price to fall. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our existing shareholders sell, or indicate an intention to sell, substantial amounts of our ordinary shares in the public market after the <FONT
STYLE="white-space:nowrap">lock-up</FONT> and other legal restrictions on resale discussed in this prospectus lapse, the trading price of our ordinary shares could decline. Based upon the number of ordinary shares outstanding as of December&nbsp;31,
2017, upon the completion of this offering, we will have&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares outstanding, assuming (i)&nbsp;the conversion of all outstanding preference shares, which includes the
conversion of 26,858,743 Series B-2 preferred shares we issued and sold in February 2018, into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares, which we expect to automatically occur upon the completion of this
offering, (ii)&nbsp;no exercise of the underwriters&#146; option to purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional ordinary shares and (iii)&nbsp;no exercise of options outstanding as of
December&nbsp;31, 2017. Of these outstanding ordinary shares, the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares sold in this offering will be freely tradable, except that any ordinary shares acquired by our
&#147;affiliates&#148; as that term is defined in Rule 144 promulgated under the Securities Act of 1933, as amended, or the Securities Act, including any ordinary shares acquired by existing holders of our ordinary shares that have indicated an
interest in purchasing ordinary shares in this offering, may only be sold if registered under the Securities Act or if such registration is not required, such as in compliance with Rule&nbsp;144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The remaining&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares are subject to <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements. The <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements pertaining to this offering will expire 180 days from the date of this prospectus. The representatives of the underwriters, however,
may permit our shareholders who are subject to these <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements to sell their ordinary shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. After the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements expire, these&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares will be eligible for sale in the public
market,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of which shares are held by directors, executive officers and other affiliates (not taking into account any shares that may be purchased in this offering by existing
holders of our ordinary shares) and will be subject to volume limitations under Rule&nbsp;144 under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
ordinary shares that are issuable upon exercise of outstanding options, or reserved for future issuance under our equity incentive plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting
schedules, the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and Rule&nbsp;144 and Rule&nbsp;701 under the Securities Act. If these additional ordinary shares are sold, or if it is perceived that they will be sold, in the public market,
the trading price of our ordinary shares could decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After this offering, the holders
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares, or approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our total outstanding ordinary shares as of December&nbsp;31, 2017 will be entitled to rights with respect
to the registration of their shares under the Securities Act, subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above. Registration of these shares under the Securities Act would result in the shares becoming freely
tradable without restriction under the Securities Act, except for shares purchased by affiliates. Any sales of securities by these shareholders could have an adverse effect on the trading price of our ordinary shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Irish law differs from the laws in effect in the United States and may afford less protection to holders of our securities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may have difficulties enforcing, in actions brought in courts in jurisdictions located outside the United States, judgments obtained in the
U.S. courts under the U.S. securities laws. In particular, if you sought to bring proceedings in Ireland based on U.S. securities laws, the Irish court might consider: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">that it did not have jurisdiction; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">that it was not the appropriate forum for such proceedings; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">that, applying Irish conflict of law rules, U.S. law (including U.S. securities laws) did not apply to the relationship between you and us or our directors and officers; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">that the U.S. securities laws were of a penal nature and violated Irish public policy and should not be enforced by the Irish court. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It may not be possible to enforce court judgments obtained in the United States against us in Ireland based on the civil liability provisions
of the U.S. federal or state securities laws. In addition, there is some uncertainty as to whether the courts of Ireland would recognize or enforce judgments of U.S. courts obtained against us or our directors or officers based on the civil
liabilities provisions of the U.S. federal or state securities laws. We have been advised that the United States currently does not have a treaty with Ireland providing for the reciprocal recognition and enforcement of judgments in civil and
commercial matters. Therefore, a final judgment for the payment of money rendered by any U.S. federal or state court based on civil liability, whether or not based solely on U.S. federal or state securities laws, would not automatically be
enforceable in Ireland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A judgment obtained against us will be enforced by the courts of Ireland only if the following general
requirements are met: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">U.S. courts must have had jurisdiction in relation to the particular defendant according to Irish conflict of law rules (the submission to jurisdiction by the defendant would satisfy this rule); and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the judgment must be final and conclusive and the decree must be final and unalterable in the court which pronounces it. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A judgment can be final and conclusive even if it is subject to appeal or even if an appeal is pending. But where the effect of lodging an
appeal under the applicable law is to stay execution of the judgment, it is possible that in the meantime the judgment may not be actionable in Ireland. It remains to be determined whether final judgment given in default of appearance is final and
conclusive. Irish courts may also refuse to enforce a judgment of the U.S. courts which meets the above requirements for one of the following reasons: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the judgment is not for a definite sum of money; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the judgment was obtained by fraud; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the enforcement of the judgment in Ireland would be contrary to natural or constitutional justice; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the judgment is contrary to Irish public policy or involves certain U.S. laws which will not be enforced in Ireland; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">jurisdiction cannot be obtained by the Irish courts over the judgment debtors in the enforcement proceedings by personal service Ireland or outside Ireland under Order 11 of the Irish Superior Courts Rules.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an Irish company, we are governed by the Irish Companies Act 2014 (the Irish Companies Act), which differs in some
material respects from laws generally applicable to U.S. corporations and shareholders, including, among others, differences relating to interested director and officer transactions and shareholder lawsuits. Likewise, the duties of directors and
officers of an Irish company generally are owed to the company only. Shareholders of Irish companies generally do not have a personal right of action against directors or officers of the company and may exercise such rights of action on behalf of
the company only in limited circumstances. Accordingly, holders of our securities may have more difficulty protecting their interests than would holders of securities of a corporation incorporated in a jurisdiction of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should also be aware that Irish law does not allow for any form of legal proceedings directly equivalent to the class action available in
the United States. For further information with respect to your rights as a holder of our ordinary shares, see &#147;Description of Share Capital.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As a newly public company, we will incur significant additional costs, and our management will be
required to devote substantial time and attention to our public reporting obligations. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a publicly-traded company, we will
incur significant additional legal, accounting and other expenses compared to historical levels. In addition, new and changing laws, regulations and standards relating to corporate governance and public disclosure, including the Dodd-Frank Wall
Street Reform and Consumer Protection Act and the rules and regulations promulgated and to be promulgated thereunder, as well as under the Sarbanes-Oxley Act of 2002 (the Sarbanes-Oxley Act), the JOBS Act and the rules and regulations of the U.S.
Securities and Exchange Commission (the SEC), and The Nasdaq Global Select Market, have created uncertainty for public companies and increased our costs and time that our board of directors and management must devote to complying with these rules
and regulations. We expect these rules and regulations to increase our legal and financial compliance costs substantially and lead to diversion of management time and attention from revenue-generating activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company,&#148; and the reduced disclosure requirements applicable to &#147;emerging growth companies&#148; may make our
ordinary shares less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in the JOBS Act, and,
therefore, we may take advantage of reduced disclosure and regulatory requirements that are otherwise generally applicable to public companies, including presenting only two years of audited financial statements and related financial disclosure, not
being required to have our internal control over financial reporting audited by our independent registered public accounting firm pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments. We may take advantage of these reduced disclosure and regulatory
requirements until we are no longer an &#147;emerging growth company.&#148; We may remain an &#147;emerging growth company&#148; until as late as December&nbsp;31, 2023 (the fiscal <FONT STYLE="white-space:nowrap">year-end</FONT> following the fifth
anniversary of the completion of this initial public offering), although we may cease to be an &#147;emerging growth company&#148; earlier under certain circumstances, including if the market value of our ordinary shares that is held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of any December&nbsp;31, in which case we would cease to be an &#147;emerging growth company&#148; as of the following December&nbsp;31, or if our gross revenue exceeds
$1.07&nbsp;billion in any fiscal year. In addition, the JOBS Act provides that an emerging growth company can delay adopting new or revised accounting standards until those standards apply to private companies. We have irrevocably elected not to
avail ourselves of this delayed adoption of new or revised accounting standards and, therefore, we are subject to the same new or revised accounting standards as public companies that are not emerging growth companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exact implications of the JOBS Act are still subject to interpretations and guidance by the SEC and other regulatory agencies, and we may
not be able to take advantage of all of the benefits of the JOBS Act. In addition, investors may find our ordinary shares less attractive if we rely on the exemptions and relief granted by the JOBS Act. If some investors find our ordinary shares
less attractive as a result, there may be a less active trading market for our ordinary shares and our share price may decline or become more volatile. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and
accurate financial statements or comply with applicable regulations could be impaired. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we will be subject
to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, and the rules and regulations of the applicable listing standards of the Nasdaq Global Select Market. We expect that the requirements of these rules and regulations will
continue to increase our legal, accounting and financial compliance costs, make some activities more difficult, time-consuming and costly and place significant strain on our personnel, systems and resources. The Sarbanes-Oxley Act requires, among
other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
continuing to develop and refine our disclosure controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we will file with the
SEC is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and that information required to be disclosed in reports under the Exchange Act is accumulated and communicated to our principal executive
and financial officers. We are also continuing to improve our internal control over financial reporting. In order to develop, maintain and improve the effectiveness of our disclosure controls and procedures and internal control over financial
reporting, we have expended, and anticipate that we will continue to expend, significant resources, including accounting-related costs and significant management oversight. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current controls and any new controls that we develop may become inadequate because of changes in conditions in our business. Further,
weaknesses in our disclosure controls and internal control over financial reporting may be discovered in the future. Any failure to develop or maintain effective controls or any difficulties encountered in their implementation or improvement could
harm our results of operations or cause us to fail to meet our reporting obligations and may result in a restatement of our consolidated financial statements for prior periods. Any failure to implement and maintain effective internal control over
financial reporting could also adversely affect the results of periodic management evaluations and annual independent registered public accounting firm attestation reports regarding the effectiveness of our internal control over financial reporting
that we will eventually be required to include in our periodic reports that will be filed with the SEC. Ineffective disclosure controls and procedures and internal control over financial reporting could also cause investors to lose confidence in our
reported financial and other information, which would likely have a negative effect on the trading price of our ordinary shares. In addition, if we are unable to continue to meet these requirements, we may not be able to remain listed on the Nasdaq
Global Select Market. We are not currently required to comply with the SEC rules that implement Section&nbsp;404 of the Sarbanes-Oxley Act and are therefore not required to make a formal assessment of the effectiveness of our internal control over
financial reporting for that purpose. As a public company, we will be required to provide an annual management report on the effectiveness of our internal control over financial reporting commencing with our second annual report on Form <FONT
STYLE="white-space:nowrap">10-K.</FONT> </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any failure to maintain effective disclosure controls and internal control over financial
reporting could have a material and adverse effect on our business, results of operations and financial condition and could cause a decline in the trading price of our ordinary shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have never paid cash dividends, do not anticipate paying any cash dividends and our ability to pay dividends, or repurchase or redeem our ordinary
shares, is limited by law. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our ordinary shares and do not anticipate paying any
dividends on our ordinary shares in the foreseeable future. Any determination to pay dividends in the future will be at the sole discretion of our board of directors after considering our financial condition, results of operations, capital
requirements, contractual restrictions, general business conditions and other factors our board of directors deems relevant, and subject to compliance with applicable laws, including the Irish Companies Act which requires Irish companies to have
distributable reserves available for distribution equal to or greater than the amount of the proposed dividend. Distributable reserves are the accumulated realized profits of the company that have not previously been utilized in a distribution or
capitalization less accumulated realized losses that have not previously been written off in a reduction or reorganization of capital. Unless the company creates sufficient distributable reserves from its business activities, the creation of such
distributable reserves would involve a reduction of the company&#146;s share premium account, which once the company has <FONT STYLE="white-space:nowrap">re-registered</FONT> as a public limited company would require the approval of (i) 75% of our
shareholders present and voting at a shareholder meeting, and (ii)&nbsp;the Irish High Court. In the event that we do not undertake a reduction of capital to create distributable reserves, no distributions by way of dividends, share repurchases or
otherwise will be permitted under Irish law until such time as the company has created sufficient distributable reserves from its business activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, the only opportunity to achieve a return on your investment in our company is
expected to be if the market price of our ordinary shares appreciates and you sell your ordinary shares at a profit. The price of our ordinary shares prevailing in the market after this offering may not exceed the price that you pay. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions in our Articles and under Irish law could make an acquisition of us more difficult, limit attempts by our shareholders to
replace or remove our current directors and management team, and limit the market price of our ordinary shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Articles will
contain provisions that may delay or prevent a change of control, discourage bids at a premium over the market price of our ordinary shares, and adversely affect the market price of our ordinary shares and the voting and other rights of the holders
of our ordinary shares. These provisions will include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">dividing our board of directors into three classes, with each class serving a staggered three-year term; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">permitting our board of directors to adopt a shareholder rights plan upon such terms and conditions as it deems expedient and in our best interests; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">permitting our board of directors to issue additional preference shares, with such rights, preferences and privileges as they may designate; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing an advance notice procedure for shareholder proposals to be brought before an annual meeting, including proposed nominations of persons for election to our board of directors; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">imposing particular approval and other requirements in relation to certain business combinations. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions would apply even if the offer may be considered beneficial by some shareholders. In addition, these provisions may frustrate
or prevent any attempts by our shareholders to replace or remove our current management team by making it more difficult for shareholders to replace members of our board of directors, which is responsible for appointing the members of our
management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Irish law differs from the laws in effect in the United States with respect to defending unwanted takeover proposals and may give our
board of directors less ability to control negotiations with hostile offerors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the authorization for trading of our
ordinary shares on Nasdaq, we will become subject to the Irish Takeover Panel Act, 1997, Irish Takeover Rules 2013 (Irish Takeover Rules). Under the Irish Takeover Rules, our board of directors is not permitted to take any action that might
frustrate an offer for our ordinary shares once our board of directors has received an approach that may lead to an offer or has reason to believe that such an offer is or may be imminent, subject to certain exceptions. Potentially frustrating
actions such as (i)&nbsp;the issue of shares, options, restricted share units or convertible securities, (ii)&nbsp;material acquisitions or disposals, (iii)&nbsp;entering into contracts other than in the ordinary course of business or (iv)&nbsp;any
action, other than seeking alternative offers, which may result in frustration of an offer, are prohibited during the course of an offer or at any earlier time during which our board of directors has reason to believe an offer is or may be imminent.
These provisions may give our board of directors less ability to control negotiations with hostile offerors than would be the case for a corporation incorporated in a jurisdiction of the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The operation of the Irish Takeover Rules may affect the ability of certain parties to acquire our ordinary shares. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Irish Takeover Rules, if an acquisition of ordinary shares were to increase the aggregate holding of the acquirer and its concert
parties to ordinary shares that represent 30% or more of the voting rights of the company, the acquirer and, in certain circumstances, its concert parties would be required (except with the consent of the Irish Takeover Panel) to make an offer for
the outstanding ordinary shares at a price not less than the highest price paid for the ordinary shares by the acquirer or its concert parties during the previous 12 months. This requirement would also be triggered by an acquisition of ordinary
shares by a person holding (together with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
its concert parties) ordinary shares that represent between 30% and 50% of the voting rights in the company if the effect of such acquisition were to increase that person&#146;s percentage of the
voting rights by 0.05% within a 12 month period. Following the authorization for trading of our ordinary shares on Nasdaq, under the Irish Takeover Rules, certain separate concert parties will be presumed to be acting in concert. Our board of
directors and their relevant family members, related trusts and &#147;controlled companies&#148; are presumed to be acting in concert with any corporate shareholder who holds 20% or more of our shares. The application of these presumptions may
result in restrictions upon the ability of any of the concert parties and/or members of our board of directors to acquire more of our securities, including under the terms of any executive incentive arrangements. Following the listing of our
ordinary shares on Nasdaq, we may consult with the Irish Takeover Panel with respect to the application of this presumption and the restrictions on the ability to acquire further securities, although we are unable to provide any assurance as to
whether the Irish Takeover Panel will overrule this presumption. For a description of certain takeover provisions applicable to us, see the section titled &#147;Description of Share Capital&#151;Irish Takeover Rules and Substantial Acquisition
Rules.&#148; Accordingly the application of the Irish Takeover Rules may restrict the ability of certain of our shareholders and directors to acquire our ordinary shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As an Irish public limited company, certain capital structure decisions require shareholder approval, which may limit our flexibility to manage our
capital structure. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Irish law, our authorized share capital can be increased by an ordinary resolution of our shareholders
and the directors may issue new ordinary or preferred shares up to a maximum amount equal to the authorized but unissued share capital, without shareholder approval, once authorized to do so by our Articles of Association or by an ordinary
resolution of our shareholders. Additionally, subject to specified exceptions, Irish law grants statutory preemption rights to existing shareholders where shares are being issued for cash consideration but allows shareholders to disapply such
statutory preemption rights either in our Articles of Association or by way of special resolution. Such disapplication can either be generally applicable or be in respect of a particular allotment of shares. Accordingly, our Articles of Association
adopted on closing of this offering will contain, as permitted by Irish company law, provisions authorizing the board to issue new shares, and to disapply statutory preemption rights. The authorization of the directors to issue shares and the
disapplication of statutory preemption rights must both be renewed by the shareholders at least every five years, and we cannot provide any assurance that these authorizations will always be approved, which could limit our ability to issue equity
and thereby adversely affect the holders of our securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc522368_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY
DATA </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements that involve risks and uncertainties. All statements other than statements
of historical facts contained in this prospectus are forward-looking statements. In some cases, you can identify forward-looking statements by words such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148;
&#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;target,&#148;
&#147;will,&#148; &#147;would,&#148; or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our use of the net proceeds from this offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to advance product candidates into, and successfully complete, clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing or likelihood of regulatory filings and approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the commercialization of our product candidates, if approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our manufacturing plans, including our plans for an Iterum-operated tableting facility; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">market acceptance of any product we successfully commercialize; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the pricing, coverage and reimbursement of our product candidates, if approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the implementation of our business model, strategic plans for our business and product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to enter into strategic arrangements and/or collaborations and the potential benefits of such arrangements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding expenses, capital requirements and needs for additional financing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our financial performance; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments relating to our competitors and our industry. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements
are subject to a number of risks, uncertainties and assumptions, including those described in &#147;Risk Factors&#148; and elsewhere in this prospectus. Moreover, we operate in a very competitive and rapidly changing environment, and new risks
emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this prospectus may not occur and actual results could
differ materially and adversely from those anticipated or implied in the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not rely upon
forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events
and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to new
information, actual results or to changes in our expectations, except as required by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the documents that we reference in this prospectus and
have filed with the SEC as exhibits to the registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance, and events and circumstances may be materially different
from what we expect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus also contains industry, market and competitive position data from our own internal estimates and
research as well as industry and general publications and research surveys and studies conducted by third parties. Industry publications, studies, and surveys generally state that they have been obtained from sources believed to be reliable,
although they do not guarantee the accuracy or completeness of such information. Our internal data and estimates are based upon information obtained from trade and business organizations and other contacts in the markets in which we operate and our
management&#146;s understanding of industry conditions. While we believe that each of these studies and publications is reliable, we have not independently verified market and industry data from third-party sources. While we believe our internal
company research is reliable and the market definitions are appropriate, neither such research nor these definitions have been verified by any independent source. The industry in which we operate is subject to a high degree of uncertainty and risks
due to various factors, including those described in the section titled &#147;Risk Factors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, statements that &#147;we
believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable
basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These
statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc522368_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from the sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares in this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, based on an assumed initial public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated
offering expenses payable by us. If the underwriters exercise their over-allotment option to purchase additional ordinary shares from us we estimate that our net proceeds will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase
(decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share would increase (decrease) our net proceeds by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming the number of
shares offered by us, as set forth on the cover page of this prospectus, remains the same, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase (decrease) by 1,000,000
shares in the number of shares offered by us would increase (decrease) the net proceeds from this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming the assumed initial public offering price remains the same, after
deducting the estimated underwriting discounts and commissions. The information discussed above is illustrative only and will adjust based on the actual initial public offering price and other terms of this offering determined at pricing. Any
increase or decrease in the net proceeds would not change our intended use of proceeds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that we will use the net proceeds
from this offering, together with our cash and cash equivalents, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to fund our Phase 3 clinical trials of oral sulopenem and sulopenem in three indications; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million for milestone payments to Pfizer Inc. (Pfizer) payable upon commencement of Phase 3 clinical development for oral sulopenem and sulopenem pursuant
to the exclusive license agreement we have entered into with Pfizer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to establish an Iterum-operated facility in Dublin as a second source supplier to produce oral sulopenem bilayer tablets; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the balance for working capital and other general corporate purposes, which may include regulatory, manufacturing, clinical supply and related costs. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the anticipated net proceeds from this offering, together with our existing cash, will enable us to complete our three planned
Phase 3 clinical trials. However, we expect that we will require additional capital to submit our applications to regulatory agencies and to commercialize oral sulopenem and sulopenem, if we receive regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected use of proceeds from this offering represent our intentions based upon our current plans and business conditions. The amounts and
timing of our actual expenditures may vary significantly depending on numerous factors and any unforeseen cash needs. As a result, management will retain broad discretion over the allocation of the net proceeds from this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending the use of the proceeds from this offering, we intend to invest the net proceeds in interest-bearing, investment-grade securities,
certificates of deposit or government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc522368_5"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid dividends on our ordinary shares. We currently intend to retain all available funds and any future earnings to
support operations and to finance the growth and development of our business. We do not intend to declare or pay cash dividends on our ordinary shares in the foreseeable future. Any future determination to pay dividends will be made at the
discretion of our board of directors subject to applicable laws (including the Irish Companies Act, which requires, inter alia, Irish companies to have profits available for distribution equal to or greater than the amount of the proposed dividend),
and will depend upon, among other factors, our results of operations, financial condition, contractual restrictions and capital requirements. Our future ability to pay cash dividends on our shares may be limited by the terms of any future debt or
preferred securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc522368_6"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents and capitalization as of December&nbsp;31, 2017: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on an actual basis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on a pro forma basis, to reflect: (1)&nbsp;the issuance and sale of 26,858,743 Series B-2 preferred shares and the receipt of $32.2 million of gross proceeds, (2) the conversion of all outstanding preferred shares into
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of our ordinary shares immediately prior to the closing of this offering, and (3)&nbsp;the filing and effectiveness of our amended and restated
constitution in connection with the closing of this offering; and </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on a pro forma as adjusted basis, to further reflect the sale by us of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares in this offering at an assumed
initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and
estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read the information in this table together with our consolidated
financial statements and related notes included elsewhere in this prospectus and the sections titled &#147;Selected Consolidated Financial and Other Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro<BR>Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per<BR>share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred shares, $0.0001 par value;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding,
actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred shares, $0.0001 par value; no shares authorized, issued or outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares authorized and no shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares, $0.0001 par value;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding,
actual; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and
outstanding, pro forma; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares
issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) each of cash and cash equivalents, additional
<FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total shareholders&#146; equity, and total capitalization by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming that the number of shares offered by us, as set forth on the
cover page of this prospectus, remains the same, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. Each increase
(decrease) of 1,000,000 shares in the number of shares offered by us would increase (decrease) cash and cash equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total shareholders&#146; equity, and total capitalization
by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming the assumed initial public offering price remains the same, after deducting the estimated underwriting discounts and commissions. The pro forma as adjusted information
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
discussed above is illustrative only and will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of ordinary shares to be outstanding after this offering is based on 95,827,720 ordinary shares outstanding as of December&nbsp;31,
2017 plus the ordinary shares issuable upon the conversion of 26,858,743 Series&nbsp;B-2 preferred shares we issued and sold in February 2018, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">3,898,334 ordinary shares issuable upon the exercise of outstanding stock options as of December&nbsp;31, 2017, with a weighted-average exercise price of $0.21 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">3,061,666 ordinary shares reserved for future issuance under our 2015 Equity Incentive Plan as of December&nbsp;31, 2017; all shares reserved for future issuance and not subject to an outstanding stock option will cease
to be available for issuance at the time our 2018 Equity Incentive Plan becomes effective in connection with this offering; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares reserved for future issuance under our 2018 Equity Incentive Plan, as well as any automatic increases in the number of ordinary
shares reserved for future issuance under this plan, which will become effective upon the execution of the underwriting agreement for this offering. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc522368_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our ordinary shares in this offering, your interest will be diluted to the extent of the difference between the initial
public offering price per ordinary share and the pro forma as adjusted net tangible book value per ordinary share after the closing of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our pro forma net tangible book value as of December&nbsp;31, 2017 was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. Pro forma net tangible book value per share is determined by subtracting our total liabilities from the total book value of our tangible assets and dividing the difference by the number of
ordinary shares deemed to be outstanding at that date, after giving effect to (i) the issuance and sale of 26,858,743 Series B-2 preferred shares and the receipt of $32.2 million of gross proceeds and (ii) the conversion of all outstanding preferred
shares into an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares immediately prior to the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary
shares in this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of December&nbsp;31, 2017, would have been $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. This represents an immediate increase in pro forma as adjusted net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to our existing shareholders and
immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to new investors purchasing ordinary shares in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table illustrates this dilution on a per share basis to new investors: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per share attributable to new investors in this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution in net tangible book value per share to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share would increase (decrease) our pro forma as adjusted net tangible book value per share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and the dilution to
new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts
and commissions and estimated offering expenses payable by us. Each increase of 1,000,000 shares in the number of ordinary shares offered by us would increase the pro forma as adjusted net tangible book value by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and decrease the dilution to new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, assuming the assumed initial public offering price remains the same and after
deducting the estimated underwriting discounts and commissions. Similarly, each decrease of 1,000,000 shares in the number of ordinary shares offered by us would decrease the pro forma as adjusted net tangible book value by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and increase the dilution to new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, assuming the assumed initial public offering price remains the same and after
deducting the estimated underwriting discounts and commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes, as of December&nbsp;31, 2017, on the pro
forma as adjusted basis described above: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the total number of ordinary shares purchased from us by our existing shareholders and by new investors purchasing shares in this offering; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the total consideration paid to us by our existing shareholders and by new investors purchasing shares in this offering, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per
share, the midpoint of the range set forth on the cover page of this prospectus, before deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the average price per share paid by existing shareholders and by new investors purchasing shares in this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Price<BR>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share would increase (decrease) the total consideration paid to us by new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million assuming the number of shares offered by us, as
set forth on the cover page of this prospectus, remains the same and before deducting the estimated underwriting discounts and commissions and estimated expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tables and calculations above are based on 95,827,720 ordinary shares outstanding as of December&nbsp;31, 2017 plus the ordinary shares
issuable upon the conversion of 26,858,743 Series B-2 preferred shares we issued and sold in February 2018, and excludes: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">3,898,334 ordinary shares issuable upon the exercise of outstanding stock options as of December&nbsp;31, 2017, with a weighted-average exercise price of $0.21 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">3,061,666 ordinary shares reserved for future issuance under our 2015 Equity Incentive Plan as of December&nbsp;31, 2017; all shares reserved for future issuance and not subject to an outstanding stock option will cease
to be available for issuance at the time our 2018 Equity Incentive Plan becomes effective in connection with this offering; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares reserved for future issuance under our 2018 Equity Incentive Plan, as well as any automatic increases in the number of ordinary
shares reserved for future issuance under this plan, which will become effective upon the execution of the underwriting agreement for this offering. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent any outstanding options are exercised, new options are issued under our equity incentive plans, or we issue additional ordinary
shares in the future, there will be further dilution to investors participating in this offering. If all outstanding options as of December&nbsp;31, 2017 were exercised, then our existing shareholders, including the holders of these options, would
own&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% and new investors would own&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of ordinary shares outstanding upon the closing of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc522368_8"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read the selected consolidated financial data below in conjunction with &#147;Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations&#148; and the consolidated financial statements, related notes, and other financial information included elsewhere in this prospectus. The selected consolidated financial and other data in this section
are not intended to replace the consolidated financial statements and are qualified in their entirety by the consolidated financial statements and related notes included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following selected consolidated statements of operations data for the years ended December&nbsp;31, 2016 and 2017 and selected
consolidated balance sheet data as of December&nbsp;31, 2017 have been derived from our audited consolidated financial statements included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that may be
expected in any future period. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>per&nbsp;share&nbsp;data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,464</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,963</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,455</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,351</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,962</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,464</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to ordinary shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,464</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36.21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average ordinary shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">371,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,704,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Net loss per share, basic and diluted is the same due to our net loss. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Working capital is equal to current assets minus current liabilities. </TD></TR></TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2018, we issued and sold 26,858,743 Series B-2 preferred shares for gross cash proceeds of $32.2 million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc522368_9"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results of operations together with the section
entitled &#147;Selected Consolidated Financial Data&#148; and our consolidated financial statements and the related notes appearing at the end of this prospectus. Some of the information contained in this discussion and analysis or set forth
elsewhere in this prospectus, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those
factors set forth in the &#147;Risk Factors&#148; section of this prospectus, our actual results could differ materially from the results described in or implied by these forward-looking statements. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a pharmaceutical
company dedicated to developing and commercializing sulopenem to be potentially the first and only oral and intravenous (IV)&nbsp;branded penem available globally. Penems, including thiopenems and carbapenems, belong to a class of antibiotics more
broadly defined as &szlig;-lactam antibiotics, the original example of which was penicillin, but which now also includes cephalosporins. Sulopenem is a potent, targeted gram-negative spectrum thiopenem delivered intravenously, which we have
successfully developed in an oral tablet formulation, sulopenem etzadroxil-probenecid. Both sulopenem products have the potential to be important new treatment alternatives to address growing concerns related to antibacterial resistance without the
known toxicities of some of the most widely-used antibiotics, specifically fluoroquinolones. We see two distinct opportunities for our sulopenem program: patients at elevated risk for treatment failure in the community setting suffering from
uncomplicated urinary tract infections (uUTI) and hospitalized patients suffering from complicated, resistant infections. Therefore, we plan to initiate a Phase 3 clinical program in the second half of 2018 for the treatment of adults in three
indications: uUTI, complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). We designed one Phase 3 clinical trial in each indication based on our end of Phase 2 meeting with the U.S. Food and Drug
Administration (the FDA) and feedback from the European Medicines Agency (the EMA). We intend to conduct the Phase 3 clinical trials under Special Protocol Assessment (SPA) agreements from the FDA. We expect to complete enrollment and produce
topline data for all three clinical trials in the second half of 2019, and file our new drug applications (NDAs) with the FDA by the end of 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception in June 2015, we have devoted substantially all of our resources to organizing and staffing our company, business
planning, raising capital, establishing a supply chain, planning for commercialization, and conducting research and development activities for our sulopenem program. We do not have any products approved for sale and have not generated any revenue
from product sales. In June 2017, we were granted a <FONT STYLE="white-space:nowrap">sub-award</FONT> of up to $1.5&nbsp;million from the Trustees of Boston University under the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator <FONT
STYLE="white-space:nowrap">(CARB-X)</FONT> program (the <FONT STYLE="white-space:nowrap">CARB-X</FONT> Award). The <FONT STYLE="white-space:nowrap">CARB-X</FONT> Award supports preclinical and clinical trials in support of our potential regulatory
filings for oral sulopenem and sulopenem, along with chemistry, manufacturing and controls optimization and development of our commercial bilayer tablet. We have funded our operations to date primarily with proceeds from the sale of preferred shares
and ordinary shares and payments received under the funding arrangement with <FONT STYLE="white-space:nowrap">CARB-X.</FONT> Through December&nbsp;31, 2017, we had received gross cash proceeds of $87.5&nbsp;million from sales of our preferred shares
and ordinary shares. In February 2018, we received gross cash proceeds of $32.2&nbsp;million from the sale of our <FONT STYLE="white-space:nowrap">Series&nbsp;B-2</FONT> preferred shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2015, we acquired an exclusive, worldwide license under certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT> to
develop and commercialize sulopenem and its oral prodrug, sulopenem etzadroxil, from Pfizer Inc. (Pfizer). We have developed an oral formulation, sulopenem etzadroxil-probenecid combined in a single bilayer tablet, which we refer to as oral
sulopenem. We refer to sulopenem delivered intravenously as sulopenem and, together with oral sulopenem, as our sulopenem program. Under an exclusive license agreement with Pfizer (the Pfizer License), we paid Pfizer a
<FONT STYLE="white-space:nowrap">one-time</FONT> nonrefundable upfront fee of $5.0&nbsp;million and are obligated to pay Pfizer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
potential future clinical and regulatory milestone payments, as well as sales milestones upon achievement of net sales ranging from $250.0&nbsp;million to $1.0&nbsp;billion for each product type
(sulopenem etzadroxil and other prodrugs, and sulopenem and other non-prodrugs). We are obligated to pay Pfizer royalties ranging from a single-digit to <FONT STYLE="white-space:nowrap">mid-teens</FONT> percentage based on marginal net sales of each
licensed product. Pfizer also received six million Series A preferred shares as additional payment for the licensed rights. In addition, if we sublicense or assign our rights to licensed products to a third party, and we receive in connection with
such transaction a threshold amount of at least a low nine figure dollar amount over a specified period of time, we will be obligated to pay Pfizer an additional <FONT STYLE="white-space:nowrap">one-time</FONT> payment of a low eight figure dollar
amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have incurred significant operating losses. Our ability to generate product revenue sufficient to achieve
profitability will depend heavily on the successful development and eventual commercialization of oral sulopenem and sulopenem. Our net losses for 2016 and 2017 were $13.5&nbsp;million and $29.4&nbsp;million, respectively. As of December&nbsp;31,
2017, we had an accumulated deficit of $54.7&nbsp;million. We expect to continue to incur significant expenses for at least the next two years as we advance our sulopenem program through Phase 3 clinical trials, seek regulatory approval and engage
in market preparation activities. In addition, if we obtain marketing approval for oral sulopenem and sulopenem, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. For
example, within a year of our product launch we expect to have an Iterum-operated facility in Dublin as a second source supplier to produce oral sulopenem bilayer tablets, and will have expenses related to leasing and renovating the site, purchasing
equipment for the site and registration and validation of the site. Furthermore, we may incur expenses in connection with the <FONT STYLE="white-space:nowrap">in-license</FONT> or acquisition of additional product candidates. Additionally, upon the
closing of this offering, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, we will require additional capital to fund our operations, continue to develop our sulopenem program and to execute our strategy.
Until such time as we can obtain marketing approval for oral sulopenem, sulopenem or any future product candidate and generate significant revenue from product sales, if ever, we expect to finance our operations through public or private equity
offerings, debt financings, collaboration agreements, other third-party funding, strategic alliances, licensing arrangements, marketing and distribution arrangements or government funding. We may be unable to raise additional funds or enter into
such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back, discontinue the development and
commercialization of our sulopenem program, or otherwise change our strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated
with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail
to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, we had cash and cash equivalents and short-term investments of $39.2&nbsp;million. In February 2018, we received
gross cash proceeds of $32.2&nbsp;million from the sale of <FONT STYLE="white-space:nowrap">Series&nbsp;B-2</FONT> preferred shares in connection with the second and final closing of our Series&nbsp;B preferred share financing. We believe that the
anticipated net proceeds from this offering, together with our existing cash, will enable us to fund our operating expenses and capital expenditure requirements for at least&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We
have based these estimates on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See the section titled &#147;&#151;Liquidity and Capital Resources.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Our Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have not
generated any revenue from product sales and do not expect to generate any revenue from the sale of oral sulopenem or sulopenem in the near future. If our development efforts for our sulopenem program are successful and result in regulatory approval
and/or license agreements with third parties, we may generate revenue in the future from product sales. To date, all of our revenue has been derived from our CARB-X Award. We expect that our revenue for the next few years will be derived primarily
from payments under the CARB-X Award or government awards that we may enter into in the future. In June 2017, CARB-X awarded us funds of up to $1.5&nbsp;million to advance the development of our sulopenem program. We receive funding from CARB-X as
we incur qualifying expenses. During the year ended December&nbsp;31, 2017, we recognized $0.5&nbsp;million of revenue under this award. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development
Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of costs incurred in connection with the development of our sulopenem
program, which include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expenses incurred under agreements with contract research organizations, or CROs, contract manufacturing organizations, or CMOs, as well as investigative sites and consultants that conduct our clinical trials,
preclinical studies and other scientific development services; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacturing <FONT STYLE="white-space:nowrap">scale-up</FONT> expenses and the cost of acquiring and manufacturing preclinical and clinical trial materials and commercial materials, including manufacturing validation
batches; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">employee-related expenses, including salaries, related benefits, travel and share-based compensation expense for employees engaged in research and development functions; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs related to compliance with regulatory requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">facilities costs, depreciation and other expenses, which include rent and utilities; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">payments made in cash, equity securities or other forms of consideration under third-party licensing agreements. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expense research and development costs as incurred. Advance payments we make for goods or services to be received in the future for use in
research and development activities are recorded as prepaid expenses. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development activities are central to our business model. Product candidates in advanced stages of clinical development generally
have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later stage clinical trials. As a result, we expect that our research and development expenses will increase
substantially over the next two years as we increase personnel costs, including share-based compensation, commence Phase&nbsp;3 clinical trials for our sulopenem program, conduct other clinical trials and prepare regulatory filings for oral
sulopenem and sulopenem. We also expect to incur additional expenses related to milestone and royalty payments payable to Pfizer with whom we have entered into the Pfizer License to acquire the rights to oral sulopenem and sulopenem. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The successful development and commercialization of oral sulopenem and sulopenem is highly uncertain. At this time, we cannot reasonably
estimate or know the nature, timing and costs of the efforts that will be necessary to complete the clinical development of our sulopenem program or when, if ever, material net cash </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inflows may commence from any of our product candidates. This uncertainty is due to the numerous risks and uncertainties associated with product development and commercialization, including the
uncertainty of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, progress, outcome and costs of our clinical trials and other research and development activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successful patient enrollment in, and the initiation and completion of, clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing, receipt and terms of any marketing approvals from applicable regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">development and timely delivery of commercial drug formulations that can be used in our clinical trials and for commercial launch; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significant and changing government regulation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining a continued acceptable safety profile of the product candidates following approval. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our clinical
trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others. Any changes in the outcome of any of these variables with respect to the development of our product candidates in clinical
development could mean a significant change in the costs and timing associated with the development of these product candidates. For example, if we experience significant delays in enrollment in any of our planned clinical trials, or are required to
add additional patients to a study to remain consistent with our original trial design assumptions, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product
candidate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of salaries, related benefits, travel and share-based compensation expense for personnel
in executive, finance and administrative functions. General and administrative expenses also include director compensation and travel expenses and professional fees for legal, patent, consulting, accounting and audit services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued
development of our sulopenem program. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance, director compensation, director and officer insurance costs as well as investor and public relations expenses
associated with being a public company. We anticipate the additional costs for these services will increase our general and administrative expenses by approximately $1.5&nbsp;million to $2.0&nbsp;million on an annual basis. Additionally, if and when
we believe regulatory approval of oral sulopenem and sulopenem appears likely, we anticipate an increase in payroll and expenses as a result of our preparation for commercial operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expense) </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest Income,
Net </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income consists of interest earned and any unrealized gains or losses on our cash equivalents and short-term investments,
which are invested in money market accounts. Our interest income has not been significant due to low interest earned on those balances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Foreign Exchange Gain (Loss) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We realize foreign currency gains (losses) in the normal course of business based on movement in the applicable exchange rates. These gains
(losses) have been insignificant to date and are included as a component of other income (expense). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provision for Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize income taxes under the asset and liability method. Deferred income taxes are recognized for differences between the financial
reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the differences are expected to reverse. The effect on deferred taxes of a change in tax rates is recognized in income in the period
that includes the enactment date. In evaluating our ability to recover our deferred tax assets, we consider all available positive and negative evidence including past operating results, the existence of cumulative income in the most recent fiscal
years, changes in the business in which we operate and our forecast of future taxable income. In determining future taxable income, we are responsible for assumptions utilized including the amount of Irish, U.S. and other foreign <FONT
STYLE="white-space:nowrap">pre-tax</FONT> operating income, the reversal of temporary differences and the implementation of feasible and prudent tax planning strategies. These assumptions require significant judgment about the forecasts of future
taxable income and are consistent with the plans and estimates that we are using to manage the underlying business. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for
uncertain tax positions using a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">more-likely-than-not</FONT></FONT></FONT> threshold for recognizing and resolving uncertain tax positions. The
evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new
audit activity and changes in facts or circumstances related to a tax position. We evaluate our tax position on a quarterly basis. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The
preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and the disclosure of contingent assets
and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making
judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different
assumptions or conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in more detail in Note&nbsp;2 to our consolidated
financial statements appearing at the end of this prospectus, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development
expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred
for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a <FONT STYLE="white-space:nowrap">pre-determined</FONT> schedule or
when contractual milestones are met; however, some require advanced payments. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time.
We periodically </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
confirm the accuracy of these estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">vendors, including central laboratories, in connection with preclinical development activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CROs and investigative sites in connection with preclinical and clinical studies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CMOs in connection with drug substance and drug product formulation of preclinical and clinical trial materials. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended
pursuant to quotes and contracts with multiple research institutions and CROs that conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to
contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on
factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period.
If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our estimates to be materially different from amounts
actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To
date, there have not been any material adjustments to our prior estimates of accrued research and development expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We measure share options and other share-based awards granted to employees and directors based on the fair value on the date of
the grant and recognize the corresponding compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. We have only issued share awards with service-based vesting conditions
and record the expense for these awards using the straight-line method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For share-based awards granted to consultants and <FONT
STYLE="white-space:nowrap">non-employees,</FONT> we recognize compensation expense over the period during which services are rendered by such consultants and <FONT STYLE="white-space:nowrap">non-employees</FONT> until completed. At the end of each
financial reporting period prior to completion of the service, the fair value of these awards is remeasured using the then-current fair value of our ordinary shares and updated assumption inputs in the Black-Scholes option-pricing model. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate the fair value of each share option grant using the Black-Scholes option-pricing model, which uses as inputs the fair value of our
ordinary shares and assumptions we make for the volatility of our ordinary shares, the expected term of our share options, the risk-free interest rate for a period that approximates the expected term of our share options and our expected dividend
yield. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Determination of the Fair Value of Ordinary Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As there has been no public market for our ordinary shares to date, the estimated fair value of our ordinary shares has been determined by our
board of directors as of the date of each option grant, with input from management, considering our most recently available third-party valuation of our ordinary shares as well as our board of directors&#146; assessment of additional objective and
subjective factors that it believed were relevant and which may have changed from the date of the most recent third-party valuation through the date of the grant. Our board of directors considered various objective and subjective factors to
determine the fair value of our ordinary shares as of each grant date, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prices at which we sold preferred shares and the superior rights and preferences of the preferred shares relative to our ordinary shares at the time of each grant; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the progress of our research and development programs, including the status of preclinical studies and clinical trials for our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our stage of development and commercialization and our business strategy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">external market conditions affecting the pharmaceutical industry and trends within the pharmaceutical industry; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our financial position, including cash on hand, and our historical and forecasted performance and operating results; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the lack of an active public market for our ordinary shares and our preferred shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the likelihood of achieving a liquidity event, such as an initial public offering, or IPO, or a sale of our company in light of prevailing market conditions; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the analysis of IPOs and the market performance of similar companies in the pharmaceutical and biotechnology industries. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our third-party valuations of ordinary shares were prepared using the option-pricing method, or OPM, which used an income and market approach
to estimate our enterprise value. The OPM treats ordinary shares and preferred shares as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a
company&#146;s securities changes. Under this method, the ordinary shares have value only if the funds available for distribution to shareholders exceeded the value of the preferred share liquidation preferences at the time of the liquidity event,
such as a strategic sale or a merger. Discounts for lack of control and marketability of the ordinary shares were applied directly or were inherent in the methodologies employed to arrive at an indication of the value for the ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions underlying these valuations represent management&#146;s best estimates, which involve inherent uncertainties and the
application of management judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our share-based compensation expense could be materially different. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the closing of this offering, the fair value of our ordinary shares will be determined based on the quoted market price of our
ordinary shares. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Grants of Share-based awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth by grant date the number of ordinary shares subject to awards granted between November 18, 2015 and December 31,
2017, the per share exercise price of the options and the per share estimated fair value of the options utilized to calculate share-based compensation expense: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="6%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:47.50pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date&nbsp;of&nbsp;Grant</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Type&nbsp;of&nbsp;Award</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number&nbsp;of&nbsp;shares<BR>underlying<BR>awards
granted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exercise&nbsp;price<BR>per share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fair</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>value&nbsp;per&nbsp;share</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on&nbsp;grant&nbsp;date</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">3/8/2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$0.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center">$0.11</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">5/25/2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;0.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center">&nbsp;&nbsp;0.11</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">8/15/2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;0.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center">&nbsp;&nbsp;0.11</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">12/7/2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;0.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center">&nbsp;&nbsp;0.11</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">3/24/2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;0.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center">&nbsp;&nbsp;0.12</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">6/6/2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;0.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center">&nbsp;&nbsp;0.12</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">9/12/2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,683,334</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;0.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center">&nbsp;&nbsp;0.12</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">12/5/2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;0.28</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center">&nbsp;&nbsp;0.16</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31, 2016 and 2017 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our operating losses for the years ended December&nbsp;31, 2016 and 2017: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in&nbsp;thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,455</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,096</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2017, CARB-X awarded us funds of up to $1.5&nbsp;million to advance the development of our sulopenem program. We receive funding from
CARB-X as we incur qualifying expenses. During the year ended December&nbsp;31, 2017, we recognized $0.5&nbsp;million of revenue under this award. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in&nbsp;thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chemistry, manufacturing and control (CMC) related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CRO and other preclinical and clinical trial related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (including share-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consulting fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;10,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;25,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;15,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase in CMC related expenses of $11.2&nbsp;million was primarily due to formulation
development, manufacturing process, and manufacturing of clinical trial material in anticipation of our Phase&nbsp;3 clinical trials in 2018. CRO and other preclinical and clinical trial related expenses increased by $1.8&nbsp;million due to
increased Phase&nbsp;1 and Phase&nbsp;4 clinical trial activity. Personnel related costs increased by $1.8&nbsp;million as a result of an increase in headcount in our CMC, clinical development and regulatory functions. Personnel related costs for
the years ended December&nbsp;31, 2016 and 2017 included share-based compensation expense of $0.1&nbsp;million and $0.1&nbsp;million, respectively. The increase in consulting fees of $0.6&nbsp;million was primarily due to the increase in consultants
used for preclinical and clinical trial activity. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in&nbsp;thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (including share-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional and consultant fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility related and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;3,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;4,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;1,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase in facility related and other costs of $0.7&nbsp;million was primarily due
to the lease of office space in Dublin that we entered into at the end of 2016, software costs, director compensation and travel expenses, and general support costs for the increase in headcount. Personnel related costs increased by
$0.5&nbsp;million as a result of an increase in headcount in our general and administrative function. Personnel related costs for the years ended December&nbsp;31, 2016 and 2017 included share-based compensation expense of $0.2&nbsp;million and
$0.3&nbsp;million, respectively. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have incurred significant operating losses and negative cash flows from our operations. We have generated limited
revenue to date from a funding arrangement with <FONT STYLE="white-space:nowrap">CARB-X.</FONT> We have funded our operations to date primarily with proceeds from the sale of preferred shares and ordinary shares and payments received under the
funding arrangement with <FONT STYLE="white-space:nowrap">CARB-X.</FONT> Through December&nbsp;31, 2017, we had received gross cash proceeds of $87.5&nbsp;million from sales of our Series&nbsp;A and Series&nbsp;B-1 preferred shares and ordinary
shares. As of December&nbsp;31, 2017, we had cash and cash equivalents and short-term investments of $39.2&nbsp;million. In February 2018, we received gross cash proceeds of $32.2&nbsp;million from the sale of
<FONT STYLE="white-space:nowrap">Series&nbsp;B-2</FONT> preferred shares. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for each of the periods presented: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,298</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(30,604</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,587</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2016, operating activities used $11.3&nbsp;million of cash, resulting from our net loss of
$13.5&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $0.4&nbsp;million and net cash provided by changes in our operating assets and liabilities of $1.8&nbsp;million. Net cash provided by changes in our
operating assets and liabilities for the year ended December&nbsp;31, 2016 consisted primarily of increases in accrued expenses and accounts payable primarily due to increases in clinical trial supply and costs, partially offset by increases in
prepaid expenses and other assets primarily related to advance payments to contract manufacturing organizations. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year
ended December&nbsp;31, 2017, operating activities used $30.6&nbsp;million of cash, resulting from our net loss of $29.4&nbsp;million and net cash used in changes in our operating assets and liabilities of $1.6&nbsp;million, partially offset by <FONT
STYLE="white-space:nowrap">non-cash</FONT> charges of $0.4&nbsp;million. Net cash used in changes in our operating assets and liabilities for the year ended December&nbsp;31, 2017 consisted of increases in prepaid expenses and other assets primarily
related to advance payments to contract manufacturing organizations, partially offset by increases in accrued expenses and accounts payable primarily due to increases in clinical trial supply and costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We did not use any
cash for investing activities during the year ended December&nbsp;31, 2016. During the year ended December&nbsp;31, 2017, net cash used in investing activities of $31.6&nbsp;million was primarily related to purchases of short-term investments of
$53.3&nbsp;million and fixed asset purchases of $0.8&nbsp;million, partially offset by sales of short-term investments of $22.5&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2016, net cash provided by financing activities was $20.9&nbsp;million, and consisted of gross cash
proceeds from the issuance of Series&nbsp;A preferred shares in December 2016. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2017, net cash
provided by financing activities was $45.9&nbsp;million, and consisted of gross cash proceeds from the issuance of <FONT STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> preferred shares in May 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding Requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect
our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the clinical trials of oral sulopenem and sulopenem. In addition, upon the closing of this offering, we expect to incur additional costs
associated with operating as a public company. Our expenses will also increase if and as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conduct additional clinical trials for oral sulopenem and sulopenem, which include our planned Phase&nbsp;1 clinical trials, which we expect will occur in 2018 and 2019, and our three planned pivotal Phase&nbsp;3
clinical trials which we plan to initiate in the second half of 2018; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">initiate other studies as part of our sulopenem program, some of which may be required for regulatory approval of our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish a sales, marketing and distribution infrastructure to commercialize oral sulopenem and sulopenem in the United States if we obtain marketing approval from the U.S. Food and Drug Administration (FDA);
</TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish manufacturing and supply chain capacity sufficient to provide commercial quantities of oral sulopenem and sulopenem, if we obtain marketing approval; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pursue the development of our sulopenem program in additional indications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain, expand, defend and protect our intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">hire additional clinical, scientific and commercial personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts, as well as to support our transition to a
public reporting company; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates or technologies. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the anticipated net proceeds from this offering, together with our existing cash, will enable us to fund our operating
expenses and capital expenditure requirements for at least the next &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available
capital resources sooner than we expect. We expect that we will require additional capital to file with regulatory agencies and commercialize oral sulopenem and sulopenem, if we receive regulatory approval, and to pursue <FONT
STYLE="white-space:nowrap">in-licenses</FONT> or acquisitions of other product candidates. If we receive regulatory approval for oral sulopenem or sulopenem, we expect to incur significant commercialization expenses related to product manufacturing,
sales, marketing and distribution, depending on where we choose to commercialize. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties
associated with research, development and commercialization of pharmaceutical product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements, both short-term and long-term will
depend on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and costs of our planned clinical trials of oral sulopenem and sulopenem; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the initiation, progress, timing, costs and results of preclinical studies and clinical trials of other potential product candidates and of our current product candidates in additional indications; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount of funding that we receive under government awards that we have applied for or may apply for in the future; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and characteristics of product candidates that we pursue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the outcome, timing and costs of seeking regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of commercialization activities for oral sulopenem and sulopenem and other product candidates if we receive marketing approval, including the costs and timing of establishing product sales, marketing,
distribution and manufacturing capabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the receipt of marketing approval and revenue received from any potential commercial sales of oral sulopenem and sulopenem; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and timing of any future collaborations, licensing or other arrangements that we may establish; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property
rights, including milestone and royalty payments and patent prosecution fees that we are obligated to pay pursuant to the Pfizer License or other future license agreements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against any intellectual property related claims; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of operating as a public company; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire other products and technologies. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs
through a combination of public or private equity offerings, debt financings, collaboration agreements, other third-party funding, strategic alliances, licensing arrangements, marketing and distribution arrangements or government funding. To the
extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your
rights as an ordinary shareholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making
capital expenditures or declaring dividends. If we raise additional funds through other third-party funding, collaborations agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish
valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when
needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market
ourselves. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Commitments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our contractual obligations as of December&nbsp;31, 2017 and the effects that such obligations are expected to
have on our liquidity and cash flows in future periods: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments Due by Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>1 Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1 to 3<BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>4 to 5<BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than<BR>5 Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease commitments<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Reflects payments due for our leases of office space under operating lease agreements that expire in 2018, 2022 and 2026. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our license agreement with Pfizer, we have agreed to make certain clinical, regulatory
and sales milestone payments, pay royalties and make a potential <FONT STYLE="white-space:nowrap">one-time</FONT> payment related to sublicensing income that exceeds a certain threshold. We have not included any contingent payment obligations, such
as milestones, royalties, or <FONT STYLE="white-space:nowrap">one-time</FONT> payments, in the table above as the amount, timing and likelihood of such payments are not known. Under the Pfizer License, we are obligated to make certain clinical,
regulatory and sales milestone payments. We expect to use $15.0&nbsp;million of the proceeds from this offering for milestone payments to Pfizer. We are obligated to pay Pfizer royalties ranging from a single-digit to
<FONT STYLE="white-space:nowrap">mid-teens</FONT> percentage based on marginal net sales of each licensed product. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, we
entered into an agreement with a supplier whereby we agreed to pay $3.0&nbsp;million to the supplier to acquire equipment, which will be used solely to manufacture product for us. This payment will be offset against the price of the product to be
supplied under a future supply agreement. As of December&nbsp;31, 2017, $0.6&nbsp;million remained outstanding to the supplier. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth
Company Status </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Jumpstart Our Business Startups Act of 2012 permits an &#147;emerging growth company&#148; such as us to take
advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected to &#147;opt out&#148; of this
provision and, as a result, we will comply with new or revised accounting standards when they are required to be adopted by public companies that are not emerging growth companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We did not have during the period presented, and we do not currently have, any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet
arrangements, as defined in the rules and regulations of the Securities and Exchange Commission. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Issued Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is
disclosed in Note&nbsp;2 to our consolidated financial statements appearing at the end of this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures
about Market Risks </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We had cash and cash equivalents of $8.5&nbsp;million as of December&nbsp;31, 2017, consisting of cash in <FONT
STYLE="white-space:nowrap">non-interest</FONT> bearing accounts in highly rated financial institutions in the United States and Ireland and money market accounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We contract with CROs and contract manufacturers globally. We may be subject to fluctuations in foreign currency rates in connection with
certain of these agreements. Transactions denominated in currencies other than the functional currency are recorded based on exchange rates at the time such transactions arise. As of December 31, 2016 and 2017, substantially all of our liabilities
were denominated in U.S. dollars. Net foreign currency gains and losses did not have a material effect on our results of operations for the years ended December&nbsp;31, 2016 and 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc522368_10"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a pharmaceutical
company dedicated to developing and commercializing sulopenem to be potentially the first and only oral and intravenous (IV)&nbsp;branded penem available globally. Penems, including thiopenems and carbapenems, belong to a class of antibiotics more
broadly defined as &szlig;-lactam antibiotics, the original example of which was penicillin, but which now also includes cephalosporins. Sulopenem is a potent, targeted gram-negative spectrum thiopenem delivered intravenously, which we have
successfully developed in an oral tablet formulation, sulopenem etzadroxil-probenecid. Both sulopenem product candidates have the potential to be important new treatment alternatives to address growing concerns related to antibacterial resistance
without the known toxicities of some of the most widely-used antibiotics, specifically fluoroquinolones. We see two distinct opportunities for our sulopenem program: patients at elevated risk for treatment failure in the community setting suffering
from uncomplicated urinary tract infections (uUTI) and hospitalized patients suffering from complicated, antibiotic-resistant infections. Therefore, we plan to initiate a Phase 3 clinical program in the second half of 2018 for the treatment of
adults in three indications: uUTI, complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). We designed one Phase 3 clinical trial in each indication based on our end of Phase 2 meeting with the U.S. Food and
Drug Administration (the FDA) and feedback from the European Medicines Agency (the EMA). We intend to conduct the Phase 3 clinical trials under Special Protocol Assessment (SPA) agreements from the FDA. We expect to complete enrollment and produce
topline data for all three clinical trials in the second half of 2019, and file our new drug applications (NDAs) with the FDA by the end of 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2015, we acquired an exclusive, worldwide license under certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT> to
develop and commercialize sulopenem and its oral prodrug, sulopenem etzadroxil, from Pfizer Inc. (Pfizer). Pfizer conducted Phase 1 and Phase 2 clinical trials of sulopenem delivered intravenously in Japan in over 1,450 patients with a variety of
hospital and community acquired infections. These clinical trials documented a treatment effect in the indications studied as well as a safety profile similar to marketed carbapenems. Pfizer subsequently developed sulopenem into a prodrug
formulation, sulopenem etzadroxil, to enable oral delivery. Once this prodrug is absorbed in the gastrointestinal tract, the etzadroxil ester is immediately cleaved off and the active moiety, sulopenem, is released into the bloodstream. We have
further enhanced this prodrug formulation with the addition of probenecid to extend sulopenem&#146;s half-life and enhance its antibacterial potential. Probenecid is a pharmacokinetic enhancer that has been safely and extensively used globally for
decades. The oral dose of sulopenem etzadroxil-probenecid will be combined in a single bilayer tablet, which we refer to as oral sulopenem. We refer to sulopenem delivered intravenously as sulopenem and, together with oral sulopenem, as our
sulopenem program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The treatment of urinary tract and intra-abdominal infections has become more challenging because of the development
of resistance by pathogens responsible for these diseases. There are approximately 13.5 million emergency room and office visits for symptoms of urinary tract infections (UTIs) and approximately 21 million uUTIs in the United States annually. Based
on market research, physicians estimated that approximately 35% of these patients are at elevated risk for treatment failure. Proper antibiotic treatment of resistant infections in this group is particularly important due to the risks associated
with treatment failure. Elevated risk patients were defined in the research as patients with recurrent UTIs, elderly patients, those who have a suspected or confirmed drug-resistant infection, patients with comorbidities (e.g., Diabetes mellitus) or
that are immunocompromised, patients that have had a recent hospitalization, patients with a history of prior antibiotic failure and patients in a long-term care setting. Treatment failures pose significant clinical and economic challenges to the
healthcare system. There are also approximately 3.6 million patients with cUTI and approximately 350,000 patients with cIAI that require antibiotic therapy every year in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Growing antibiotic resistance to <I>E. coli, </I>the primary cause of UTIs, has complicated the choice of treatment alternatives in both the
community and hospital settings, reducing effective treatment choices for physicians. In addition, the Infectious Diseases Society of America and European Society for Microbiology and Infectious Diseases recommend against empiric use, or prescribing
without results from a bacterial culture, of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fluoroquinolones for uUTIs in their 2010 Update to the International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women. Similarly, the FDA
in its November 2015 Advisory Committee meeting stated that the risk of serious side effects caused by fluoroquinolones generally outweighs the benefits for patients with uUTIs and other uncomplicated infections. Subsequently, the FDA mandated
labeling modifications for quinolone antibiotics directing healthcare professionals to reserve fluoroquinolones for patients with no other treatment alternatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the most commonly used oral antibiotics for treatment of uUTIs were initially approved by the FDA within the last two decades.&nbsp;We
believe oral sulopenem will be an important empiric treatment option for elevated risk uUTI patients because of its potency against resistant pathogens, as well as its spectrum of antibacterial activity.&nbsp;In addition, oral sulopenem will allow
patients who develop an infection with a resistant pathogen, but are stable enough to be treated in the community, to avoid the need for an IV catheter and even hospitalization. The primary endpoint of our uUTI Phase 3 clinical trial is designed to
demonstrate <FONT STYLE="white-space:nowrap">non-inferiority</FONT> in patients with ciprofloxacin-susceptible pathogens but also provides an opportunity to demonstrate superiority to ciprofloxacin for oral sulopenem in patients with
ciprofloxacin-resistant pathogens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the hospital setting, the lack of effective oral stepdown options results in the potential for
lengthy hospital stays or insertion of a peripherally inserted central catheter (PICC) to facilitate administration of IV antibiotics, even for some patients with relatively straightforward infections. Our sulopenem program may enable faster
discharges, providing cost-saving advantages for the hospital and mitigating the risk of catheter-related infection for patients. Based on potency, safety and formulation advantages, we believe our sulopenem program is uniquely positioned to address
unmet medical needs for patients suffering from uncomplicated and complicated infections in both the community and hospital settings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
the FDA approves oral sulopenem and sulopenem, we plan to build a commercial infrastructure to launch both product candidates in the United States. Data from a study we commissioned in 2017 to quantify zip code level quinolone resistance, in
addition to data from our clinical trials and available prescriber data, will inform our initial targeted sales force as to where the medical need for a new, effective therapy for UTIs is highest in the community and hospital settings. Outside of
the United States, we are evaluating our options to maximize the value of our sulopenem program. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to employ a dual sourcing
strategy for critical elements of our sulopenem supply chain. We expect to register and validate two suppliers for the manufacture of the active pharmaceutical ingredient (API) at the time of our planned regulatory filings in the United States by
the end of 2019. Also, given the importance of oral sulopenem to our potential commercial results, we plan to utilize two sites to manufacture sulopenem tablets: one third-party facility registered and validated to supply product for our launch and
an Iterum-operated facility registered and validated within one year of product launch. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Sulopenem-etzadroxil</FONT> has an issued composition of matter patent in the United States (which we have
exclusively licensed from Pfizer) that is scheduled to expire in 2029, subject to potential extension to 2034 under The Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). In addition, the FDA has designated
sulopenem and oral sulopenem as Qualified Infectious Disease Products (QIDP) for the indications of uUTI, cUTI and cIAI pursuant to the Generating Antibiotic Incentives Now Act (the GAIN Act), which provides the potential for a more rapid NDA review
cycle and could add five years to any regulatory exclusivity period that we may be granted. QIDP status for other indications, such as respiratory tract infections, gonorrhea and diabetic foot infection is also possible given the coverage of
gram-negative and gram-positive bacteria by sulopenem, pending submission of additional documentation and acceptance by the FDA. None of the licensed patents cover the IV formulation of sulopenem. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were founded in June 2015 by former executives of Durata Therapeutics,&nbsp;Inc. (Durata), a biopharmaceutical company, which developed
dalbavancin, another antibiotic from the Pfizer portfolio, and successfully obtained FDA approval, launched the product in the United States, and submitted a marketing authorization application (MAA) to the EMA (approval was received in 2015).
Durata was acquired by Allergan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(formerly Actavis, Inc.) in late 2014. To date, we have raised approximately $120 million to develop our sulopenem program from a leading investor group including Advent Life Sciences, Arix
Bioscience plc, Bay City Capital, Canaan Partners, Domain Associates, Frazier Healthcare Partners, New Leaf Venture Partners, Pivotal bioVenture Partners, and Sofinnova Ventures, as well as our founders. Pfizer is also one of our shareholders. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sulopenem Program, Clinical and Regulatory Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to pursue three initial indications for oral sulopenem and sulopenem, as summarized in the chart below. We designed these Phase 3
clinical trials based on extensive <I>in vitro</I> microbiologic surveillance data, Phase 1 pharmacokinetic data from healthy volunteers as well as population pharmacokinetic data from patients, animal models in relevant disease settings, Phase 2
data from a program performed with sulopenem by Pfizer in Japan in the early 1990s, and regulatory feedback from FDA at an end of Phase 2 meeting, all supported by an advanced commercial manufacturing program which will provide clinical supplies.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to conduct the Phase 3 clinical trials under SPA agreements from the FDA. We expect to complete enrollment and produce topline
data for all three clinical trials in the second half of 2019, and file our NDAs with the FDA by the end of 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g522368g20i14.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy is to develop and commercialize our sulopenem program for multiple indications, and in the long term to build a market-leading
anti-infective business. The key elements of this strategy include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Complete sulopenem clinical development in three initial indications</I></B>.<B><I> </I></B>Conduct single Phase 3 clinical trials in each of our three initial indications: uUTI, cUTI and cIAI. We have received
SPA agreements from the FDA for cIAI, cUTI and uUTI. We plan to begin enrollment in all three clinical trials in the second half of 2018 and expect to conclude enrollment in the second half of 2019, with
<FONT STYLE="white-space:nowrap">top-line</FONT> data available in the same period. </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Obtain regulatory approval for oral sulopenem and sulopenem in the United States and subsequently in the European Union</I></B><B>.</B> We designed our Phase 3 clinical program based on extensive discussions with
the FDA, including our end of Phase 2 meeting in July 2017, and considered scientific advice received from the EMA to meet the regulatory filing requirements in the European Union. If our Phase 3 clinical trials are successful, we plan to submit
NDAs for both oral sulopenem and sulopenem to the FDA by the end of 2019 and subsequently submit an MAA to the EMA. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Maximize commercial potential of sulopenem program.</I></B> If approved, we intend to directly commercialize our sulopenem program in the United States with a targeted community and hospital sales force. Outside
of the United States, we are evaluating our options to maximize the value of the sulopenem program. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Pursue the development of oral sulopenem and sulopenem in additional indications</I></B>. In the future, we may pursue development of our sulopenem program in additional indications in adults and children,
including respiratory tract infections, gonorrhea and diabetic foot infection, as well as new formulations to support these indications. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Build a portfolio of differentiated anti-infective products</I></B>. We intend to enhance our product pipeline through strategically <FONT STYLE="white-space:nowrap">in-licensing</FONT> or acquiring clinical stage
product candidates or approved products for the community and/or hospital, and acute care markets. We believe that our focus on acute care in both the community and hospital markets will make us an attractive partner for companies seeking to <FONT
STYLE="white-space:nowrap">out-license</FONT> products or product candidates in our areas of focus. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Medical Need </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Urinary Tract and Intra-Abdominal Infections </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">UTIs are among the most common bacterial infections encountered in the ambulatory setting. A UTI occurs when one or more parts of the urinary
system (kidneys, ureters, bladder or urethra) become infected with a pathogen (most frequently, bacteria). While many UTIs are not considered life-threatening, if the infection is caused by a multi-drug resistant (MDR) bacterial pathogen, or reaches
the kidneys, serious illness, and even death, can occur. UTI diagnoses are stratified between either complicated or uncomplicated infections. uUTI refers to the invasion of a structurally and functionally normal urinary tract by a nonresident
infectious organism (e.g. acute cystitis), and is diagnosed and commonly treated with an oral agent in an outpatient setting. Conversely, cUTIs, including acute pyelonephritis, are defined as a urinary tract infection ascending from the bladder
accompanied by local and systemic signs and symptoms, including fever, chills, malaise, flank pain, back pain, and/or costo-vertebral angle pain or tenderness, that occur in the presence of a functional or anatomical abnormality of the urinary tract
or in the presence of catheterization, with treatment typically initiated by IV therapy in a hospital setting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">cIAIs have similar
challenges to that of cUTIs. These complicated infections extend from a gastrointestinal source, such as the appendix or the colon, into the peritoneal space and can be associated with abscess formation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Antimicrobial Resistance is Increasing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>E. coli</I> is growing increasingly resistant to many classes of antibiotics, which is especially problematic for patients suffering from
UTIs because <I>E. coli</I> is the primary cause of those infections. The market leading antibiotics, fluoroquinolones (e.g., Cipro, Levaquin) and trimethoprim-sulfamethoxazole (e.g., Bactrim, Septra), currently have <I>E. coli </I>resistance rates
over 20% nationally. In 2015, approximately 75% of oral prescriptions for UTIs given in the United States were for fluoroquinolones or trimehoprim-sulfamethoxazole. In hospitals, fluoroquinolones have greater than 30% resistance in approximately
half the states in the United States, and have greater than 25% resistance rates in nearly 80% of the states. Between 2000 and 2009 the prevalence of extended spectrum beta-lactamases (ESBL)-producing <I>E.&nbsp;coli</I> and ESBL-producing <I>K.
pneumoniae</I> more than doubled from 3.3% to 8.0% and from 9.1% to 18.6%, respectively. During the same timeframe, hospitalizations caused by ESBL-producing organisms increased by about 300%. The national resistance rate of <I>E. coli</I> to
cephalosporins was estimated to be approximately 13% for the combined years of 2011 to 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have further delineated the prevalence of
bacterial resistance to antibiotics used to treat UTIs in the United States. In 2015, 25 states identified as high prevalence for <I>E.</I> <I>coli</I> resistance produced approximately 75% of all UTI prescriptions in the United States. Based on
urine culture results obtained at the zip code level from outpatient UTIs, we concluded that the prevalence of resistance of Enterobacteriaceae to quinolone antibiotics is over 20% in a significant portion of the country. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Geographic prevalence of quinolone <FONT STYLE="white-space:nowrap">non-susceptible</FONT>
Enterobacteriaceae by zip code in outpatient urine&nbsp;cultures. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g522368g29x80.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>Numbers represent hospital centers from which data were derived. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As antibiotic resistance leads to increased costs of treatment and increased morbidity as well as increased mortality, there is an urgent
unmet medical need for antimicrobial agents that can be utilized in community and hospital infections. The antimicrobial class of penems has the potential to address many of the relevant resistance issues associated with &szlig;-lactam antibiotics
because of a targeted spectrum of antibacterial activity and intrinsic stability against hydrolytic attack by many &szlig;-lactamases, including ESBL and AmpC enzymes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>There is a Significant Population at Risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are approximately 13.5 million emergency room and office visits for symptoms of urinary tract infections (UTIs) and approximately 21
million uUTIs in the United States annually. Based on market research, physicians estimated that approximately 35% of these patients are at elevated risk for treatment failure. Proper antibiotic treatment of resistant infections in this group is
particularly important due to the consequences associated with treatment failure. Elevated risk patients were defined in the research as patients with recurrent UTIs, elderly patients, those patients who have a suspected or confirmed drug-resistant
infection, patients with comorbidities (e.g., Diabetes mellitus) or that are immunocompromised, patients that have had a recent hospitalization, patients with a history of prior antibiotic failure and patients in a long-term care setting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are also approximately 3.6 million patients with cUTI and approximately 350,000 patients with cIAI that require antibiotic therapy every
year in the United States. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Limited Treatment Options </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to worsening antibiotic resistance, many of the antibiotics currently used for first-line empiric oral treatment of uUTIs, such as
nitrofurantoin and trimethoprim-sulfamethoxazole, suffer from significant safety and tolerability concerns. Pulmonary fibrosis and diffuse interstitial pneumonitis has been observed in patients treated with nitrofurantoin, which is contraindicated
in pregnant women after 38 weeks of gestation and newborn children due to hemolytic anemia and in patients with poor renal function. Trimethoprim-sulfamethoxazole is associated with fatal hypersensitivity reactions, embryofetal toxicity,
hyperkalemia, gastrointestinal disturbances and rashes, including rare cases of Stevens-Johnson Syndrome. In addition, some antibiotics, such as nitrofurantoin and fosfomycin, have poor tissue penetration. The limited oral antibiotic treatment
options for patients with uUTIs can sometimes result in hospitalization to facilitate administration of IV antibiotics for patients whose infection progresses; in addition, some patients whose uUTI remains uncomplicated may require
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hospital admission for IV therapy. For patients with cUTIs, the lack of effective oral stepdown options, which is demonstrated by the fact that none of the most commonly used oral agents were
initially approved by the FDA in the last two decades, results in the potential for lengthy hospital stays or insertion of a PICC to facilitate administration of IV antibiotics, even for some patients with relatively straightforward infections.
Therefore, based both on the epidemiology described above and confirmed after recent discussions with practicing clinicians and pharmacists, we believe there is a pressing need for a novel oral antibacterial therapy for UTI, both complicated and
uncomplicated, that has potent activity against ESBL producing and quinolone resistant gram-negative organisms. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Challenge of Developing
Antibiotics </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Antibiotics work by targeting a critical function of the bacteria and rendering it
<FONT STYLE="white-space:nowrap">non-functional.</FONT> These critical functions include the ability to make proteins, to replicate further, and to build protective envelopes against the harsh external environment. These functions are coded in the
bacteria&#146;s DNA, which is copied over to each generation. Occasionally errors are made in the copying; typically, these errors kill off the progeny but can sometimes actually help them survive under specific circumstances, namely when threatened
by an antibiotic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Bacterial mutations, these errors in the DNA coding, allow the organism to change their protein structures sufficiently
to prevent target-specific antibiotics from working. Over time, the subsequent generations of bacteria retain these mutations and even develop additional ones that make them resistant to multiple classes of antibiotics. Furthermore, bacteria have
also developed mechanisms that allow them to pass these genetic mutations directly to other nearby bacteria, even those from a different species. When they contain more than one resistance mechanism, these organisms are known as multi-drug resistant
(MDR) pathogens. The limited number of antibiotic classes poses a concern that eventually we will not have any antibiotics available to treat patients who develop an infection caused by these MDR bacteria. We continue to need new antibiotics that
stay one step ahead of these mutating bacteria in order to protect against the infections that they cause. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Market Leader for Treatment of UTIs is
Failing Patients </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fluoroquinolones are now the most widely used antibiotic class in treating community and hospital gram-negative
infections. However, the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases now recommend against empiric use of fluoroquinolones for uUTIs in their 2010 Update to the International Clinical
Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women as they &#147;have a propensity for collateral damage and should be reserved for important uses other than acute cystitis and thus should be considered
alternative antimicrobials for acute cystitis.&#148; Similarly, the FDA in its November 2015 Advisory Committee meeting stated that the risk of serious side effects caused by fluoroquinolones generally outweighs the benefits for patients with uUTIs
and other uncomplicated infections. Serious side effects associated with fluoroquinolones include tendon rupture, tendinitis, and worsening symptoms of myasthenia gravis and peripheral neuropathy. Subsequently, the FDA mandated labeling
modifications for quinolone antibiotics directing healthcare professionals to reserve fluoroquinolones for patients with no other treatment alternatives. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Solution to Rising Resistance </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
solution to the problem of resistance is based on strategies to use those antibiotics only when patients really need them, limiting the number of opportunities for the bacteria to develop these mutations, and to continue efforts aimed at the
discovery and development of new and effective antibacterial agents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These new agents will need to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">kill the organisms responsible for the actual infection; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">target a specific bacterial function and overcome the existing resistance mechanisms around that function; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be powerful enough to require a minimal amount of drug to kill the organism at the site of infection; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be delivered to a patient in a manner which is safe, tolerable and convenient. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the last
thirty years, the penem class of antibiotics, including carbapenems such as imipenem, meropenem, doripenem and ertapenem, have been potent and reliable therapeutic options for patients with serious infections. Their spectrum of activity includes
those pathogens responsible for infections such as those in the intra-abdominal space, urinary tract, and respiratory tract with a potency as good or better than any other antibiotic class, targeting the cell wall of bacteria, a critical element of
bacterial defense. Resistance to the class, generally caused by organisms which have acquired a carbapenemase, is rarely, if ever, seen in the community setting and is primarily localized to patients with substantial healthcare exposures,
particularly recent hospitalizations. These drugs are generally very well tolerated. Their limitation is the requirement to be delivered intravenously, restricting their utility to hospitalized patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Sulopenem Program </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the limitations of existing agents. Sulopenem has <I>in vitro</I> activity against gram-negative organisms with resistance to one or more established
antibiotics and can be delivered in an oral formulation. If a UTI occurs in the community setting, oral sulopenem can be provided as a tablet, offering an option for care of those with a culture proven or suspected MDR pathogen, potentially avoiding
the need for hospitalization. If a patient requires hospitalization for an infection due to a resistant organism, treatment can be initiated intravenously with sulopenem and once the infection begins to improve, stepped down to oral sulopenem,
potentially enabling the patient to leave the hospital. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potential Advantages of Oral Sulopenem and Sulopenem </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing our sulopenem program to offer patients and clinical care providers a new option to treat resistant gram-negative infections
with confidence in its antimicrobial activity, and the flexibility to treat patients in the community while getting those hospitalized back home. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sulopenem&#146;s differentiating characteristics include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Activity as an oral agent and favorable pharmacokinetic profile. </I></B>Sulopenem is the active moiety with antibacterial activity. Oral sulopenem is a prodrug specifically selected among many other prodrug
candidates because it enables the absorption of sulopenem from the gastrointestinal tract. It is this oral agent, sulopenem etzadroxil, that we believe meets an urgent medical need to allow patients with resistant pathogens to be treated safely in
the community, as well as allowing hospitalized patients to continue their treatment at home. Oral sulopenem is sufficiently absorbed from the gastrointestinal tract to allow the parent compound, sulopenem, to achieve adequate exposure in the
tissues and, as demonstrated in animal models, to significantly reduce the burden of offending pathogens. Based on pharmacokinetic modeling and supported by prior clinical data from Japan, we believe dosing of the oral agent twice daily will provide
tissue exposure sufficient to resolve clinical infection. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Targeted spectrum of activity against relevant pathogens without pressure on other incidental <FONT STYLE="white-space:nowrap">gram-negative</FONT> organisms</I></B>. Sulopenem is active against the pathogens that
are most likely to cause infection of the urinary and gastrointestinal tract, including <I>E. coli</I>, <I>K. pneumoniae</I>, <I>P. mirabilis </I>and<I> B.&nbsp;fragilis</I>.<I> </I>Like ertapenem, sulopenem is not active against certain
gram-negative organisms such as <I>Pseudomonas aeruginosa</I> and <I>Acinetobacter baumannii</I>. These organisms are not typically seen in community UTIs and are infrequently identified in UTIs in the hospital, except when patients have had an
indwelling urinary catheter for an extended duration. As a result, we believe the targeted spectrum of sulopenem is less likely to put pressure on those pathogens which could otherwise have led to carbapenem resistance. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Activity against multidrug resistant pathogens. </I></B>Bacteria are accumulating resistance mechanisms to multiple classes of antibiotics within the same organism, and as a consequence physicians are losing
confidence in existing antibiotics as empiric therapy before culture results become available. Sulopenem is active against organisms that have multiple resistance mechanisms and can help avoid some of the consequences of ineffective antibiotic
therapy. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Documented safety and tolerability profile. </I></B>Adverse event data collected as part of the Japanese Phase&nbsp;2 development program with the IV formulation documents the overall safety profile of sulopenem,
which is similar to that of the marketed carbapenems. Data is also available for the oral formulation collected in healthy volunteers in the Phase&nbsp;1 program conducted by us that is consistent with a well-tolerated regimen and similar to the
adverse event profile observed with the IV formulation. One additional adverse event identified with the oral prodrug is loose stools, which were considered of mild severity and were self-limited, as seen with other broad spectrum oral antibiotics
with activity against the anaerobic flora of the gastrointestinal tract. In the Japanese program, one patient reported a serious adverse event related to sulopenem of a transient elevation in liver function tests. The patient died due to metastatic
lung cancer. Other serious adverse events recorded in patients receiving sulopenem in the Japanese program, which were not related by the investigator to sulopenem, included myocardial infarction with respiratory failure and progression of
underlying ovarian carcinoma, in both cases resulting in death. For each of these patients, sulopenem was not determined to be the cause of death. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Availability of an IV formulation. </I></B>Sulopenem is expected to be available intravenously. Patients sick enough to require hospitalization may not be good candidates for initial oral therapy, given potential
uncertainties around the ability to absorb drugs due to diminished gastrointestinal and target tissue perfusion in patients with compromised cardiovascular status associated with sepsis or reduced gastrointestinal motility. An IV and oral
formulation will enable the conduct of clinical registration trials in a manner consistent with typical clinical practice, allow for confidence in the initiation of therapy in seriously ill patients and, if approved, offer both important
formulations as therapeutic options. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Advanced manufacturing program. </I></B>The synthetic pathway for sulopenem, initially defined in the 1980s, has now evolved through its third iteration, incorporating improvements in yield and scalability. We
expect to register two different contract manufacturing organizations to manufacture the active pharmaceutical ingredient (API) for oral sulopenem and sulopenem. Both of the contract manufacturers have the capability to produce vials for IV
delivery. We plan to utilize two sites to produce sulopenem tablets: one third-party facility registered and validated to supply product for our launch and an Iterum-operated facility registered and validated within one year of product launch.
</TD></TR></TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Market Opportunity for Oral Sulopenem and Sulopenem </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon the clinical evidence to date in eradicating key pathogens, coupled with unmet medical needs, if approved, we expect the commercial
opportunity for oral sulopenem and sulopenem to be substantial with initial focus on the following areas: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">treating uUTI with an oral formulation in community treatment settings; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">treating cUTI with initiation of IV therapy in the hospital, and transitioning to oral formulation upon discharge to complete therapy in the community setting; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">treating cIAI with initiation of IV therapy in the hospital, and transitioning to oral formulation upon discharge to complete therapy in the community setting. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acute cystitis remains one of the most common indications for prescribing antimicrobials to otherwise healthy women, resulting in as many as
13.5&nbsp;million office or emergency room visits in the United States annually, according to a review published in 2015. Up to 50% of all women experience one episode by 32 years of age. In addition, there are approximately 3.6 million patients a
year in the United States for the more serious cases of cUTI. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, cIAIs are the second most common cause of infectious mortality in intensive
care units. Among approximately 350,000 cIAI patients in the United States each year, broad spectrum antibiotics are generally administered as first line treatment; treatment failure is more common due to the serious nature of these infections. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, <I>E. coli</I> resistance presently exceeds 20% for fluoroquinolones, trimethoprim-sulfamethoxazole and ampicillin. Our
market research indicated that physicians identified the lack of effective oral agents for these more difficult drug-resistant infections as a key unmet need in their practice. Physicians are particularly concerned by drug-resistant infections in
the 35% of patients considered to be at elevated risk for treatment failure, as they pose significant potential clinical and economic challenges to the healthcare system when initial therapy is unsuccessful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the growing prevalence of bacterial resistance that has rendered existing oral therapies ineffective, coupled with the FDA mandating new
safety labeling changes to enhance warnings limiting fluoroquinolone use in uncomplicated infections due to the association with disabling and potentially permanent side effects, physicians are seeking new alternatives to safely and effectively
treat their patients. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our oral sulopenem&#146;s value proposition will aid physicians in the community setting to address
the unmet need for a safe and effective oral uUTI therapy to treat the growing number of patients with suspected or confirmed resistant pathogen(s). In addition, we believe our sulopenem program will offer a compelling value proposition to hospitals
by enabling the transition of patients from IV therapy in the inpatient setting to an oral therapy in the community. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Oral Sulopenem and
Sulopenem Clinical Development Program </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following graphic provides an overview of the past development of sulopenem
etzadroxil and sulopenem by Pfizer and Iterum. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Discovery, Development, and Regulatory History of Sulopenem and Sulopenem
Etzadroxil </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g522368g19c10.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The objective of the sulopenem development program is to deliver to patients an oral and IV
formulation of sulopenem approved in the United States and Europe for the treatment of infections due to resistant gram-negative pathogens. Sulopenem&#146;s spectrum of activity, the availability of an oral agent delivered in a convenient dosing
schedule and the promising evolving safety profile support its further development for the target indications of uUTI, cUTI and cIAI. Oral sulopenem is the oral prodrug metabolized to sulopenem, its therapeutically active form. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Both sulopenem and oral sulopenem have received QIDP designation status for the
indications of uUTI, cUTI and cIAI. QIDP designation status for other indications, such as respiratory tract infections, gonorrhea and diabetic foot infection, is also possible given the coverage of gram-negative and gram-positive bacteria by
sulopenem, pending submission of additional documentation and acceptance by the FDA. We have received feedback on the development program in an end of Phase 2 meeting with the FDA, which provided guidance on the size of the safety database, the <FONT
STYLE="white-space:nowrap">non-clinical</FONT> study requirements, the design of the Phase 1 and Phase 3 clinical trials, the pediatric development plan, as well as support for the proposed CMC development activities through production of commercial
supplies. The Phase 3 clinical trials for treatment of cIAI, cUTI and uUTI have received SPA agreements with the FDA. We expect topline delivery of data and submission of the program for regulatory review to the FDA in the second half of 2019. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Microbiology Surveillance Data </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sulopenem has demonstrated potent <I>in vitro</I> activity against nearly all genera of Enterobacteriaceae, in anaerobes such as Bacteroides,
Prevotella, Porphyromonas, Fusobacterium and Peptostreptococcus, gram-positive organisms including methicillin-susceptible staphylococci, <I>Streptococcus pyogenes</I> and<I> Streptococcus pneumoniae</I>, as well as other community respiratory
pathogens such as <I>Haemophilus influenzae </I>and <I>Moraxella catarrhalis</I>.<I> </I>The minimum inhibitory concentration (MIC), is a measure used to describe the results of an <I>in vitro </I>assay in which a fixed number of strain of bacteria
are added to a 96-well plate and increasing concentrations of antibiotic are sequentially added to the wells. The concentration of antibiotic which inhibits growth of the bacteria in a well is considered the MIC. When looking across a collection of
many strains of a species of bacteria, the MIC<SUB STYLE="font-size:85%; vertical-align:bottom">90</SUB> is the lowest concentration of antibiotic at which 90% of the strains are inhibited. Sulopenem lacks <I>in vitro</I> activity (MIC<SUB
STYLE="font-size:85%; vertical-align:bottom">90</SUB> <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 16 &micro;g/mL) against the oxidative <FONT STYLE="white-space:nowrap">non-fermenting</FONT> pathogens such as <I>Pseudomonas aeruginosa</I>,<I>
Acinetobacter baumanii</I>, <I>Burkholderia cepacia</I>,<I> </I>and<I> Stenotrophomonas maltophilia</I>.<I> </I>Given its lack of potency against <I>Pseudomonas aeruginosa</I>, its use in treatment of infections caused by pathogenic
Enterobacteriaceae should not select for pseudomonas resistant to carbapenems, as can occur with imipenem and meropenem. For various species of enterococci, the MIC<SUB STYLE="font-size:85%; vertical-align:bottom">90</SUB> values were 4 to <FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 64 &micro;g/mL. Methicillin-resistant staphylococci also have high MIC values. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table
below highlights the MIC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> and MIC<SUB STYLE="font-size:85%; vertical-align:bottom">90</SUB> of key target pathogens collected by International Health Management Associates (IHMA) between 2013
and 2015 responsible for the infections that will be studied in our planned Phase 3 program. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:54.35pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Organism Class</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>MIC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB></B><br><B>(&micro;g/mL)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>MIC<SUB STYLE="font-size:85%; vertical-align:bottom">90</SUB></B><br><B>(&micro;g/mL)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>E. coli</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.03</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ESBL negative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">69&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.03</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ESBL positive</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">20&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.03</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.06</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Klebsiella spp.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.03</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.06</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ESBL negative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">08&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.03</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.06</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EBSL positive</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">16&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.03</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.25</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>P. mirabilis</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.25</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>E. aerogenes</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.06</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.25</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>C. koseri</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.03</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.03</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>S. marcescens</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.50</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gram-negative anaerobes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.25</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Staphylococcus saprophyticus</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.25</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A comparison of the <I>in vitro</I> activity of sulopenem relative to other carbapenems,
as well as to currently prescribed oral agents for UTI, is provided below. The activity of sulopenem at slightly higher doses was very similar to that of ertapenem and meropenem, which are currently commercially available. In addition, sulopenem is
noted to have potent <I>in vitro</I> activity against relevant organisms that are resistant to fluoroquinolones and trimethoprim-sulfamethoxazole and are ESBL positive. The prevalence of resistance for the existing generic antibiotics, now exceeding
20% for many pathogens, underscores the challenge of treating patients with uUTI in an outpatient setting or releasing patients from the hospital with a cUTI or cIAI on a reliable step down oral therapy. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B><B><I>E. coli</I></B><B></B><br><B>N=189</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B><B><I>K. pneumoniae</I></B><B></B><br><B>N=65</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B><B><I>P. mirabilis</I></B><B></B><br><B>N=19</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:57.55pt; display:inline; font-size:10pt; font-family:Times New Roman; "><B>Penem Class:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>MIC<SUB STYLE="font-size:85%; vertical-align:bottom">90</SUB><SUB STYLE="font-size:85%; vertical-align:bottom"></SUB><BR>(&micro;g/mL)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;S</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>MIC<SUB STYLE="font-size:85%; vertical-align:bottom">90</SUB><SUB STYLE="font-size:85%; vertical-align:bottom"></SUB></B><br><B>(&micro;g/mL)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;S</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>MIC<SUB STYLE="font-size:85%; vertical-align:bottom">90</SUB><SUB STYLE="font-size:85%; vertical-align:bottom"></SUB><BR>(&micro;g/mL)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;S</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Sulopenem</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.06</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.12</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.25</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>*</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ertapenem</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">100</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">97</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">100</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Meropenem</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">100</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">97</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">100</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Oral Agents Currently on Market:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nitrofurantoin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">97</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">23</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">0</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fosfomycin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">98</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">86</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">95</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ciprofloxacin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">77</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">91</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">74</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trimethoprim-Sulfamethoxazole</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">74</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">86</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">58</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amoxicillin-Clavulanate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">76</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">80</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">74</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">N&nbsp;=</TD>
<TD ALIGN="left" VALIGN="top">bacterial samples; each product candidate was tested using the same sample size </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">%&nbsp;S&nbsp;=</TD>
<TD ALIGN="left" VALIGN="top">percentage susceptible, meaning the proportion of the number of isolates tested that had a MIC below the FDA defined susceptibility breakpoint; boxed values signify a percentage susceptible below 80%, which is the
threshold for concern for use of an antibiotic before a culture is available </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Susceptibility breakpoints have not yet been determined for sulopenem </TD></TR></TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Animal Models </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sulopenem reduced the bacterial burden in the bladder and tissues of infected animals in a uUTI model in both diabetic and normal C3H/HeN mice
using a MDR ST131 <I>E. coli</I>, a strain which is ESBL positive and resistant to fluoroquinolones and trimethoprim-sulfamethoxazole. Sulopenem was highly efficacious and remarkably robust in its reduction in bacterial burden, leading to complete
resolution of bacteriuria in all or most of the animals in both study arms with the high dose treatment regimen also reducing bacterial burden in bladder tissue and the kidney. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Nonclinical Pharmacology </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Metabolic
clearance is primarily characterized by hydrolysis of the &szlig;-lactam ring. Sulopenem does not inhibit the major cytochrome P450 isoforms suggesting a low potential for drug interactions at therapeutic concentrations. It is predominantly excreted
in the urine. Plasma protein binding for sulopenem is low at approximately 11%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 1 Program </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below outlines the Phase 1 clinical trials that have been conducted with sulopenem etzadroxil and sulopenem. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Protocol</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.90pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Dose&nbsp;(mg),&nbsp;other&nbsp;medication</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Subjects on</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>sulopenem or</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>sulopenem</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>etzadroxil</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Treatment</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Days)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="9"><B>Sulopenem <FONT STYLE="white-space:nowrap">(CP-70,429)&#151;Phase</FONT> 1 Single Dose Clinical Trial</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">A109001</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">1987</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">1000 mg</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Japanese PK</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">250&nbsp;mg,&nbsp;500&nbsp;mg,&nbsp;1000 mg</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">A7371007</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">2007</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">400 mg, 800 mg, 1600 mg, 2400 mg, 2800 mg, placebo</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">24</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="9"><B>Sulopenem <FONT STYLE="white-space:nowrap">(CP-70,429)&#151;Phase</FONT> 1 Multiple Dose Clinical Trials</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Japanese PK</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">500 mg, 1000 mg</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">12</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Japanese PK</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">1000 mg</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">A1091001</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">2009</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">800 mg, 1200 mg, 1600 mg, 2000 mg, placebo</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">40</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="9"><B>Sulopenem etzadroxil <FONT STYLE="white-space:nowrap">(PF-03709270)&#151;Phase</FONT> 1 Single Dose Clinical Trials</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">A8811001</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">2007</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">400 mg, 600 mg, 1000 mg, 2000 mg, placebo</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">A8811006</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">2008</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2000 mg</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">A8811007</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">2007</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">600 mg, probenecid</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">A8811008</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">2008</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">1200 mg, probenecid</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">24</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A8811018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">2008</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">1000 mg, 1200 mg, probenecid, aluminum hydroxide, pantoprazole</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">17</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">A8811003</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">2008</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2000 mg, 4000 mg, 6000 mg, 8000 mg, placebo</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">IT001-101</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">500 mg, 1000 mg, probenecid</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">48</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">IT001-102</FONT><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">500 mg, probenecid</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="9"><B>Sulopenem etzadroxil <FONT STYLE="white-space:nowrap">(PF-03709270)&#151;Phase</FONT> 1 Multiple Dose Clinical Trials</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">A8811003</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">2008</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2000 mg, 1200 mg, probenecid, placebo</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A8811015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">2009</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">500 mg, 1000 mg, 1500 mg, probenecid, placebo, Augmentin</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">48</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">IT001-101</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">500 mg, probenecid</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">64</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="9"><B>Sulopenem (CP-70,429), Sulopenem etzadroxil (PF-03709270)&#151;Phase 1 Renal Impairment Clinical Trial</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">A8811009</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">2010</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">200mg, 800 mg sulopenem or 1000 mg sulopenem etzadroxil</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">29</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">395</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Final report pending. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Oral Sulopenem </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have designed oral sulopenem to include probenecid, a pharmacokinetic enhancer that delays the excretion through the kidneys of sulopenem
and other &szlig;-lactam antibiotics and has been extensively used for this purpose and the treatment of gout. It enables us to maximize the antibacterial potential of any given dose of oral sulopenem. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted two Phase 1 clinical trials, IT001-101 and IT001-102, in healthy volunteers, in part to select the prodrug and explore various
doses of probenecid combined with 500 mg of sulopenem etzadroxil. Findings from these clinical trials are consistent with those from other pharmacokinetic studies that employed different total doses of sulopenem etzadroxil. Specifically, the AUC and
C<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB> are generally dose-proportional, and the concomitant use of probenecid increases the plasma exposure of sulopenem with any dose with which it was studied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The mean total sulopenem exposures in the urine after a single 500 mg dose in IT001-101 exceeded the MIC<SUB
STYLE="font-size:85%; vertical-align:bottom">90</SUB> for the entire twice-daily dosing interval in the 32 healthy volunteers who received 500 mg of sulopenem etzadroxil, as illustrated in the graph below. In a urine antibacterial assay, urine
collected at two hours post dose was bactericidal for numerous strains of <I>E. coli</I> and <I>K. pneumoniae</I>, including a strain of <I>K. pneumoniae</I> that was resistant to meropenem and imipenem, with a sulopenem MIC of 16 &micro;g/mL. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Mean total sulopenem exposure in urine after single 500 mg dose of sulopenem
etzadroxil with or without probenecid </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g522368g43z47.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In IT001-102, we evaluated sulopenem etzadroxil administered with and without probenecid in a randomized
cross-over trial in healthy volunteers in a fasted state. Subjects receiving sulopenem etzadroxil <FONT STYLE="white-space:nowrap">co-administered</FONT> with probenecid demonstrated an increase in the time over MIC (of a 12 hour dosing interval)
and AUC (area under the curve, a measure of total exposure) of sulopenem, as shown in the table below. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:36.40pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Treatment</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>N</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Descriptive</B><br><B>Statistic</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Sulopenem Parameter (Day 1)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>C<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB></B><br><B>(ng/mL)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AUC<SUB STYLE="font-size:85%; vertical-align:bottom"><FONT STYLE="white-space:nowrap">0-</FONT></SUB></B><FONT STYLE="font-size:5pt"><FONT STYLE="FONT-FAMILY:SYMBOL">&#165;
</FONT><B></B></FONT><B></B><br><B>(hr*ng/mL)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>T&gt;MIC</B><br><B>(0.5&nbsp;&micro;g/mL)</B><br><B>[hr]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>T&gt;MIC</B><br><B>(0.5&nbsp;&micro;g/mL)</B><br><B>[%]</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>500 mg Sulopenem etzadroxil</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Mean</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1928</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3871</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">23.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>500 mg Sulopenem etzadroxil</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>+ 500 mg probenecid</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Mean</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">1929</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">4964</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">3.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">30.2</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">N =
number of subjects; C<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB> = maximum plasma concentration; AUC<SUB STYLE="font-size:85%; vertical-align:bottom">0-<FONT STYLE="font-family:Times New Roman; font-size:5pt"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#165;</FONT></FONT></SUB> = area under the curve from the initiation of dosing extrapolated through infinite time </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, results from IT001-101 demonstrated that food increases the mean AUC and mean time over MIC (0.5 &micro;g/mL) of 500 mg sulopenem
etzadroxil dosed with 500 mg probenecid on Day 1 by 62% and 68%, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to conduct additional Phase 1 clinical trials,
including a hepatic impairment study, drug interaction studies with itraconazole and valproic acid, a study to evaluate the effect on fecal, as well as standard bioavailability and bioequivalency studies of new formulations to support our NDA. Other
Phase 1 clinical trials may be added as the needs of the program dictate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sulopenem, IV Formulation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Doses of sulopenem up to 2800&nbsp;mg as a single IV dose and 2000 mg BID of sulopenem as IV over fourteen days were studied in
three&nbsp;Phase&nbsp;1 clinical trials in healthy adults and one study in patients with renal insufficiency in the United States and two Phase 1 clinical trials in Japan. Results from these pharmacokinetic studies with various IV doses of sulopenem
delivered over various durations established dose proportionality among the various regimens with regard to area under the curve (AUC) and maximal plasma concentrations (C<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB>). A representative
analysis of pharmacokinetic parameters, a subset of study A1091001, is described in the table below. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>N</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dose</B><br><B>(mg)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Infusion<BR>duration&nbsp;(h)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>C<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB></B><br><B>(&micro;g/mL)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AUC <SUB STYLE="font-size:85%; vertical-align:bottom"><FONT STYLE="white-space:nowrap">0-</FONT></SUB></B><FONT STYLE="font-size:5pt"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#165;</FONT><B></B></FONT><B></B><br><B>(&micro;g&nbsp;hr/mL)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>T<SUB STYLE="font-size:85%; vertical-align:bottom">1/2</SUB></B><br><B>(h)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>CL<SUB STYLE="font-size:85%; vertical-align:bottom">total</SUB><BR>(mL/min/kg)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Day 1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Day 14</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">N =
number of subjects; C<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB> = maximum plasma concentration; AUC<SUB STYLE="font-size:85%; vertical-align:bottom">0-<FONT STYLE="font-family:Times New Roman; font-size:5pt"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#165;</FONT></FONT></SUB> = area under the curve from the initiation of dosing extrapolated through infinite time; T<SUB STYLE="font-size:85%; vertical-align:bottom">&#189;</SUB> = half-life; CL<SUB
STYLE="font-size:85%; vertical-align:bottom">total</SUB> = clearance (only measured on Day 14) </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Modeling and Dose Selection </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on <I>in vitro</I> susceptibility data from surveillance studies, pharmacokinetics gathered from Phase 1 clinical trials, and population
pharmacokinetic data from patients, we performed modeling to help choose the doses for the Phase 3 program. The MIC<SUB STYLE="font-size:85%; vertical-align:bottom">90</SUB> for all Enterobacteriaceae potentially involved in the target indications
was 0.25 &micro;g/mL and for the weighted distribution of pathogens most likely to be associated with the indication was 0.06 &micro;g/mL. We have performed modeling both for the weighted distribution of MICs expected in the clinical studies as well
as at a fixed MIC of 0.5 &micro;g/mL. Data obtained from animal experiments confirmed that, similar to carbapenems and lower than that for other &szlig;-lactams, the %T<SUB STYLE="font-size:85%; vertical-align:bottom">free</SUB> &gt;MIC required for
bacteriostasis is approximately 10&#150;19%, depending on the dosing regimen; we have used 17% in our models. Based on the outputs from those models, the IV dose of sulopenem will be 1000 mg sulopenem delivered over 3 hours once a day. The oral dose
will be 500 mg of sulopenem etzadroxil given with 500 mg of probenecid in a single bilayer tablet twice daily. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Japanese Clinical Data </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pfizer&#146;s affiliate in Japan conducted extensive clinical development of sulopenem in over 1,450 patients in Phase 1 and Phase 2 clinical
trials in Japan in patients with skin infections, respiratory tract infections, gynecologic infections, cUTI and intra-abdominal infections. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Phase 2 clinical trials conducted by Pfizer in Japan, 1991-1993 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:26.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Study #</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Sulopenem Dose</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Comparator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>N</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">91-002</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Multiple infections in:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Internal
medicine</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Surgery: includes cIAI</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Urology: pyelonephritis
cystitis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">250 mg IV BID</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">500 mg IV BID</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">None</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">108</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">92-002</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Multiple infections in:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Internal
medicine</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Surgery: includes cIAI</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Urology: pyelonephritis
cystitis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">250 mg IV BID</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">500 mg IV BID</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">None</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">959</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">91-002</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">92-002</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Population-Pharmacokinetics (only)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">250 mg IV BID</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">500 mg IV BID</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">216</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">93-001</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Respiratory&nbsp;Tract Infection</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">250 mg IV BID</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">500 mg IV BID</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Cefotiam IV</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">75</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">93-002</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">cUTI</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">250 mg IV BID</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">500 mg IV BID</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Imipenem&nbsp;IV</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">114</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>1472</B></TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A treatment effect in small Phase 2 clinical trials was observed in a number of infections
including<B> </B>skin infections, respiratory tract infections, gynecologic infections and, most relevant to the targeted indications being pursued in our Phase 3 program, cUTI and cIAI. The data from these clinical trials may not be directly
comparable to data from clinical trials that would be conducted today or the data that we anticipate from our Phase 3 program for a variety of reasons, including that the protocols were designed for different purposes and as a consequence had
different enrollment and efficacy evaluation criteria. While these data are not required for<B> </B>approval of our intended indications, we believe these results support our decision to develop sulopenem for our targeted indications and informed
our dose selection. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 1993, Pfizer Japan conducted 93-002, a randomized clinical trial in subjects with cUTI, comparing 250&nbsp;mg
twice daily and 500 mg twice daily of sulopenem administered intravenously to an intravenously-delivered imipenem-cilastatin, also given twice daily. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trial enrolled patients who were hospitalized, with an underlying disease of the urinary tract and with evidence of pyuria, measured by <FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 5 WBC/hpf (white blood cells per high power field, a measure of inflammation in the urinary tract) at baseline.&nbsp;Study therapy was administered for five days and was open-label with respect to sulopenem
versus the comparator, but was blinded as to the sulopenem dose.&nbsp;Efficacy was assessed by the investigator based on subjective and objective criteria, as shown below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The criteria for patient enrollment in the Phase 2 clinical trial 93-002 are different
than those currently established by the FDA in guidelines for Phase 3 cUTI registrational trials published in 2015.&nbsp;In addition to an Intent-to-Treat (ITT) analysis, which includes all randomized patients, of the investigator&#146;s assessment
of overall efficacy based on the original inclusion criteria, a <I>post</I> <I>hoc</I> analysis was also performed by Iterum of the investigator&#146;s assessment of overall efficacy in the population of patients that met enrollment criteria
consistent with current FDA guidance, such as baseline urinalysis with &gt;10 WBC/hpf and a urine culture which grew &gt;10<SUP STYLE="font-size:85%; vertical-align:top">5</SUP> susceptible organisms, as shown below. ITT analyses are performed in
the population of all randomized patients. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Investigator Assessment of Overall Efficacy</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Sulopenem</B><br><B>(CP&nbsp;70,429)<BR>250&nbsp;mg&nbsp;BID&nbsp;IV<BR>n/N (%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Sulopenem</B><br><B>(CP&nbsp;70,429)<BR>500&nbsp;mg&nbsp;BID IV<BR>n/N (%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Comparator<BR>n/N (%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Success</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">33/36&nbsp;(91.7)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">36/38&nbsp;(94.7)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">32/39&nbsp;(82.1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Failure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2/36 (5.6)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2/38 (5.3)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2/39 (5.1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indeterminant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1/36 (2.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5/39 (12.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Difference vs. comparator (95% CI)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">9.6&nbsp;(-6.6,&nbsp;25.9)</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">12.7&nbsp;(-2.1,&nbsp;28.4)</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinically Evaluable using FDA inclusion criteria (<I>post hoc</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Success</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">19/20 (95.0)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">22/22 (100.0)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16/16&nbsp;(100.0)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Failure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1/20 (5.0)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Difference vs. comparator (95% CI)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">-5.0&nbsp;(-24.0,&nbsp;15.3)</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0 <FONT STYLE="white-space:nowrap">(-15.2,</FONT> 19.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">One</TD>
<TD ALIGN="left" VALIGN="top">patient received a dose other than 250 mg or 500 mg IV BID. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of a subset analysis
that included patients from clinical trials conducted in 1991 and 1992, <FONT STYLE="white-space:nowrap">91-002</FONT> and 92-002, with a diagnosis that fit the FDA&#146;s definition of complicated intra-abdominal infections are provided below,
based on the investigator&#146;s assessment of clinical response at the end of therapy in the ITT and clinically evaluable populations. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Investigator Assessment of Outcome</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Sulopenem</B><br><B>(CP&nbsp;70,429)<BR>250&nbsp;mg&nbsp;BID&nbsp;IV</B><br><B>n/N (%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Sulopenem</B><br><B>(CP&nbsp;70,429)</B><br><B>500&nbsp;mg&nbsp;BID&nbsp;IV</B><br><B>n/N (%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Success</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14/15&nbsp;(93.3)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">78/88&nbsp;(88.6)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Failure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1/15&nbsp;(6.7)</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4/88&nbsp;(4.5)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indeterminant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6/88&nbsp;(6.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinically Evaluable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Success</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14/15&nbsp;(93.3)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">77/81&nbsp;(95.1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Failure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1/15&nbsp;(6.7)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4/81&nbsp;(4.9)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">Three</TD>
<TD ALIGN="left" VALIGN="top">patients received a dose other than 250 mg or 500 mg IV BID. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We used the data collected in
these studies to inform the design of the cUTI proposed regimens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of a Phase 2 clinical trial conducted in 1993 in
hospitalized patients with community acquired pneumonia (CAP), 93-001, are provided below, including the investigator&#146;s assessment of clinical response at the end of therapy in the ITT and clinically and bacteriologically evaluable populations
with the bacteriologically evaluable population meaning the clinically evaluable patients who had a baseline pathogen and follow up microbiology data to allow an assessment of bacteriological efficacy. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Investigator Response at End of Treatment</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Sulopenem</B><br><B>CP&nbsp;70,429<BR>250&nbsp;mg&nbsp;BID&nbsp;IV<BR>n/N (%)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Sulopenem</B><br><B>CP&nbsp;70,429<BR>500&nbsp;mg&nbsp;BID&nbsp;IV<BR>n/N (%)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Comparator<BR>n/N (%)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Success</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">19/26&nbsp;(73.1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">17/23&nbsp;(73.9)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">22/25&nbsp;(88.0)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Failure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4/26 (15.4)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3/23 (13.0)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2/25 (8.0)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indeterminant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3/26 (11.5)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3/23 (13.0)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1/25 (4.0)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Difference vs. comparator (95% CI)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">-14.9&nbsp;(-36.7,&nbsp;7.7)</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">-14.1&nbsp;(-37.1,&nbsp;8.8)</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinically Evaluable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Success</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18/20 (90.0)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">15/17 (88.2)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">20/20&nbsp;(100.0)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Failure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2/20 (10.0)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2/17 (11.8)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Difference vs. comparator (95% CI)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-10.0 <FONT STYLE="white-space:nowrap">(-30.4,</FONT> 7.3)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-11.8 <FONT STYLE="white-space:nowrap">(-34.7,</FONT> 5.8)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bacteriologically Evaluable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Success</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8/8 (100.0)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5/6 (83.3)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9/9 (100.0)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Failure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1/6 (16.7)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Difference vs. comparator (95% CI)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.0 <FONT STYLE="white-space:nowrap">(-33.8,</FONT> 31.2)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">-16.7&nbsp;(-57.6,&nbsp;18.1)</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 2 Clinical Trial with sulopenem and sulopenem etzadroxil </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2009, Pfizer initiated a Phase 2, randomized, double-blind, double-dummy clinical trial in hospitalized patients with community acquired
pneumonia comparing two regimens of IV sulopenem followed by oral sulopenem to ceftriaxone IV followed by amoxicillin-clavulanate. The sulopenem regimens were a single 600 mg IV dose of sulopenem followed by 1000 mg BID of oral sulopenem or a 600 mg
of sulopenem for a minimum of four doses followed by 1000 mg BID of oral sulopenem. The clinical trial was terminated early for business reasons after 33 of 250 planned total patients were enrolled and treated. Clinical response rates at the test of
cure visit (7&#150;14 days after end of therapy) of the ITT patients were similar on each regimen (9/10, 9/11 and 7/12, on sulopenem single IV dose, sulopenem multidose IV and ceftriaxone, respectively).
<FONT STYLE="white-space:nowrap">Treatment-emergent</FONT> adverse events were reported in six subjects each in the sulopenem groups and eight subjects in the ceftriaxone group. The most common
<FONT STYLE="white-space:nowrap">treatment-emergent</FONT> adverse event was diarrhea, reported by a total of six subjects (two in each treatment group). Treatment related diarrhea was reported by one subject following sulopenem single dose IV, and
by a further two subjects following ceftriaxone. There was one <FONT STYLE="white-space:nowrap">treatment-related</FONT> serious adverse event in the ceftriaxone group. There were no deaths reported in this clinical trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Planned Phase 3 Clinical Trials </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on FDA Guidance from February 2015 (Complicated Intra-Abdominal Infections: Developing Drugs for Treatment. Guidance for Industry;
Complicated Urinary Tract Infections: Developing Drugs for Treatment. Guidance for Industry) and on recently conducted studies by other sponsors, we negotiated SPA agreements for cUTI, cIAI and uUTI. Oral sulopenem alone will be studied for the
treatment of outpatients with uUTI, while oral sulopenem and sulopenem will be studied for the treatment of cUTI and cIAI. A brief overview of the comparator agents, sample size, timing of efficacy assessments and duration of oral and IV dosing is
provided in the graphic below. <FONT STYLE="white-space:nowrap">Non-inferiority</FONT> in these clinical trials is defined by the lower limit of the confidence interval in the treatment difference of no more than
<FONT STYLE="white-space:nowrap">-10%.</FONT> The uUTI clinical trial will also test for superiority in the subset of patients with ciprofloxacin resistant pathogens at baseline. An open label noncomparative treatment study of oral ciprofloxacin 250
mg twice-daily for three days in uUTI patients is underway to help characterize certain sample size assumptions as well as enable study logistics for this Phase 3 clinical trial. Patients in the cUTI and cIAI clinical trials will receive five days
of sulopenem IV or comparator and then step down to two to five additional days of oral treatment with either oral sulopenem or ciprofloxacin. In the cIAI trial, clinical outcome at the test of cure visit will be noted as cure for those patients who
are alive, have resolution in signs and symptoms of the index infection and for whom no new antibiotics or interventions for treatment failure were required. In the uUTI and cUTI trials, clinical outcome at the test of cure visit will be noted as
cure for patients who are alive and who demonstrate resolution of the symptoms of uUTI or cUTI, as applicable, present at trial entry (and no new symptoms) such that no new antibiotics are required, as well as the demonstration that the bacterial
pathogen(s) found at trial entry are reduced to &lt;10<SUP STYLE="font-size:85%; vertical-align:top">3</SUP> CFU/mL on urine culture on Day 12 or Day 21, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Patients with an organism resistant to ciprofloxacin in the cUTI and cIAI clinical trials will be allowed to substitute amoxicillin-clavulanate for the step down oral therapy. Patients getting
ciprofloxacin in the cIAI trial will also receive metronidazole. Patients receiving oral sulopenem will be encouraged, but not required, to dose with food. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g522368g47p15.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Safety of Oral Sulopenem and Sulopenem </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sulopenem is a thiopenem and a member of the class of beta-lactam antibiotics, a class from which numerous safe and well tolerated antibiotics
have been available for over thirty years. Adverse event data collected as part of the Japanese Phase 2 development program with the IV formulation documented an overall safety profile for sulopenem similar to that of the marketed carbapenems. We
view the clinical safety profile of sulopenem established by the Japanese data as also relevant and supportive of oral sulopenem because it metabolizes to the active metabolite, sulopenem, in plasma. A summary of the adverse event data from the
Japanese program is provided below: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Sulopenem</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Comparators</B><br><B>(N = 64)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>(N&nbsp;=&nbsp;1472)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>250&nbsp;mg&nbsp;BID</B><br><B>(N = 296)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>500&nbsp;mg&nbsp;BID</B><br><B>(N = 865)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Miscellaneous*</B><br><B>(N = 247)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No. of patients who experienced at least one:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adverse Event</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14&nbsp;(4.7)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">35&nbsp;(4.0)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1&nbsp;(0.4)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3&nbsp;(4.7)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">53 (3.6)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug-Related Adverse Event</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9 (3.0)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">22 (2.5)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 (0.4)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3 (4.7)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">35 (2.4)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serious Adverse Event</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2 (0.7)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 (0.1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 (1.6)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4 (0.3)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug-Related Serious Adverse Event</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 (0.3)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 (1.6)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2 (0.1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SAE Leading to Death</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2 (0.7)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 (0.1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 (1.6)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4 (0.3)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AE Leading to Premature Discontinuation of Study Drug</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8 (2.7)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16 (1.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2 (3.1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">26&nbsp;(1.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SAE Leading to Premature Discontinuation of Study Drug</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 (0.3)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 (0.1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Miscellaneous doses include patients receiving a total daily dose of 250 mg, 750 mg, 1500 mg or 2000 mg, including patients receiving a single dose of sulopenem in the population PK
<FONT STYLE="white-space:nowrap">sub-study.</FONT> </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Common adverse events occurring in more than one patient on a sulopenem regimen included
diarrhea (0.7%), pyrexia (0.5%) and rash (1.0%). The most common adverse event leading to discontinuation was rash (0.7%). Clinically significant laboratory test abnormalities were infrequent. Elevations in serum aminotransferases occurred in less
than 3% of patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Data is also available for the oral formulation collected in healthy volunteers in the Phase 1 program Iterum
conducted that is consistent with the adverse event profile observed with the IV formulation. One additional adverse event of interest identified with the oral prodrug in this study is loose stool/diarrhea which was considered of mild severity and
self-limited, as seen with other broad spectrum oral antibiotics with activity against the anaerobic flora of the gastrointestinal tract. During the <FONT STYLE="white-space:nowrap">seven-day</FONT> dosing interval, the incidence of diarrhea,
defined as having three or more episodes of loose stool in one day or having two or more episodes of loose stool per day for two consecutive days, peaked at 13% on Day 3 and fell to 2% by Day 7, with no patient discontinuing their dosing due to this
event. For patients who took their dose with food, the peak incidence was 9%, dropping again to 3% by Day 4, similar to placebo. Some patients also identified a mild change in the odor of their urine after dosing with either the oral or IV
formulations, as can be seen with other &szlig;-lactam antibiotics. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have received a waiver from the FDA for the requirement of
performing a thorough QT interval study given the lack both of any significant preclinical findings and signals in Phase 1 clinical trials during which intensive ECG monitoring was performed. The EMA in written scientific advice also agreed that a
QT interval study is not warranted. A preclinical study of the hydrolysis product of etzadroxil <FONT STYLE="white-space:nowrap">(2-ethylbutyric</FONT> acid) has been performed in which no effect on plasma carnitine in rats was identified while a
significant effect of a different prodrug moiety, pivoxil, was observed. No reports of seizures, seen with some members of the carbapenem class, were noted in preclinical studies or clinical trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pfizer License Agreement </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November
2015, we and our wholly owned subsidiary, Iterum Therapeutics International Limited, entered into a license agreement with Pfizer (the Pfizer License), pursuant to which we acquired from Pfizer an exclusive, royalty-bearing license under certain
patents and <FONT STYLE="white-space:nowrap">know-how</FONT> to develop, manufacture and commercialize sulopenem and related compounds, including, among others, oral sulopenem and three other sulopenem prodrugs, globally for the treatment, diagnosis
and prevention of infectious diseases and infections in humans. The licensed patents include two U.S. patents, one of which covers the composition of matter of oral sulopenem, one patent in Japan, one patent in Hong Kong and one patent in Mexico.
None of the licensed patents cover the IV formulation of sulopenem. All patents directed to the compound sulopenem expired prior to us entering into the Pfizer License. Pursuant to the Pfizer License, our exclusive license from Pfizer includes
certain <FONT STYLE="white-space:nowrap">know-how,</FONT> data and regulatory documents that will support the development of sulopenem. We have the right to grant sublicenses to third parties, provided that we (1)&nbsp;obtain Pfizer&#146;s prior
written consent in connection with such sublicense, (2)&nbsp;enter into a written sublicense agreement consistent with the terms and conditions of the Pfizer License and (3)&nbsp;include Pfizer as a third party beneficiary under such sublicense. As
between Pfizer and us, we own all right, title and interest in any intellectual property rights that are developed by us in connection with the Pfizer License. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Pfizer License, we have sole responsibility for and control over the development, regulatory approval, manufacture and
commercialization of licensed products worldwide, including bearing all costs and expenses associated therewith. We are obligated to use commercially reasonable efforts to develop and seek regulatory approval for one licensed product in the United
States and in at least one in each of France, Germany, Italy, Japan, Spain or the United Kingdom (Major Market Countries) and, if deemed appropriate by us in our exercise of commercially reasonable efforts, for a second licensed product in the
United States and at least one Major Market Country. In addition, we must use commercially reasonable efforts to commercialize a licensed product in the United States and each Major Market Country in which we have received regulatory approval for
such product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Pfizer License, we have paid Pfizer a
<FONT STYLE="white-space:nowrap">one-time</FONT> nonrefundable upfront fee of $5.0&nbsp;million and are obligated to pay Pfizer potential future clinical and regulatory milestone payments, as well as potential sales milestones upon achievement of
net sales ranging from $250.0&nbsp;million to $1.0&nbsp;billion for each product type (oral sulopenem and other prodrugs, and sulopenem and other non-prodrugs). We are obligated to pay Pfizer royalties ranging from a single-digit to <FONT
STYLE="white-space:nowrap">mid-teens</FONT> percentage of marginal net sales of each licensed product increasing as we achieve aggregate net sales above certain amounts. Pfizer also received six million of our Series A preferred shares at a value of
$1.00 per share as additional payment for the licensed rights. In addition, if we sublicense or assign our rights to licensed products to a third party, and we receive in connection with such transaction a threshold amount of at least a low nine
figure dollar amount over a specified period of time, we will be obligated to pay Pfizer an additional <FONT STYLE="white-space:nowrap">one-time</FONT> payment of a low eight figure dollar amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our cost and expense, we are responsible for the prosecution and maintenance of the licensed patents worldwide, using specific legal
counsel in various jurisdictions as set forth in the Pfizer License. If we elect to forgo prosecution or maintenance of a licensed patent, we must notify Pfizer and Pfizer has the right to continue prosecution and maintenance of such licensed patent
and the exclusive license granted to us under such licensed patent will become a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> and <FONT STYLE="white-space:nowrap">non-sublicensable</FONT> license. Subject to certain consultation rights
granted to Pfizer, we have the first right, but not the obligation, to enforce the licensed patents at our cost and expense. If we elect to enforce any licensed patent, we may not enter into a settlement agreement that would: (1)&nbsp;adversely
affect the validity, enforceability or scope of any of the licensed patents, (2)&nbsp;give rise to any liability for Pfizer, (3)&nbsp;admit <FONT STYLE="white-space:nowrap">non-infringement</FONT> of any of the licensed patents or (4)&nbsp;otherwise
impair Pfizer&#146;s rights in any of the licensed patents or licensed <FONT STYLE="white-space:nowrap">know-how</FONT> without the prior written consent of Pfizer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Pfizer License continues in effect until the expiration of all royalty terms thereunder, unless earlier terminated. The royalty term for
each licensed product in each country begins as of the first commercial sale of such licensed product in such country and lasts until the later of (1)&nbsp;the expiration of the applicable licensed patents in such country, (2)&nbsp;the expiration of
regulatory or data exclusivity for such licensed product in such country and (3)&nbsp;fifteen years after the first commercial sale of such licensed product in such country. Pursuant to the terms of the Pfizer License, each party has the right to
terminate the Pfizer License upon the other party&#146;s (1)&nbsp;material breach of the Pfizer License that remains uncured after 60 days (or, if the breach cannot be cured in 60 days, up to 150 days) of receipt of notice or (2)&nbsp;insolvency. In
addition, we have the unilateral right to terminate the Pfizer License for convenience by providing 90 days&#146; written notice to Pfizer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to
protect the proprietary technology that we believe is important to our business, including seeking and maintaining rights in patents intended to cover our product candidates and compositions, their methods of use and processes for their manufacture
and any other inventions that are commercially important to the development of our business. However, we do not own any patents or patent applications and rely heavily on the Pfizer License for intellectual property rights that are important or
necessary for the development of oral sulopenem and the IV formulation of sulopenem. In addition, we do not license any patent rights that cover the IV formulation of sulopenem and all patent rights covering the compound sulopenem expired prior to
us entering into the Pfizer License. We also rely, in some circumstances, on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success will significantly depend on our ability to obtain and maintain patent and other proprietary protection for commercially important
technology and inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> related to our business, defend and enforce our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patents we may own in the future, preserve the
confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on <FONT STYLE="white-space:nowrap">know-how</FONT> and continuing technological
innovation to develop and maintain our proprietary position. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Licensed Intellectual Property Relating to Oral Sulopenem </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As noted above, we have been granted an exclusive license from Pfizer under one patent in the United States and one patent each in Japan,
Mexico and Hong Kong directed to the composition of matter, formulation and/or use of oral sulopenem. Our sulopenem program contains one United States patent covering composition of matter of oral sulopenem licensed exclusively to us. This United
States patent is scheduled to expire in 2029, subject to potential extension under the Hatch-Waxman Act to 2034. The FDA has designated sulopenem and oral sulopenem as QIDPs for the indications of uUTI, cUTI and cIAI. QIDP status provides the
potential for a more rapid new drug application (NDA) review cycle and adds five years to any other regulatory exclusivity period awarded. QIDP status for other indications, such as respiratory tract infections, gonorrhea and diabetic foot infection
is also possible given the coverage of gram-negative and gram-positive bacteria by sulopenem, pending submission of additional documentation and acceptance by the FDA. Patent term adjustments or patent term extensions could result in later
expiration dates. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Term and Patent Term Extensions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the legal term for patents in the countries in which they are obtained. In most countries,
including the United States, the patent term is 20 years from the earliest filing date of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. In the United States, a patent&#146;s term may be lengthened by patent term
adjustment, which compensates a patentee for administrative delays by the United States Patent and Trademark Office in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier filed patent. The term
of a patent that covers a drug, biological product or medical device approved pursuant to a <FONT STYLE="white-space:nowrap">pre-market</FONT> approval may also be eligible for patent term extension when FDA approval is granted, provided statutory
and regulatory requirements are met. The length of the patent term extension is related to the length of time the drug is under regulatory review while the patent is in force. The Hatch-Waxman Act permits a patent term extension of up to five years
beyond the expiration date set for the patent. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent applicable to each regulatory review period may be granted an
extension and only those claims reading on the approved drug are extended. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trade Secrets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely, in some
circumstances, on trade secrets to protect our unpatented technology. However, trade secrets can be difficult to protect. We seek to protect our trade secrets and proprietary technology and processes, in part, by entering into <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with our employees, consultants, scientific advisors, suppliers, contractors and other third parties. We also seek to preserve the integrity and confidentiality of our
data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security
measures may be breached and our trade secrets and other proprietary information may be disclosed. We may not have adequate remedies for any breach and could lose our trade secrets and other proprietary information through such a breach. In
addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise
as to the rights in related or resulting trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and inventions. For more information regarding the risks related to our intellectual property, see the section titled &#147;Risk
Factors&#151;Risks Related to our Intellectual Property.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pharmaceutical industry is characterized by intense competition and rapid innovation. Our potential competitors include large
pharmaceutical and biotechnology companies, specialty pharmaceutical companies and generic drug companies. Many of our potential competitors have greater financial, technical human resources than we do, as well as greater experience in the discovery
and development of product candidates, obtaining FDA </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and other regulatory approvals of products and the commercialization of those products. Accordingly, our potential competitors may be more successful than us in obtaining FDA approved drugs and
achieving widespread market acceptance. We anticipate that we will face intense and increasing competition as new drugs enter the market and advanced technologies become available. Finally, the development of new treatment methods for the diseases
we are targeting could render our product candidates <FONT STYLE="white-space:nowrap">non-competitive</FONT> or obsolete. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the
key competitive factors that will affect the development and commercial success of oral sulopenem and sulopenem, if approved, will be efficacy, coverage of drug-resistant strains of bacteria, safety and tolerability profile, reliability, convenience
of oral dosing, price, availability of reimbursement from governmental and other third-party payers and susceptibility to drug resistance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If approved, oral sulopenem would compete with several oral antibiotics currently in clinical development, including ceftibuten clavulanate
from Achaogen, Inc., tebipenem pivoxil from Spero Therapeutics, Inc., delafloxacin from Melinta Therapeutics and omadacycline from Paratek Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also expect that oral sulopenem, if approved, would compete with future and current generic versions of marketed oral antibiotics. If
approved, we believe that oral sulopenem would compete effectively against these compounds on the basis of sulopenem&#146;s potential: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">broad range of activity against a wide variety of resistant and MDR gram-negative bacteria; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">low probability of drug resistance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a favorable safety and tolerability profile; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a convenient oral dosing regimen and opportunity to step down from <FONT STYLE="white-space:nowrap">IV-administered</FONT> therapy; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as a monotherapy treatment for resistant and MDR gram-negative infections. </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If approved,
sulopenem would compete with several <FONT STYLE="white-space:nowrap">IV-administered</FONT> product candidates marketed for the treatment of gram-negative infections, including Avycaz from Allergan plc and Pfizer and Zerbaxa from Merck&nbsp;&amp;
Co. and Vabomere from Melinta Therapeutics. There are also a number of <FONT STYLE="white-space:nowrap">IV-administered</FONT> product candidates in late-stage clinical development that are intended to treat gram-negative infections, including
plazomicin from Achaogen Inc., cefiderocol from Shionogi&nbsp;&amp; Co. Ltd. and relabactam from Merck&nbsp;&amp; Co. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If approved,
we believe that sulopenem would compete effectively and potentially occupy an earlier place in treatment against these compounds on the basis of sulopenem&#146;s potential, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">allows physicians to stay in the same molecule with step down therapy to oral sulopenem; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">convenient once a day dosing over a <FONT STYLE="white-space:nowrap">three-hour</FONT> infusion period; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">broad spectrum activity against a wide variety of resistant and MDR gram-negative bacteria; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">low probability of drug resistance; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a favorable safety and tolerability profile. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation and Product Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States, at the federal, state and local level, and in other countries, extensively regulate, among other
things, the research, development, clinical trials, testing, manufacture, including any manufacturing changes, authorization, pharmacovigilance, adverse event reporting, recalls, packaging, storage, recordkeeping, labeling, advertising, promotion,
distribution, marketing, import and export of pharmaceutical products and product candidates such as those we are developing. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent
compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United States Government Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations. The
process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the
applicable United States requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#146;s refusal to approve
pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts,
restitution, disgorgement or civil and/or criminal penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process required by the FDA before a drug may be marketed in the United
States generally involves the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with GLP regulations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission to the FDA of an IND which must become effective before human clinical trials may begin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">performance of adequate and well-controlled human clinical trials in accordance with GCP to establish the safety and efficacy of the proposed drug product for each indication; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission to the FDA of an NDA; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">satisfactory completion of an FDA advisory committee review, if applicable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">satisfactory completion of an FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good
manufacturing practices, or cGMP, and to assure that the facilities, methods and controls are adequate to preserve the drug&#146;s identity, strength, quality and purity; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of clinical data; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">payment of user fees and securing FDA review and approval of the NDA. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential
safety and efficacy. Preclinical tests intended for submission to the FDA to support the safety of a product candidate must be conducted in compliance with GLP regulations and the United States Department of Agriculture&#146;s Animal Welfare Act. A
drug sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may
continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical
trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Trials </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve
the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
all research subjects provide their informed consent in writing for their participation in any clinical trial along with the requirement to ensure that the data and results reported from the
clinical trials are credible and accurate. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the criteria for determining subject eligibility, the dosing plan, the parameters to be used in
monitoring safety, the procedure for timely reporting of adverse events, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In
addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution. Information about certain clinical trials must be submitted within specific
timeframes to the NIH for public dissemination on their <I>www.clinicaltrials.gov </I>website. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically
conducted in three sequential phases, which may overlap or be combined: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Phase 1</I></B>: The drug is initially introduced into
healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness. During Phase 1
clinical trials, sufficient information about the investigational drug&#146;s pharmacokinetics and pharmacological effects may be obtained to permit the design of well-controlled and scientifically valid Phase 2 clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Phase 2</I></B>: The drug is administered to a larger, but still limited patient population to identify possible adverse effects and
safety risks, to preliminarily evaluate the efficacy of the product for specific targeted indications and to determine dosage tolerance and optimal dosage. Phase 2 clinical trials are typically well-controlled and closely monitored. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Phase 3</I></B>: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites,
in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the
labeling of the product. Phase 3 clinical trials usually involve a larger number of participants than a Phase 2 clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Progress
reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any
specified period, or at all. Results from one trial may not be predictive of results from subsequent trials. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the
research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s
requirements or if the drug has been associated with unexpected serious harm to patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Marketing Approval </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, together with
detailed information relating to the product&#146;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most
cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#147;filing&#148; of a
standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#147;filing&#148; decision.
Furthermore, the FDA is not required to complete its review within the established <FONT STYLE="white-space:nowrap">ten-month</FONT> timeframe and may extend the review process by issuing requests for additional information or clarification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the Pediatric Research Equity Act of 2003, as amended and reauthorized, certain NDAs or supplements to an NDA must contain
data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric
data until after approval of the product for use in adults or full or partial waivers from the pediatric data requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA also
may require submission of a risk evaluation and mitigation strategy, or REMS, plan to mitigate any identified or suspected serious risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and elements to
assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA conducts a
preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than
accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the
FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facilities in which it is manufactured, processed,
packaged or held meet standards designed to assure the product&#146;s continued safety, quality and purity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may refer an
application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application
should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve
an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving
an NDA, the FDA will typically inspect one or more clinical trial sites to assure compliance with GCP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA generally accepts data
from foreign clinical trials in support of an NDA if the trials were conducted under an IND. If a foreign clinical trial is not conducted under an IND, the FDA nevertheless may accept the data in support of an NDA if the study was conducted in
accordance with GCPs and the FDA is able to validate the data through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection, if deemed necessary. The testing and approval process for an NDA requires substantial time, effort and financial
resources, and each may take several years to complete. Data obtained from preclinical and clinical testing are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA
may not grant approval on a timely basis, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After evaluating the NDA and all related information, including the advisory
committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally
contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing in order for FDA to reconsider the application. Even with submission of this
additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#146;s satisfaction, the FDA will typically issue an approval
letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or
precautions be included in the product labeling , require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#146;s safety after approval, require </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under
a REMS which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types
of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Special FDA Expedited Review and Approval Programs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has various programs that are intended to expedite or simplify the process for the development and FDA review of drugs that are
intended for the treatment of serious or life threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard
FDA review procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a
product is intended to treat a serious or life threatening disease or condition and demonstrates the potential to address an unmet medical need, or if the drug qualifies as a QIDP under the GAIN Act. The FDA will determine that a product will fill
an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. Fast track designation provides additional opportunities for
interaction with the FDA&#146;s review team and may allow for rolling review of NDA components before the completed application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept
sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. The FDA may decide to rescind the fast track designation if it determines that the
qualifying criteria no longer apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may give a priority review designation to drugs that offer major advances in treatment for a
serious condition, or provide a treatment where no adequate therapy exists. Most products that are eligible for fast track designation are also likely to be considered appropriate to receive a priority review. A priority review means that the goal
for the FDA to review an application is six months, rather than the standard review of ten months under current PDUFA guidelines. These six and ten month review periods are measured from the &#147;filing&#148; date for NDAs for new molecular
entities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the
conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Post-Approval Requirements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among
other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such
as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program user fee requirements for any marketed products, as well as new application fees for supplemental
applications with clinical data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For
example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register
their establishments with the FDA and state agencies, and are subject to periodic </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval
before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to
use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates the marketing, labeling, advertising and promotion of drug products that are placed on the market. A product cannot
be commercially promoted before it is approved, and approved drugs may generally be promoted only for their approved indications. Promotional claims must also be consistent with the product&#146;s <FONT STYLE="white-space:nowrap">FDA-approved</FONT>
label, including claims related to safety and effectiveness. The FDA and other federal agencies also closely regulate the promotion of drugs in specific contexts such as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, industry-sponsored scientific and education activities, and promotional activities involving the Internet and social media. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or
if problems occur after the product reaches the market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Later discovery of previously unknown problems with a product, including adverse
events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market
studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences of regulatory <FONT STYLE="white-space:nowrap">non-compliance</FONT> include, among other
things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on, or suspensions of, the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">interruption of production processes, including the shutdown of manufacturing facilities or production lines or the imposition of new manufacturing requirements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fines, warning letters or other enforcement letters or holds on post-approval clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizure or detention, or refusal to permit the import or export of products; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions or the imposition of civil or criminal penalties. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the distribution
of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of
drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exclusivity and Approval of Competing Products </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Hatch-Waxman Exclusivity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market and data
exclusivity provisions under the FDCA can delay the submission or the approval of certain applications for competing products. The FDCA provides a five-year period of <FONT STYLE="white-space:nowrap">non-patent</FONT> data exclusivity within the
United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion
responsible for the activity of the drug substance. We believe that our product candidates are new chemical entities. During the exclusivity period, the FDA may not accept for review an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company that references the previously approved drug. However, an ANDA or 505(b)(2) NDA may be submitted after
four years if it contains a certification of patent invalidity or <FONT STYLE="white-space:nowrap">non-infringement.</FONT> The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA, or supplement to an existing NDA or
505(b)(2) NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant, are deemed by the FDA to be essential to the approval of the application or supplement. Three year exclusivity may
be awarded for changes to a previously approved drug product, such as new indications, dosages, strengths or dosage forms of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical
investigations and, as a general matter, does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for generic versions of the original, unmodified drug product. Five-year and three-year exclusivity will not delay the submission or approval
of a full NDA; however, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and
effectiveness. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Qualified Infectious Disease Product Exclusivity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the GAIN Act, the FDA may designate a product as a qualified infectious disease product, or QIDP. In order to receive this designation, a
drug must qualify as an antibiotic or antifungal drug for human use intended to treat serious or life-threatening infections, including those caused by either (i)&nbsp;an antibiotic or antifungal resistant pathogen, including novel or emerging
infectious pathogens, or (ii)&nbsp;a <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;qualifying pathogen&#148; found on a list of potentially dangerous, drug-resistant organisms established and maintained by the FDA. A sponsor must request
such designation before submitting a marketing application. We obtained a QIDP designation for sulopenem and oral sulopenem for the indications of cUTI, uUTI and cIAI in 2016 and 2017, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon approving an application for a qualified infectious disease product, the FDA will extend by an additional five years any regulatory
exclusivity period awarded, such as a five-year exclusivity period awarded for a new molecular entity. This extension is in addition to any pediatric exclusivity extension awarded, and the extension will be awarded only to a drug first approved on
or after the date of enactment. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The GAIN Act provisions prohibit the grant of an exclusivity extension where the application is a
supplement to an application for which an extension is in effect or has expired, is a subsequent application for a specified change to an approved product, or is an application for a product that does not meet the definition of qualified infectious
disease product based on the uses for which it is ultimately approved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and
commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of foreign countries or economic areas, such as the European Union, before we
may commence clinical trials or market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product authorization, pricing and reimbursement vary greatly from place to place, and the
time may be longer or shorter than that required for FDA approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under European Union regulatory systems, a company may submit
marketing authorization applications either under a centralized or decentralized procedure. The centralized procedure is compulsory for medicinal products produced by biotechnology or those medicinal products containing new active substances for
specific indications such as the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, viral diseases and designated orphan medicines, and optional for other medicines which are highly innovative. Under the centralized procedure, a
marketing application is submitted to the European Medicines Agency where it will be evaluated by the Committee for Medicinal Products for Human Use and a favorable opinion typically results in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the grant by the European Commission of a single marketing authorization that is valid for all European Union member states within 67 days of receipt of the opinion. The initial marketing
authorization is valid for five years, but once renewed is usually valid for an unlimited period. The decentralized procedure provides for approval by one or more &#147;concerned&#148; member states based on an assessment of an application performed
by one member state, known as the &#147;reference&#148; member state. Under the decentralized approval procedure, an applicant submits an application, or dossier, and related materials to the reference member state and concerned member states. The
reference member state prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. Within 90 days of receiving the reference member state&#146;s assessment report, each concerned member state
must decide whether to approve the assessment report and related materials. If a member state does not recognize the marketing authorization, the disputed points are eventually referred to the European Commission, whose decision is binding on all
member states. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pharmaceutical Coverage and Reimbursement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of drug products depend, in part, on the availability and extent of coverage and reimbursement by third-party payors, such as government
health programs, including Medicare and Medicaid, commercial insurance and managed healthcare organizations. Obtaining coverage and reimbursement approval for a drug product from third-party payors is a time-consuming and costly process that can
require the provision of supporting scientific, clinical and cost effectiveness data for the use of drug products to the payor. There may be significant delays in obtaining such coverage and reimbursement for newly approved drug products, and
coverage may be more limited than the purposes for which the drug product is approved by the FDA or similar regulatory authorities outside of the United States. Moreover, eligibility for coverage and reimbursement does not imply that a drug product
will be paid for in all cases or at a rate that covers operating costs, including research, development, intellectual property, manufacture, sale and distribution expenses. Reimbursement rates may vary according to the use of the drug product and
the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drug products and may be incorporated into existing payments for other services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved drug products. In the United States,
third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies, but also have their own methods and approval process apart from Medicare coverage and reimbursement determinations. It
is difficult to predict what third party payors will decide with respect to coverage and reimbursement for new drug products. An inability to promptly obtain coverage and adequate reimbursement rates from third-party payors for any approved drug
products could have a material adverse effect on a pharmaceutical manufacturer&#146;s operating results, ability to raise capital needed to commercialize drug products and overall financial condition </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reimbursement may impact the demand for, and/or the price of, any drug product which obtains marketing approval. Even if coverage is obtained
for a given drug product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. Patients who are prescribed
medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with those medications. Patients are unlikely to use a drug product, and
physicians may be less likely to prescribe a drug product, unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of the drug product. Therefore, coverage and adequate reimbursement is critical to
new drug product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The containment of healthcare costs has become a priority of federal and state governments, and the prices of drugs have been a focus in this
effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
coverage and reimbursement, and requirements for substitution of generic drug products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in
jurisdictions with existing controls and measures, could further limit a pharmaceutical manufacture&#146;s net revenue and results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, it is expected that the increased emphasis on managed care and cost containment measures in the United States by third-party payors will continue and place further pressure on pharmaceutical pricing and coverage. Coverage policies and
third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more drug products that gain regulatory approval, less favorable coverage policies and reimbursement rates may be
implemented in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be
lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, in the EU, the sole legal instrument at the EU level governing the pricing and reimbursement of medicinal products is Council Directive
89/105/EEC, or the Price Transparency Directive. The aim of this Directive is to ensure that pricing and reimbursement mechanisms established in the EU Member States are transparent and objective, do not hinder the free movement of and trade in
medicinal products in the EU, and do not hinder, prevent or distort competition on the market. The Price Transparency Directive does not provide any guidance concerning the specific criteria on the basis of which pricing and reimbursement decisions
are to be made in individual EU Member States, nor does it have any direct consequence for pricing or reimbursement levels in individual EU Member States. The EU Member States are free to restrict the range of medicinal products for which their
national health insurance systems provide reimbursement, and to control the prices and/or reimbursement levels of medicinal products for human use. An EU Member State may approve a specific price or level of reimbursement for the medicinal product,
or alternatively adopt a system of direct or indirect controls on the profitability of the company responsible for placing the medicinal product on the market, including volume-based arrangements, caps and reference pricing mechanisms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Health Technology Assessment, or HTA, of medicinal products is becoming an increasingly common part of the pricing and reimbursement
procedures in some EU Member States, including the United Kingdom, France, Germany, Ireland, Italy and Sweden. The HTA process in the EU Member States is governed by the national laws of these countries. HTA is the procedure according to which the
assessment of the public health impact, therapeutic impact, and the economic and societal impact of use of a given medicinal product in the national healthcare systems of the individual country is conducted. HTA generally focuses on the clinical
efficacy and effectiveness, safety, cost, and cost-effectiveness of individual medicinal products as well as their potential implications for the healthcare system. Those elements of medicinal products are compared with other treatment options
available on the market. The outcome of HTA regarding specific medicinal products will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. The extent
to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product vary between EU Member States. A negative HTA of one of our products by a leading and recognized HTA body, such as the National Institute for
Health and Care Excellence in the United Kingdom, could not only undermine our ability to obtain reimbursement for such product in the EU Member State in which such negative assessment was issued, but also in other EU Member States. For example, EU
Member States that have not yet developed HTA mechanisms could rely to some extent on the HTA performed in countries with a developed HTA framework, such as the United Kingdom, when adopting decisions concerning the pricing and reimbursement of a
specific medicinal product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Healthcare Laws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians and third-party payors play a primary role in the recommendation and prescription of drug product candidates
which obtain marketing approval. In addition to FDA restrictions on marketing of pharmaceutical products, pharmaceutical manufacturers are exposed, directly, or indirectly, through customers, to broadly applicable fraud and abuse and other
healthcare laws and regulations that may affect the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business or financial arrangements and relationships through which a pharmaceutical manufacturer can market, sell and distribute drug products. Such laws include, without limitation: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or
rebate), directly or indirectly, overtly or covertly, in cash or in kind, in return for either the referral of an individual, or the purchase, leasing, furnishing or arranging for the purchase, lease or order of a good, facility, item or service
reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers and formulary
managers on the other hand. The Patient Protection and Affordable Care Act (as amended by the Health Care and Education Reconciliation Act), or ACA, amended the intent requirement of the federal Anti-Kickback Statute, such that a person or entity no
longer needs to have actual knowledge of this statute or specific intent to violate it; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal false claims and civil monetary penalty laws, including the federal False Claims Act, which prohibits, among other things, individuals or entities from, among other things, knowingly presenting, or causing
to be presented, claims for payment or approval from Medicare, Medicaid or other government payors that are false or fraudulent. In addition, the ACA provides, and recent government cases against pharmaceutical and medical device manufacturers
support the view, that federal Anti-Kickback Statute violations and certain marketing practices, including <FONT STYLE="white-space:nowrap">off-label</FONT> promotion, may implicate the False Claims Act. Further, pharmaceutical manufacturers can be
held liable under the False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#147;cause&#148; the submission of false or fraudulent claims. Criminal prosecution is also possible for making or
presenting a false, fictitious or fraudulent claim to the federal government; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which, among other things, imposes criminal liability for executing or attempting to execute a scheme to defraud any healthcare benefit
program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and creates federal criminal laws that prohibit
knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statements or representations, or making or using any false writing or document knowing the same to contain any
materially false, fictitious or fraudulent statement or entry in connection with the delivery of, or payment for, benefits, items or services; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HIPAA, as amended by the Health Information Technology and Clinical Health Act of 2009, or HITECH, and its implementing regulations, which impose certain requirements relating to the privacy, security, transmission and
breach reporting of individually identifiable health information upon health plans, healthcare clearinghouses and healthcare providers and their respective business associates that perform services for them that involve individually identifiable
health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for
damages or injunctions in U.S. federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal physician payment transparency requirements, sometimes referred to as the &#147;Physician Payments Sunshine Act,&#148; and its implementing regulations, which require certain manufacturers of drugs, devices,
biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to the United States Department of Health and Human Services, or HHS,
information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by
physicians and their immediate family members; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">State and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed
by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">State and foreign laws that require pharmaceutical companies to implement compliance programs, comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance
promulgated by the federal government, or to track and report gifts, compensation and other remuneration provided to physicians and other healthcare providers, and other federal, state and foreign laws that govern the privacy and security of health
information or personally identifiable information in certain circumstances, including state health information privacy and data breach notification laws which govern the collection, use, disclosure, and protection of health-related and other
personal information, many of which differ from each other in significant ways and often are not <FONT STYLE="white-space:nowrap">pre-empted</FONT> by HIPAA, thus requiring additional compliance efforts. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of their exceptions and safe harbors, it is possible that business activities can be
subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent
and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and
settlements in the healthcare industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ensuring that business arrangements with third parties comply with applicable healthcare laws and
regulations is costly and time consuming. If business operations are found to be in violation of any of the laws described above or any other applicable governmental regulations a pharmaceutical manufacturer may be subject to penalties, including
civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from governmental funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits
and future earnings, additional reporting obligations and oversight if subject to a corporate integrity agreement or other agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and curtailment or
restructuring of operations, any of which could adversely affect a pharmaceutical manufacturer&#146;s ability to operate its business and the results of its operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Healthcare Reform </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States,
there have been, and continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect the future results of pharmaceutical manufactures&#146; operations. In particular, there have been
and continue to be a number of initiatives at the federal and state levels that seek to reduce healthcare costs. Most recently, ACA, which was enacted in March 2010, which includes measures to significantly change the way healthcare is financed by
both governmental and private insurers. Among the provisions of the ACA of greatest importance to the pharmaceutical and biotechnology industry are the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some
government healthcare programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped
the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, that are inhaled, infused, instilled, implanted or injected;
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extension of manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals
with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#146; Medicaid rebate liability; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated
prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of the entities eligible for discounts under the Public Health program; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishment of a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">implementation of the federal physician payment transparency requirements, sometimes referred to as the &#147;Physician Payments Sunshine Act.&#148; </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the provisions of the ACA have yet to be implemented, and there have been legal and political challenges to certain aspects of the
ACA. Since January 2017, President Trump has signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or
repeal and replace all or part of the ACA. While Congress has not passed repeal legislation, the Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT>
shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#147;individual mandate.&#148; Congress may consider other
legislation to repeal or replace elements of the ACA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted in the United States since
the ACA was enacted. For example, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at
least $1.2 trillion for the years 2012 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to
providers of up to 2% per fiscal year, which went into effect in April 2013 and due to subsequent legislative amendments to the statute, including the Bipartisan Budget Act of 2015, will remain in effect through 2025 unless additional Congressional
action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment
centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost
of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the
relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, Congress and the Trump Administration have each indicated that it will continue to seek new
legislative and/or administrative measures to control drug costs. At the state level, legislatures have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and
bulk purchasing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercialization Strategy and Organization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given our stage of development, we have not yet established a commercial organization or distribution capabilities. If approved, we intend to
directly commercialize our sulopenem program in the United States with a targeted sales force across the community and hospital settings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to receiving approval, we plan to establish a health resources group to familiarize doctors in the community setting with the rising
rate of resistance of pathogens to the current oral therapies for UTI. If approved, we will direct our health resources group to promote antibiotic stewardship, particularly of oral sulopenem, by educating physicians in the community setting about
patients for whom sulopenem may be an appropriate treatment option. In the hospital setting, we believe our sulopenem program will support stewardship efforts in the hospital focused on reduction in treatment <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">length-of-stay</FONT></FONT> by providing a safe and effective oral therapy that can be completed in an outpatient setting. A team of regional medical physicians will also work with hospitals, provider organizations and
payors to demonstrate that the use of sulopenem may reduce the length of a patients&#146; hospital stay or avoid hospital admission altogether, which we believe would lower the total cost of treatment of cUTI, and in some cases uUTI when
inappropriate therapy leads to higher hospitalization rates or poor clinical outcomes for elevated risk patients. In addition, we expect that our health resources group will also work with doctors in the infectious disease field to answer questions
regarding sulopenem&#146;s clinical results and its pharmacokinetic profile, conduct medical education events regarding the emerging science and build awareness of sulopenem. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA approves oral sulopenem and sulopenem, we plan to build a commercial infrastructure to launch both product candidates in the United
States. We expect that our commercial infrastructure, led by highly-experienced management personnel, would be comprised of a targeted sales force, an internal marketing and health resources group, as well as a managed markets group focused on
reimbursement activities with third-party payors and a specialty distribution team. We also plan to have in place a patient and healthcare practitioner support group to assist with information requests, reimbursement logistics and assistance, and
provide educational materials where appropriate. To ensure successful execution of these critical activities, we may need to hire personnel to fill some of these functions in advance of the anticipated approval date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to direct our sales and marketing efforts toward the community and hospital practitioner settings that account for a substantial
majority of the potential market for oral sulopenem and sulopenem across geographies with the highest prevalence of bacterial resistance to fluoroquinolones. Based on a 2017 market survey data of outpatient urine cultures of Enterobacteriaceae and
quinolone resistance by zip code, we estimate that our initial sales force could successfully target key customers including top hospitals and emergency room clinics, as well as specialty and primary care practices in the community setting. As
access for, and awareness of, our sulopenem program increases, we would plan to broaden our target audience and geography by increasing the number of sales representatives to capture a larger percentage of the market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focusing our initial commercial efforts on the U.S. market, which we believe represents the largest market opportunity for our
sulopenem program. We are currently evaluating our commercialization strategy outside the United States, and believe that Europe and Asia represent significant opportunities because of rising rates of ESBL and quinolone resistance in these
geographies, which in many countries exceeds the United States&#146; resistance rate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently own or operate manufacturing facilities for the production of any of our product candidates; however, we have plans to
establish our own tableting facility in Ireland in the future. We currently rely on four third-party contract manufacturers for all of our required raw materials, drug substance, and finished drug product for our preclinical research and clinical
trials. We currently have a ten person team dedicated to managing the relationships with these manufacturers and the manufacturing process. Due to the complex and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
critical nature of drug manufacturing, we have employed a dual sourcing strategy in order to register and validate two suppliers for sulopenem&#146;s active pharmaceutical ingredient at the time
of filing our NDAs, with each supplier capable of producing kilogram quantities for commercial scale under cGMP conditions. We also intend to have two sources for the production of the oral sulopenem bilayer tablets, one of which will be a
third-party manufacturer registered and validated at the time of our product launch with the second facility operated by us. We anticipate that the second facility will be at a site in Dublin which is leased to us and with equipment that we will own
and will be registered and validated within a year of our product launch. We plan to have two FDA-approved IV manufacturing sites. One IV manufacturer will be registered and validated at approval with a secondary manufacturer also capable of
producing sulopenem but not initially registered. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may be involved in legal proceedings or be subject to claims arising out of our operations.&nbsp;We are not currently a
party to any legal proceedings that in the opinion of our management, would have a material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our headquarters are located in Dublin, Ireland, where we lease approximately 5,551 square feet of office space. Our lease extends through
November 2026, and we have the option to terminate the lease in November 2021 with one year&#146;s notice and a six months&#146; rent penalty. We also lease office space in Old Saybrook, CT. Our lease extends through June 2022, and we have the
option to extend the term of the lease for such space through June 2025. We currently sublease office space in Chicago, Illinois but are in the process of finalizing the terms of a five year lease for alternative premises in Chicago. We believe that
our current facilities are adequate to meet our near-term needs, and that suitable additional or substitute space will be available as needed on commercially reasonable terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017,
we had 29 full-time employees, including a total of seven employees with M.D. or Ph.D. degrees. Nineteen employees were primarily engaged in research and development activities, with the rest providing administrative, business and operations
support. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our employee relations to be good. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc522368_11"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth certain information regarding our current executive officers and directors as of March&nbsp;1, 2018: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="59%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position(s)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corey N. Fishman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Dunne, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Scientific Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Judith M. Matthews</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeff Schaffnit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Commercial Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul R. Edick<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP><SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairman of the Board of Directors</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brenton K. Ahrens<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Chin<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James I. Healy, M.D., Ph.D<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick J. Heron<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Hopfner, Ph.D<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ronald M. Hunt<SUP STYLE="font-size:85%; vertical-align:top">(1)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David G. Kelly<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shahzad Malik, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Member of the compensation committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Member of the audit committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Member of the nominating and corporate governance committee. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Corey N. Fishman </I>has served as our Chief Executive Officer and member of our board of directors since November 2015. From August 2010 to
February 2015, Mr.&nbsp;Fishman served as chief operating officer of Durata Therapeutics, Inc., a pharmaceutical company acquired by Actavis plc, a pharmaceutical company, and he also served as chief financial officer of Durata from June 2012 to
February 2015. From 2008 to 2010, Mr.&nbsp;Fishman served as chief financial officer of GANIC Pharmaceuticals, Inc., a pharmaceutical company. From 2002 to 2008, Mr.&nbsp;Fishman served in a variety of roles at MedPointe Healthcare, Inc., a
specialty pharmaceutical company acquired by Meda AB, including as chief financial officer from 2006 to 2008. Mr.&nbsp;Fishman currently serves as a member of the board of directors of Momenta Pharmaceuticals, Inc. Mr.&nbsp;Fishman holds a B.A. in
economics from the University of Illinois at Urbana-Champaign and an M.S.M. in finance from the Krannert School of Management at Purdue University. We believe Mr.&nbsp;Fishman is qualified to serve on our board of directors due to his role as a
founder of our company, his deep knowledge of our company and his extensive background in the pharmaceutical industry. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Michael W.
Dunne, M.D.</I> has served as our Chief Scientific Officer since November 2015. From November 2014 until September 2015, Dr.&nbsp;Dunne was vice president research and development at Actavis. From September 2010 to October 2014, Dr.&nbsp;Dunne
served as chief medical officer of Durata, where he previously served as acting chief medical officer on a consulting basis from December 2009 to September 2010. From 1992 to 2009, Dr.&nbsp;Dunne served in a variety of roles in connection with the
clinical development of numerous infectious disease compounds at Pfizer Inc., a biopharmaceutical company, including as the vice president, therapeutic head of development for infectious disease from 2001 to 2009. Dr.&nbsp;Dunne holds a B.A. in
economics from Northwestern University and an M.D. from the State University of New York Health Sciences Center. He completed his internal medicine residency and fellowships in infectious diseases and pulmonary medicine at Yale University School of
Medicine. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Judith M. Matthews</I> has served as our Chief Financial Officer since November 2015. From 2012 to February 2015,
Ms.&nbsp;Matthews served as vice president of finance at Durata. From 2009 to 2012, Ms.&nbsp;Matthews served as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
head of financial planning&nbsp;&amp; analysis at Bally Total Fitness Corporation, a fitness club chain. From 2004 to 2008, Ms.&nbsp;Matthews served as vice president of finance for the Sterno
Group, a subsidiary of Blyth, Inc., a home products company. Ms.&nbsp;Matthews holds a B.A. in accounting from the University of Illinois at <FONT STYLE="white-space:nowrap">Urbana-Champaign</FONT> and a Master of Management in finance and marketing
from the Kellogg School of Management at Northwestern University. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Jeff Schaffnit</I> has served as our Chief Commercial Officer
since February 2018. From April 2017 to January 2018, Mr. Schaffnit served as group vice president and head of patient engagement and experience at Shire plc, a biopharmaceutical company, where he previously served as vice president and head of U.S.
hematology from June 2016 to March 2017. From January 2016 to June 2016, Mr. Schaffnit served as vice president and North American region head, hematology at Baxalta Inc., a biopharmaceutical company acquired by Shire. From January 2015 to December
2015, Mr. Schaffnit served as vice president of hemophilia marketing for Baxalta Inc. From August 2013 to December 2014, Mr. Schaffnit served as senior director, U.S. hemophilia marketing at Baxter International Inc., a healthcare company. From
October 2012 to July 2013, Mr. Schaffnit served as vice president of sales and marketing at M&#233;rieux NutriSciences Corporation, a food safety and nutrition consulting company. Mr. Schaffnit has a B.S. in chemical engineering from the University
of Illinois at Urbana-Champaign and an M.B.A. in strategy, finance and marketing from the Kellogg School of Management at Northwestern University. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Paul R. Edick </I>has served as Chairman of our board of directors since November 2015. Since January 2017, Mr.&nbsp;Edick has served as
president, chief executive officer and a director of Xeris Pharmaceuticals, Inc., a biopharmaceutical company. Since November 2014, Mr.&nbsp;Edick served as founding partner of 3G Advisors, LLC, a consultancy to the pharmaceutical, healthcare and
healthcare investor communities. From July 2010 to November 2014, Mr.&nbsp;Edick served as chief executive officer and member of the board of directors of Durata. From 2008 to 2010, Mr.&nbsp;Edick served as chief executive officer of GANIC
Pharmaceuticals, Inc., a pharmaceutical company. From 2002 to 2008, Mr.&nbsp;Edick served in a variety of roles at MedPointe, including as chief executive officer from 2006 to 2008. Mr.&nbsp;Edick also currently serves as a member of the board of
directors of Newlink Genetics Corporation, Sucampo Pharmaceuticals, Inc., Neos Therapeutics, Inc., PDL BioPharma, Inc. and Xeris Pharmaceuticals. Mr.&nbsp;Edick previously served on the boards of directors of Circassia Pharmaceuticals and Durata.
Mr.&nbsp;Edick holds a B.A. in psychology from Hamilton College in Clinton, New York. We believe Mr.&nbsp;Edick is qualified to serve on our board of directors due to his extensive experience with pharmaceutical companies at various stages of
development, including service on the boards of directors of other healthcare companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Brenton K. Ahrens</I> has served as a member
of our board of directors since November 2015. Since 1999, Mr.&nbsp;Ahrens has served as a general partner with Canaan Partners LLP, a venture capital firm. Prior to joining Canaan Partners, Mr.&nbsp;Ahrens worked in both commercial and technical
roles at General Surgical Innovations, Ethicon (J&amp;J), and IAP Research. Mr.&nbsp;Ahrens previously served on the board of directors of Durata. Mr.&nbsp;Ahrens holds a B.S. and an M.S. in mechanical engineering from the University of Dayton and
an M.B.A. from the Tuck School of Business at Dartmouth College. We believe Mr.&nbsp;Ahrens is qualified to serve on our board of directors due to his investment experience, including service on the boards of directors of other healthcare companies.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Mark Chin</I> has served as a member of our board of directors since May 2017. Since August 2016, Mr.&nbsp;Chin has served as an
investment manager at Arix Bioscience plc, a life science investment company. From September 2012 to July 2016, Mr.&nbsp;Chin served as a principal at Longitude Capital LLC, a healthcare venture capital firm. From January 2011 to September 2012,
Mr.&nbsp;Chin served as a consultant with the Boston Consulting Group. Mr.&nbsp;Chin has a B.S. in management science from the University of California at San Diego, an M.B.A. from the Wharton School at the University of Pennsylvania and an M.S. in
biotechnology from the University of Pennsylvania. We believe Mr.&nbsp;Chin is qualified to serve on our board of directors due to his investment experience in biotechnology and medical technology industries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>James I. Healy, M.D., Ph.D</I>. has served as a member of our board of directors since
November 2015. Dr.&nbsp;Healy has been a general partner at Sofinnova Ventures, Inc. since 2000. Prior to this, Dr. Healy held positions at Bayer Healthcare Pharmaceuticals Inc. and Sanderling Ventures. Dr. Healy is currently on the board of
directors of Ascendis Pharma A/S, Coherus BioSciences, Inc., Edge Therapeutics, Inc., ObsEva SA, Natera, Inc., NuCana plc and several private companies. Previously, Dr. Healy served as a board member of Amarin Corporation plc, Anthera
Pharmaceuticals, Inc., Auris Medical Holding AG, Durata, Hyperion Therapeutics, Inc., InterMune, Inc., KaloBios Pharmaceuticals, Inc., Movetis NV and a number of private companies. Dr. Healy holds a B.A. in molecular biology and a B.A. in
Scandinavian studies from the University of California at Berkeley and an M.D. and Ph.D. in immunology from Stanford University School of Medicine. We believe Dr. Healy is qualified to serve on our board of directors due to his medical training and
his extensive experience in the biopharmaceutical industry, including as a venture capital investor and a member of the boards of directors of other biopharmaceutical companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Patrick J. Heron</I> has served as a member of our board of directors since November 2015. Since 1999, Mr.&nbsp;Heron has served as a
general partner with Frazier Healthcare Partners, a venture capital firm. Prior to joining Frazier Healthcare Partners, Mr.&nbsp;Heron worked at the management consulting firm McKinsey&nbsp;&amp; Company. Before McKinsey, Mr.&nbsp;Heron held
positions with Massachusetts General Hospital and biotechnology firm Cetus Corporation. Mr.&nbsp;Heron previously served on the boards of directors of Tobira Therapeutics, Inc. and Collegium Pharmaceuticals, Inc. Mr.&nbsp;Heron holds a B.A. in
political science from the University of North Carolina at Chapel Hill and received an M.B.A. from Harvard Business School. We believe Mr.&nbsp;Heron is qualified to serve on our board of directors due to his extensive business experience, his
experience in investing, and his experience in the life sciences industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Robert Hopfner, Ph.D. </I>has served as a member of our
board of directors since December 2017. Since October 2017, Dr.&nbsp;Hopfner has served as a managing partner at Pivotal bioVenture Partners LLC, a venture capital firm. From 2007 to September 2017, Dr.&nbsp;Hopfner served as an Investment Partner
at Bay City Capital, a venture capital firm. Before joining Bay City Capital, Dr.&nbsp;Hopfner worked as an associate in DuPont Pharmaceuticals&#146; Business Development&nbsp;&amp; Strategic Planning group and as an analyst at <FONT
STYLE="white-space:nowrap">Ag-West</FONT> Biotech, a Western Canadian seed-stage biotech venture capital firm. Dr.&nbsp;Hopfner previously served on the boards of directors of Durata and Hyperion Therapeutics, Inc. Dr.&nbsp;Hopfner holds Ph.D. in
Pharmacology and a B.S. in Pharmacy from the University of Saskatchewan and an M.B.A. with specializations in Entrepreneurship, Finance and Strategy from the University of Chicago Booth School of Business. We believe Dr.&nbsp;Hopfner is qualified to
serve on our board of directors due to his investment experience in the life science industry, as well as his medical background. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Ronald M. Hunt</I> has served as a member of our board of directors since November 2015. Since 2005, Mr.&nbsp;Hunt has served as a Managing
Director and member of New Leaf Venture Partners, L.L.C., a venture capital firm. Previously, Mr.&nbsp;Hunt served at the Sprout Group, a venture capital firm and was a consultant with consulting firms Coopers&nbsp;&amp; Lybrand Consulting and The
Health Care Group. Mr.&nbsp;Hunt also previously served in various sales and marketing positions at Johnson&nbsp;&amp; Johnson and SmithKline Beecham Pharmaceuticals. Mr.&nbsp;Hunt previously served on the board of directors of Durata and Relypsa,
Inc. Mr.&nbsp;Hunt holds a B.S. from Cornell University and an M.B.A. from the Wharton School of the University of Pennsylvania. We believe Mr.&nbsp;Hunt is qualified to serve on our board of directors due to his investment experience, his
experience in the pharmaceuticals industry and his service on the boards of directors of other biopharmaceutical companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>David G.
Kelly</I> has served as a member of our board of directors since August 2016. Since September 2014, Mr.&nbsp;Kelly has served as the executive vice president, managing director, Ireland of Horizon Pharma, plc, a biopharmaceutical company. From
February 2012 to September 2014, Mr.&nbsp;Kelly served as Chief Financial Officer of Vidara Therapeutics Inc., a pharmaceutical company. From May 2005 to January 2012, Mr.&nbsp;Kelly served as chief financial officer of AGI Therapeutics plc, a
pharmaceutical company. Mr.&nbsp;Kelly also served as senior vice president, finance and planning of Warner Chilcott plc (formerly Galen Holdings plc), a pharmaceutical company listed on the London Stock Exchange (LSE). In addition, Mr.&nbsp;Kelly
held roles at Elan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Corporation and KPMG. Mr.&nbsp;Kelly holds a B.A. in economics from Trinity College, Dublin and is also a member of the Institute of Chartered Accountants in Ireland (ACA). We believe
Mr.&nbsp;Kelly is qualified to serve on our board of directors due to his experience as a senior executive, particularly within the life science industry, including his experience in finance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Shahzad Malik, M.D</I>. has served as a member of our board of directors since May 2017. Since 1999, Dr.&nbsp;Malik has served as a general
partner at Advent Life Sciences LLP, a venture capital firm. Prior to joining Advent, Dr.&nbsp;Malik spent six years practicing medicine before joining the London office of McKinsey&nbsp;&amp; Company, a management consulting firm. Dr.&nbsp;Malik
also currently serves on the board of directors of Versartis, Inc. He previously served on the boards of directors of Conatus Pharmaceuticals Inc. and Agenus Inc. Dr.&nbsp;Malik holds an M.A. from Oxford University and an M.D. from Cambridge
University. He subsequently specialized in interventional cardiology while also pursuing research interests in heart muscle disorders both in the clinic and basic science laboratory. We believe Dr.&nbsp;Malik is qualified to serve on our board of
directors due to his experience practicing medicine and his investment experience. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Family Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of the directors or executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business and
affairs are managed under the direction of our board of directors, which currently consists of ten members. Certain members of our board of directors were elected pursuant to the provisions of a voting agreement among certain of our shareholders.
Under the terms of this voting agreement, the shareholders who are party to the voting agreement have agreed to vote their respective shares so as to elect directors as follows: (i)&nbsp;one individual designated by Frazier Healthcare VII, L.P. and
Frazier Healthcare <FONT STYLE="white-space:nowrap">VII-A,</FONT> L.P. (Mr.&nbsp;Heron), (ii)&nbsp;one individual designated by Canaan X, L.P. (Mr.&nbsp;Ahrens), (iii) one individual designated by New Leaf Ventures III, L.P. (Mr.&nbsp;Hunt), (iv)
one individual designated by Sofinnova Venture Partners IX, L.P. (Dr.&nbsp;Healy), (v) one individual designated by Arix Bioscience Holdings Ltd. (Mr.&nbsp;Chin), (vi) one individual designated by Pivotal bioVenture Partners I, L.P.
(Dr.&nbsp;Hopfner), (vii) one individual designated by Advent Life Sciences LLP and Advent Life Sciences Fund II LP (Dr.&nbsp;Malik), (viii) the person then serving as Chief Executive Officer (Mr.&nbsp;Fishman), (ix) a Chairman of the Board
acceptable to at least a majority of the board of directors (Mr.&nbsp;Edick) and (x)&nbsp;one industry representative not affiliated with our company or any investor in our company acceptable to at least a majority of the board of directors
(Mr.&nbsp;Kelly). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors will consist of ten members upon the closing of this offering. Upon completion of this offering,
our directors will be divided among three classes with staggered three-year terms as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Class&nbsp;I, whose members will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The terms of the Class&nbsp;I directors will expire at our 2019 annual meeting of shareholders; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Class&nbsp;II, whose members will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The terms of the Class&nbsp;II directors will expire at our 2020 annual meeting of shareholders; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Class&nbsp;III, whose members will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The terms of the Class&nbsp;III directors will expire at our 2021 annual meeting of shareholders.
</TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied to list our ordinary shares on The Nasdaq Global Select Market, or Nasdaq. Applicable Nasdaq rules
require a majority of a listed company&#146;s board of directors to be comprised of independent directors within one year of listing. In addition, the Nasdaq rules require that, (i)&nbsp;on the date of the completion of the offering, at least one
member of each of a listed company&#146;s audit, compensation and nominating and corporate governance committees be independent, (ii)&nbsp;within 90 days of the date of the completion of the offering, a majority of the members of such committees be
independent and (iii)&nbsp;within one year of the date of the completion of the offering, all the members of such committees be independent. Audit committee members must also satisfy the independence criteria set forth in Rule <FONT
STYLE="white-space:nowrap">10A-3</FONT> under the Securities Exchange Act of 1934, as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amended, or the Exchange Act. Under applicable Nasdaq rules, a director will only qualify as an &#147;independent director&#148; if, in the opinion of the listed company&#146;s board of
directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act, a member of
an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other
compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors undertook a review of the composition of our board of directors and its committees and the independence of each
director. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our board of directors has determined that all directors other than Corey
Fishman are &#147;independent directors&#148; as defined under applicable Nasdaq rules. In making such determination, our board of directors considered the relationships that each such <FONT STYLE="white-space:nowrap">non-employee</FONT> director
has with our company and all other facts and circumstances that our board of directors deemed relevant in determining his or her independence, including the beneficial ownership of our capital stock by each
<FONT STYLE="white-space:nowrap">non-employee</FONT> director. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has the authority to appoint committees to perform certain management and administration functions. Our board of
directors has established an audit committee, a compensation committee, and a nominating and corporate governance committee. The composition and responsibilities of each committee are described below. Members will serve on these committees until
their resignation or until otherwise determined by the board of directors. Following the closing of this offering, the charters for each of these committees will be available on our website at www.iterumtx.com. Information contained on or accessible
through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only. The composition of all of our committees will comply with all applicable requirements of the
Irish Companies Act, the Sarbanes-Oxley Act of 2002, Nasdaq and Securities and Exchange Commission, or SEC, rules and regulations. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit
Committee </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit committee will consist of&nbsp;Brenton K. Ahrens, Robert Hopfner, Ph.D. and David G. Kelly. Our board of
directors has determined each of Mr. Ahrens, Dr. Hopfner and Mr. Kelly to be independent under the listing standards and Rule <FONT STYLE="white-space:nowrap">10A-3(b)(1)</FONT> of the Exchange Act and for the purposes of Section 167(4) of the Irish
Companies Act. The chairperson of our audit committee is Mr. Kelly. Our board of directors has determined that Mr. Kelly is an &#147;audit committee financial expert&#148; within the meaning of SEC regulations. Our board of directors has also
determined that each member of our audit committee has the requisite financial expertise required under the applicable requirements of Nasdaq. In arriving at this determination, the board of directors has examined each audit committee member&#146;s
scope of experience and the nature of their employment in the corporate finance sector. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary purpose of the audit committee
is to discharge the responsibilities of our board of directors with respect to our accounting, financial, and other reporting and internal control practices and to oversee our independent registered accounting firm. Specific responsibilities of our
audit committee include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">selecting a qualified firm to serve as the independent registered public accounting firm to audit our financial statements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">helping to ensure the independence and performance of the independent registered public accounting firm; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the independent accountants, our interim and
<FONT STYLE="white-space:nowrap">year-end</FONT> operating results; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing, upon completion of the audit, the Irish statutory financial statements proposed to be filed with our annual return at the Irish Companies Registration Office; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developing procedures for employees to submit concerns anonymously about questionable accounting or audit matters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing our policies on risk assessment and risk management; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing related party transactions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining and reviewing a report by the independent registered public accounting firm at least annually, that describes our internal quality-control procedures, any material issues with such procedures, and any steps
taken to deal with such issues when required by applicable law; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approving (or, as permitted, <FONT STYLE="white-space:nowrap">pre-approving)</FONT> all audit and all permissible <FONT STYLE="white-space:nowrap">non-audit</FONT> service to be performed by the independent registered
public accounting firm. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation committee will consist of Paul R. Edick, Mark Chin, James I. Healy, M.D., Ph.D., Ronald M. Hunt and Shahzad Malik, M.D.. Our
board of directors has determined each of Mr. Edick, Mr. Chin, Dr. Healy, Mr. Hunt&nbsp;and Dr. Malik to be a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT>
promulgated under the Exchange Act. The chairperson of our compensation committee is Mr. Hunt. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary purpose of our
compensation committee is to discharge the responsibilities of our board of directors to oversee our compensation policies, plans and programs and to review and determine the compensation to be paid to our executive officers, directors and other
senior management, as appropriate. Specific responsibilities of our compensation committee include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving, or recommending that our board of directors approve, the compensation of our executive officers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and recommending to our board of directors the compensation of our directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving, or recommending that our board of directors approve, the terms of compensatory arrangements with our executive officers; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">administering our stock and equity incentive plans; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">selecting independent compensation consultants and assessing whether there are any conflicts of interest with any of the committee&#146;s compensation advisors; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving, or recommending that our board of directors approve, incentive compensation and equity plans, severance agreements,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control</FONT></FONT> protections and any other compensatory arrangements for our executive officers and other senior management, as appropriate; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and establishing general policies relating to compensation and benefits of our employees; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing our overall compensation philosophy. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our nominating and corporate governance committee will consist of Paul R. Edick, Patrick J. Heron, Ronald M. Hunt, David G.
Kelly and Shahzad Malik, M.D.. Our board of directors has determined each of Mr. Edick, Mr. Heron, Mr. Hunt, Mr. Kelly and Dr. Malik to be independent under the listing standards. The chairperson of our nominating and corporate governance committee
is Mr. Edick. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specific responsibilities of our nominating and corporate governance committee include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing periodically and evaluating director performance on our board of directors and its applicable committees, and recommending to our board of directors and management areas for improvement; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">interviewing, evaluating, nominating and recommending individuals for membership on our board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">administering the process outlined in our constitution concerning shareholder nominations for director candidates; </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing developments in corporate governance practices; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overseeing and reviewing our processes and procedures to provide information to our board of directors and its committees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and recommending to our board of directors any amendments to our corporate governance policies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and assessing, at least annually, the performance of the nominating and corporate governance committee and the adequacy of its charter. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
will adopt a Code of Business Conduct and Ethics that applies to all of our employees, officers and directors, including those officers responsible for financial reporting. Following the closing of this offering, the Code of Business Conduct and
Ethics will be available on our website at www.iterumtx.com. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference
only. We intend to disclose any amendments to the Code of Business Conduct and Ethics, or any waivers of its requirements, on our website to the extent required by the applicable rules and exchange requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No member of our compensation committee has ever been an officer or employee of our company. None of our executive officers serve, or have
served during the last year, as a member of the board of directors, compensation committee, or other board committee performing equivalent functions of any other entity that has one or more executive officers serving as one of our directors or on
our compensation committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2017 <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding compensation earned by or paid to our <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors during 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned<BR>or&nbsp;Paid&nbsp;in<BR>Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other<BR>Compensation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brenton K. Ahrens</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Chin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul R. Edick<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,992<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James I. Healy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick J. Heron</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Hopfner, Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ronald M. Hunt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David G. Kelly<SUP STYLE="font-size:85%; vertical-align:top">(3)(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,195<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shahzad Malik, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">The amounts reported do not reflect the amounts actually received by our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors. Instead, these amounts reflect the aggregate grant date fair value of each stock option granted to our <FONT STYLE="white-space:nowrap">non-employee</FONT>
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
directors during 2017, as computed in accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, 718. Assumptions used in the calculation of these
amounts are included in Note&nbsp;7 to our audited financial statements included in this prospectus. As required by SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service-based vesting conditions. Our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors who have received options will only realize compensation with regard to these options to the extent the trading price of our ordinary shares is greater than the exercise price of such options.
The table below lists the aggregate number of shares subject to outstanding option awards held by each of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="21%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares&nbsp;Subject&nbsp;to</B><br><B>Outstanding&nbsp;Options</B><br><B>as of December&nbsp;31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brenton K. Ahrens</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Chin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul R. Edick<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James I. Healy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick J. Heron</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Hopfner, Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ronald M. Hunt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David G. Kelly<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shahzad Malik, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Edick was granted an option to purchase 16,667 of our ordinary shares at an exercise price of $0.21 per share on September&nbsp;12, 2017. The shares are scheduled to vest over a four-year period as follows: 1/4<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> of the shares vest on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the vesting commencement date, September&nbsp;12, 2017, and
1/48<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the total shares will vest each month thereafter, subject to continued service with us through each relevant vesting date. The vesting of Mr.&nbsp;Edick&#146;s option award will
accelerate in full if within 30 days prior to or 12 months following a change of control Mr.&nbsp;Edick (i)&nbsp;is terminated without cause or (ii)&nbsp;resigns for good reason. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Kelly was granted an option to purchase 10,000 of our ordinary shares at an exercise price of $0.21 per share on September&nbsp;12, 2017. The shares are scheduled to vest over a four-year period as follows: 1/4<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> of the shares vest on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the vesting commencement date, September&nbsp;12, 2017, and
1/48<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the total shares will vest each month thereafter, subject to continued service with us through each relevant vesting date. The vesting of Mr.&nbsp;Kelly&#146;s option award will
accelerate in full if within 30 days prior to or 12 months following a change of control Mr.&nbsp;Kelly (i)&nbsp;is terminated without cause or (ii)&nbsp;resigns for good reason. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Kelly&#146;s compensation is set in US$, however he is paid in Euros using the average of the closing monthly average exchange rates for the 12 months ended December&nbsp;31, 2017. Applying this formula to
years ended December&nbsp;31, 2017, US$1.00 was equal to &#128;0.9034. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director
Compensation Policy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to adopt a <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy, pursuant
to which our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors will be eligible to receive compensation for service on our board of directors and committees of our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc522368_12"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers, consisting of our principal executive officer and the next two most highly compensated executive officers, as of
December&nbsp;31, 2017, were: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Corey N. Fishman, President and Chief Executive Officer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Michael W. Dunne, M.D., Chief Scientific Officer; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Judith M. Matthews, Chief Financial Officer. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2017 Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents all of the compensation paid or awarded to or earned by our named executive officers during 2017: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:97.90pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive&nbsp;
Plan<BR>Compensation<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Other<BR>Compensation<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corey N. Fishman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">420,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">210,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD VALIGN="bottom" ALIGN="right">2,208<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">754,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Dunne, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">367,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">603,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Scientific Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Judith M. Matthews</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported do not reflect the amounts actually received by our executive officers. Instead, these amounts reflect the aggregate grant date fair value of each stock option granted to our executive officers
during 2017, as computed in accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, 718. Assumptions used in the calculation of these amounts are included in Note 2 to our audited financial
statements included in this prospectus. As required by SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service-based vesting conditions. Our executive officers who have received options will only realize
compensation with regard to these options to the extent the trading price of our ordinary shares is greater than the exercise price of such options. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Amount represent cash bonuses earned for the <FONT STYLE="white-space:nowrap">12-month</FONT> period from January&nbsp;1, 2017 to December&nbsp;31, 2017, and exclude payments made in 2017 for 2016 bonuses.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Includes the dollar value of life insurance premiums paid by the company for the benefit of such executive. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards as of December&nbsp;31, 2017 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents information regarding outstanding equity awards held by our named executive officers as of December&nbsp;31, 2017.
All stock options were granted under our 2015 Equity Incentive Plan. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vesting<BR>Commencement<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options
(#)<BR>Unexercisable<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price&nbsp;Per<BR>Share<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corey N. Fishman</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/12/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/12/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,026,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/11/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Dunne, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/12/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/12/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">653,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/11/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Judith M. Matthews</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/12/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/12/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/11/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The shares are scheduled to vest over a four-year period as follows: 25% of the shares underlying the options vest on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the vesting commencement date and
thereafter 1/48th of the shares vest each month, subject to continued service with us through each relevant vesting date. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Pursuant to the equity agreements between the named executive officer and us, the vesting of such named executive officer&#146;s stock and option awards will accelerate under certain circumstances as described under the
section titled &#147;&#151;Employment, Severance and Change in Control Arrangements.&#148; </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">The exercise price per share of the stock options reflects the fair market value per ordinary share on the date of grant. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pension Benefits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive
officers did not participate in, or otherwise receive any benefits under, any pension or defined benefit retirement plan sponsored by us in 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nonqualified Deferred Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
named executive officers did not participate in, or earn any benefits under, a <FONT STYLE="white-space:nowrap">non-qualified</FONT> deferred compensation plan sponsored by us during 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company Status </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an
&#147;emerging growth company,&#148; as defined in the JOBS Act. As an emerging growth company we will be exempt from certain requirements related to executive compensation, including, but not limited to, the Nasdaq requirements to hold a nonbinding
advisory vote on executive compensation and to provide information relating to the ratio of total compensation of our Chief Executive Officer to the median of the annual total compensation of all of our employees, each as required by the Investor
Protection and Securities Reform Act of 2010, which is part of the Dodd-Frank Wall Street Reform and Consumer Protection Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment, Severance
and Change in Control Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into offer letters with each of our named executive officers. The offer letters
generally provide for <FONT STYLE="white-space:nowrap">at-will</FONT> employment and set forth the executive&#146;s initial base salary, target variable compensation, eligibility for employee benefits, the terms of initial equity grants and in some
cases severance benefits on a qualifying termination. Each of our named executive officers has also executed our standard form of proprietary information agreement. Any potential payments and benefits due upon a termination of employment or a change
of control of us are further described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Corey N. Fishman </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Fishman serves as our President and Chief Executive Officer. On November&nbsp;18, 2015, Mr.&nbsp;Fishman entered into an offer letter
with Iterum Therapeutics US Limited, our indirect wholly owned subsidiary. The offer letter has no specific term and constitutes an <FONT STYLE="white-space:nowrap">at-will</FONT> employment arrangement. Mr.&nbsp;Fishman&#146;s current base salary
is $420,000, and his discretionary annual target performance bonus is 50% of his annual base salary. In connection with his employment, in September 2017 Mr.&nbsp;Fishman was granted an option to purchase 1,026,667 of our ordinary shares at an
exercise price of $0.21 per share. The shares underlying the option vest as to 25% on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the vesting commencement date and 1/48<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>
of the shares vest each month thereafter, subject to Mr.&nbsp;Fishman&#146;s continued service with us through each relevant vesting date. The vesting of Mr.&nbsp;Fishman&#146;s option award is also subject to acceleration as detailed in the section
titled &#147;&#151;Potential Payments Upon Termination or Change in Control.&#148; </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Michael W. Dunne, M.D. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Dunne serves as our Chief Scientific Officer. On November&nbsp;18, 2015, Dr.&nbsp;Dunne entered into an offer letter with Iterum
Therapeutics US Limited, our indirect wholly owned subsidiary. The offer letter has no specific term and constitutes an <FONT STYLE="white-space:nowrap">at-will</FONT> employment arrangement. Dr.&nbsp;Dunne&#146;s current base salary is $367,500,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and his discretionary annual target performance bonus is 40% of his annual base salary. In connection with his employment, in September 2017 Dr.&nbsp;Dunne was granted an option to purchase
653,333 of our ordinary shares at an exercise price of $0.21 per share. The shares underlying the option vest as to 25% on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the vesting commencement date and 1/48<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> of the shares vest each month thereafter, subject to Dr.&nbsp;Dunne&#146;s continued service with us through each relevant vesting date. The vesting of Dr.&nbsp;Dunne&#146;s option award is also
subject to acceleration as detailed in the section titled &#147;&#151;Potential Payments Upon Termination or Change in Control.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Judith M.
Matthews </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Matthews serves as our Chief Financial Officer. Ms.&nbsp;Matthew&#146;s current base salary is $236,250, and her
discretionary annual target performance bonus is 25% of her annual base salary. The offer letter has no specific term and constitutes an <FONT STYLE="white-space:nowrap">at-will</FONT> employment arrangement. In connection with her employment, in
September 2017 Ms.&nbsp;Matthews was granted an option to purchase 186,667 of our ordinary shares at an exercise price of $0.21 per share. The shares underlying the option vest as to 25% on the <FONT STYLE="white-space:nowrap">one-year</FONT>
anniversary of the vesting commencement date and 1/48<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the shares vest each month thereafter, subject to Ms.&nbsp;Matthews&#146; continued service with us through each relevant vesting date.
The vesting of Ms.&nbsp;Matthews&#146; option award option award is also subject to acceleration as detailed in the section titled &#147;&#151;Potential Payments Upon Termination or Change in Control.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potential Payments Upon Termination or Change in Control </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our offer letter agreements with each of our named executive officers provides that upon the termination of his or her employment by us other
than for cause, or by the named executive officer with good reason (each as defined in the offer letters), he or she will be entitled to receive the following severance benefits: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cash severance equal to a fixed number of months of such executive&#146;s base salary (twelve months in the case of Mr.&nbsp;Fishman, nine months in the case of Dr.&nbsp;Dunne and six months in the case of
Ms.&nbsp;Matthews); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">company-paid COBRA premiums for up to 12 months following such executive&#146;s termination date. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a qualifying termination occurs within the period beginning one month prior to and ending 12 months following a change on control of us,
such executive will also be entitled to receive cash payments equal to 100% of such executive&#146;s target annual bonus for the year of termination, and Dr.&nbsp;Dunne and Ms.&nbsp;Matthews&#146; cash severance benefits described above will also
increase to 12 months&#146; worth of such individual&#146;s then-current base salary. In addition, each of Mr.&nbsp;Fishman, Dr.&nbsp;Dunne and Ms.&nbsp;Matthews&#146; currently outstanding stock options will accelerate in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each offer letter also contains a &#147;better <FONT STYLE="white-space:nowrap">after-tax&#148;</FONT> provision, which provides that if any
of the payments to such named executive officer constitutes a parachute payment under Section&nbsp;280G of the Internal Revenue Code of 1986, as amended, or the Code, the payments will either be (i)&nbsp;reduced or (ii)&nbsp;provided in full to the
executive, whichever results in the executive receiving the greater amount after taking into consideration the payment of all taxes, including the excise tax under Section&nbsp;4999 of the Code, in each case based upon the highest marginal rate for
the applicable tax. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment of any of the severance benefits described above is also conditioned on the named executive
officer&#146;s delivery and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of a general release of claims in our favor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, pursuant to ordinary share subscription deeds dated as of October&nbsp;14, 2015, upon a change in control each of Mr.&nbsp;Fishman, Dr.&nbsp;Dunne and Ms.&nbsp;Matthews are entitled to acceleration of all of the remaining unvested ordinary
shares issued thereunder, provided that such individual remains a service provider as of the time of consummation of the change in control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Incentive Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our ability to grant equity-based awards is a valuable and necessary compensation tool that aligns the long-term financial
interests of our employees, consultants, and directors with the financial interests of our shareholders. In addition, we believe that our ability to grant options and other equity-based awards helps us to attract, retain, and motivate employees,
consultants, and directors and encourages them to devote their best efforts to our business and financial success. The principal features of our equity incentive plans are summarized below. These summaries are qualified in their entirety by
reference to the actual text of the plans, which are filed as exhibits to the registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2018
Equity Incentive Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors adopted the 2018 Equity Incentive Plan, or the 2018 Plan, in
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2018 and our shareholders approved the 2018 Plan in
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2018. The 2018 Plan will become effective upon the execution immediately on the execution and delivery of the underwriting
agreement related to this offering. Once the 2018 Plan is effective, no further grants will be made under the 2015 Equity Incentive Plan, or the 2015 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Awards</I>. Our 2018 Plan authorizes the award of incentive stock options that may qualify for favorable tax treatment under
U.S. tax laws to their recipients under Section&nbsp;422 of the Code, or ISOs, nonstatutory stock options, or NSOs, stock appreciation rights, or SARs, restricted stock, restricted stock units, or RSUs, performance-based awards, and other stock
awards, which are collectively referred to as awards. We may grant awards under the 2018 Plan to our employees, including our officers, our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and consultants and the employees and
consultants of our affiliates. We may grant ISOs to our employees and employees of a subsidiary corporation or parent corporation (within the meaning of Sections&nbsp;424(e) and 424(f) of the Code). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Share Reserve.</I> Initially, the aggregate number of our ordinary shares that may be issued pursuant to awards under our 2018 Plan is the
sum of (1) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares, plus (2)&nbsp;any shares subject to outstanding options or other awards that were granted under our 2015 Plan and that are forfeited, terminated, expire or
are otherwise not issued, up to a maximum of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares. Additionally, the number of ordinary shares reserved for issuance under our 2018 Plan will automatically increase on
January&nbsp;1 of each calendar year for ten years, starting on January&nbsp;1, 2019 (assuming the 2018 Plan becomes effective in calendar year 2018) and ending on and including
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2028, in an amount equal to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of our ordinary shares
outstanding on December&nbsp;31 of the prior calendar year, or a lesser number of shares determined by our board of directors. The maximum number of our ordinary shares that may be issued upon the exercise of ISOs under our 2018 Plan is equal to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares subject to awards granted under
our 2018 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, do not reduce the number of shares available for issuance under our 2018 Plan. Additionally, shares become available for
future grant under our 2018 Plan if they were issued under awards under our 2018 Plan if we repurchase them or they are forfeited. This includes shares used to pay the exercise price of an award or to satisfy the tax withholding obligations related
to an award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration.</I> Our 2018 Plan will be administered by our compensation committee, or by our board of directors
or another duly authorized committee or by our board of directors, acting in place of our compensation committee. Our board of directors or our compensation committee may also delegate to one or more of our officers the authority to designate
employees (other than officers) to receive specified stock awards, and determine the number of shares subject to such stock awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
compensation committee will have the authority to construe and interpret our 2018 Plan, grant and amend awards, determine the terms of such awards and make all other determinations necessary or advisable for the administration of the plan,
including, but not limited to, repricing options or SARs without prior shareholder approval. Awards granted under the 2018 Plan may vest over time based on the holder&#146;s continued service with us, or following the achievement of certain <FONT
STYLE="white-space:nowrap">pre-established</FONT> performance goals. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Options.</I> Options represent the right to purchase our ordinary shares on the date of
exercise at a stated exercise price. ISOs may only be granted The exercise price of an option generally must be at least equal to the fair market value of our ordinary shares on the date of grant. Our compensation committee may provide for options
to be exercised only as they vest or to be immediately exercisable with any shares issued on exercise being subject to our right of repurchase that lapses as the shares vest. The maximum term of options granted under our 2018 Plan is ten years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Awards. </I>Restricted stock awards represent an offer by us to issue or sell our ordinary shares subject to vesting
restrictions, which may lapse based on time or achievement of performance conditions. The price (if any) of a restricted stock award will be determined by our compensation committee. Unless otherwise determined by our compensation committee at the
time of grant, vesting will cease on the date the participant no longer provides services to us and unvested shares will be forfeited to or repurchased by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Unit Awards.</I> RSUs represent the right to receive our ordinary shares at a specified date in the future, subject to
forfeiture of that right because of termination of employment or failure to achieve certain performance conditions. If an RSU award has not been forfeited, then on the date specified in the RSU agreement, we will deliver to the holder a number of
whole ordinary shares, cash or a combination of our ordinary shares and cash. Additionally, dividend equivalents may be credited in respect of shares covered by an RSU award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights.</I> SARs provide for a payment, or payments, in cash or ordinary shares, to the holder based upon the difference
between the fair market value of our ordinary shares on the date of exercise and the stated exercise price. The maximum term of SARs granted under our 2018 Plan is ten years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Other Stock Awards.</I> Our compensation committee may grant other awards based in whole or in part by reference to our ordinary shares.
Our compensation committee will determine the number of shares under such award and all other terms and conditions of such awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transferability. </I>Awards granted under our 2018 Plan may not be transferred in any manner other than by will or by the laws of descent
and distribution or as otherwise determined by our compensation committee or under the terms of our 2018 Plan or an applicable award agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital Structure.</I> In the event that there is a specified type of change in our capital structure, such as a share split or
recapitalization, appropriate adjustments will be made to (1)&nbsp;the class and the maximum number of shares reserved for issuance under our 2018 Plan, (2)&nbsp;the class and the maximum number of shares by which the share reserve may increase
automatically each year, (3)&nbsp;the class and the maximum number of shares that may be issued upon the exercise of ISOs, and (4)&nbsp;the class and the number of shares and exercise price, strike price, or purchase price, if applicable, of all
outstanding awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions.</I> Our 2018 Plan provides that in the event of certain specified significant corporate
transactions, each outstanding award will be treated as the determined by our board of directors unless otherwise provided in an award agreement or other written agreement between us and the award holder. The board of directors may take one of the
following actions with respect to such awards: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Arrange for the assumption, continuation or substitution of an award by a successor corporation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Arrange for the assignment of any reacquisition or repurchase rights held by us to a successor corporation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Accelerate the vesting, in whole or in part, of the award and provide for its termination prior to the transaction; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by us; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Cancel or arrange for the cancellation of the award, to the extent not vested or not exercised prior to the closing of the transaction, in exchange for a cash payment or no payment, as determined by our board of
directors; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Cancel or arrange for the cancellation of the award to the extent not vested but not exercised prior to the closing of the transaction, in exchange for a payment, in the form determined by our board of directors, equal
to the excess, if any, of (A)&nbsp;the per share amount payable to holders of our ordinary shares in the transaction over (B)&nbsp;any exercise price payable by the participant in connection with the award, multiplied by the number of shares subject
to the award. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A corporate transaction generally will be deemed to occur in the event of: (1)&nbsp;a sale of all or
substantially all of our assets, (2)&nbsp;the sale or disposition of more than 50% of our outstanding securities, (3)&nbsp;the consummation of a merger or consolidation where we do not survive the transaction and (4)&nbsp;the consummation of a
merger or consolidation where we do survive the transaction but our ordinary shares outstanding prior to such transaction are converted or exchanged into other property by virtue of the transaction, In addition, any one or more of the above events
may be effected pursuant to (x)&nbsp;a takeover under Irish takeover rules; (y)&nbsp;a compromise or arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of the Republic of Ireland or (z)&nbsp;Chapter 2 of Part 9 of the Companies Act 2014
of the Republic of Ireland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors is not obligated to treat all awards or portions of stock awards, even those that are
of the same type, in the same manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment and Termination.</I> Our board of directors or another duly authorized committee has
the authority to amend, suspend, or terminate our 2018 Plan, provided that such action does not materially impair the existing rights of any participant without such participant&#146;s written consent. Certain material amendments also require the
approval of our stockholders. No ISOs may be granted after the tenth anniversary of the date our board of directors adopted our 2018 Plan, and no awards may be granted under our 2018 Plan while it is suspended or after it is terminated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2015 Equity Incentive Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
board of directors adopted and our shareholders approved the 2015 Plan in November 2015. The 2015 Plan was amended most recently in May 2017. The 2015 Plan provides for the grant of ISOs, NSOs, restricted stock awards, RSUs, SARs, and other stock
awards to our employees, directors and consultants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the effectiveness of the 2018 Plan, we will no longer grant awards under the
2015 Plan. However, any outstanding awards granted under the 2015 Plan will remain outstanding, subject to the terms of the 2015 Plan and stock option agreements, until such outstanding options are exercised or until they terminate or expire by
their terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares.</I> As of December&nbsp;31, 2017, we have reserved 6,960,000 ordinary shares for issuance under our
2015 Plan. As of December&nbsp;31, 2017 options to purchase 3,898,334 ordinary shares were outstanding under our 2015 Plan, with a weighted-average exercise price of $0.21 per share. The maximum number of ordinary shares that may be issued on the
exercise of ISO under our 2011 Plan is the share reserve. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration.</I> Our 2015 Plan is administered by our board of
directors or another duly authorized committee. Following the offering, our 2015 Plan will be administered by our compensation committee. Our board of directors or another duly authorized committee has the authority to construe and interpret our
2015 Plan, amend the plan and outstanding awards and make all other determinations necessary or advisable for the administration of the plan, including, but not limited to, repricing options or SARs without prior shareholder approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions.</I> Our 2015 Plan provides that in the event of a corporate
transaction, each outstanding award will be treated as the determined by our board of directors unless otherwise provided in an award agreement or other written agreement between us and the award holder. The board of directors may generally take the
same actions as summarized above in connection with awards under the 2018 Plan, and the definition of a corporate transaction under the 2015 Plan is the substantially the same such defined term in the 2018 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transferability.</I> Awards granted under our 2015 Plan may not be transferred in any manner other than by will or by the laws of descent
and distribution or as otherwise determined by our compensation committee or under the terms of our 2015 Plan or an applicable award agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Amendment or Termination.</I> Our board of directors or another duly authorized committee has the authority to has the authority to
amend, suspend, or terminate our 2015 Plan, provided that such action does not materially impair the existing rights of any participant without such participant&#146;s written consent. Certain material amendments also require the approval of our
stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Health and Welfare Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our named executive officers are eligible to participate in our employee benefit plans, including our medical, dental, and vision
insurance plans, in each case on the same basis as all of our other full-time employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>401(k) Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a defined contribution retirement plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax
advantaged basis. Eligible employees may defer eligible compensation on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> basis, up to the statutorily prescribed annual limits on contributions under the Code. We have not historically made
discretionary contributions to the 401(k) plan for the benefit of employees. Employee contributions are allocated to each participant&#146;s individual account and are then invested in selected investment alternatives according to the
participant&#146;s directions. Employees are immediately and fully vested in their contributions. The 401(k) plan is intended to be qualified under Section&nbsp;401(a) of the Code with the 401(k) plan&#146;s related trust intended to be tax exempt
under Section&nbsp;501(a) of the Code. As a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan, contributions to the 401(k) plan and earnings on those contributions are not taxable to the employees until distributed from the
401(k) plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation on Liability and Indemnification of Directors and Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Articles of Association, and indemnification agreements with our board of directors and executive officers provide for indemnification for
our directors and officers. For a description of these protections, see the section titled &#147;Description of Share Capital&#151;Indemnification of Directors and Officers; Insurance.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Sales Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors and officers may adopt written plans, known as Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plans, in which they will
contract with a broker to buy or sell ordinary shares on a periodic basis. Under a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan, a broker executes trades pursuant to parameters established by the director or officer when entering into
the plan, without further direction from them. The director or officer may amend a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan in some circumstances and may terminate a plan at any time. Our directors and executive officers also may buy
or sell additional shares outside of a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan when they are not in possession of material nonpublic information, subject to compliance with the terms of our insider trading policy. Prior to 180 days
after the date of this offering, the sale of any shares under such plan would be subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement that the director or officer has entered into with the underwriters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc522368_13"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of transactions since January&nbsp;1, 2015 to which we have been a participant, in which: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount involved exceeded or will exceed $120,000; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any of our directors, executive officers, or holders of more than 5% of our ordinary shares, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect material interest, other
than compensation and other arrangements that are described in the section titled &#147;Executive Compensation&#148; or that were approved by our compensation committee. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the terms obtained or consideration that we paid or received, as applicable, in connection with the transactions described below
were comparable to terms available or the amounts that would be paid or received, as applicable in <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales of Preferred Shares </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
November 2015, we issued an aggregate of 23,790,001 of our Series A preferred shares at a purchase price of $1.00 per share for an aggregate purchase price of $20.8&nbsp;million. In December 2016, we issued an aggregate of 23,849,998 of our Series A
preferred shares at a purchase price of $1.00 per share for an aggregate purchase price $20.8&nbsp;million. In May 2017, we issued an aggregate of 41,697,721 of our Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares at a purchase
price of $1.10 per share for an aggregate purchase price $45.9&nbsp;million. In February 2018, we issued an aggregate of 26,858,743 of our Series&nbsp;B-2 preferred shares at a purchase price of $1.20 per share for an aggregate purchase price of
$32.2&nbsp;million. The following table summarizes purchases of preferred shares by holders of more than 5% of our capital shares and their affiliated entities, our directors and our executive officers. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A<BR>Preferred&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B-1<BR>Preferred&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B-2<BR>Preferred&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Purchase&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Advent Life
Sciences<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,363,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,552,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,262,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arix Bioscience Holdings Ltd.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,907,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,388,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Canaan X, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,333,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,327,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,607,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,422,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Frazier
Healthcare<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,818,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,183,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,020,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Leaf Ventures III, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,333,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,334,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,214,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pivotal bioVenture Partners Fund I,
L.P.<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,363,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,552,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,262,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sofinnova Venture Partners IX,
L.P.<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,333,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,327,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,607,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,422,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corey N. Fishman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">522,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">622,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Dunne, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">324,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Judith M. Matthews</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">271,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul R. Edick</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David G. Kelly</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Includes preferred shares purchased by Advent Life Sciences LLP and Advent Life Sciences Fund II LP. Dr.&nbsp;Malik, a member of our board of directors, is a general partner of Advent Life Sciences. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Chin, a member of our board of directors, is an investment manager of Arix Bioscience. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Ahrens, a member of our board of directors, is a general partner of Canaan. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Includes preferred shares purchased by Frazier Healthcare VII, L.P. and Frazier Healthcare <FONT STYLE="white-space:nowrap">VII-A,</FONT> L.P. Mr.&nbsp;Heron, a member of our board of directors, is a general partner of
Frazier Healthcare Partners. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Hunt, a member of our board of directors, is a managing director of New Leaf Ventures Partner. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Hopfner, a member of our board of directors, is a managing partner of Pivotal bioVenture Partners. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Healy, a member of our board of directors, is a general partner of Sofinnova Ventures. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Rights Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2017, we entered into an amended and restated investor rights agreement with holders of our preferred shares and ordinary shares,
including certain holders of more than 5% of our capital stock, our executive officers, certain of our directors, and entities affiliated with certain of our directors. After the closing of this offering, these holders will be entitled to certain
registration rights, including the right to demand that we file a registration statement or request that their shares be covered by a registration statement that we are otherwise filing. For a more detailed description of these registration rights,
see the section titled &#147;Description of Share Capital&#151;Registration Rights.&#148; In addition, this agreement gives the shareholders that are parties thereto the right to participate in new issuances of equity securities by us, subject to
certain exceptions. This right to participate in new issuances of equity securities will terminate by its terms upon the completion of our initial public offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Offer Letters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into offer
letters with our executive officers. For more information regarding these offer letters, see the section titled &#147;Executive Compensation&#151;Employment, Severance and Change in Control Arrangements.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Grants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted stock
options to the <FONT STYLE="white-space:nowrap">non-employee</FONT> members of our board of directors. For a description of these stock options, see the section titled &#147;Management&#151;2017 <FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Director Compensation.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and executive officers. In addition, our Iterum Therapeutics US
Limited subsidiary has entered into an indemnification agreement with each of our directors and executive officers. These agreements, among other things, require us to indemnify an indemnitee to the fullest extent permitted by applicable law,
including indemnification of expenses such as attorneys&#146; fees, judgments, fines and settlement amounts incurred by the indemnitee in any action or proceeding, including any action or proceeding by us or in our right, arising out of the
person&#146;s services as a director or executive officer. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Party Transaction Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will adopt a formal written policy in connection with this offering that our executive officers, directors, key employees, holders of more
than 5% of any class of our voting securities, and any member of the immediate family of and any entity affiliated with any of the foregoing persons, are not permitted to enter into a related-party transaction with us without the prior consent of
our audit committee, or other independent body of our board of directors in the event it is inappropriate for our audit committee to review such transaction due to a conflict of interest. Any request for us to enter into a transaction with an
executive officer, director, principal shareholder, or any of their immediate family members or affiliates, in which the amount involved exceeds $120,000, will be required to first be presented to our audit committee for review, consideration, and
approval. In approving or rejecting any such proposal, our audit committee will consider the relevant facts and circumstances available and deemed relevant to our audit committee, including, but not limited to, whether the transaction will be on
terms no less favorable than terms generally available to an unaffiliated third-party under the same or similar circumstances and the extent of the related-party&#146;s interest in the transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the transactions described in this section were entered into prior to the adoption of this policy. Although we have not had a written
policy for the review and approval of transactions with related persons, our board of directors has historically reviewed and approved any transaction where a director or officer had a financial interest, including the transactions described above.
Prior to approving such a transaction, the material facts as to a director&#146;s or officer&#146;s relationship or interest in the agreement or transaction were disclosed to our board of directors. Our board of directors took this information into
account when evaluating the transaction and in determining whether such transaction was fair to us and in the best interest of all our shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc522368_14"></A>PRINCIPAL SHAREHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information with respect to the beneficial ownership of our ordinary shares as of March&nbsp;1, 2018 by: </P>
 <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our ordinary shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our named executive officers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our directors; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our executive officers and directors as a group </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The percentage of shares
beneficially owned before the offering shown in the table is based on 122,686,463 ordinary shares outstanding as of March&nbsp;1, 2018, after giving effect to the conversion of all of our Series A preferred shares, Series <FONT
STYLE="white-space:nowrap">B-1</FONT> preferred shares and Series B-2 preferred shares into ordinary shares. The percentage of shares beneficially owned after this offering assumes the sale by us
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined according to the rules of the SEC and generally means that a person has beneficial ownership of a security
if he, she, or it possesses sole or shared voting or investment power of that security, including stock options that are exercisable within 60 days of March&nbsp;1, 2018. Our ordinary shares issuable pursuant to stock options are deemed outstanding
for computing the percentage of the person holding such options and the percentage of any group of which the person is a member but are not deemed outstanding for computing the percentage of any other person. Except as indicated by the footnotes
below, we believe, based on the information furnished to us, that the persons named in the table below have sole voting and investment power with respect to all ordinary shares shown that they beneficially own, subject to community property laws
where applicable. The information does not necessarily indicate beneficial ownership for any other purpose, including for purposes of Section&nbsp;13(d) and 13(g) of the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, the address of each beneficial owner listed in the table below
is c/o Iterum Therapeutics Limited, 200 West Monroe St., Suite 1575, Chicago, IL 60606. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially</B><br><B>Owned&nbsp;Prior&nbsp;to</B><br><B>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially<BR>Owned&nbsp;After&nbsp;the&nbsp;Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:89.90pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Greater than 5% shareholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Advent Life
Sciences<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,915,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arix Bioscience Holdings Ltd.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,907,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Canaan X, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,268,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Frazier
Healthcare<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,001,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Leaf Ventures III, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,467,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pivotal bioVenture Partners Fund I,
L.P.<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,915,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sofinnova Venture Partners IX,
L.P.<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,268,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Named Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corey N. Fishman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,691,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Dunne, MD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,269,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Judith M. Matthews</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">818,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brenton K. Ahrens<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,268,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Chin<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,907,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul R. Edick</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James I. Healy, M.D., Ph.D<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,268,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick J. Heron<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,001,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Hopfner, Ph.D<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,915,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ronald M. Hunt<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,467,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David G. Kelly<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shahzad Malik, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,915,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers and directors as a group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,080,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than one percent </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Includes 9,575,027 shares purchased by Advent Life Sciences II LP and 340,796 shares purchased by Advent Life Sciences Fund LLP. Dr.&nbsp;Malik, a member of our board of directors, is a general partner of Advent Life
Sciences. The address for these entities is <FONT STYLE="white-space:nowrap">158-160</FONT> North Gower Street, London, NW1&nbsp;2ND, United Kingdom. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Chin, a member of our board of directors, is an investment manager of Arix Bioscience. The address for Arix Bioscience Holdings Ltd. is 20 Berkeley Square, Mayfair, London W1J 6EQ, United Kingdom.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Ahrens, a member of our board of directors, is a general partner of Canaan. The address for Canaan X, L.P. is 2765 Sand Hill Road, Menlo Park, CA 94025. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Includes 13,231,174 shares purchased by Frazier Healthcare VII, L.P. and 3,770,507 shares purchased by Frazier Healthcare <FONT STYLE="white-space:nowrap">VII-A,</FONT> L.P. Mr.&nbsp;Heron, a member of our board of
directors, is a general partner of Frazier Healthcare. The address for these entities is 601 Union Street, Suite 3200, Seattle, WA 98101. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Hunt, a member of our board of directors, is a managing director of New Leaf Ventures. The address for New Leaf Ventures III, L.P. is 7 Times Square, Suite 3502, New York, NY 10036. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Hopfner, a member of our board of directors, is a managing partner of Pivotal bioVenture Partners. The address for Pivotal bioVenture Partners Fund I, L.P. is 1700 Owners Street, Suite 595, San Francisco,
CA&nbsp;94158. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Healy, a member of our board of directors, is a general partner of Sofinnova Ventures. The address for Sofinnova Venture Partners IX, L.P. is 3000 Sand Hill Road, Bldg. 4, Suite 250, Menlo Park, CA 94025.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">Includes (a) 150,000 shares and (b)&nbsp;16,666 shares issuable pursuant to stock options exercisable within 60&nbsp;days of March&nbsp;1, 2018. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc522368_15"></A>DESCRIPTION OF SHARE CAPITAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of some of the terms of our ordinary shares, based on our Articles of Association, as they will become effective
upon their amendment prior to the completion of this offering and the Irish Companies Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary is subject to, and is
qualified in its entirety by reference to, the provisions of our Articles of Association, the form of which is filed as an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise specified below, references to voting by our shareholders contained in this Description of Share Capital are references to
voting by holders of ordinary shares entitled to attend and vote generally at general meetings of our shareholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Organization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an Irish private limited company. We were incorporated in Ireland on June&nbsp;24, 2015 under the name Iterum Therapeutics Limited with
registered number 563531. Prior to closing of this offering, we will <FONT STYLE="white-space:nowrap">re-register</FONT> as a public limited company and be renamed Iterum Therapeutics plc. Our affairs are governed by our Constitution including our
Articles of Association that will come into effect immediately upon completion of this offering and Irish law. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Objective </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As provided by and described in our Constitution, our principal objective is to carry on the business of a holding company and all associated
related activities and to carry on various activities associated with that objective. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately after the completion of this offering, our authorized share capital will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, divided into 700,000,000 ordinary shares with a nominal value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share
and&nbsp;100,000,000 undesignated preferred shares with a nominal value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. Upon the completion of this offering and the use of proceeds therefrom, we expect to
have&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares outstanding, including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares
issued pursuant to restricted stock issuances that are subject to repurchase, and no outstanding shares of any other class. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
rights and restrictions to which the ordinary shares will be subject will be prescribed in our Articles of Association. Our Articles of Association entitle the Board, without shareholder approval, to determine the terms of the undesignated preferred
shares issued by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Irish law does not recognize fractional shares held of record. Accordingly, our Articles of Association will not
provide for the issuance of fractional shares of Iterum, and the official Irish register of Iterum will not reflect any fractional shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever an alteration or reorganization of the share capital of Iterum would result in any Iterum shareholder becoming entitled to fractions
of a share, the Board of Iterum may, on behalf of those shareholders that would become entitled to fractions of a share, arrange for the sale of the shares representing fractions and the distribution of the net proceeds of sale in due proportion
among the shareholders who would have been entitled to the fractions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer and Registration of Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our share register will be maintained by our transfer agent. Registration in this share register will be determinative of membership in us. Any
of our shareholders who only hold ordinary shares beneficially will not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be the holder of record of such ordinary shares. Instead, the depository or other nominee will be the holder of record of such shares. Accordingly, a transfer of ordinary shares from a person who
holds such ordinary shares beneficially to a person who will also hold such ordinary shares beneficially through the same depository or other nominee will not be registered in our official share register, as the depository or other nominee will
remain the holder of record of such ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A written instrument of transfer will be required under Irish law in order to
register on our official share register any transfer of ordinary shares (i)&nbsp;from a person who holds such ordinary shares directly to any other person or (ii)&nbsp;from a person who holds such ordinary shares beneficially to another person who
also will hold such ordinary shares beneficially where the transfer involves a change in the depository or other nominee that is the record owner of the transferred ordinary shares. An instrument of transfer will be required for a shareholder who
directly holds ordinary shares to transfer those ordinary shares into his or her own broker account (or vice versa). Such instruments of transfer may give rise to Irish stamp duty, which must be paid prior to registration of the transfer on our
official Irish share register. However, a shareholder who directly holds ordinary shares may transfer those ordinary shares into his or her own broker account (or vice versa) without giving rise to Irish stamp duty, provided that there is no change
in the beneficial ownership of the ordinary shares as a result of the transfer and the transfer is not made in contemplation of a sale of the ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, we strongly recommend that shareholders hold their shares through DTC (or through a broker who holds such shares through DTC).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any transfer of our ordinary shares that is subject to Irish stamp duty will not be registered in the name of the buyer unless such stamp
duty is paid and details of the transfer are provided to our transfer agent. Our Articles of Association allow us, in our absolute discretion, to pay (or cause one of our affiliates to pay) any stamp duty. We do not expect to pay any stamp duty on
behalf of any acquirer of ordinary shares in our capital. See the section titled &#147;Taxation&#151;Material Irish Tax Considerations.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Articles of Association provide that, in the event of any such payment, we (i)&nbsp;may seek reimbursement from the transferor or
transferee (at our discretion), (ii) may <FONT STYLE="white-space:nowrap">set-off</FONT> the amount of the stamp duty against future dividends payable to the transferor or transferee (at our discretion) and (iii)&nbsp;will have a lien against our
shares in respect of which we have paid stamp duty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Articles of Association grant our board of directors general discretion to
decline to register an instrument of transfer unless the transfer is in respect of one class of shares only, the instrument of transfer is accompanied by the certificate of shares to which it relates (if any) and such other evidence as the directors
may reasonably require to show the right of the transferor to make the transfer, the instrument of transfer is in favor of not more than four transferees and it is lodged at our registered office or such other place as our directors or secretary may
appoint. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration of transfers may be suspended at such times and for such periods, not exceeding 30 days in any year, as
our board of directors may from time to time determine (except as may be required by law). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuance of Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the authority, pursuant to our Articles of Association, to increase or reduce our authorized but unissued share capital by ordinary
resolution (unless otherwise determined by the Board) by creating additional shares of any class or series. An ordinary resolution of our company requires more than 50% of the votes cast at the shareholder meeting by shareholders entitled to vote at
that meeting. As a matter of Irish law, the board of directors of a company may issue authorized but unissued new shares without shareholder approval once authorized to do so by the Articles of Association of the company or by an ordinary resolution
adopted by the shareholders at a general meeting. The authority conferred can be granted for a maximum period of five years, at which point it must be renewed by the shareholders by an ordinary resolution. Because of this requirement of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Irish law, our Articles of Association will authorize our board of directors to issue new shares up to the amount of our authorized but unissued share capital without shareholder approval for a
period of five years from the date our Articles of Association are adopted in substantially the form attached as an exhibit to the registration statement of which this prospectus forms a part. We expect that we will seek to renew such general
authority at an annual general meeting before the end of that five-year period. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Certificates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Irish Companies Act, a shareholder is entitled to be issued a share certificate on request and subject to payment of a nominal
fee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sinking Fund </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ordinary
shares will have no sinking fund provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Liability for Further Calls or Assessments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ordinary shares to be sold in this offering will be duly and validly issued, will be credited as fully paid up and will be <FONT
STYLE="white-space:nowrap">non-assessable.</FONT> </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Pre-emption</FONT> Rights, Share Warrants and Share Options
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Irish law, certain statutory <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights apply automatically in favor of our
ordinary shareholders when our ordinary shares are issued for cash. However, we will opt out of these <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights in our Articles of Association as permitted under Irish law. This <FONT
STYLE="white-space:nowrap">opt-out</FONT> may be renewed every five years under Irish law by a special resolution of the shareholders. A special resolution requires not less than 75% of the votes cast by our shareholders at a meeting of
shareholders. We expect that we will seek renewal of the <FONT STYLE="white-space:nowrap">opt-out</FONT> at an annual general meeting within five years from the date on which our Articles of Association are adopted in substantially the form attached
as an exhibit to the registration statement of which this prospectus forms a part. If the <FONT STYLE="white-space:nowrap">opt-out</FONT> expires and is not renewed, ordinary shares issued for cash must be offered to our <FONT
STYLE="white-space:nowrap">pre-existing</FONT> ordinary shareholders pro rata based on their existing shareholding before the ordinary shares can be issued to any new shareholders or <FONT STYLE="white-space:nowrap">pre-existing</FONT> shareholders
in an amount greater than their pro rata entitlements. The statutory <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">generally do not apply where shares are issued for <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">do not apply to the issuance of <FONT STYLE="white-space:nowrap">non-equity</FONT> shares (that is, shares that have the right to participate only up to a specified amount in any dividend and capital distribution, which
are sometimes referred to as <FONT STYLE="white-space:nowrap">non-participating</FONT> shares); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">do not apply to the issuance of shares pursuant to certain employee compensation plans. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
Articles of Association provide that, subject to any shareholder approval requirement under any laws, regulations or the rules of any stock exchange to which we are subject, the board is authorized, from time to time, in its discretion, to grant
such persons, for such periods and upon such terms as the board deems advisable, options to purchase such number of shares of any class or classes or of any series of any class as the Board of Directors may deem advisable, and to cause warrants or
other appropriate instruments evidencing such options to be issued. The Irish Companies Act provides that directors may issue share warrants or options without shareholder approval once authorized to do so by the articles of association. We will be
subject to the rules of Nasdaq that require shareholder approval of certain equity plans and share issuances. Our Board of Directors may authorize the issuance of shares upon exercise of warrants or options without shareholder approval or
authorization (up to the relevant authorized share capital limit). </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Irish law, we are prohibited from allotting shares without consideration. Accordingly,
at least the nominal value of the shares issued underlying any restricted share award, restricted share unit, performance share award, bonus share or any other share based grant must be paid pursuant to the Irish Companies Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to an
investor rights agreement that provides that holders of our preferred shares, including certain officers, holders of 5% of our capital shares and entities affiliated with certain of our directors, have certain registration rights, as set forth
below. This investor rights agreement was entered into in November 2015 and has been amended and restated from time to time in connection with our preferred share financings. The registration of our ordinary shares pursuant to the exercise of
registration rights described below would enable the holders to sell these shares without restriction under the Securities Act when the applicable registration statement is declared effective. We will pay the registration expenses, other than
underwriting discounts and selling commissions, of the shares registered pursuant to the demand, piggyback and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registrations described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, in an underwritten offering, the managing underwriter, if any, has the right, subject to specific conditions, to limit the number
of shares such holders may include. The demand, piggyback and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights described below will expire after both (i)&nbsp;the effective date of the registration statement, of which this
prospectus forms a part, and (ii)&nbsp;all shareholders entitled to registration rights can sell all of their shares under Rule 144 of the Securities Act during any <FONT STYLE="white-space:nowrap">90-day</FONT> period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
holders of 89,337,720 ordinary shares issuable upon conversion of outstanding preferred shares will be entitled to certain demand registration rights. Beginning after the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period on
these shares, the holders of a majority of these shares may, on not more than two occasions, request that we file a registration statement having an aggregate offering price to the public of not less than $10,000,000, net of selling expenses, to
register the offer and sale of all or a portion of their shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, the holders of 95,827,720 ordinary shares issued or issuable upon the conversion of outstanding preferred
shares were entitled to, and the necessary percentage of holders waived, their rights to include their shares of registrable securities in this offering. If we propose to register the offer and sale of any of our securities under the Securities Act
either for our own account or for the account of other security holders, the holders of these shares will be entitled to certain &#147;piggyback&#148; registration rights allowing them to include their shares in such registration, subject to certain
marketing and other limitations. As a result, whenever we propose to file a registration statement under the Securities Act including a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> as discussed below, other than with
respect to a demand registration or a registration statement on Forms <FONT STYLE="white-space:nowrap">S-4</FONT> or <FONT STYLE="white-space:nowrap">S-8,</FONT> the holders of these shares are entitled to notice of the registration and have the
right, subject to limitations that the underwriters may impose on the number of shares included in the registration, to include their shares in the registration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of 89,337,720 ordinary shares issued or issuable upon the conversion of outstanding preferred shares will be entitled to certain
Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights. The holders of at least 20% of these shares may make a request that we register their shares on Form <FONT STYLE="white-space:nowrap">S-3</FONT> if we are qualified to file a
registration statement on Form <FONT STYLE="white-space:nowrap">S-3.</FONT> Such request for registration on Form <FONT STYLE="white-space:nowrap">S-3</FONT> must cover securities the aggregate offering price of at least $1,000,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Repurchases and Redemptions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Articles of
Association provide that any ordinary share we agree to acquire shall be deemed to be a redeemable share. Accordingly, for Irish law purposes, the repurchase of ordinary shares by us may technically be effected as a redemption of those ordinary
shares as described below under &#147;Repurchases and Redemptions.&#148; If our Articles of Association did not contain such provisions, repurchases by us would be subject to many of the same rules that apply to purchases of our ordinary shares by
subsidiaries described below under &#147;Purchases by Subsidiaries,&#148; including the shareholder approval requirements described below. Except where otherwise noted, when we refer elsewhere in this prospectus to repurchasing or buying back our
ordinary shares, we are referring to the redemption of ordinary shares by us pursuant to the Articles of Association or the purchase of our ordinary shares by a subsidiary of the Company, in each case in accordance with our Articles of Association
and Irish law as described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Repurchases and Redemptions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Irish law, a company can issue redeemable shares and redeem them out of distributable reserves (which are described below under
&#147;Dividends&#148;) or the proceeds of a new issue of shares for that purpose. The redemption of redeemable shares may only be made by a public limited company where the nominal value of the issued share capital that is not redeemable is not less
than 10% of the nominal value of the total issued share capital of the company. All redeemable shares must also be fully paid and the terms of redemption of the shares must provide for payment on redemption. Redeemable shares may, upon redemption,
be cancelled or held in treasury. Shareholder approval will not be required to redeem our shares. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors will also be
entitled to issue other classes or series of shares that may be redeemed at the option of either us or the shareholder, depending on the terms of such shares. See the section titled &#147;&#151; Share Capital.&#148; Repurchased and redeemed shares
may be cancelled or held as treasury shares. The nominal value of treasury shares held by us at any time must not exceed 10% of the nominal value of our issued share capital. While we hold shares as treasury shares, we cannot exercise any voting
rights in respect of those shares. Treasury shares may be cancelled by us or <FONT STYLE="white-space:nowrap">re-issued</FONT> subject to certain conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Purchases by Subsidiaries </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
Irish law, it may be permissible for an Irish or <FONT STYLE="white-space:nowrap">non-Irish</FONT> subsidiary to purchase our shares. A general authority of our shareholders is required to allow a subsidiary of ours to make <FONT
STYLE="white-space:nowrap">on-market</FONT> purchases of our shares; however, as long as this general authority has been granted, no specific shareholder authority for a particular <FONT STYLE="white-space:nowrap">on-market</FONT> purchase by a
subsidiary of our shares is required. We may elect to seek such general authority, which must expire no later than 18 months after the date on which it was granted, at our annual general meetings. For an
<FONT STYLE="white-space:nowrap">off-market</FONT> purchase by our subsidiary, the proposed purchase contract must be authorized by special resolution of our shareholders before the contract is entered into. The person whose shares are to be bought
back cannot vote in favor of the special resolution and, from the date of the notice of the meeting at which the resolution approving the contract is to be proposed, the purchase contract must be on display or must be available for inspection by
shareholders at our registered office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares held by our subsidiaries at any time will count as treasury shares and will
be included in any calculation of the permitted treasury share threshold of 10% of the nominal value of our issued share capital. While a subsidiary holds our shares, it cannot exercise any voting rights in respect of those shares. The acquisition
of our shares by a subsidiary must be funded out of distributable reserves of the subsidiary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Irish law, dividends and distributions may only be made from distributable reserves. Distributable reserves, broadly, means the
accumulated realized profits of a company, less accumulated realized losses of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company on a standalone basis. In addition, no dividend or distribution may be made unless the net assets of a company are not less than the aggregate of a company&#146;s called up share capital
plus undistributable reserves and the distribution does not reduce the company&#146;s net assets below such aggregate. Undistributable reserves include a company&#146;s undenominated capital (effectively its share premium and capital redemption
reserve) and the amount by which the company&#146;s accumulated unrealized profits, so far as not previously utilized by any capitalization, exceed the company&#146;s accumulated unrealized losses, so far as not previously written off in a reduction
or reorganization of capital. The determination as to whether or not a company has sufficient distributable reserves to fund a dividend must be made by reference to &#147;relevant accounts&#148; of the company. The &#147;relevant accounts&#148; are
either the last set of unconsolidated annual audited financial statements or unaudited financial statements prepared in accordance with the Irish Companies Act, which give a &#147;true and fair view&#148; of the company&#146;s unconsolidated
financial position in accordance with accepted accounting practice in Ireland. These &#147;relevant accounts&#148; must be filed in the Companies Registration Office (the official public registry for companies in Ireland). Our Articles of
Association authorize the board of directors to declare such dividends as appear justified from the profits of the company without the approval of the shareholders. The board of directors may also recommend a dividend to be approved and declared by
our shareholders at a general meeting. Our dividends can be declared and paid in the form of cash or <FONT STYLE="white-space:nowrap">non-cash</FONT> assets, subject to applicable law. We may pay dividends in any currency but, if we elect to pay
dividends, we intend to do so in US dollars. Our board of directors may deduct from any dividend or other moneys payable to any shareholder all sums of money, if any, due from the shareholder to the company in respect of ordinary shares of the
Company. Our board of directors is also authorized to issue shares in the future with preferred rights to participate in dividends declared by the Company. The holders of such preference shares may, depending on their terms, rank senior to the
holders of the ordinary shares of the company with respect to dividends. We do not anticipate paying any cash dividends in the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For information about the Irish tax considerations relating to dividend payments, see the section titled &#147;Taxation&#151;Irish Tax
Considerations.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bonus Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our Articles of Association, our board of directors may resolve to capitalize any amount credited to any reserve or fund available for
distribution or the share premium account or other of our undistributable reserves for issuance and distribution to shareholders as fully paid up bonus shares on the same basis of entitlement as would apply in respect of a dividend distribution.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lien on Shares, Calls on Shares and Forfeiture of Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Articles of Association provide that we will have a first and paramount lien on every share for all debts and liabilities of any
shareholder to the company, whether presently due or not, payable in respect of such share. Subject to the terms of the allotment, directors may call for any unpaid amounts in respect of any shares to be paid, and if payment is not made, the shares
may be forfeited. These provisions are standard inclusions in the articles of association of an Irish company limited by shares such as Iterum and will only be applicable to shares of Iterum that have not been fully paid up. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation and Division; Subdivision </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our Articles of Association, we may, by ordinary resolution (unless the board of directors determines otherwise), divide any or all of
our share capital into shares of smaller nominal value than its existing shares (often referred to as a share split) or consolidate any or all of our share capital into shares of larger nominal value than its existing shares (often referred to as a
reverse share split). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reduction of Share Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may, by ordinary resolution, reduce our authorized but unissued share capital. We also may, by special resolution and subject to
confirmation by the Irish High Court, reduce our issued share capital, and any undenominated share capital. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Meetings of Shareholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required under Irish law to hold an annual general meeting within 18&nbsp;months of incorporation and thereafter at intervals of no more
than 15 months, provided that an annual general meeting is held in each calendar year and no more than nine months after our fiscal <FONT STYLE="white-space:nowrap">year-end.</FONT> Any annual general meeting may be held outside Ireland, provided
that technological means are provided to enable shareholders to participate in the meeting without leaving Ireland. Our Articles of Association include a provision requiring annual general meetings to be held within such time periods as required by
Irish law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The only matters which must, as a matter of Irish company law, be transacted at an annual general meeting are (i)&nbsp;the
consideration of the statutory financial statements, report of the directors and report of the statutory auditors, (ii)&nbsp;review by the members of the company&#146;s affairs and (iii)&nbsp;the appointment or
<FONT STYLE="white-space:nowrap">re-appointment</FONT> of the statutory auditors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any annual general meeting, only such business may
be conducted as has been brought before the meeting: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the notice of the meeting; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by or at the direction of the Board of Directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in certain circumstances, at the direction of the Irish High Court; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as required by law; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">that the chairman of the meeting determines is properly within the scope of the meeting. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, and subject to compliance with our Articles of Association, shareholders entitled to vote at an annual general meeting may propose business to be considered thereat. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our extraordinary general meetings may be convened (i)&nbsp;by our board of directors, (ii)&nbsp;on requisition of the shareholders holding
the number of our shares prescribed by the Irish Companies Act (currently 10% of the <FONT STYLE="white-space:nowrap">paid-up</FONT> share capital of the Company carrying voting rights), or (iii)&nbsp;in certain circumstances, on requisition of our
auditors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Extraordinary general meetings are generally held for the purposes of approving such of our shareholder resolutions as may be
required from time to time. The business to be conducted at any extraordinary general meeting must be set forth in the notice of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of an extraordinary general meeting requisitioned by our shareholders, the proposed purpose of the meeting must be set out in the
requisition notice of the meeting. The requisition notice can propose any business to be considered at the meeting. Under Irish law, upon receipt of this requisition notice, the board of directors has 21 days to convene the extraordinary general
meeting of our shareholders to vote on the matters set out in the requisition notice. This meeting must be held within two months of receipt of the requisition notice. If the board does not proceed to convene the meeting within such <FONT
STYLE="white-space:nowrap">21-day</FONT> period, the requisitioning shareholders, or any of them representing more than <FONT STYLE="white-space:nowrap">one-half</FONT> of the total voting rights of all of them, may themselves convene a meeting,
which meeting must be held within three months of the receipt of the requisition notice by the board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our board of directors becomes
aware that our net assets are half or less of the amount of our called up share capital, the board must, not later than 28 days from the date that it learns of this fact, convene an extraordinary general meeting of our shareholders to be held not
later than 56 days from such date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This meeting must be convened for the purposes of considering whether any, and if so what,
measures should be taken to address the situation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At least 21 days&#146; notice of any annual general meeting or general meeting at
which a special resolution is proposed and 14 days in all other circumstances must be given to shareholders, each director and our auditors, under our Articles of Association. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quorum for Shareholder Meetings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our Articles of Association, the presence, in person or by proxy, of one or more shareholders holding not less than a majority of our
issued shares that carry the right to vote at the meeting constitutes a quorum for the conduct of any business at a general meeting. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Generally </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our
ordinary shares vote on all matters submitted to a vote of shareholders and are entitled to one vote per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All votes at a general
meeting will be decided by way of a poll. Voting rights on a poll may be exercised by shareholders registered in our share register as of the record date for the meeting or by a duly appointed proxy of such a registered shareholder, which proxy need
not be a shareholder. All proxies must be appointed in accordance with our Articles of Association. Our Articles of Association provide that our board of directors may permit the appointment of proxies by the shareholders to be notified to us
electronically. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with our Articles of Association, our board of directors may, from time to time, cause us to issue
preferred or any other class or series of shares. These shares may have such voting rights, if any, as may be specified in the terms of such shares (e.g., they may carry more votes per share or may entitle their holders to a class vote on such
matters as may be specified in the terms of the shares). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Treasury shares (i.e., shares held by us) and our shares held by our
subsidiaries will not entitle their holders to vote at general meetings of shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except where a greater threshold is required by
Irish law or our Articles of Association, any question proposed for consideration at any of our general meetings or of any class of shareholders will be decided by an ordinary resolution passed by a simple majority of the votes cast by shareholders
entitled to vote at such meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Irish law requires special resolutions of the shareholders at a general meeting to approve certain
matters. A special resolution requires not less than 75% of the votes cast by shareholders at a meeting of shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Examples of
matters requiring special resolutions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">amending our objects as contained in our memorandum of association; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">amending our Articles of Association; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approving a change of name; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorizing the entry into a guarantee or the granting of security in connection with a loan, quasi loan or credit transaction in favor of a director or connected person of a director (which generally includes a family
member or business partner of the director and any entity controlled by the director); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">opting out of <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights on the issuance of new shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">re-registering</FONT> from a public limited company to a private company; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">purchasing of our own shares <FONT STYLE="white-space:nowrap">off-market;</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reducing issued share capital; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">resolving that we be wound up by the Irish courts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">resolving in favor of a shareholders&#146; voluntary <FONT STYLE="white-space:nowrap">winding-up;</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">re-designating</FONT> shares into different share classes; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">setting the <FONT STYLE="white-space:nowrap">re-issue</FONT> price of treasury shares. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Action by
Written Consent </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Written resolutions by shareholders are not permitted under our Articles of Association. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Variation of Rights Attaching to a Class&nbsp;or Series of Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our Articles of Association and the Irish Companies Act, any variation of class rights attaching to our issued shares by us must be
approved by an ordinary resolution passed at a general meeting of the shareholders of the affected class or with the consent in writing of the holders of a majority of the issued shares of that class of shares entitled to vote on such variation. The
rights conferred upon the holder of any <FONT STYLE="white-space:nowrap">pre-existing</FONT> issued shares in Iterum shall not be deemed to be varied by the issuance of any preferred shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of our Articles of Association relating to general meetings apply to general meetings of the holders of any class of shares
except that the necessary quorum is determined in reference to the shares of the holders of the class. Accordingly, for general meetings of holders of a particular class of shares, a quorum consists of one or more shareholders present in person or
by proxy holding not less than a majority of the issued and outstanding shares of the class entitled to vote at the meeting in question. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Record
Dates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Articles of Association provide that the board may fix in advance a date as the record date (a)&nbsp;for any such
determination of members entitled to notice of or to vote at a meeting of the members, which record date shall not be more than sixty (60)&nbsp;days before the date of such meeting, and (b)&nbsp;for the purpose of determining the members entitled to
receive payment of any dividend or other distribution, or in order to make a determination of members for any other proper purpose, which record date shall not be more than sixty (60)&nbsp;days prior to the date of payment of such dividend or other
distribution or the taking of any action to which such determination of members is relevant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If no record date is fixed for the
determination of members entitled to notice of or to vote at a meeting of members, the date immediately preceding the date on which notice of the meeting is deemed given under our Articles of Association will be the record date for such
determination of members. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shareholder Proposals </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Irish law, there is no general right for a shareholder to put items on the agenda of an annual general meeting of a U.S.-listed company,
other than as set out in the Articles of Association of a company. Under our Articles of Association, in addition to any other applicable requirements, for business or nominations to be properly brought before an annual general meeting by a
shareholder, such shareholder must have given timely notice thereof in proper written form to our corporate secretary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To be timely for an annual general meeting, a shareholder&#146;s notice to our secretary
as to the business or nominations to be brought before the meeting must be delivered to or mailed and received at our registered office (i) with respect to our first annual general meeting as a public limited company, not later than the 10<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> day following the day on which public announcement of the date of such annual general meeting is made and (ii) with respect to all other annual general meetings not less than 90 days nor more than
120 days before the first anniversary of the notice convening our annual general meeting for the prior year. In the event that the date of the annual general meeting is changed by more than 30 days from the first anniversary date of the preceding
year&#146;s annual general meeting, notice by the member must be so delivered by close of business on the day that is not earlier than 120 days prior to such annual general meeting and not later than the close of business on the later of (a) 90 days
prior to the day of the contemplated annual general meeting or (b)&nbsp;ten days after the day on which public announcement of the date of the contemplated annual general meeting is first made by us. In no event shall the public announcement of an
adjournment or postponement of an annual general meeting commence a new time period (or extend any time period) for the giving of a shareholder&#146;s notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To be timely for business or nominations of a director at an extraordinary general meeting, notice must be delivered, or mailed and received
not less than 90 days nor more than 120 days prior to the date of such extraordinary general meeting. If the first public announcement of the date of the extraordinary general meeting is less than 100 days prior to the date of the meeting, by close
of business 10 days after the day on which the public announcement of the date of the extraordinary general meeting is first made by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For nominations to the board, the notice must include all information about the director nominee that is required to be disclosed by SEC rules
regarding the solicitation of proxies for the election of directors pursuant to Regulation&nbsp;14A under the Exchange Act. For other business that a shareholder proposes to bring before the meeting, the notice must include a brief description of
the business, the reasons for proposing the business at the meeting and a discussion of any material interest of the shareholder in the business. Whether the notice relates to a nomination to the board of directors or to other business to be
proposed at the meeting, the notice also must include information about the shareholder and the shareholder&#146;s holdings of our shares. The chairman of the meeting shall have the power and duty to determine whether any business proposed to be
brought before the meeting was made or proposed in accordance with these procedures (as set out in our Articles of Association), and if any proposed business is not in compliance with these provisions, to declare that such defective proposal shall
be disregarded. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; Suits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Ireland, the decision to institute proceedings on behalf of a company is generally taken by the company&#146;s board of directors. In
certain limited circumstances, a shareholder may be entitled to bring a derivative action on our behalf. The central question at issue in deciding whether a minority shareholder may be permitted to bring a derivative action is whether, unless the
action is brought, a wrong committed against us would otherwise go unredressed. The cause of action may be against a director, another person or both. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A shareholder may also bring proceedings against us in his or her own name where the shareholder&#146;s rights as such have been infringed or
where our affairs are being conducted, or the powers of the board of directors are being exercised, in a manner oppressive to any shareholder or shareholders or in disregard of their interests as shareholders. Oppression connotes conduct that is
burdensome, harsh or wrong. This is an Irish statutory remedy under Section&nbsp;212 of the Irish Companies Act and the court can grant any order it sees fit, including providing for the purchase or transfer of the shares of any shareholder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Inspection of Books and Records </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
Irish law, shareholders have the right to (i)&nbsp;receive a copy of our constitution, (ii)&nbsp;inspect and obtain copies of the minutes of our general meetings and resolutions, (iii)&nbsp;inspect and receive a copy of the register of shareholders,
register of directors and secretaries, register of directors&#146; interests and other statutory registers maintained by us, (iv)&nbsp;receive copies of financial statements and directors&#146; and auditors&#146; reports which have previously been
sent to shareholders prior to an annual general meeting, and (v)&nbsp;receive financial statements of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subsidiary company of ours which have previously been sent to shareholders prior to an annual general meeting for the preceding ten years. Our auditors will also have the right to inspect all of
our books, records and vouchers. The auditors&#146; report must be circulated to the shareholders with our audited financial statements 21 days before the annual general meeting and must be presented to our shareholders at our annual general
meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Acquisitions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are a
number of mechanisms for acquiring an Irish public limited company, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a court-approved scheme of arrangement under the Irish Companies Act. A scheme of arrangement with one or more classes of shareholders requires a court order from the Irish High Court and the approval of: (i)&nbsp;more
than 50% in number of the shareholders of each participating class or series voting on the scheme of arrangement, and (ii)&nbsp;representing 75% or more by value of the shares of such participating class or series held by the shareholders voting on
the scheme of arrangement, in each case at the relevant meeting or meetings. A scheme of arrangement, if authorized by the shareholders of each participating class or series and the court, is binding on all of the shareholders of each participating
class or series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">through a tender offer by a third party pursuant to the Irish Takeover Rules. Where the holders of 80% or more in value of a class of our shares (excluding any shares already beneficially owned by the offeror) have
accepted an offer for their shares, the remaining shareholders in that class may be statutorily required to also transfer their shares, unless, within one month, the <FONT STYLE="white-space:nowrap">non-tendering</FONT> shareholders can obtain an
Irish court order otherwise providing. If the offeror has acquired acceptances of 80% of all of our shares but does not exercise this &#147;squeeze out&#148; right, the <FONT STYLE="white-space:nowrap">non-accepting</FONT> shareholders also have a
statutory right to require the offeror to acquire their shares on the same terms as the original offer, or such other terms as the offeror and the <FONT STYLE="white-space:nowrap">non-tendering</FONT> shareholders may agree or on such terms as an
Irish court, on application of the offeror or <FONT STYLE="white-space:nowrap">non-tendering</FONT> shareholder, may order. If our shares were listed on the Irish Stock Exchange or another regulated stock exchange in the European Union, this 80%
threshold would be increased to 90%; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by way of a merger with a company incorporated in the European Economic Area (EEA) under the European Communities (Cross-Border Mergers) Regulations 2008, which implement the EU Cross Border Merger Directive 2005/56 in
Ireland or with another Irish company under the Irish Companies Act. Such a merger must be approved by a special resolution. Shareholders also may be entitled to have their shares acquired for cash. See the section titled &#147;&#151;Appraisal
Rights.&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The approval of our board of directors, but not shareholder approval, is required for a sale, lease or
exchange of all or substantially all of our assets, except that such a transaction between us and one of our directors or a person or entity connected to such a director may require shareholder approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appraisal Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, under Irish
law, shareholders of an Irish company do not have statutory appraisal rights. If we are being merged as the transferor company with another EEA company under the European Communities (Cross-Border Mergers) Regulations 2008 or if we are being merged
with another Irish company under the Irish Companies Act, (i)&nbsp;any of our shareholders who voted against the special resolution approving the merger or (ii)&nbsp;if 90% of our shares are held by the successor company, any other of our
shareholder, may be entitled to require that the successor company acquire its shares for cash. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Disclosure of Interests in Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Irish Companies Act, there is a notification requirement for shareholders who acquire or cease to be interested in 3% of the shares
of an Irish public limited company. Our shareholders must therefore make such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a notification to us if as a result of a transaction the shareholder will be interested in 3% or more of our shares; or if as a result of a transaction a shareholder who was interested in more
than 3% of our shares ceases to be so interested. Where a shareholder is interested in more than 3% of our shares, any alteration of his or her interest that brings his or her total holding through the nearest whole percentage number, whether an
increase or a reduction, must be notified to us. The relevant percentage figure is calculated by reference to the aggregate par value of the shares in which the shareholder is interested as a proportion of the entire par value of our share capital.
Where the percentage level of the shareholder&#146;s interest does not amount to a whole percentage this figure may be rounded down to the next whole number. All such disclosures should be notified to us within five business days of the transaction
or alteration of the shareholder&#146;s interests that gave rise to the requirement to notify. Where a person fails to comply with the notification requirements described above no right or interest of any kind whatsoever in respect of any of our
shares concerned, held by such person, shall be enforceable by such person, whether directly or indirectly, by action or legal proceeding. However, such person may apply to the court to have the rights attaching to the shares concerned reinstated.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the above disclosure requirement, under the Irish Companies Act, we may by notice in writing require a person whom we know
or have reasonable cause to believe to be, or at any time during the three years immediately preceding the date on which such notice is issued, to have been interested in shares comprised in our relevant share capital to (a)&nbsp;indicate whether or
not it is the case and (b)&nbsp;where such person holds or has during that time held an interest in our shares, to give such further information as may be required by us including particulars of such person&#146;s own past or present interests in
our shares. Any information given in response to the notice is required to be given in writing within such reasonable time as may be specified in the notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where such a notice is served by us on a person who is or was interested in our shares and that person fails to give us any information
required within the reasonable time specified, we may apply to court for an order directing that the affected shares be subject to certain restrictions. Failure to comply with such a court order is a criminal offence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Irish Companies Act, the restrictions that may be placed on the shares by the court are as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any transfer of those shares, or in the case of unissued shares any transfer of the right to be issued with shares and any issue of shares, shall be void; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no voting rights shall be exercisable in respect of those shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no further shares shall be issued in right of those shares or in pursuance of any offer made to the holder of those shares; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no payment shall be made of any sums due from us on those shares, whether in respect of capital or otherwise. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where our shares are subject to these restrictions, the court may order the shares to be sold and may also direct that the shares shall cease
to be subject to these restrictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Provisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business Combinations with Interested Shareholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Articles of Association provide that, subject to certain exceptions, we may not engage in certain business combinations with any person
that acquires beneficial ownership of 15% or more of our outstanding voting shares for a period of three years following the date on which the person became a 15% shareholder unless: (i)&nbsp;a committee of our disinterested directors approved the
business combination; and (ii)&nbsp;in certain circumstances, the business combination is authorized by a special resolution of disinterested shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shareholder Rights Plans and Share Issuances </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Irish law does not expressly authorize or prohibit companies from issuing share purchase rights or adopting a shareholder rights plan as an
anti-takeover measure; there is no directly relevant case law on this issue. We do not currently have a rights plan in place. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
Articles of Association expressly authorize our board of directors to adopt a shareholder rights plan, subject to applicable law, including the Irish Takeover Rules and Substantial Acquisition Rules described below and the requirement for
shareholder authorization for the issue of shares described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the Irish Takeover Rules described below, our board of
directors also has power to issue any of our authorized and unissued shares on such terms and conditions as it may determine and any such action should be taken in the best interests of Iterum. It is possible, however, that the terms and conditions
of any issue of preferred shares could discourage a takeover or other transaction that holders of some or a majority of the ordinary shares believe to be in their best interests or in which holders might receive a premium for their shares over the
then market price of the shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Irish Takeover Rules and Substantial Acquisition Rules </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A transaction by virtue of which a third party is seeking to acquire 30% or more of our voting rights will be governed by the Irish Takeover
Panel Act 1997 and the Irish Takeover Rules made thereunder and will be regulated by the Irish Takeover Panel. The &#147;General Principles&#148; of the Irish Takeover Rules and certain important aspects of the Irish Takeover Rules are described
below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General Principles </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Irish
Takeover Rules are built on the following General Principles which will apply to any transaction regulated by the Irish Takeover Panel: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the event of an offer, all classes of shareholders of the target company should be afforded equivalent treatment and, if a person acquires control of a company, the other holders of securities must be protected;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the holders of securities in the target company must have sufficient time to allow them to make an informed decision regarding the offer; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the board of a company must act in the interests of the company as a whole. If the board of the target company advises the holders of securities as regards the offer it must advise on the effects of the implementation
of the offer on employment, employment conditions and the locations of the target company&#146;s place of business; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">false markets in the securities of the target company or any other company concerned by the offer must not be created; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a bidder can only announce an offer after ensuring that he or she can fulfill in full the consideration offered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a target company may not be hindered longer than is reasonable by an offer for its securities. This is a recognition that an offer will disrupt the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> running of a target company particularly if the offer is hostile and the board of the target company must divert its attention to resist the offer; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a &#147;substantial acquisition&#148; of securities (whether such acquisition is to be effected by one transaction or a series of transactions) will only be allowed to take place at an acceptable speed and shall be
subject to adequate and timely disclosure. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mandatory Bid </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under certain circumstances, a person who acquires shares or other of our voting rights may be required under the Irish Takeover Rules to make
a mandatory cash offer for our remaining outstanding shares at a price not less than the highest price paid for the shares by the acquirer (or any parties acting in concert with the acquirer) during the previous 12 months. This mandatory bid
requirement is triggered if, unless the Irish Takeover Panel otherwise consents, an acquisition of shares would (i)&nbsp;increase the aggregate holding of an acquirer (including the holdings of any parties acting in concert with the acquirer) to
shares representing 30% or more of our voting rights, or (ii)&nbsp;in the case of a person holding (together with its concert parties) shares representing 30% or more of our voting rights, after giving effect to the acquisition, increase the
percentage of the voting rights held by that person (together with its concert parties) by 0.05% within a <FONT STYLE="white-space:nowrap">12-month</FONT> period. Any person (excluding any parties acting in concert with the holder) holding shares
representing more than 50% of the voting rights of a company is not subject to these mandatory offer requirements in purchasing additional securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voluntary Bid; Requirements to Make a Cash Offer and Minimum Price Requirements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A voluntary offer is an offer that is not a mandatory offer. If a bidder or any of its concert parties acquire our ordinary shares within the
period of three months prior to the commencement of the offer period, the offer price must be not less than the highest price paid for our ordinary shares by the bidder or its concert parties during that period. The Irish Takeover Panel has the
power to extend the &#147;look back&#148; period to 12 months if the Irish Takeover Panel, having regard to the General Principles, believes it is appropriate to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the bidder or any of its concert parties has acquired our ordinary shares: (i)&nbsp;during the period of 12 months prior to the
commencement of the offer period which represent more than 10% of our total ordinary shares or (ii)&nbsp;at any time after the commencement of the offer period, the offer shall be in cash (or accompanied by a full cash alternative) and the price per
ordinary share shall be not less than the highest price paid by the bidder or its concert parties during, in the case of (i), the period of 12 months prior to the commencement of the offer period and, in the case of (ii), the offer period. The Irish
Takeover Panel may apply this rule to a bidder who, together with its concert parties, has acquired less than 10% of our total ordinary shares in the <FONT STYLE="white-space:nowrap">12-month</FONT> period prior to the commencement of the offer
period if the Panel, having regard to the General Principles, considers it just and proper to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An offer period will generally
commence from the date of the first announcement of the offer or proposed offer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Substantial Acquisition Rules </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Irish Takeover Rules also contain rules governing substantial acquisitions of shares which restrict the speed at which a person may
increase his or her holding of shares and rights over shares to an aggregate of between 15% and 30% of our voting rights. Except in certain circumstances, an acquisition or series of acquisitions of shares or rights over shares representing 10% or
more of our voting rights is prohibited, if such acquisition(s), when aggregated with shares or rights already held, would result in the acquirer holding 15% or more but less than 30% of our voting rights and such acquisitions are made within a
period of seven days. These rules also require accelerated disclosure of acquisitions of shares or rights over shares relating to such holdings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Frustrating Action </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Irish
Takeover Rules, our board of directors is not permitted to take any action which might frustrate an offer for our shares once the board of directors has received an approach which may lead to an offer or has reason to believe an offer is imminent
except as noted below. Potentially frustrating actions such as (i)&nbsp;the issue of shares, options or convertible securities, (ii)&nbsp;material acquisitions or disposals, (iii)&nbsp;entering into </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contracts other than in the ordinary course of business or (iv)&nbsp;any action, other than seeking alternative offers, which may result in frustration of an offer, are prohibited during the
course of an offer or at any time during which the board has reason to believe an offer is imminent. Exceptions to this prohibition are available where: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the action is approved by the offeree at a general meeting; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">with the consent of the Irish Takeover Panel where: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Irish Takeover Panel is satisfied the action would not constitute a frustrating action; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the holders of 50% of the voting rights state in writing that they approve the proposed action and would vote in favor of it at a general meeting; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the action is taken in accordance with a contract entered into prior to the announcement of the offer; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the decision to take such action was made before the announcement of the offer and either has been at least partially implemented or is in the ordinary course of business. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For other provisions that could be considered to have an anti-takeover effect, see the sections titled &#147;&#151;Transfer and Registration
of Shares,&#148; <FONT STYLE="white-space:nowrap">&#147;&#151;Pre-emption</FONT> Rights, Share Warrants and Share Options,&#148; &#147;&#151;Voting&#151;Generally,&#148; &#147;&#151;Voting&#151;Variation of Rights Attaching to a Class&nbsp;or Series
of Shares,&#148; &#147;&#151;Disclosure of Interests in Shares&#148; and &#147;&#151;Corporate Governance.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Governance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Generally </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Articles of
Association allocate authority over the management of the Company to our board of directors. Our board of directors may then delegate management of the Company to committees of the board or such other persons as it thinks fit. Regardless of any
delegation, the board of directors will remain responsible, as a matter of Irish law, for the proper management of the affairs of our Company. The board of directors may create new committees or change the responsibilities of existing committees
from time to time. See the section titled &#147;Management&#151;Committees of the Board of Directors.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Directors: Term and Appointment
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Directors are elected or appointed at the annual general meeting or at any extraordinary general meeting called for that purpose.
Each director is elected by the affirmative vote of a majority of the votes cast with respect to such director. In the event of a &#147;contested election&#148; of directors, directors shall be elected by the vote of a plurality of the votes cast at
any meeting for the election of directors at which a quorum is present. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Articles of Association provide that our board of
directors is divided into three classes serving staggered three-year terms. Shareholders do not have cumulative voting rights. Accordingly, the holders of a majority of the voting rights attaching to our ordinary shares will, as a practical matter,
be entitled to control the election of all directors. At each annual general meeting, directors will be elected for a full term of three years to succeed those directors of the relevant class whose terms are expiring. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our Articles of Association, our board of directors has the authority to appoint directors to the board either to fill a vacancy or as
an additional director. A vacancy on the board of directors created by the removal of a director may be filled by an ordinary resolution of the shareholders at the meeting at which such director is removed and, in the absence of such election or
appointment, the remaining directors may fill the vacancy. The board of directors may fill a vacancy by an affirmative vote of a majority of the directors constituting a quorum. If there is an insufficient number of directors to constitute a quorum,
the board may nonetheless act to fill such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
vacancies or call a general meeting of the shareholders. Under our Articles of Association, if the board fills a vacancy, the director will hold this position as a director for a term that will
coincide with the remaining term of the relevant class of director. If there is an appointment to fill a casual vacancy or an addition to the board, the total number of directors shall not at any time exceed the number of directors from time to time
fixed by the board in accordance with our Articles of Association. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Removal of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Irish Companies Act provides that, notwithstanding anything contained in the Articles of Association of a company or in any agreement
between that company and a director, the shareholders may, by an ordinary resolution, remove a director from office before the expiration of his or her term, provided that notice of any such resolution be given to the shareholders not less than 28
days before the meeting at which the director is to be removed, and the director will be entitled to be heard at such meeting. The power of removal is without prejudice to any claim for damages for breach of contract (e.g., employment agreement)
that the director may have against us in respect of his or her removal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Directors&#146; Duties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors have certain statutory and fiduciary duties. All of the directors have equal and overall responsibility for the management of the
Company (although directors who also serve as employees will have additional responsibilities and duties arising under their employment agreements and will be expected to exercise a greater degree of skill and diligence than <FONT
STYLE="white-space:nowrap">non-executive</FONT> directors). The principal fiduciary duties include the statutory and common law fiduciary duties of acting in good faith in the interests of the company and exercising due care and skill. Other
statutory duties include ensuring the maintenance of proper books of account, having annual accounts prepared, having an annual audit performed, maintaining certain registers and making certain filings as well as the disclosure of personal
interests. Particular duties also apply to directors of insolvent companies (for example, the directors could be liable to sanctions where they are deemed by the court to have carried on our business while insolvent, without due regard to the
interests of creditors). For public limited companies, directors are under a specific duty to ensure that the corporate secretary is a person with the requisite knowledge and experience to discharge the role. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conflicts of Interest </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a matter
of Irish law, a director is under a fiduciary duty to avoid conflicts of interest. Irish law and our Articles of Association provide that: (i)&nbsp;a director may be a director of or otherwise interested in a company relating to us and will not be
accountable to us for any remuneration or other benefits received as a result, unless we otherwise direct; (ii)&nbsp;a director or a director&#146;s firm may act for us in a professional capacity other than as auditor; and (iii)&nbsp;a director may
hold an office or place of profit in us and will not be disqualified from contracting with us. If a director has a personal interest in an actual or proposed contract with us, the director must declare the nature of his or her interest and we are
required to maintain a register of such declared interests that must be available for inspection by the shareholders. Such a director may vote on any resolution of the board of directors in respect of such a contract, and such a contract will not be
voidable solely as a result. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification of Directors and Officers; Insurance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the fullest extent permitted by Irish law, our Articles of Association will confer an indemnity on our directors and officers. However, this
indemnity is limited by the Irish Companies Act, which prescribes that an advance commitment to indemnify only permits a company to pay the costs or discharge the liability of a director or corporate secretary where judgment is given in favor of the
director or corporate secretary in any civil or criminal action in respect of such costs or liability, or where an Irish court grants relief because the director or corporate secretary acted honestly and reasonably and ought fairly to be excused.
Any provision whereby an Irish company seeks to commit in advance to indemnify its directors or corporate secretary over and above the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limitations imposed by the Irish Companies Act will be void under Irish law, whether contained in its Articles of Association or any contract between the company and the director or corporate
secretary. This restriction does not apply to our executives who are not directors, the corporate secretary or other persons who would be considered &#147;officers&#148; within the meaning of that term under the Irish Companies Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Articles of Association will also contain indemnification and expense advancement provisions for persons who are not directors or our
corporate secretary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are permitted under our Articles of Association and the Irish Companies Act to take out directors&#146; and
officers&#146; liability insurance, as well as other types of insurance, for our directors, officers, employees and agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we and certain of our subsidiaries have entered into agreements to indemnify our directors and our executive officers to the
maximum extent allowed under applicable law. These agreements, among other things, provide that we will indemnify our directors and executive officers for certain expenses (including attorneys&#146; fees), judgments, fines and settlement amounts
reasonably incurred by such person in any action or proceeding, including any action by or in our right, on account of any services undertaken by such person on our behalf or that person&#146;s status as our director or executive officer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Duration; Dissolution; Rights upon Liquidation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our duration will be unlimited. We may be dissolved at any time by way of either a shareholder&#146;s voluntary winding up or a creditors&#146;
winding up. In the case of a shareholder&#146;s voluntary winding up, the Company must be solvent and a special resolution of the shareholders is required. We may also be dissolved by way of court order on the application of a creditor, or by the
Director of Corporate Enforcement in Ireland where the affairs of the Company have been investigated by an inspector and it appears from the report or any information obtained by the Director of Corporate Enforcement that the Company should be wound
up. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights of the shareholders to a return of our assets on dissolution or winding up, following the settlement of all claims of
creditors, may be prescribed in our Articles of Association or the terms of any shares issued by the board of directors from time to time. If the Articles of Association and terms of issue of the shares of the Company contain no specific provisions
in respect of a dissolution or winding up then, subject to the shareholder priorities and the rights of any creditors, the assets will be distributed to shareholders in proportion to the <FONT STYLE="white-space:nowrap">paid-up</FONT> nominal value
of the shares held. Our Articles of Association provide that our ordinary shareholders may be entitled to participate in a winding up, and the method by which the property will be divided shall be determined by the liquidator, subject to a special
resolution of the shareholders, but such rights of ordinary shareholders to participate may be subject to the rights of any preferred shareholders to participate under the terms of any series or class of preferred shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
transfer agent and registrar for our ordinary shares is Computershare Limited. The transfer agent&#146;s address is 1290&nbsp;Avenue of Americas 9th&nbsp;Floor, New York, New York 10104. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied to list our
ordinary shares on the Nasdaq Global Select Market under the symbol &#147;ITRM.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc522368_16"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, no public market for our ordinary shares existed, and a liquid trading market for our ordinary shares may not develop
or be sustained after this offering. Future sales of our ordinary shares in the public market could adversely affect prevailing market prices of our ordinary shares from time to time and could impair our future ability to raise equity capital in the
future. As described below, only a limited number of shares will be available for sale shortly after this offering due to contractual and legal restrictions on resale. Nevertheless, sales of our ordinary shares in the public market after such
restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price at such time and our ability to raise equity capital in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon the number of shares outstanding as of December&nbsp;31, 2017, upon the closing of this
offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of our ordinary shares will be outstanding, assuming no exercise of the underwriters&#146; over-allotment option to purchase additional ordinary shares from us and no
exercise of outstanding options. All of the shares sold in this offering will be freely tradable, except that any shares held by our affiliates, as that term is defined in Rule 144 under the Securities Act, may only be sold in compliance with the
limitations described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The remaining&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares
outstanding after this offering are restricted securities as defined in Rule 144 under the Securities Act or are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with us as described below. Following the expiration of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> period, restricted securities may be sold in the public market only if the offer and sale is registered or if the offer and sale qualifies for an exemption from registration, including under Rule 144 or 701
promulgated under the Securities Act, described in greater detail below. These remaining shares will generally become available for sale in the public market as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no shares will be eligible for sale in the public market on the date of this prospectus; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares will be eligible for sale in the public market upon the expiration of
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements 180 days after the date of this prospectus, subject in certain circumstances to the volume, manner of sale and other limitations of Rule 144 and Rule 701. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, of the 3,898,334 ordinary shares issuable upon exercise of options outstanding,
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares will be vested and eligible for sale 180 days after the date of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue ordinary shares from time to time as consideration for future acquisitions, investments, or other corporate purposes. In the
event that any such acquisition, investment, or other transaction is significant, the number of ordinary shares that we may issue may in turn be significant. We may also grant registration rights covering those ordinary shares issued in connection
with any such acquisition and investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the ordinary shares reserved for future issuance under our 2018 Plan will become
eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, a registration statement under the Securities Act or an exemption from
registration, including Rule 144 and Rule 701. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, persons who have beneficially owned restricted ordinary shares for at least six months, and any affiliate of the company who owns
either restricted or unrestricted ordinary shares, are entitled to sell their securities without registration with the SEC under an exemption from registration provided by Rule 144 under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Persons who have beneficially owned our restricted ordinary shares for at least six months would be entitled to sell their securities provided
that (1)&nbsp;such person is not deemed to have been one of our affiliates at the time </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of, or at any time during the 90 days preceding a sale and (2)&nbsp;we are subject to the periodic reporting requirements of the Exchange Act for at least 90 days before the sale and (3)&nbsp;we
are current in our Exchange Act reporting at the time of sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Persons who have beneficially owned our restricted ordinary shares for at
least six months but who are our affiliates at the time of, or any time during the 90 days preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of
securities that does not exceed the greater of either of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1% of the number of ordinary shares outstanding after this offering, which will equal approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares immediately after the closing
of this offering, based on the number of ordinary shares outstanding as of December&nbsp;31, 2017; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the average weekly trading volume of our ordinary shares on the during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale; provided, in each case, that we are subject to the
periodic reporting requirements of the Exchange Act for at least 90 days before the sale. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such sales by affiliates must
also comply with the manner of sale, current public information and notice provisions of Rule 144. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rule 701 under the Securities Act, as in effect on the date of this prospectus, permits resales of shares in reliance upon Rule 144 but without
compliance with certain restrictions of Rule 144, including the holding period requirement. Most of our employees, executive officers or directors who purchased shares under a written compensatory plan or contract may be entitled to rely on the
resale provisions of Rule 701, but all holders of Rule 701 shares are required to wait until 90 days after the date of this prospectus before selling their shares. However, substantially all Rule 701 shares are subject to <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements as described below and in the section of this prospectus captioned &#147;Underwriting&#148; and will become eligible for sale upon the expiration of the restrictions set forth in those agreements.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulation S </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulation S under the
Securities Act, as in effect on the date of this prospectus, provides an exemption from registration for certain sales of securities made outside of the United States. Many of our securities sold to <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
shareholders have been issued pursuant to Regulation S. Securities sold pursuant to Regulation S are deemed to be &#147;restricted securities&#148; and any resale of such securities may only be made in accordance with Regulation S, the registration
requirements of the Securities Act or an exemption from registration, such as Rule 144 under the Securities Act, which is described above. In general, persons who have beneficially owned our restricted ordinary shares, including shares issued in
accordance with Regulation S, and any affiliate of ours who owns either our restricted or unrestricted ordinary shares, including shares issued in accordance with Regulation S, are entitled to sell their securities without registration with the SEC
under an exemption from registration provided by Rule 144 (subject to the volume limitations and other restrictions described above). In addition, our ordinary shares issued in accordance with Regulation S may be resold in accordance with Regulation
S or the registration requirements of the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form <FONT STYLE="white-space:nowrap">S-8</FONT> Registration Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As soon as practicable after the closing of this offering, we intend to file a Form <FONT STYLE="white-space:nowrap">S-8</FONT> registration
statement under the Securities Act to register the issuance of our ordinary shares under our equity compensation plans and agreements. This registration statement will become effective immediately upon filing, and shares covered by such registration
statement will be eligible for sale in the public markets, subject to vesting restrictions, the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above and Rule 144 limitations applicable to affiliates. For a more complete
discussion of our equity compensation plans, see the section titled &#147;Executive Compensation&#151;Equity Incentive Plans.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our officers, directors, and substantially all of our shareholders and option holders have agreed with the underwriters that for a period of
180 days following the date of this prospectus, subject to certain exceptions, that they will not offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, any of our ordinary shares or securities convertible into or
exchangeable or exercisable for any of our ordinary shares, enter into a transaction that would have the same effect, or enter into any swap, hedge or other arrangement that transfers, in whole or in part, any of the economic consequences of
ownership of our ordinary shares, whether any of these transactions are to be settled by delivery of our ordinary shares or other securities, in cash or otherwise. Leerink Partners LLC and RBC Capital Markets, LLC may, in their sole discretion, at
any time, release all or any portion of the shares from the restrictions in this agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the restrictions contained in
the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement described above, we have entered into agreements with certain securityholders, including the investor rights agreement and our standard form option agreement, that contain market <FONT
STYLE="white-space:nowrap">stand-off</FONT> provisions imposing restrictions on the ability of such securityholders to offer, sell, or transfer our equity securities for a period of 180 days following the date of this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of
this offering, the holders of 95,827,720 ordinary shares or their transferees, will be entitled to certain rights with respect to the registration of those shares under the Securities Act. If the offer and sale of these shares are registered, they
will be freely tradable without restriction under the Securities Act immediately upon the effectiveness of the registration. For a description of these registration rights, see the section titled &#147;Description of Share Capital&#151;Registration
Rights.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc522368_17"></A>TAXATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Irish Tax Considerations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scope of Discussion
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material Irish tax considerations for certain beneficial owners of our ordinary shares. The
summary is based upon Irish tax laws and the practice of the Irish Revenue Commissioners in effect on the date of this prospectus and correspondence with the Irish Revenue Commissioners. Changes in law and/or administrative practice may result in
alteration of the tax considerations described below, possibly with retrospective effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summary does not constitute tax advice and
is intended only as a general guide. This summary is not exhaustive and shareholders should consult their own tax advisors about the Irish tax consequences (and the tax consequences under the laws of other relevant jurisdictions) which may arise as
a result of being a shareholder in our company including the acquisition, ownership and disposition of our ordinary shares. The summary applies only to shareholders who will own our ordinary shares as capital assets and does not apply to other
categories of shareholders, such as dealers in securities, trustees, insurance companies, collective investment schemes and shareholders who have, or who are deemed to have, acquired our ordinary shares by virtue of an Irish office or employment
(performed or carried on in Ireland). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax on Chargeable Gains </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current rate of tax on chargeable gains (where applicable) in Ireland is 33%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A disposal of our ordinary shares by a shareholder who is not resident or ordinarily resident for tax purposes in Ireland will not give rise
to Irish tax on any chargeable gain realized on such disposal unless such shares are used, held or acquired for the purposes of a trade or business carried on by such shareholder through a branch or agency in Ireland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of our ordinary shares who is an individual and who is temporarily <FONT STYLE="white-space:nowrap">non-resident</FONT> in Ireland
may, under Irish <FONT STYLE="white-space:nowrap">anti-avoidance</FONT> legislation, be liable to Irish tax on any chargeable gain realized on a disposal of our ordinary shares during the period in which such individual is <FONT
STYLE="white-space:nowrap">non-resident.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stamp Duty </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rate of stamp duty (where applicable) on transfers of shares of Irish incorporated companies is 1% of the price paid or the market value of
the shares acquired, whichever is greater. Where Irish stamp duty arises, it is generally a liability of the transferee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Irish stamp duty
may, depending on the manner in which our ordinary shares are held, be payable in respect of transfers of our ordinary shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shares Held through
DTC </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is expected that a transfer of our ordinary shares effected by means of the transfer of book entry interests in DTC will
not be subject to Irish stamp duty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shares Held Outside of DTC or Transferred Into or Out of DTC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A transfer of our ordinary shares where any party to the transfer holds such shares outside of DTC may be subject to Irish stamp duty.
Shareholders wishing to transfer their shares into (or out of) DTC may do so without giving rise to Irish stamp duty provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">there is no change in the beneficial ownership of such shares as a result of the transfer; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the transfer into (or out of) DTC is not effected in contemplation of a sale of such shares by a beneficial owner to a third party. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Withholding Tax on Dividends Paid on Our Ordinary Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As noted elsewhere in this prospectus, we do not expect to pay dividends for the foreseeable future. To the extent that Iterum does make
dividend payments (or other returns to shareholders that are treated as &#147;distributions&#148; for Irish tax purposes), it should be noted that such distributions made by Iterum will, in the absence of one of many exemptions, be subject to Irish
dividend withholding tax, which is referred to in this prospectus as &#147;DWT,&#148; currently at a rate of 20%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For DWT purposes, a
distribution includes any distribution that may be made by Iterum to its shareholders, including cash dividends, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividends and additional stock taken in lieu of a cash dividend. Where an exemption
does not apply in respect of a distribution made to a particular shareholder, we are responsible for withholding DWT prior to making such distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General Exemptions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
is a general overview of the scenarios where it will be possible for us to make payments of dividends without deduction of DWT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Irish
domestic law provides that a <FONT STYLE="white-space:nowrap">non-Irish</FONT> resident shareholder is not subject to DWT on dividends received from Iterum if such shareholder is beneficially entitled to the dividend and is either: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a person (not being a company) resident for tax purposes in a Relevant Territory (including the United States) and is neither resident nor ordinarily resident in Ireland (for a list of Relevant Territories for DWT
purposes, see the section titled &#147;&#151;Relevant Territories for the Purposes of Irish Dividend Withholding Tax&#148;); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a company resident for tax purposes in a Relevant Territory, provided such company is not under the control, whether directly or indirectly, of a person or persons who is or are resident in Ireland; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a company, wherever resident, that is controlled, directly or indirectly, by persons resident in a Relevant Territory and who is or are (as the case may be) not controlled by, directly or indirectly, persons who are not
resident in a Relevant Territory; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a company, wherever resident, whose principal class of shares (or those of its 75% direct or indirect parent) is substantially and regularly traded on a stock exchange in Ireland, on a recognized stock exchange in a
Relevant Territory or on such other stock exchange approved by the Irish Minister for Finance; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a company, wherever resident, that is wholly-owned , directly or indirectly, by two or more companies where the principal class of shares of each of such companies is substantially and regularly traded on a stock
exchange in Ireland, on a recognized stock exchange in a Relevant Territory or on such other stock exchange approved by the Irish Minister for Finance, </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and provided, in all cases noted above, Iterum has received from the
shareholder, where required, the relevant Irish Revenue Commissioners DWT form(s) which are referred to in this prospectus as &#147;DWT Forms,&#148; prior to the payment of the dividend and such DWT Form(s) remain valid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For <FONT STYLE="white-space:nowrap">non-Irish</FONT> resident shareholders that cannot avail themselves of one of Ireland&#146;s domestic law
exemptions from DWT, it may be possible for such shareholders to rely on the provisions of a double tax treaty to which Ireland is party to reduce the rate of DWT. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Iterum shareholders that do not fall within any of the categories specifically referred to
above may nonetheless fall within other exemptions from DWT. If any Iterum shareholders are exempt from DWT, but receive dividends subject to DWT, such shareholders may apply for refunds of such DWT from the Irish Revenue Commissioners. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Tax on Dividends Paid on Our Ordinary Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Irish income tax may arise for certain persons in respect of dividends received from Irish resident companies. A shareholder that is not
resident or ordinarily resident in Ireland and that is entitled to an exemption from DWT generally has no liability to Irish income tax or the universal social charge on a dividend received from us. An exception to this position may apply where such
shareholder holds our ordinary shares through a branch or agency in Ireland through which a trade is carried on. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A shareholder that is
not resident or ordinarily resident in Ireland and that is not entitled to an exemption from DWT generally has no additional Irish income tax liability or a liability to the universal social charge. The DWT deducted by us discharges the liability to
income tax. An exception to this position may apply where the shareholder holds our ordinary shares through a branch or agency in Ireland through which a trade is carried on. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Capital Acquisitions Tax </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Irish
capital acquisitions tax (&#147;CAT&#148;) comprises principally gift tax and inheritance tax. CAT could apply to a gift or inheritance of our ordinary shares irrespective of the place of residence, ordinary residence or domicile of the parties.
This is because our ordinary shares are regarded as property situated in Ireland for Irish CAT purposes as our share register must be held in Ireland. The person who receives the gift or inheritance has primary liability for CAT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CAT is levied at a rate of 33% above certain <FONT STYLE="white-space:nowrap">tax-free</FONT> thresholds. The appropriate tax free threshold
is dependent upon (i)&nbsp;the relationship between the donor and the donee, and (ii)&nbsp;the aggregation of the values of previous gifts and inheritances received by the donee from persons within the same group threshold. Gifts and inheritances
passing between spouses of the same marriage or civil partners of the same civil partnership are exempt from CAT. Children have a tax free threshold of &#128;310,000 in respect of taxable gifts or inheritances received from their parents. Our
shareholders should consult their own tax advisors as to whether CAT is creditable or deductible in computing any domestic tax liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is also a &#147;small gift exemption&#148; from CAT whereby the first &#128;3,000 of the taxable value of all taxable gifts taken by a
donee from any one donor, in each calendar year, is exempt from CAT and is also excluded from any future aggregation. This exemption does not apply to an inheritance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relevant Territories for the Purposes of Irish Dividend Withholding Tax </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Albania</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Armenia</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Australia</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Austria</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bahrain</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Belarus</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Belgium</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bosnia&nbsp;&amp;&nbsp;Herzegovina</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Botswana</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bulgaria</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canada</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chile</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">China</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Croatia</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cyprus</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Czech&nbsp;Republic</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Denmark</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Egypt</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Estonia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ethiopia</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finland</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">France</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Georgia</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Germany</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Greece</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hong Kong</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hungary</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Iceland</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">India</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Israel</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Italy</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Japan</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazakhstan</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Korea</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kuwait</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Latvia</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lithuania</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Luxembourg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Macedonia</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Malaysia</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Malta</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mexico</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moldova</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Montenegro</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Morocco</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Netherlands</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Zealand</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Norway</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pakistan</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Panama</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Poland</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Portugal</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Qatar</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Romania</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Russia</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Saudi Arabia</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Serbia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Singapore</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Slovak&nbsp;Republic</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Slovenia</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">South Africa</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Spain</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sweden</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Switzerland</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thailand</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The&nbsp;Republic&nbsp;Of&nbsp;Turkey</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ukraine</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United Arab&nbsp;Emirates</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United&nbsp;Kingdom</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Uzbekistan</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vietnam</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Zambia</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THE IRISH TAX CONSIDERATIONS SUMMARIZED ABOVE ARE FOR GENERAL INFORMATION ONLY. EACH SHAREHOLDER SHOULD
CONSULT HIS OR HER OWN TAX ADVISOR AS TO THE PARTICULAR CONSEQUENCES THAT MAY APPLY TO SUCH SHAREHOLDER. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material U.S. Federal Income Tax
Considerations for U.S. Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion describes the material U.S. federal income tax consequences relating to the
ownership and disposition of our ordinary shares by U.S. Holders (as defined below). This discussion applies to U.S. Holders that purchase our ordinary shares pursuant to this offering and hold such ordinary shares as capital assets. This discussion
is based on the U.S. Internal Revenue Code of 1986, as amended (the Code), U.S. Treasury regulations promulgated thereunder and administrative and judicial interpretations thereof, all as in effect on the date hereof and all of which are subject to
change, possibly with retroactive effect. This discussion does not address all of the U.S. federal income tax consequences that may be relevant to specific U.S. Holders in light of their particular circumstances or to U.S. Holders subject to special
treatment under U.S. federal income tax law (such as certain financial institutions; insurance companies; brokers, dealers or traders in securities or other persons that generally mark their securities to market for U.S. federal income tax purposes;
<FONT STYLE="white-space:nowrap">tax-exempt</FONT> entities or governmental organizations; retirement plans; regulated investment companies; real estate investment trusts; grantor trusts; brokers, dealers or traders in commodities, currencies or
notional principal contracts; certain former citizens or long-term residents of the United States; persons who hold our ordinary shares as part of a &#147;straddle,&#148; &#147;hedge,&#148; &#147;conversion transaction,&#148; &#147;synthetic
security&#148; or integrated investment; persons that have a &#147;functional currency&#148; other than the U.S. dollar; persons that own directly, indirectly or through attribution 10% or more of our common shares; corporations that accumulate
earnings to avoid U.S. federal income tax; and partnerships and other pass-through entities and investors in such pass-through entities). This discussion does not address any U.S. state or local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
tax consequences or any U.S. federal estate, gift or alternative minimum tax consequences. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As used in this discussion, the term &#147;U.S. Holder&#148; means a beneficial owner of our ordinary shares that
is, for U.S. federal income tax purposes, (1)&nbsp;an individual who is a citizen or resident of the United States, (2)&nbsp;a corporation (or entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the
laws of the United States, any state thereof, or the District of Columbia, (3)&nbsp;an estate the income of which is subject to U.S. federal income tax regardless of its </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
source or (4)&nbsp;a trust (x)&nbsp;with respect to which a court within the United States is able to exercise primary supervision over its administration and one or more United States persons
have the authority to control all of its substantial decisions or (y)&nbsp;that has elected under applicable U.S. Treasury regulations to be treated as a domestic trust for U.S. federal income tax purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an entity treated as a partnership for U.S. federal income tax purposes holds our ordinary shares, the U.S. federal income tax treatment of
a partner with respect to an investment in such ordinary shares will depend in part upon the status and activities of such entity and the particular partner. Any such entity, and any partners in such an entity, should consult their own tax advisor
regarding the U.S. federal income tax consequences of the purchase, ownership and disposition of our ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Persons considering
an investment in our ordinary shares should consult their own tax advisors as to the particular tax consequences applicable to them relating to the purchase, ownership and disposition of our ordinary shares, including the applicability of U.S.
federal, state and local tax laws and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Passive Foreign Investment Company Consequences
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, a corporation organized outside the United States will be treated as a passive foreign investment company, or PFIC,
for any taxable year in which either (1)&nbsp;at least 75% of its gross income is &#147;passive income&#148; (the PFIC Income Test), or (2)&nbsp;on average at least 50% of its assets, determined on a quarterly basis, are assets that produce passive
income or are held for the production of passive income (the PFIC Asset Test). Passive income for this purpose generally includes, among other things, dividends, interest, royalties, rents, and gains from the sale or exchange of property that give
rise to passive income. Assets that produce or are held for the production of passive income generally include cash, even if held as working capital or raised in a public offering, marketable securities, and other assets that may produce passive
income. Generally, in determining whether a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest
(by value) is taken into account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although PFIC status is determined on an annual basis and generally cannot be determined until the end
of the taxable year, based on the nature of our current and expected income and the current and expected value and composition of our assets, we were a PFIC for our 2017 tax year but we do not expect to be a PFIC for our current taxable year. In
part, because we may hold a substantial amount of cash and cash equivalents following this offering, and because the calculation of the value of our assets after this offering may be based in part on the value of our ordinary shares, which may
fluctuate considerably, there can be no assurance that we will not be a PFIC in future taxable years. Even if we determine that we are not a PFIC for a taxable year, there can be no assurance that the Internal Revenue Service (the IRS) will agree
with our conclusion and that the IRS would not successfully challenge our position. Because of the uncertainties involved in establishing our PFIC status, our U.S. counsel expresses no opinion regarding our PFIC status. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are a PFIC in any taxable year during which a U.S. Holder owns our ordinary shares, the U.S. Holder could be liable for additional taxes
and interest charges under the &#147;PFIC excess distribution regime&#148; upon (1)&nbsp;a distribution paid during a taxable year that is greater than 125% of the average annual distributions paid in the three preceding taxable years, or, if
shorter, the U.S. Holder&#146;s holding period for our ordinary shares, and (2)&nbsp;any gain recognized on a sale, exchange or other disposition (including, in certain circumstances, a pledge) of our ordinary shares, whether or not we continue to
be a PFIC. Under the PFIC excess distribution regime, the tax on such distribution or gain would be determined by allocating the distribution or gain ratably over the U.S. Holder&#146;s holding period for our ordinary shares. The amount allocated to
the current taxable year (i.e., the year in which the distribution occurs or the gain is recognized) and any year prior to the first taxable year in which we are a PFIC will be taxed as ordinary income earned in the current taxable year. The amount
allocated to other taxable years will be taxed at the highest marginal rates in effect for individuals or corporations, as applicable, to ordinary income for each such taxable year, and an interest charge, generally applicable to underpayments of
tax, will be added to the tax. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are a PFIC for any year during which a U.S. Holder holds our ordinary shares, we must
generally continue to be treated as a PFIC by that holder for all succeeding years during which the U.S. Holder holds such ordinary shares, unless we cease to meet the requirements for PFIC status and the U.S. Holder makes a &#147;deemed sale&#148;
election with respect to our ordinary shares. If the election is made, the U.S. Holder will be deemed to sell our ordinary shares it holds at their fair market value on the last day of the last taxable year in which we qualified as a PFIC, and any
gain recognized from such deemed sale would be taxed under the PFIC excess distribution regime, as described above. After the deemed sale election, the U.S. Holder&#146;s ordinary shares will not be treated as shares of a PFIC unless we subsequently
become a PFIC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are a PFIC for any taxable year during which a U.S. Holder holds our ordinary shares and one of our <FONT
STYLE="white-space:nowrap">non-United</FONT> States subsidiaries is also a PFIC (i.e., a lower-tier PFIC), such U.S. Holder would be treated as owning a proportionate amount (by value) of the shares of the lower-tier PFIC and would be taxed under
the PFIC excess distribution regime on distributions by the lower-tier PFIC and on gain from the disposition of shares of the lower-tier PFIC even though such U.S. Holder would not receive the proceeds of those distributions or dispositions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are a PFIC, a U.S. Holder will not be subject to tax under the PFIC excess distribution regime on distributions or gain recognized on
our ordinary shares if a valid <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;mark-to-market&#148;</FONT></FONT> election is made by the U.S. Holder for our ordinary shares. An electing U.S. Holder generally would take into
account as ordinary income each year, the excess of the fair market value of our ordinary shares held at the end of such taxable year over the adjusted tax basis of such ordinary shares. The U.S. Holder would also take into account, as an ordinary
loss each year, the excess of the adjusted tax basis of such ordinary shares over those shares&#146; fair market value at the end of the taxable year, but only to the extent of the excess of amounts previously included in income over ordinary losses
deducted as a result of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election. The U.S. Holder&#146;s tax basis in our ordinary shares would be adjusted to reflect any income or loss recognized
as a result of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election. Any gain from a sale, exchange or other disposition of our ordinary shares in any taxable year in which we are a PFIC would
be treated as ordinary income and any loss from such sale, exchange or other disposition would be treated first as ordinary loss (to the extent of any net <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT>
gains previously included in income) and thereafter as capital loss. If, after having been a PFIC for a taxable year, we cease to be classified as a PFIC because we no longer meet the PFIC Income Test or PFIC Asset Test, the U.S. Holder would not be
required to take into account any latent gain or loss in the manner described above and any gain or loss recognized on the sale or exchange of the ordinary shares would be classified as a capital gain or loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election is available to a U.S. Holder only
for &#147;marketable stock.&#148; Generally, stock will be considered marketable stock if it is &#147;regularly traded&#148; on a &#147;qualified exchange&#148; within the meaning of applicable U.S. Treasury regulations. A class of stock is
regularly traded during any calendar year during which such class of stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ordinary shares will be marketable stock as long as they remain listed on Nasdaq and are regularly traded. A <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election will not apply to the ordinary shares for any taxable year during which we are not a PFIC, but will remain in effect with respect to any subsequent
taxable year in which we become a PFIC. Such election will not apply to any of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> subsidiaries. Accordingly, a U.S. Holder may continue to be subject to tax under the PFIC excess distribution regime
with respect to any lower-tier PFICs notwithstanding the U.S. Holder&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election for the ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tax consequences that would apply if we are a PFIC would also be different from those described above if a U.S. Holder were able to make a
valid qualified electing fund (QEF) election. As we do not expect to provide U.S. Holders with the information necessary for a U.S. Holder to make a QEF election, prospective investors should assume that a QEF election will not be available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The U.S. federal income tax rules relating to PFICs are very complex. Prospective U.S. investors are strongly urged to consult their own
tax advisors with respect to the impact of the purchase, ownership and </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>
disposition of our ordinary shares, the consequences to them of an investment in a PFIC, any elections available with respect to the ordinary shares and the IRS information reporting obligations
with respect to the purchase, ownership and disposition of ordinary shares of a PFIC. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion above under &#147;&#151;Passive Foreign Investment Company Consequences,&#148; a U.S. Holder that receives a
distribution with respect to our ordinary shares generally will be required to include the gross amount of such distribution in gross income as a dividend when actually or constructively received by the U.S. Holder to the extent of the U.S.
Holder&#146;s pro rata share of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). To the extent a distribution received by a U.S. Holder is not a dividend because it exceeds the U.S.
Holder&#146;s pro rata share of our current and accumulated earnings and profits, it will be treated first as a <FONT STYLE="white-space:nowrap">tax-free</FONT> return of capital and reduce (but not below zero) the adjusted tax basis of the U.S.
Holder&#146;s ordinary shares. To the extent the distribution exceeds the adjusted tax basis of the U.S. Holder&#146;s ordinary shares, the remainder will be taxed as capital gain. Because we may not account for our earnings and profits in
accordance with U.S. federal income tax principles, U.S. Holders should expect all distributions to be reported to them as dividends. The amount of a dividend will include any amounts withheld by the Company in respect of Irish taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to applicable limitations, some of which vary depending upon the U.S. Holder&#146;s particular circumstances, Irish income taxes
withheld from dividends on the ordinary shares at a rate not exceeding the rate provided by the income tax treaty between Ireland and the United States will be creditable against the U.S. Holder&#146;s U.S. federal income tax liability. The rules
governing foreign tax credits are complex and U.S. Holders should consult their tax advisors regarding the creditability of foreign taxes in their particular circumstances. In lieu of claiming a foreign tax credit, U.S. Holders may, at their
election, deduct foreign taxes, including any Irish income tax withheld from dividends on ordinary shares. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued by a taxpayer in a
taxable year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Distributions on our ordinary shares that are treated as dividends generally will constitute income from sources outside
the United States for foreign tax credit purposes and generally will constitute passive category income. Such dividends will not be eligible for the &#147;dividends received&#148; deduction generally allowed to corporate shareholders with respect to
dividends received from U.S. corporations. Dividends paid by a &#147;qualified foreign corporation&#148; are eligible for taxation at a reduced capital gains rate rather than the marginal tax rates generally applicable to ordinary income provided
that a holding period requirement (more than 60 days of ownership, without protection from the risk of loss, during the <FONT STYLE="white-space:nowrap">121-day</FONT> period beginning 60 days before the
<FONT STYLE="white-space:nowrap">ex-dividend</FONT> date) and certain other requirements are met. Each U.S. Holder is advised to consult its tax advisor regarding the availability of the reduced tax rate on dividends. However, if we are a PFIC for
the taxable year in which the dividend is paid or the preceding taxable year, we will not be treated as a qualified foreign corporation, and therefore the reduced capital gains tax rate described above will not apply. See the discussion above under
&#147;&#151;Passive Foreign Investment Company Consequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-United</FONT> States corporation
(other than a corporation that is classified as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year) generally will be considered to be a qualified foreign corporation with respect to any dividend it pays on
ordinary shares if (i)&nbsp;such foreign corporation is eligible for benefits under a comprehensive income tax treaty that the IRS determines is satisfactory and that includes an exchange of information program and (ii) such ordinary shares are
readily tradable on an established securities market in the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sale, Exchange or Other Disposition of Our Ordinary Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion above under &#147;&#151;Passive Foreign Investment Company Consequences,&#148; a U.S. Holder generally will recognize
capital gain or loss for U.S. federal income tax purposes upon the sale, exchange </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or other disposition of our ordinary shares in an amount equal to the difference, if any, between the amount realized (i.e., the amount of cash plus the fair market value of any property
received) on the sale, exchange or other disposition and such U.S. Holder&#146;s adjusted tax basis in the ordinary shares. Such capital gain or loss generally will be long-term capital gain taxable at a reduced rate for <FONT
STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders or long-term capital loss if, on the date of sale, exchange or other disposition, the ordinary shares are held by the U.S. Holder for more than one year. Any capital gain of a <FONT
STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder that is not long-term capital gain is taxed at ordinary income rates. The deductibility of capital losses is subject to limitations. Any gain or loss recognized from the sale or other
disposition of our ordinary shares will generally be gain or loss from sources within the United States for U.S. foreign tax credit purposes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Medicare Tax </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain U.S. Holders
that are individuals, estates or trusts and whose income exceeds certain thresholds generally are subject to a 3.8% tax on all or a portion of their net investment income, which may include their gross dividend income and net gains from the
disposition of our ordinary shares. If you are a United States person that is an individual, estate or trust, you are encouraged to consult your tax advisors regarding the applicability of this Medicare tax to your income and gains in respect of
your investment in our ordinary shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and Backup Withholding </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. Holders may be required to file certain U.S. information reporting returns with the IRS with respect to an investment in our ordinary
shares, including, among others, IRS Form 8938 (Statement of Specified Foreign Financial Assets). As described above under &#147;Passive Foreign Investment Company Consequences,&#148; each U.S. Holder who is a shareholder of a PFIC must file an
annual report containing certain information. U.S. Holders paying more than $100,000 for our ordinary shares may be required to file IRS Form 926 (Return by a U.S. Transferor of Property to a Foreign Corporation) reporting this payment. Substantial
penalties may be imposed upon a U.S. Holder that fails to comply with the required information reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends on and proceeds from
the sale or other disposition of our ordinary shares may be reported to the IRS unless the U.S. Holder establishes a basis for exemption. Backup withholding may apply to amounts subject to reporting if the holder (1)&nbsp;fails to provide an
accurate U.S. taxpayer identification number or otherwise establish a basis for exemption, or (2)&nbsp;is described in certain other categories of persons. However, U.S. Holders that are corporations generally are excluded from these information
reporting and backup withholding tax rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts withheld under the backup
withholding rules generally will be allowed as a refund or a credit against a U.S. Holder&#146;s U.S. federal income tax liability if the required information is furnished by the U.S. Holder on a timely basis to the IRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>U.S. Holders should consult their own tax advisors regarding the backup withholding tax and information reporting rules. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO IT OF AN INVESTMENT IN OUR ORDINARY SHARES
IN LIGHT OF THE INVESTOR&#146;S OWN CIRCUMSTANCES. IN ADDITION, SIGNIFICANT CHANGES IN U.S. FEDERAL INCOME TAX LAWS WERE RECENTLY ENACTED. PROSPECTIVE INVESTORS SHOULD ALSO CONSULT WITH THEIR TAX ADVISORS WITH RESPECT TO SUCH CHANGES IN U.S. TAX LAW
AS WELL AS POTENTIAL CONFORMING CHANGES IN STATE TAX LAWS. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc522368_18"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC and RBC Capital Markets, LLC are acting as representatives of each of the underwriters named below and as joint
bookrunning managers for this offering. Subject to the terms and conditions set forth in the underwriting agreement among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not
jointly, to purchase from us, the number of ordinary shares set forth opposite its name below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:43.10pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RBC Capital Markets, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Guggenheim Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Needham&nbsp;&amp; Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have agreed,
severally and not jointly, to purchase all of the shares (other than those covered by the over-allotment option described below) sold under the underwriting agreement if they purchase any of the shares. If an underwriter defaults, the underwriting
agreement provides that the purchase commitments of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may be increased or the underwriting agreement may be terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to
payments the underwriters may be required to make in respect of those liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares, subject to
prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel, including the validity of the shares, and other conditions contained in the underwriting agreement, such as the receipt by the
underwriters of officers&#146; certificates and legal opinions. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commissions and Discounts </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
representatives have advised us that the underwriters propose initially to offer the shares to the public at the public offering price set forth on the cover page of this prospectus and to dealers at that price less a concession not in excess of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. After the initial offering of the shares, the public offering price, concession or any other term of the offering may be changed by the representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the public offering price, underwriting discounts and commissions and proceeds before expenses to us. The
information assumes either no exercise or full exercise by the underwriters of their over-allotment option. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With<BR>Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With<BR>Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and
commissions referred to above, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We also have agreed to reimburse the underwriters for up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for their FINRA counsel fee. In
accordance with FINRA Rule 5110, this reimbursed fee is deemed underwriting compensation for this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Over-Allotment Option </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted an option to the underwriters, exercisable for 30 days after the date of this prospectus, to purchase up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares at the public offering price, less the underwriting discounts and commissions. If the underwriters exercise this option, each underwriter will be obligated, subject to conditions
contained in the underwriting agreement, to purchase a number of additional shares proportionate to that underwriter&#146;s initial amount reflected in the above table. The underwriters may exercise this option solely for the purpose of covering
over-allotments, if any, made in connection with the offering of the ordinary shares offered by this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, our executive officers and directors and all of our other existing shareholders have agreed not to sell or transfer any ordinary
shares or securities convertible into or exchangeable or exercisable for ordinary shares, for 180 days after the date of this prospectus without first obtaining the written consent of Leerink Partners LLC and RBC Capital Markets, LLC on behalf of
the underwriters. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">offer, pledge, sell or contract to sell any ordinary shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sell any option or contract to purchase any ordinary shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">purchase any option or contract to sell any ordinary shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">grant any option, right or warrant for the sale of any ordinary shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">otherwise dispose of or transfer any ordinary shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">request or demand that we file a registration statement related to the ordinary shares; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enter into any swap or other agreement or any transaction that transfers, in whole or in part, the economic consequence of ownership of any ordinary shares, whether any such swap, agreement or transaction is to be
settled by delivery of ordinary shares or other securities, in cash or otherwise. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
<FONT STYLE="white-space:nowrap">lock-up</FONT> provision applies to ordinary shares and to securities convertible into or exchangeable or exercisable for ordinary shares. It also applies to ordinary shares owned now or acquired later by the person
executing the agreement or for which the person executing the agreement later acquires the power of disposition. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Select Market
Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied to list our ordinary shares on The Nasdaq Global Select Market, subject to notice of issuance, under the
symbol &#147;ITRM.&#148; </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Determination of Offering Price </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before this offering, there has been no public market for our ordinary shares. The initial public offering price will be determined through
negotiations between us and the representatives. In addition to prevailing market conditions, the factors to be considered in determining the initial public offering price are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the valuation multiples of publicly traded companies that the representatives believe to be comparable to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our financial information; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the history of, and the prospects for, our company and the industry in which we compete; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an assessment of our management, its past and present operations, and the prospects for, and timing of, our future revenues; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the present state of our development; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the above factors in relation to market values and various valuation measures of other companies engaged in activities similar to ours. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An active trading market for the shares may not develop. It is also possible that after the offering the shares will not trade in the public
market at or above the initial public offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters do not expect to sell more than 5% of the shares in the aggregate
to accounts over which they exercise discretionary authority. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization, Short Positions and Penalty Bids </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until the distribution of the shares is completed, SEC rules may limit underwriters and selling group members from bidding for and purchasing
our ordinary shares. However, the representatives may engage in transactions that stabilize the price of the ordinary shares, such as bids or purchases to peg, fix or maintain that price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriters may purchase and sell our ordinary shares in the open market. These transactions may include
short sales, purchases on the open market to cover positions created by short sales, which may include purchases pursuant to the over-allotment option, and stabilizing transactions. Short sales involve the sale by the underwriters of a greater
number of shares than they are required to purchase in the offering. &#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; over-allotment option described above. The underwriters may close out any
covered short position by either exercising their over-allotment option or purchasing shares in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the
price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the over-allotment option granted to them. &#147;Naked&#148; short sales are sales in excess of such over-allotment option.
The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our ordinary
shares in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of ordinary shares made by the underwriters in the open market prior to the
closing of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the
underwriters a portion of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to other purchase transactions, the underwriters&#146; purchases to cover the syndicate short sales may have the effect of raising or
maintaining the market price of our ordinary shares or preventing or retarding a decline in the market price of our ordinary shares. As a result, the price of our ordinary shares may be higher than the price that might otherwise exist in the open
market. The underwriters may conduct these transactions on The Nasdaq Global Select Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the
transactions described above may have on the price of our ordinary shares. In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these transactions or that these transactions, once
commenced, will not be discontinued without notice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means, such as <FONT
STYLE="white-space:nowrap">e-mail.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and certain of their affiliates are full service financial institutions engaged in various activities, which may include
securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Some of the underwriters and certain of their affiliates may in
the future engage in investment banking and other commercial dealings in the ordinary course of business with us and our affiliates, for which they may in the future receive customary fees, commissions and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of
investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities
may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial
instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling
Restrictions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in the European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a &#147;Relevant Member
State&#148;), with effect from and including the date on which the Prospectus Directive is implemented in that Relevant Member State, no offer of shares may be made to the public in that Relevant Member State other than: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the
representatives; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such
offer of shares shall require the Company or the representatives to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person in a Relevant Member State who initially acquires any shares or to whom any offer is made will be deemed to have represented,
acknowledged and agreed that it is a &#147;qualified investor&#148; within the meaning of the law in that Relevant Member State implementing Article 2(1)(e) of the Prospectus Directive. In the case of any shares being offered to a financial
intermediary as that term is used in Article 3(2) of the Prospectus Directive, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a <FONT
STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer
or resale in a Relevant Member State to qualified investors as so defined or in circumstances in which the prior consent of the representatives has been obtained to each such proposed offer or resale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, the representatives and each of our and the representatives&#146; and their affiliates will rely upon the truth and accuracy of the
foregoing representations, acknowledgements and agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has been prepared on the basis that any offer of shares in
any Relevant Member State will be made pursuant to an exemption under the Prospectus Directive from the requirement to publish a prospectus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for offers of shares. Accordingly, any person making or intending to make an offer in that Relevant Member State of shares which are the subject of the offering contemplated in this prospectus
may only do so in circumstances in which no obligation arises for the company or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Directive in relation to such offer. Neither the company nor the underwriters
have authorized, nor do they authorize, the making of any offer of shares in circumstances in which an obligation arises for the company or the underwriters to publish a prospectus for such offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purpose of the above provisions, the expression &#147;an offer to the public&#148; in relation to any shares in any Relevant Member
State means the communication in any form and by any means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase or subscribe the shares, as the same may be varied in the
Relevant Member State by any measure implementing the Prospectus Directive in the Relevant Member State and the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (including the 2010 PD Amending Directive, to the extent
implemented in the Relevant Member States) and includes any relevant implementing measure in the Relevant Member State and the expression &#147;2010 PD Amending Directive&#148; means Directive 2010/73/EU. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>MiFID II Product Governance </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
person offering, selling or recommending the shares (a &#147;distributor&#148;) should take into consideration the manufacturers&#146; target market assessment; however, a distributor subject to MiFID II is responsible for undertaking its own target
market assessment in respect of the shares (by either adopting or refining the manufacturers&#146; target market assessment) and determining appropriate distribution channels. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in the United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may
only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Directive)&nbsp;(i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;Order&#148;) and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the
Order (all such persons together being referred to as &#147;relevant persons&#148;) or otherwise in circumstances which have not resulted and will not result in an offer to the public of the shares in the United Kingdom within the meaning of the
Financial Services and Markets Act 2000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any person in the United Kingdom that is not a relevant person should not act or rely on the
information included in this document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in Canada </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus
requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser
with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the
securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with
a legal advisor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National Instrument
<FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI
<FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective
Investors in Switzerland </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange
(&#147;SIX&#148;) or on any other stock exchange or regulated trading facility in Switzerland. This document does not constitute a prospectus within the meaning of, and has been prepared without regard to the disclosure standards for issuance
prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility
in Switzerland. Neither this document nor any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither this document nor any other offering or marketing material relating to the offering, the Company, the shares have been or will be
filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority (&#147;FINMA&#148;), and the offer of
shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (&#147;CISA&#148;). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not
extend to acquirers of shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in the Dubai International Financial Centre (&#147;DIFC&#148;) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document relates to an Exempt Offer in accordance with the Markets Rules 2012 of the Dubai Financial Services Authority
(&#147;DFSA&#148;). This document is intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or
verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has no responsibility for this document. The securities to which this
document relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the contents of this document you
should consult an authorized financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to its use in the DIFC, this document is strictly private and confidential
and is being distributed to a limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may not be offered or sold
directly or indirectly to the public in the DIFC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in the United Arab Emirates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the Dubai
International Financial Center) other than in compliance with the laws of the United Arab Emirates (and the Dubai International Financial Center) governing the issue, offering and sale of securities. Further, this prospectus does not constitute a
public offer of securities in the United Arab Emirates (including the Dubai International Financial Center) and is not intended to be a public offer. This prospectus has not been approved by or filed with the Central Bank of the United Arab
Emirates, the Securities and Commodities Authority or the Dubai Financial Services Authority. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in Australia
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">does not constitute a product disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001 (Cth) (the &#147;Corporations Act&#148;); </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">has not been, and will not be, lodged with the Australian Securities and Investments Commission (&#147;ASIC&#148;), as a disclosure document for the purposes of the Corporations Act and does not purport to include the
information required of a disclosure document under Chapter 6D.2 of the Corporations Act; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">does not constitute or involve a recommendation to acquire, an offer or invitation for issue or sale, an offer or invitation to arrange the issue or sale, or an issue or sale, of interests to a &#147;retail client&#148;
(as defined in section 761G of the Corporations Act and applicable regulations) in Australia; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the categories of investors, or Exempt Investors, available under section 708 of the Corporations
Act. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to
subscribe for or buy the shares may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any shares may be distributed in Australia, except where disclosure to investors is not required
under Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the shares, you represent and warrant to us that you are an Exempt Investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As any offer of shares under this document will be made without disclosure in Australia under Chapter 6D.2 of the Corporations Act, the offer
of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions in section 708 applies to that resale. By applying for the
shares you undertake to us that you will not, for a period of 12&nbsp;months from the date of issue of the shares, offer, transfer, assign or otherwise alienate those securities to investors in Australia except in circumstances where disclosure to
investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in Japan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act.
Accordingly, none of the shares nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any &#147;resident&#148; of Japan (which term as used herein means any person resident in Japan,
including any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except
pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant
time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a
&#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or
document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or
read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional
investors&#148; as defined in the Securities and Futures Ordinance and any rules made under that Ordinance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in Singapore </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or
purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (the &#147;SFA&#148;), (ii) to a relevant person
pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275 of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other
applicable provision of the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person
which is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals,
each of whom is an accredited investor; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that
trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where no consideration is or will be given for the transfer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where the transfer is by operation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Section&nbsp;276(7) of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in China </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus does not constitute a public offer of shares, whether by sale or subscription, in the People&#146;s Republic of China (the
&#147;PRC&#148;). The shares are not being offered or sold directly or indirectly in the PRC to or for the benefit of, legal or natural persons of the PRC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, no legal or natural persons of the PRC may directly or indirectly purchase any of the shares or any beneficial interest therein
without obtaining all prior PRC&#146;s governmental approvals that are required, whether statutorily or otherwise. Persons who come into possession of this document are required by the issuer and its representatives to observe these restrictions.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc522368_19"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the ordinary shares being offered by this prospectus will be passed upon for us by A&amp;L Goodbody, Dublin, Ireland. Certain
other legal matters relating to this offering will be passed upon for us by Cooley LLP. Certain legal matters in connection with this offering will be passed upon for the underwriters by Davis Polk&nbsp;&amp; Wardwell LLP. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc522368_20"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Iterum Therapeutics Limited as of December&nbsp;31, 2016 and December&nbsp;31, 2017 and for each of
the years in the two-year period ended December&nbsp;31, 2017, have been included herein in reliance upon the report of KPMG, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts
in accounting and auditing. </P>  <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc522368_21"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have submitted with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> including exhibits and schedules,
under the Securities Act, with respect to the ordinary shares being offered by this prospectus. This prospectus, which constitutes part of the registration statement, does not contain all of the information in the registration statement and its
exhibits. For further information with respect to us and the ordinary shares offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any contract or any
other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by
this reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You can read our SEC filings, including the registration statement, over the internet at the SEC&#146;s website at
www.sec.gov. You may also read and copy any document we file with the SEC at its public reference facilities at 100 F Street, NE, Washington, D.C. 20549. You may also obtain copies of these documents at prescribed rates by writing to the Public
Reference Section of the SEC at 100 F Street, NE, Washington, D.C. 20549. Please call the SEC at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330</FONT></FONT></FONT> for further
information on the operation of the public reference facilities. You may also request a copy of these filings, at no cost, by writing us at 200 West Monroe Street, Suite 1575, Chicago, IL 60606. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, we will be subject to the information reporting requirements of the Securities Exchange Act of 1934 and we
will file reports, proxy statements and other information with the SEC. These reports, proxy statements and other information will be available for inspection and copying at the public reference room and web site of the SEC referred to above. We
also maintain a website at www.iterumtx.com, at which, following the closing of this offering, you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC.
Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc522368_22"></A>ITERUM THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin522368_1">Report of Independent Registered Public Accounting Firm </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin522368_2">Consolidated Balance Sheet</A>s</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin522368_3">Consolidated Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin522368_4">Consolidated Statements of Changes in Convertible Preferred Shares and Shareholders&#146;
 Equity</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin522368_5">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin522368_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin522368_1"></A>Report of Independent Registered Public Accounting Firm
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Shareholders and Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Iterum
Therapeutics Limited: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Opinion on the Consolidated Financial Statements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated balance sheets of Iterum Therapeutics Limited and subsidiaries (the Company) as of December 31, 2016 and 2017,
the related consolidated statements of operations and comprehensive loss, changes in convertible preferred shares and shareholders&#146; equity, and cash flows for each of the years in the two-year period ended December 31, 2017, and the related
notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2016 and 2017, and the results of
its operations and its cash flows for each of the years in the two-year period ended December&nbsp;31, 2017, in conformity with U.S. generally accepted accounting principles. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Basis for Opinion </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These consolidated financial
statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company
Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the
consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated
financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our
audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><I>/s/ KPMG </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since December 31, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dublin, Ireland </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 9, 2018 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin522368_2"></A>ITERUM THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Convertible Preferred Shares and Shareholders&#146; Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (<I>Note 11</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A convertible preferred shares, $0.0001 par value per share; 47,640,000 shares authorized,
47,639,999 shares issued at December&nbsp;31, 2017 and 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred shares, $0.0001 par value per share; 58,078,977 shares authorized,
41,697,721 shares issued at December&nbsp;31, 2017 (2016: nil)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares, $0.0001 par value per share; 125,000,000 (2016; 57,490,000) shares authorized,
6,490,000 shares issued at December&nbsp;31, 2017 and 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,331</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(54,737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, convertible preferred shares and shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See Accompanying Notes to the Consolidated Financial Statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin522368_3"></A>ITERUM THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended</B><br><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,464</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,963</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,455</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,351</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,962</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,464</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to ordinary shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,464</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to ordinary shareholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36.21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average ordinary shares outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">371,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,704,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See Accompanying Notes to the Consolidated Financial Statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin522368_4"></A>ITERUM THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Changes in Convertible Preferred Shares and Shareholders&#146; Equity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible<BR>Preferred&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Shares&nbsp;to<BR>be Issued</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>Paid in<BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Balance, December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,790,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,490,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,867</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of Series A convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,849,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,464</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,464</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Balance, December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,639,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,490,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,331</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of Series B convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,697,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Balance, December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,337,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,490,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">94,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(54,737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See Accompanying Notes to the Consolidated Financial Statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin522368_5"></A>ITERUM THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended</B><br><B>December&nbsp;31,</B><br><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended</B><br><B>December&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,464</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash loss on short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(95</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(966</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,815</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,052</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(782</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,298</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,604</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(812</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from sale of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,587</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Series A convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Series B convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (decrease) / increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental Disclosure of Cash Flow Information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax paid&#151;U.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See Accompanying Notes to the Consolidated Financial Statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin522368_6"></A>ITERUM THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(1)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Nature of Operations and Basis of Presentation </B></TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Iterum Therapeutics Limited (the
&#147;Company&#148;) was incorporated under the laws of the state of Ireland in June 2015 and maintains its registered office at Block 2 Floor 3 Harcourt Centre, Harcourt Street, Dublin 2, Ireland. The Company commenced operations in November 2015.
The Company licensed global rights to its novel anti-infective compound, sulopenem, from Pfizer Inc. (&#147;Pfizer&#148;). The Company is a clinical-stage pharmaceutical company dedicated to developing and commercializing sulopenem to be the first
and only oral and intravenous (&#147;IV&#148;)&nbsp;branded penem available globally. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, the Company has devoted
substantially all of its efforts to research and development, recruiting management and technical staff, and raising capital, and has financed its operations through the issuance of convertible preferred shares. The Company has not generated any
product revenue. The Company is subject to risks and uncertainties common to early-stage companies in the pharmaceutical industry, including, but not limited to, development by competitors of new technological innovations, dependence on key
personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and
development efforts, including preclinical and clinical testing and regulatory approval prior to commercialization. Even if the Company&#146;s product development efforts are successful, it is uncertain when, if ever, the Company will realize
significant revenue from product sales. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared in accordance with
accounting principles generally accepted in the United States of America (&#147;GAAP&#148;) and include the accounts of the Company and its subsidiaries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Going Concern </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with Accounting Standards Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">2014-15,</FONT> <I>Disclosure of
Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern (Subtopic <FONT STYLE="white-space:nowrap">205-40</FONT></I>), the Company has evaluated whether there are conditions and events, considered in aggregate, that raise
substantial doubt about the Company&#146;s ability to continue as a going concern within one year of the date of issue of the consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has incurred operating losses since inception, including a net loss of $13,464 and $29,406 for the years ended December 31, 2016
and December 31, 2017, respectively. The Company had an accumulated deficit of $54,737 as of December&nbsp;31, 2017. The Company expects to continue to incur net losses for the next several years and is highly dependent on its ability to find
additional sources of funding in the form of debt or equity financing to fund its operations. Management believe that its cash and cash equivalents balance of $8,485 and short-term investments balance of $30,731 at December&nbsp;31, 2017, the
$32,230 Series B-2 funding raised on February 16, 2018, and amounts available subsequent to this date are sufficient to fund operations for at least one year from the date the consolidated financial statements are issued. In making this assessment
management have considered the future financing options available to the Company (excluding potential proceeds from an IPO), the planned operations of the Company and the ability to adjust its plans if required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will be required to obtain additional funding in order to continue to fund its operations after at least one year from the date
the consolidated financial statements are issued and intends to pursue a public offering of its ordinary shares to fund future operations. However, if the Company is unable to complete a sufficient public offering in a timely manner it would need to
pursue other financing alternatives including private financing of debt or equity or collaboration agreements. There can be no assurances, however, that the current operating plan will be achieved or that additional funding will be available on
terms acceptable to the Company, or at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ITERUM THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(2)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Summary of Significant Accounting Policies </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these
consolidated financial statements include, but are not limited to, the accrual for research and development expenses, revenue from grant awards, the valuation of restricted ordinary shares and the valuation of share-based compensation awards. The
Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are
changes in circumstances, facts and experience. Actual results could differ materially from those estimates. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive
Loss </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss includes net loss as well as other changes in shareholders&#146; equity that result from transactions
and economic events other than those with shareholders. For the periods presented in the accompanying consolidated financial statements, there was no difference between net loss and comprehensive loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Consolidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements include the accounts of Iterum Therapeutics Limited and its wholly owned subsidiaries
(collectively, the &#147;Company&#148;). All significant intercompany balances and transactions have been eliminated on consolidation. The Company has no involvement with variable interest entities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Short-term investments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company classifies short-term investments as available for sale in accordance with the terms of FASB ASC 320, <I>Investments - Debt and
Equity Securities. </I>Realized gains and losses are determined using specific identification. The investments are reported at fair value, with unrealized gains or losses recorded in the consolidated statements of operations and comprehensive loss.
Any difference between the cost and fair value of the investments are represented by unrealized gains or losses. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash
Equivalents </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s cash and cash equivalents consist of cash balances and highly liquid investments with
maturities of three months or less at the date of purchase. Accounts held at U.S. financial institutions are insured by the FDIC up to $250, while accounts held at Irish financial institutions are insured under the Deposit Guarantee Scheme up to
&#128;100 ($120). </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Foreign currencies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Items included in the consolidated financial statements are measured using the currency of the primary economic environment in which the entity
operates (&#145;functional currency&#146;). The consolidated financial statements are presented in U.S. dollars. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ITERUM THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Transactions in foreign currencies are recorded at the rate of exchange at the date of
the transaction. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are retranslated into the functional currency at the rate of exchange at the balance sheet date, and the resulting gains and losses are
recognized in the consolidated statement of operations and comprehensive loss. <FONT STYLE="white-space:nowrap">Non-monetary</FONT> items in a foreign currency that are measured in terms of historical cost are translated using the exchange rate at
the date of transaction. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost less accumulated depreciation. Property and equipment are depreciated using the straight-line method
over the estimated useful life of each asset as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:36.15pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Asset class</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Shorter&nbsp;of&nbsp;lease&nbsp;term&nbsp;or&nbsp;10&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are
removed from the accounts and any resulting gain or loss is included in loss from operations. Repairs and maintenance costs are expensed as incurred. The Company reviews the recoverability of all long-lived assets, including the related useful life,
whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses the cost of research and development as incurred. Research and development expenses comprise costs incurred in performing
research and development activities, including salaries, share-based compensation and benefits, facilities costs, depreciation, manufacturing expenses and external costs of third-parties engaged to supply active pharmaceutical ingredient and drug
product and conduct preclinical and clinical development activities and trials, as well as the cost of licensing technology, license fees, and other external costs. Advance payments for goods and services that will be used in future research and
development activities are recorded as prepaid expenses and expensed when the activity is performed or when the goods have been received. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into various research and development contracts with research institutions and other companies both inside and outside
of Ireland. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. This process involves reviewing open contracts and purchase orders, communicating with Company personnel to
identify services that have been performed on the Company&#146;s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual costs.
The majority of the Company&#146;s service providers invoice in arrears for services performed, on a <FONT STYLE="white-space:nowrap">pre-determined</FONT> schedule or when contractual milestones are met; however, some require advanced payments. The
Company estimates accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known at that time. It periodically confirms the accuracy of these estimates with the service
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ITERUM THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
providers and makes adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Vendors, including central laboratories, in connection with preclinical development activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Contract Research Organizations, or CROs, and investigative sites in connection with preclinical and clinical studies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Contract Manufacturing Organizations, or CMOs, in connection with drug substance and drug product formulation of preclinical and clinical trial materials. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company bases expenses related to preclinical studies and clinical trials on estimates of the services received and efforts expended
pursuant to quotes and contracts with multiple research institutions and CROs that conduct and manage preclinical studies and clinical trials on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to
contract and may result in uneven payment flows. There may be instances in which payments made to vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors
such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each
period. If the actual timing of the performance of services or the level of effort varies from the estimate, the accrual or the amount of prepaid expenses is adjusted accordingly. Although the Company does not expect the estimates to be materially
different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in
any particular period. To date, there have not been any material adjustments to prior estimates of accrued research and development expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Patent Costs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All
patent related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative
expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures all share-based awards granted to employees and directors based on the fair value on the date of grant using the
Black-Scholes option-pricing model. Compensation expense of those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company issues awards with only service based vesting
conditions and records the expense for these awards using the straight-line method. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For awards granted to consultants and <FONT
STYLE="white-space:nowrap">non-employees,</FONT> compensation expense is recognized over the period during which services are rendered until completed. At the end of each financial reporting period prior to completion of the service, the fair value
of these awards is remeasured using the then-current fair value of the Company&#146;s ordinary shares and updated assumption inputs in the Black-Scholes option-pricing model. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company classifies share-based compensation expense in its consolidated statement of operations and comprehensive loss in the same manner
in which the award recipient&#146;s payroll costs are classified or in which the award recipient&#146;s service payments are classified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Black-Scholes option-pricing model uses key inputs and assumptions including the expected term of the option, share price volatility,
risk-free interest rate, dividend yield, share price and exercise price. Many of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ITERUM THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assumptions require significant judgment and any changes could have a material impact in the determination of share-based compensation expense. The Company has elected to account for forfeitures
as they occur. There have been no forfeitures through December&nbsp;31, 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Grant Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may generate revenue from grant awards that reimburse certain allowable costs for specified projects. For contracts with third
parties, when the Company has concluded that it is the principal in conducting the research and development, and where the funding arrangement is considered central to the Company&#146;s ongoing operations, it classifies the recognized funding
received as revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2017, the Company was granted a sub-award from the Trustees of Boston University under the Combating
Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (&#147;CARB-X&#148;) program (the &#147;CARB-X award&#148;) in the amount of $1,497. The CARB-X award is structured as a cost reimbursement arrangement and is being recognized over a period
of 20 months from August 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes the CARB-X award as revenue, rather than as a reduction of research and development
expenses, because the Company is the principal in conducting the research and development activities and this contract is central to its ongoing operations. Revenue is recognized as the qualifying expenses related to the contract are incurred.
Revenue recognition commences only once persuasive evidence of a contract exists, services have been rendered, the reimbursement amounts under the contract are fixed or determinable, and collectability is reasonably assured. Revenue recognized upon
incurring qualifying expenses in advance of receipt of funding is recorded in the Company&#146;s consolidated balance sheet as other prepaid assets. The related costs incurred by the Company are included in research and development expenses in the
Company&#146;s consolidated statements of operations and comprehensive loss. There was no revenue recognized for the year ended December&nbsp;31, 2016. $508 was recognized as revenue for the year ended December&nbsp;31, 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Credits </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development credits are available to the Company under the tax laws in Ireland, based on qualifying research and development spend
as defined under those tax laws. Research and development credits are generally recognized as a reduction of research and development expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Transaction Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred transaction costs primarily consist of direct incremental legal, accounting, and other fees relating to the Company&#146;s
contemplated initial public offering (&#147;IPO&#148;) and are capitalized as incurred. The deferred transaction costs will be offset against IPO proceeds upon the consummation of the offering. In the event the IPO is terminated, which would include
a postponement of 90 days or greater, any deferred transaction costs will be expensed. There were no transaction costs deferred as of December&nbsp;31, 2016. Transaction costs of $180 were deferred as of December&nbsp;31, 2017 and are included
within prepaid expenses and other current assets in the accompanying consolidated balance sheets. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial
Instruments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial Accounting Standards Board (&#147;FASB&#148;) guidance specifies a hierarchy of valuation techniques based
on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ITERUM THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets
for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The three
levels of the fair value hierarchy are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 1&#151;Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level&nbsp;1 primarily consists of financial
instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 2&#151;Inputs other than quoted prices included within Level&nbsp;1 that are observable for the asset or liability, either directly or indirectly (e.g. quoted prices of similar assets or liabilities in active
markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level&nbsp;2 includes financial instruments that are valued using models or other valuation methodologies. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 3&#151;Unobservable inputs for the asset or liability. Financial instruments are considered Level&nbsp;3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and
at least one significant model assumption or input is unobservable. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s short-term investments and its
advance payments to a supplier are carried at fair value, determined according to the fair value hierarchy above, see <I>Note 3</I> for further details. The carrying amounts reported in the consolidated balance sheets for prepaid expenses and other
current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and
short-term investments. The Company has most of its cash and cash equivalents and short-term investments at two accredited financial institutions in the United States, in amounts that exceed federally insured limits. The Company does not believe
that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company accounts for income taxes under the asset and liability method which requires deferred tax assets and liabilities to be recognized for the estimated future tax consequences attributable to differences between the financial statement carrying
amounts of existing assets and liabilities and their respective tax bases, as well as net operating loss carryforwards and research and development tax credits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Valuation allowances are provided if it is more likely than not that some portion or all of the deferred tax assets will not be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those
temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company recognizes the effect of
income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are
reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ITERUM THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss Per Ordinary Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per ordinary share is determined by dividing net loss attributable to ordinary shareholders by the weighted-average
ordinary shares outstanding during the period; in accordance with ASC&nbsp;260, <I>Earnings per Share</I>. For the periods presented, the ordinary shares underlying the preferred shares and options, and unvested restricted ordinary shares have been
excluded from the calculation because they would be anti-dilutive. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following potentially dilutive securities have been excluded
from the computation of diluted weighted-average shares outstanding as they would be anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended<BR>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">775,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,898,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred shares convertible into ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,639,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,337,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,597,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,974,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,012,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,210,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average shares outstanding used to calculate both basic and diluted loss per ordinary
share are the same. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Segment Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines and presents operating segments based on the information that is internally provided to the Chief Executive Officer,
Chief Scientific Officer and Chief Financial Officer, who together are considered the Company&#146;s chief operating decision maker, in accordance with ASC 280, <I>Segment Reporting</I>. The Company has determined that it operates as a single
business segment, which is the development and commercialization of innovative treatments for drug resistant bacterial infections. Reportable segment information as at and for the years ended December&nbsp;31, 2016 and December&nbsp;31, 2017 is as
follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of total operating expenses by geographical area was as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:68.80pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Operating expenses </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ireland</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of long-lived assets by geographical area was as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:58.35pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Long-lived assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ireland</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ITERUM THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Retirement Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has a defined contribution plan under Section&nbsp;401(k) of the Internal Revenue Code (the &#147;401(k) Plan&#148;). The 401(k)
Plan covers all employees who meet defined minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> basis. The Company is required to
contribute a deferral rate of up to 3% to the 401(k) Plan on behalf of certain employees. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Inventory </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventories are valued at the lower of cost or market. Cost is determined using the <FONT STYLE="white-space:nowrap">first-in,</FONT> <FONT
STYLE="white-space:nowrap">first-out</FONT> method for all inventories. The Company&#146;s policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in
excess of expected requirements. The estimate of excess quantities is subjective and primarily dependent on the estimates of future demand for a particular product. If the estimate of future demand changes, the Company considers the impact on the
reserve for excess inventory and adjusts the reserve as required. Increases in the reserve are recorded as charges in cost of product sales. For product candidates that have not been approved by the FDA, inventory used in clinical trials is expensed
at the time of production and recorded as research and development expenses. For products that have been approved by the FDA, inventory used in clinical trials is expensed at the time the inventory is packaged for the clinical trial. Prior to an
advisory committee providing a recommendation to the FDA that the Company&#146;s application should be approved, costs related to purchases of the API and the manufacturing of the product candidate are recorded as research and development expenses.
All direct manufacturing costs incurred after this recommendation will be capitalized into inventory. The Company had no inventory as of December&nbsp;31, 2016 or December&nbsp;31, 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Contingent Consideration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain licence agreements contain milestone payments that could result in the requirement to make contingent consideration payments, see
<I>Note 11</I> for further details. Contingent consideration is recorded at the acquisition date estimated fair value of the contingent payment. The fair value of the contingent consideration is measured at each reporting period. Any related
unwinding of discount is recognized as a finance expense. Other changes in fair value are recognized in profit or loss or capitalized as an intangible asset depending on the stage of development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2017, the FASB issued ASU <FONT STYLE="white-space:nowrap">2017-11,</FONT> <I>Earnings Per Share (Topic 260), Distinguishing
Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) I. Accounting for Certain Financial Instruments with Down Round Features II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain
Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Part I applies to entities
that issue financial instruments such as warrants, convertible debt or convertible preferred shares that contain down-round features. Part II replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and
mandatorily redeemable financial instruments of nonpublic entities contained within ASC Topic 480 with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. ASU
<FONT STYLE="white-space:nowrap">2017-11</FONT> is required to be adopted for annual periods beginning after December&nbsp;15, 2018, including interim periods within those fiscal years. The adoption of ASU
<FONT STYLE="white-space:nowrap">2017-11</FONT> is not expected to have a significant impact on the consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
May 2017, the FASB issued ASU <FONT STYLE="white-space:nowrap">2017-09,</FONT><B> </B><I>Compensation&#151;Stock Compensation (Topic 718): Scope of Modification Accounting, </I>which clarifies what constitutes a modification of a share-based payment
award. This </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ITERUM THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ASU is effective for all entities for annual and interim periods in fiscal years beginning after December&nbsp;15, 2017. The adoption of ASU <FONT STYLE="white-space:nowrap">2017-09</FONT> is not
expected to have a significant impact on the consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2017, the FASB issued ASU <FONT
STYLE="white-space:nowrap">2017-07,</FONT> <I>Compensation&#151;Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, </I>which requires companies to present the
service cost component of net benefit cost in the same line items in which they report compensation cost. Companies will present all other components of net benefit cost outside operating income, if this subtotal is presented. This ASU is effective
for public business entities for annual and interim periods in fiscal years beginning after December&nbsp;15, 2017. The adoption of ASU <FONT STYLE="white-space:nowrap">2017-07</FONT> is not expected to have a significant impact on the consolidated
financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-15,</FONT> <I>Statement of Cash
Flows: Classification of Certain Cash Receipts and Cash Payments </I>(&#147;ASU <FONT STYLE="white-space:nowrap">2016-15&#148;),</FONT> to address diversity in practice in how certain cash receipts and cash payments are presented and classified in
the statement of cash flows. The standard is effective for annual periods beginning after December&nbsp;15, 2017, including interim periods within those fiscal years. The adoption of ASU <FONT STYLE="white-space:nowrap">2016-15</FONT> is not
expected to have a significant impact on the consolidated financial statements. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <FONT
STYLE="white-space:nowrap">2016-02,</FONT> <I>Leases (Topic 842</I>). ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> was issued to increase transparency and comparability among entities by recognizing lease assets and lease liabilities on the
consolidated balance sheet and disclosing key information about lease arrangements. ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning
after December&nbsp;15, 2018. The Company is currently evaluating the impact of adopting ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> on the consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued ASU No. 2014-09, <I>Revenue from Contracts with Customers (Topic 606) </I>(&#147;ASU 2014-09&#148;), which
supersedes existing revenue recognition guidance under GAAP. The standard&#146;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which
the Company expects to be entitled in exchange for those goods or services. The standard defines a five-step process to achieve this principle, and will require companies to use more judgment and make more estimates than under the current guidance.
The Company expects that these judgments and estimates will include identifying performance obligations in the customer contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction
price to each separate performance obligation. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. In August 2015, the FASB issued ASU 2015-14,
<I>Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</I>, which delays the effective date of ASU 2014-09 such that the standard is effective for public entities for annual periods beginning after December 15, 2017 and
for interim periods within those fiscal years. Early adoption of the standard is permitted for annual periods beginning after December 15, 2016. The standard is effective for public companies for annual periods beginning after December 15, 2017,
including interim periods within those fiscal years. In March 2016, the FASB issued ASU No. 2016-08, <I>Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations</I> <I></I>(&#147;ASU 2016-08&#148;), which further
clarifies the implementation guidance on principal versus agent considerations in ASU 2014-09. In April 2016, the FASB issued ASU No. 2016-10, <I>Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and
Licensing</I>, clarifying the implementation guidance on identifying performance obligations and licensing. Specifically, the amendments in this update reduce the cost and complexity of identifying promised goods or services and improve the guidance
for determining whether promises are separately identifiable. The amendments in this update also provide implementation guidance on determining whether an entity&#146;s promise to grant a license </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ITERUM THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provides a customer with either a right to use the entity&#146;s intellectual property (which is satisfied at a point in time) or a right to access the entity&#146;s intellectual property (which
is satisfied over time). In May 2016, the FASB issued ASU No. 2016-12, <I>Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients </I>(&#147;ASU 2016-12&#148;), which clarifies the objective of the
collectability criterion, presentation of taxes collected from customers, non-cash consideration, contract modifications at transition, completed contracts at transition and how guidance in ASU 2014-09 is retrospectively applied. ASU 2016-08, ASU
2016-10 and ASU 2016-12 have the same effective dates and transition requirements as ASU 2014-09. The adoption of ASU 2014-09 is not expected to have a significant impact on the consolidated financial statements as the only revenue currently being
recorded by the Company relates to the sub-award granted by CARB-X. </P>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(3)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Fair Value of Financial Assets </B></TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents information about the
Company&#146;s financial assets that have been measured at fair value at December&nbsp;31, 2016 and December 31, 2017 and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:21.30pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other asset&#151;advance payment to supplier</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:21.30pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other asset&#151;advance payments to supplier</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See <I>Note 4</I> for further details on the short-term investments held. The other asset above
relates to advance payments made to a supplier that were recorded at fair value using the discounted cash flow model, or DCF, as at December&nbsp;31, 2016 and 2017. Key assumptions used in the DCF include a discount rate of 15% and the expected time
to recovery of the payment. See <I>Note 11</I>&#151;<I>Payment to Supplier,</I> for further details on these advance payments. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(4)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Short-term Investments </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company classifies its short-term investments as available
for sale. Short-term investments comprise highly liquid investments with minimum &#147;A-&#148; rated securities and as at year-end consist of U.S. Treasury and agency bonds and corporate entity commercial paper with maturities of more than three
months but less than one year at the date of purchase. Short-term investments as at December 31, 2017 have an average maturity of 0.26 years. The investments are reported at fair value with unrealized gains or losses recorded in the consolidated
statements of operations and comprehensive loss. Any differences between the cost and fair value of investments are represented by unrealized gains / losses. The fair value of short-term investments are represented by Level 1 fair value measurements
&#150; quoted prices in active markets for identical assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company did not hold any available for sale securities as at December
31, 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ITERUM THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table represents our available for sale short-term investments by major
security type as at December 31, 2017: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cost<BR>Total</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized<BR>gains</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized<BR>(losses)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value<BR>Total</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maturity&nbsp;by&nbsp;period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:59.45pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Available for sale</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than&nbsp;1<BR>year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1&nbsp;to&nbsp;5<BR>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Treasury and Agency Bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(5)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Prepaid Expenses and Other Current Assets </B></TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current
assets consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other prepaid assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Value added tax receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred IPO expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development tax credit receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(6)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Property and Equipment, net </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment and related accumulated depreciation
are as follows: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(65</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There was no depreciation expense for the year ended December 31, 2016. Depreciation expense was $65
for the year ended December 31, 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ITERUM THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(7)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Accrued Expenses </B></TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses consist of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued manufacturing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll and bonus expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued clinical trial costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(8)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Shareholders&#146; Equity </B></TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s capital structure consists of
ordinary shares and preferred shares with certain rights and privileges summarized below. Under Irish law, the Company is prohibited from allotting shares without consideration. Accordingly, at least the nominal value of the shares issued underlying
any restricted share award, restricted share unit, performance share award, bonus share or any other share based grant must be paid pursuant to the Irish Companies Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Ordinary Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company was initially incorporated without a cap on its authorized share capital as permitted by the Companies Act 2014 of Ireland. On
October&nbsp;14, 2015, the Company authorized and issued 6,490,000 ordinary shares of $0.0001 each. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;18, 2015, the
Company increased the authorized ordinary share capital to 57,490,000 shares of $0.0001 each. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May 18, 2017, the Company increased the
authorized ordinary share capital to 125,000,000 shares of $0.0001 each. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of ordinary shares are entitled to one vote for
each share held. The holders of ordinary shares have no preemptive or other subscription rights, and there are no redemption or sinking fund provisions with respect to such shares. The ordinary shares are subordinate to the preferred shares with
respect to dividend rights and rights upon liquidation, winding up and dissolution of the Company. The holders of ordinary shares are entitled to liquidation proceeds after all liquidation preferences for the preferred shares are satisfied. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Preferred Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;18, 2015, the Company authorized 47,490,000 Series A convertible preferred shares of $0.0001 each. On the same day, the
Company issued 23,790,001 Series A convertible preferred shares for $1.00 each for: (1) gross cash proceeds of $20,701; (2) the issue of 3,000,000 preferred shares to Pfizer as part consideration for the licence agreement; and (3) the conversion of
$90 debt owed by the Company to the founders for a total of 90,000 preferred shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;9, 2016, the Company authorized
150,000 Series A convertible preferred shares of $0.0001 each. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ITERUM THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;16, 2016, the Company issued 23,849,998 Series A convertible preferred
shares for $1.00 each for: (1) gross cash proceeds of $20,851; and (2) the issue of an additional 3,000,000 preferred shares to Pfizer as part consideration for the license agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;18, 2017, the Company authorized 41,697,727 Series B-1 convertible preferred shares of $0.0001 each and 16,381,250 Series B-2
convertible preferred shares of $0.0001 each, the &#147;Series B Preferred Shares&#148;. On the same day, the Company issued 41,697,721 Series B-1 convertible preferred shares for $1.10 each, for gross cash proceeds of $45,867. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the preferred shares have the following rights and preferences: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of preferred shares are entitled to vote, together with the holders of ordinary shares, on all matters submitted to shareholders
for a vote, except the election of ordinary share directors and except as required by law. In addition, a number of actions require consent of at least two thirds of the holders of the preferred shares which must include holders of at least 55% of
the then outstanding Series B preferred shares. Each preferred shareholder is entitled to the number of votes equal to the number of ordinary shares into which each preferred share is convertible as of the day of the vote (being 1:1, subject to any
adjustments arising). </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Preferences </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the Company liquidates, dissolves or winds up, whether voluntarily or involuntarily, or sells all or substantially all of its
assets, or sells the Company or a controlling interest in the Company or if certain events deemed to be a liquidation occur, then the holders of the Series B preferred shares shall be entitled to receive in preference to the holders of the Series A
preferred shares and the ordinary shares; and the holders of the Series A preferred shares shall be entitled to receive in preference of the ordinary shares, an amount per share equal to the original purchase price for the preferred shares, plus any
dividends, if declared but unpaid thereon. Following all preferential payments to holders of the preferred shares as required, any remaining undistributed assets shall be shared ratably to the holders of the ordinary shares and the preferred shares
with the latter&#146;s share number being determined on an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;as-if-converted&#148;</FONT></FONT> basis, until such time as the preferred shareholders have received, in total, an
amount equal to three times the applicable original purchase price. Thereafter, any remaining net assets available are distributed ratably to the ordinary shareholders only. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
holders of the preferred shares are entitled to receive, if declared by the Board, <FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividends at the rate of 8% of the original purchase price per annum. Such dividends shall only be payable when
and if declared and are not cumulative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of preferred shares have liquidation and dividend rights in preference to the holders
of ordinary shares. No dividends on the ordinary shares shall be declared and paid unless dividends on the preferred shares have been declared and paid. Through December&nbsp;31, 2017, the Company has not declared any dividends. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Redemption Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preferred shares are not redeemable at the option of the holder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ITERUM THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Conversion Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each preferred share is convertible at any time at the option of the shareholder into fully paid ordinary shares. The conversion ratio is fixed
at 1:1, except in the event that the Company issues additional shares of stock below the purchase price of the preferred share, share splits and combinations, dividends and distributions whereby, the conversion price may be adjusted, with certain
exceptions. In the event of a liquidation, dissolution, winding up or deemed liquidation event, the conversion rights will be terminated at the close of business on the last day preceding the date fixed for payment of liquidation amounts to the
holders of preferred shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Mandatory Conversion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All outstanding shares will automatically convert into ordinary shares, based on the then effective applicable conversion price upon the
closing of the sale of ordinary shares to the public in a firm-commitment underwritten public offering on the New York Stock Exchange, The Nasdaq Global Select Market, Nasdaq Global Market or such other market or exchange as approved by the Board
pursuant to an effective registration statement under the Securities Act of 1933, as amended, in which the per share price is at least $3.30 and the gross cash proceeds to the company are at least forty million dollars ($40,000); or the affirmative
election (in writing) of the holders of at least two thirds of the preferred shares, which must include holders of at least 55% of the then outstanding Series B preferred shares. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(9)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Share-Based Compensation </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;18, 2015, the Company&#146;s Board of
Directors adopted and approved the 2015 Equity Incentive Plan (the &#147;Plan&#148;), which authorized the Company to grant up to 3,510,000 ordinary shares in the form of incentive stock options, nonstatutory stock options, stock appreciation
rights, restricted stock awards, restricted stock units and other stock awards. The types of share-based awards, including share purchase rights amount, terms, and exercisability provisions of grants are determined by the Company&#146;s Board of
Directors. The purpose of the Plan is to provide the Company with the flexibility to issue share-based awards as part of an overall compensation package to attract and retain qualified personnel. On May&nbsp;18, 2017, the Company amended the 2015
Equity Incentive Plan to increase the number of ordinary shares available for issuance under the plan by 3,450,000 shares to 6,960,000 shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Ordinary Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Company&#146;s formation, 6,490,000 restricted ordinary shares were issued on October&nbsp;14, 2015 to the
Company&#146;s founders at par value. These ordinary shares are subject to various restrictions pursuant to ordinary share purchase agreements between the Company and each founder, including restrictions on transfer and a Company right of
repurchase. The restricted ordinary shares were 25% vested as of October&nbsp;14, 2016 and 1/36<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the remaining restricted ordinary shares vest on a monthly basis thereafter (subject to
acceleration of vesting in connection with certain change of control transactions). A change in status occurred on November&nbsp;18, 2015 when the founders became employees of the Company. The grant date of these shares is now considered to be
November&nbsp;18, 2015 when the fair value was $0.20 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records share-based compensation expense for the restricted
ordinary shares based on the grant date fair value. The Company recorded an expense of $333 and $333 for the years ended December&nbsp;31, 2016 and December 31, 2017, respectively. Total unamortized compensation expense related to restricted
ordinary shares was $925 and $592 as of December&nbsp;31, 2016 and December 31, 2017, respectively, expected to be recognized over a weighted average period of 2.88 years and 1.88 years as of December 31, 2016 and December 31, 2017, respectively.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ITERUM THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of the Company&#146;s restricted ordinary share activity and related information is
as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;Average<BR>grant date fair<BR>value per share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested at December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,490,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,892,917</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,597,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,622,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,974,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Share Options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless specified otherwise in an individual option agreement, share options granted under the Plan generally have a ten year term and a four
year vesting period. The vesting requirement is conditioned upon a grantee&#146;s continued service with the Company during the vesting period. Once vested, all awards are exercisable from the date of grant until they expire. The option grants are <FONT
STYLE="white-space:nowrap">non-transferable.</FONT> Vested options generally remain exercisable for 90 days subsequent to the termination of the option holder&#146;s service with the Company. In the event of an option holder&#146;s disability or
death while employed by or providing service to the Company, the exercisable period extends to twelve months or eighteen months, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of options granted during the years ended December&nbsp;31, 2016 and December&nbsp;31, 2017 was estimated using the
Black-Scholes option-pricing model. The inputs for the Black-Scholes model require management&#146;s significant assumptions. The ordinary share price was determined by the Board of Directors. In the absence of market data for the Company&#146;s
ordinary shares, the Board of Directors considered various factors in estimating the fair value of the ordinary shares at the time of grant which include but are not limited to the ordinary shares valuation performed by a third-party independent
valuation firm, the Company&#146;s performance and future economic outlook, the potential financing available to the Company, and the valuation of ordinary shares of similar companies in the industry. Following the closing of this offering, the fair
value of ordinary shares will be determined based on the quoted market price of the Company&#146;s shares. The risk-free interest rate was based on a normalized estimate of the <FONT STYLE="white-space:nowrap">7-year</FONT> U.S. treasury yield. The
expected life was based on the simplified method in accordance with the Securities and Exchange Commission (&#147;SEC&#148;) Staff Accounting Bulletin Nos. 107 and 110 as the Company&#146;s shares are not publicly traded. The expected volatility was
estimated based on historical volatility information of reasonably comparable guideline public companies that are publicly available. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to
pay any cash dividend in the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company granted 775,000 and 3,123,334 stock options to employees and directors
during the years ended December&nbsp;31, 2016 and December&nbsp;31, 2017, respectively. There were 775,000 and 3,594,792 unvested employee options outstanding as of December&nbsp;31, 2016 and December&nbsp;31, 2017, respectively. Total expense
recognized related to the employee stock options was $15 and $59 for the years ended December&nbsp;31, 2016 and December&nbsp;31, 2017, respectively. Total unamortized compensation expense related to employee stock options was $75 and $396 as of
December&nbsp;31, 2016 and December&nbsp;31, 2017, respectively which is expected to be recognized over a remaining average vesting period of 3.54 years and 3.51 years as of December&nbsp;31, 2016 and December&nbsp;31, 2017, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ITERUM THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions that the Company used to determine the grant date fair value of employee and
director options granted were as follows, presented on a weighted average basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term in years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.63</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of option on grant date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the number of options outstanding and the weighted-average exercise price:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;Average<BR>Remaining<BR>Contractual Life<BR>in Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic&nbsp;Value</B><br><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options outstanding at December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">775,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options outstanding at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">775,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,123,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options outstanding at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,898,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value of share options is calculated as the difference between the exercise
price of the share options and the fair value of the Company&#146;s ordinary shares for those share options that had exercise prices lower than the fair value of the Company&#146;s ordinary shares at December&nbsp;31, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s share-based compensation expense was classified in the consolidated statements of operations and comprehensive loss as
follows: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There was a total of $1,000 and $988 unamortized share-based compensation expense for restricted
ordinary shares and options as of December 31, 2016 and December 31, 2017, respectively, which is expected to be recognized over a remaining average vesting period of 2.93 years and 2.53 years as of December 31, 2016 and December 31, 2017,
respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ITERUM THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(10)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Income Taxes </B></TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provision for income taxes consists of the following components:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended<BR>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended<BR>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ireland</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ireland</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income taxes have been based on the following components of income (loss) before provision for income
taxes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended<BR>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended<BR>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ireland</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,414</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,464</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Irish federal statutory rate is reconciled to the effective tax rate as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended<BR>December&nbsp;31,</B><br><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,683</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact of U.S. tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.10</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact of valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12.69</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.75</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.84</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended<BR>December&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact of U.S. tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.79</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact of valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13.43</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development tax credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(220</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.54</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.51</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ITERUM THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The significant components of the Company&#146;s deferred tax assets and liabilities are as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,709</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,658</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a Company incorporated in Ireland, it is principally subject to taxation in Ireland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has net operating loss carryforwards in Ireland which result in tax benefits of approximately $1,706 and $5,409 for the years
ended December&nbsp;31, 2016 and December&nbsp;31, 2017, respectively, for which a full valuation allowance has been recognized as it was determined that it is <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">more-likely-than-not</FONT></FONT></FONT> that these net deferred tax assets will not be realized. The net operating loss carryforwards do not expire, but are carried forward indefinitely. Realization of these deferred tax
assets is dependent on the generation of sufficient taxable income. If the Company demonstrates consistent profitability in the future, the evaluation of the recoverability of these deferred tax assets may change and the remaining valuation
allowance may be released in part or in whole. While management expects to realize the deferred tax assets, net of valuation allowances, changes in estimates of future taxable income or in tax laws may alter this expectation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at January&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is generally subject to examination in the Company&#146;s primary tax jurisdictions for tax
years beginning 2015. The Company is not currently subject to any audits or examination. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(11)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Commitments and Contingencies </B></TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2017, the Company entered into an operating lease agreement for office space in Connecticut for a period of five years that commenced
in July 2017. Annual lease payments are $131, subject to certain escalations, with a renewal option to extend the lease for an additional three years. Under the terms of the lease, the Company provided a security deposit of $17 to the landlord,
which is included in other assets in the accompanying consolidated balance sheets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ITERUM THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2016, the Company entered into an operating lease agreement for office space
in Dublin that commenced on December&nbsp;1, 2016 and expires on December&nbsp;1, 2026. The lease requires annual payments of $346 over the <FONT STYLE="white-space:nowrap">ten-year</FONT> term with a renewal option to extend the lease for an
additional five years. Under the terms of the lease, the Company provided a security deposit of $348 to the landlord, which is included in other assets in the accompanying consolidated balance sheets. The lease is subject to a review in December
2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2015, the Company entered into an operating lease agreement with a <FONT STYLE="white-space:nowrap">sub-lessor</FONT>
for office space in Chicago that commenced in January 2016 and expires in March 2018. This lease requires annual payments of $50. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table summarizes the future minimum payments due under the operating leases as of December&nbsp;31, 2017: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:92.45pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Year Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;18, 2015, the Company entered into a license agreement with Pfizer for the worldwide exclusive rights to research, develop,
manufacture and commercialize sulopenem. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the license agreement, the Company is obligated to pay Pfizer potential future
clinical and regulatory milestone payments, as well as sales milestones upon achievement of net sales ranging from $250.0&nbsp;million to $1.0&nbsp;billion for each product type. The Company is also obligated to pay Pfizer royalties ranging from a
single-digit to <FONT STYLE="white-space:nowrap">mid-teens</FONT> percentage based on marginal net sales of each licensed product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Payment to Supplier </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, the Company entered into an agreement with a supplier whereby the Company will pay $3,000 to the supplier to acquire equipment
which will be used solely to manufacture product for the Company. This payment will be offset against the price of the product to be supplied under a future supply agreement. $1,578 and $599 remained outstanding to the supplier as of
December&nbsp;31, 2016 and December&nbsp;31, 2017, respectively. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Contingencies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties and other sources are recorded when it is
probable that a liability has been incurred and the amount can be reasonably estimated. At each reporting date the Company evaluates whether or not a potential loss amount or a potential loss range is probable and reasonably estimable under the
provisions of the authoritative guidelines that address accounting for contingencies. The Company expenses costs as incurred in relation to such legal proceedings. The Company is not currently involved in any legal matters arising in the normal
course of business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ITERUM THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of their respective employment agreements, each of the named executive
officers is eligible to receive severance payments and benefits upon a termination without &#147;cause&#148; or due to &#147;permanent disability&#148;, or upon &#147;resignation for good reason&#148;, contingent upon the named executive
officer&#146;s delivery to the Company of a satisfactory release of claims, and subject to the named executive officer&#146;s compliance with <FONT STYLE="white-space:nowrap">non-competition</FONT> and
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> restrictive covenants for one year following the termination date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(12)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Subsequent Events </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For its consolidated financial statements as of December&nbsp;31,
2017 and for the year then ended, the Company evaluated subsequent events through March&nbsp;9, 2018, the date on which these consolidated financial statements were issued. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Shareholders&#146; Equity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;16, 2018, the Company increased its authorized ordinary shares by 575,000,000 to 700,000,000 ordinary shares of $0.0001 each,
and increased its authorized Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares to 33,733,745 shares of $0.0001 each. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Financing </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
February 16, 2018, the Company issued 26,858,743 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares for consideration of $1.20 per share for gross cash proceeds of $32,230. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g522368g73n73.jpg" ALT="LOGO">
 </P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp; Ordinary Shares </B></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 </B></P>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top"><B>Leerink&nbsp;Partners</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>RBC&nbsp;Capital&nbsp;Markets</B></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Guggenheim Securities </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Needham&nbsp;&amp; Company </B></P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Through and
including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 (the 25th day after the date of this prospectus), all dealers effecting transactions in these securities,
whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&#146;s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.
</B></P> <P STYLE="font-size:30pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;13. </B><B><I>Other Expenses of Issuance and Distribution.</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth all costs and expenses, other than underwriting discounts and commissions, payable by Iterum Therapeutics
Limited (the &#147;Registrant&#148;) in connection with the sale of the ordinary shares being registered. All amounts shown are estimates except for the Securities and Exchange Commission (&#147;SEC&#148;) registration fee, the Financial Industry
Regulatory Authority, Inc. (&#147;FINRA&#148;) filing fee and the initial listing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq initial filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent and registrar fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">To be filed by amendment. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;14. </B><B><I>Indemnification of Directors and Officers.</I></B><B>
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the fullest extent permitted by Irish law, our Articles of Association (which are substantially in the form attached as an exhibit
to this registration statement) will confer an indemnity on our directors and officers. However, this indemnity is limited by the Irish Companies Act, which prescribe that an advance commitment to indemnify only permits a company to pay the costs or
discharge the liability of a director or corporate secretary where judgment is given in favor of the director or corporate secretary in any civil or criminal action in respect of such costs or liability, or where an Irish court grants relief because
the director or corporate secretary acted honestly and reasonably and ought fairly to be excused. Any provision whereby an Irish company seeks to commit in advance to indemnify its directors or corporate secretary over and above the limitations
imposed by the Irish Companies Act will be void under Irish law, whether contained in its articles of association or any contract between the company and the director or corporate secretary. This restriction does not apply to our executives who are
not directors, the corporate secretary or other persons who would be considered &#147;officers&#148; within the meaning of that term under the Irish Companies Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Articles of Association will also contain indemnification and expense advancement provisions for persons who are not directors or our
corporate secretary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are permitted under our Articles of Association and the Irish Companies Act to purchase directors&#146; and
officers&#146; liability insurance, as well as other types of insurance, for our directors, officers, employees and agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we have entered into agreements to indemnify our directors and executive officers to the maximum extent allowed under Irish law.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, one of our Delaware subsidiaries has entered into indemnification agreements with each of our directors and executive
officers whereby we have agreed to indemnify our directors and officers to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred in legal proceedings to which the director or officer was, or is
threatened to be made, a party by reason of the fact that such director or officer is or was a director, officer, employee or agent of Iterum, provided that such director or officer acted in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
good faith and in a manner that the director or officer reasonably believed to be in, or not opposed to, the best interest of Iterum. At present, there is no pending litigation or proceeding
involving a director or officer of Iterum regarding which indemnification is sought, nor is the registrant aware of any threatened litigation that may result in claims for indemnification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the time of the closing of this offering, we will have in place insurance policies that indemnify our directors and officers against
various liabilities arising under the Securities Act and the Securities Exchange Act of 1934, as amended, that might be incurred by any director or officer in his or her capacity as such </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters are obligated, under certain circumstances, pursuant to the underwriting agreement to be filed as Exhibit 1.1 hereto, to
indemnify us and our officers and directors against liabilities under the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;15. </B><B><I>Recent Sales of Unregistered
Securities.</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following sets forth information regarding all unregistered securities issued and sold by the Registrant
since January&nbsp;1, 2015: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">In October 2015, we sold an aggregate of 6,490,000 of our ordinary shares to six accredited investors at a price per share of $0.0001 per share, for an aggregate purchase price of $649.00. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">From March 2016 to date, we have granted stock options under our 2015 Equity Incentive Plan to purchase an aggregate of 3,898,334 ordinary shares with exercise prices ranging between $0.20 and $0.28 per share to of 31
employees, directors and consultants, all of which remain outstanding. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">In November 2015, we issued an aggregate of 23,790,001 of our Series A preferred shares to 12 accredited investors at a purchase price of $1.00 per share, for an aggregate purchase price of $20.8&nbsp;million plus the
receipt of a license to certain intellectual property. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">In December 2016, we issued an aggregate of 23,849,998 of our Series A preferred shares to 12 accredited investors at a purchase price of $1.00 per share, for an aggregate purchase price $20.8&nbsp;million plus the
receipt of a license to certain intellectual property. </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">In May 2017, we issued an aggregate of 41,697,721 of our Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares to 17 accredited investors at a purchase price of $1.10 per share, for an aggregate purchase
price $45.9&nbsp;million. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">In February 2018, we issued an aggregate of 26,858,743 of our Series B-2 preferred shares to 17 accredited investors at a purchase price of $1.20 per share, for an aggregate purchase price of $32.2&nbsp;million.
</TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offers, sales and issuances of the securities described in paragraphs 1, 3, 4 and 5 above were exempt from
registration under Section&nbsp;4(a)(2) of the Securities Act (or Regulation D promulgated thereunder) in that the transactions were by an issuer not involving any public offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offers, sales and issuances of the securities described in paragraphs 2 above were exempt from registration under compensatory benefit
plans and contracts relating to compensation as provided under either (a)&nbsp;Rule 701 promulgated under the Securities Act or (b)&nbsp;under Section&nbsp;4(a)(2) of the Securities Act (or Regulation D promulgated thereunder). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Registrant did not pay or give, directly or indirectly, any commission or other remuneration, including the underwriting discounts and
commissions, in connection with any of the issuances of securities listed above. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for
sale in connection with any distribution thereof, and appropriate legends were placed upon the share certificates issued in these transactions. All recipients had adequate access, through their employment or other relationship with us or through
other access to information provided by the Registrant, to information about it. The sales of these securities were made without any general solicitation or advertising. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16. </B><B><I>Exhibits and Financial Statement Schedules</I></B><B>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(a) Exhibits. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.10pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Document</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;1.1*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;3.1*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Constitution, as currently in effect.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;3.2*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Constitution (including the Articles of Association), to be effective upon the closing of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;4.1*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Ordinary Share Certificate of Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;5.1*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of A&amp;L Goodbody.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.1**&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">License Agreement by and among Registrant, Iterum Therapeutics International Limited and Pfizer Inc. dated as of November&nbsp;18, 2015.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.2**</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Investor Rights Agreement by and between Registrant and certain of its shareholders dated May&nbsp;18, 2017.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.3**+</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2015 Equity Incentive Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.4**+</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Forms of U.S. Stock Option Agreement, Stock Option Grant Notice and Notice of Exercise under the 2015 Equity Incentive Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.5**+</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Forms of Irish Stock Option Agreement, Stock Option Grant Notice and Notice of Exercise under the 2015 Equity Incentive Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.6*+</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2018 Equity Incentive Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.7*+</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Forms of Stock Option Agreement, Notice of Stock Option Grant Notice and Notice of Exercise under the 2018 Equity Incentive Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.8*+</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Restricted Share Unit Award Agreement under the 2018 Equity Incentive Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.9*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnity Agreement by and between the Registrant and its directors and officers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.10**</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnity Agreement by and between Iterum Therapeutics US Limited and its directors and officers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.11**+</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Terms by and between Iterum Therapeutics US Limited and Corey N. Fishman dated November&nbsp;18, 2015.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.12**+</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Terms by and between Iterum Therapeutics US Limited and Michael W. Dunne dated November&nbsp;18, 2015.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.13**+</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Terms by and between Iterum Therapeutics US Limited and Judith M. Matthews dated November&nbsp;18, 2015.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subsidiaries of the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.1*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of KPMG, Independent Registered Public Accounting Firm.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.2*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of A&amp;L Goodbody (reference is made to Exhibit 5.1).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">24.1*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (reference is made to the signature page hereto).</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">To be filed by amendment. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">Previously filed. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top">Indicates management contract or compensatory plan. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top">Confidential treatment has been requested for certain provisions omitted from this Exhibit pursuant to Rule 406 promulgated under the Securities Act. The omitted information has been filed separately with the Securities
and Exchange Commission. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(b) Financial Statement Schedules. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No financial statement schedules are provided because the information called for is not required or is shown either in the financial statements
or the notes thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;17. </B><B><I>Undertakings.</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates in such
denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as
indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise the Registrant has been advised that in the
opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment
by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with
the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Act and will be governed by the final adjudication of such issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned Registrant hereby
undertakes that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a
form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this Registration Statement to be signed on its
behalf by the undersigned, thereunto duly authorized, in the City of Chicago, State of Illinois, on the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; day
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="98%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ITERUM THERAPEUTICS LIMITED</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Corey N. Fishman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Corey N. Fishman and Judith M. Matthews
and each of them as his true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, each with the full power of substitution, for him in his name, place or stead, in any and all
capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to sign any registration statement for the same offering covered by this Registration Statement that is to be effective upon filing
pursuant to Rule 462(b) promulgated under the Securities Act of 1933, and all post-effective amendments thereto, and to file the same, with exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission,
granting unto said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be
done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and
agents, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the
Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:47.65pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>SIGNATURE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:24.50pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:22.30pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>DATE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Corey N. Fishman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer (Principal Executive Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Judith M. Matthews</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer (Principal Financial and Accounting Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Paul R. Edick</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chairman of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Brenton K. Ahrens</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Chin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">James I. Healy, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:47.65pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>SIGNATURE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:24.50pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:22.30pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>DATE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Patrick J. Heron</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Ronald M. Hunt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">David G. Kelly</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Shahzad Malik, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Robert Hopfner, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>LIST OF SUBSIDIARIES OF ITERUM THERAPEUTICS LIMITED </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:36.85pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Subsidiary</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Jurisdiction</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Iterum Therapeutics International Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Ireland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Iterum Therapeutics US Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Delaware</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Iterum Therapeutics US Holding Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Delaware</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g522368g19c10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g522368g19c10.jpg
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ML[6VT=/7,C-!5G.3L;*WTM36)C11EK0D)7%RD8&A_\0 &P$!  (# 0$
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M$D$^&Q/D -_QC.LO:_U4?U8UCM79^L(W7C>5TQK2]7.E.6NODJ)@)8FZ;8"
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M-=.I/+'"G)4YRNJ*7<A40%B 6=B%11Z3,0J@D@9/568[*I8^)V ).P\2?#U
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M,V)_#JW?S^0Y)M?9-C\_+\XV8JGV+6_1X?FUS*VW26Y*#71]OO.J-CTZJ%I
MV(-LEHI-D @ILLR%9LH:(P5*#8L)<HQ6Y,:QB8V'O7D@$F,:A-OC'V92]?%=
MISR-%!:KS2H&+1Q31NZA',;DJK$[)(#&YVV60%&V8$9+:.10&9&53MXE2!XC
M<>)'K'B/:/$>&9F]=;^PNL*-5=G[*T5N'7VM[TIA%+OUUUK<:M3+8N7$<(0T
M5VS&PT$,87,'LO$(28$Q]4N T[-C8=C-J=QX@U&A9GEK5KM2Q8@WZT$-B&6:
M+8\3U(T=G39B%/(#9O ['PSZT,J*KO'(B-\%F1E5O#?P) !W'B/:/',=:OO4
MZE_=^QOYS!\VLOV-6_'/_P"M<UT'V9>_%5^;?)N\/?1GZ)7N_P!6-(O0_;Q5
M\W918EHB^K];Z='$&&+%?5^K\LI7ZBEASTC*5^3>?5?IF4M^DK%?UZ[[G:+J
M=T'B\%.<Q'R^ONAC@^.9T'^N;6K'U;,$>VX:1>7Y(.[?^4'/J7^JV=Y^I =1
MNM,"9Y^\2]YWE:X&%^7JL!H<:A4"7EO'^'B1DYLIG"U>CZO,7.$>GZQ?H<T_
MHKI;OJNHL/@K!2B;;SYDSSC?\'"L=O7OZMO'<ZY)X00CVM(W^FRK\>[_ !9\
M?>J?U-E?Q3V__?&<[95_^8_19O\ ^N5&[YU/TV']TF:Q2-=W[9A=X!KJE6N]
MG(P^27E":A7RMB(Q1,-;+4LI*B"8LM^,-BNR8S4B<^AN*R[(CMN.I6\TE6OF
ML05U#V)HH$+! \TB1J7()"@N0"Q )"CQ(!.VP.3U1G.R*6.V^R@GP'K\/5FW
M4+KWOK:=^,:JUGI3;&P=G5[!7-@UW2]>6VS7<#@%*Q!-Y-U4,(F'!/NB<I,$
MG[?!C^PS5HB2?52%H;SBGOT:L"6K-RK7K2<.G8FL110OS').$KN$;FOI+Q8[
MKXCP\<]+%*[%$C=G&^Z*C%AMX'< ;C8^!W\CX9ID8*9K=YC5ZQ"28 ^#M3 @
MV#-0)0LP'+#BR(A 85&3FF)H\A!E-.QID*6PS)BR&G&7VD.(4G$R!TD,,D;*
M\;F-T=&#(ZL05964D,K @@@D$'<',$X(CF!!!"2 @C8@A2""#X@@^8S)[7^^
MELK^']Q_I$1YFM?9-C\_+\XV8:?V'4_1H/FESEN&H=KZ]$ S]]UG?J4#LWJ\
M5XQ:Z@?KXLVIT2+/M-BYQ4?$C37G0!P&>:9CNN.N S88PA"AI4?)D0(K=6P[
MQP68)I(_[1(IHY'3TFCW=48E1U$=-R .:.GPE8"6R.@!9&4'R+*0#X ^!(\?
M @_B(/D<V3976_L+IFN52X;>T5N#5M3O:/64JR[$UM<:8!MB/9TS,9KI:Q!Q
MT$QE4);<Y*(#[ZU0G6IB4YC.MNJQU]0H6Y)8:EVI9E@_MHZ]F&9XO';ZXD;L
MR>/AZ0'CX>?AGIXI8P&>.1%;X)=&4-^(D '_ $S'7G[WVE/X+6W_ (CVOFVF
M^QZ?YN7_ +B3-=7^RM0_.P?]K%F,J6H=KW\(<LM%UG?KE7:SZ_%B.U:H'SX@
M(J*')6*4@H1%P)42$Y&KP8S8)+4AUMR.!#EC+R4#1DZ4QK9;=6!TCGLP0R2;
M=-)9HXW?=UC'!78%MY'2,; [NZ(/2909ZH[ E49@/,JI('@3XD#V G\0)\@<
MQM UW?MKVT30=84JU;#O!Y4M(2H4H"3LUE+9'P)12?[N"AXTPC+Q!&0IA&8I
MB.M,6#$DRW\H88=<3ZGL058GGLS15X8]N<LSK'&G)@J\G<A1R9@HW/BQ 'B1
MA$9V"(K.QWV5023L"3L!X^ !/XAFS:T_6#=/\4^?^)FM>3Z_P+7Z,?GX,@VO
M[2C^F?\ XMK-7I&O;[LLN\ UW2[5>CD8=*+R1-1 %+$1BB8*F432LJ()BRWX
MPV(N1'1)GOH;BL+?80ZZE3K>%0)K$%9!)8FB@0L$#RR+&I<[D*"Y +'8[*/$
M['8>&3E1W.R*S';?902=O;X>KQ'QYL]-T-O+8MZ-:NU]IG:][V96T%7+%KJF
MZ[M]GO0!L%/8%'%FJB$#SK *0&)R8PXJJ</8P.GR&(<O+,AUMM6.:]2KP)9G
MN58*TG#IV)K$4<$G44NG"5W6-N:@LG%CR4$C<#?/JQ2,Q18W9UWW148L-CL=
MU W&Q\#N/ YKVPM:[&U):9U&VM0+MK*[#&84@E3MA54[2[2/8)1&2 YZ=7K)
M &EHC,^!(CS83DB(VB5$?9DL*<9=0M62O9KVXA-5GALPL2%EKRI-$Q4E6 DC
M9D)4@@@'P((/CGQD=#Q=61AYJRE2-_+P(!\<V'>_W[-N?QDW7^D1'D^Y]EV?
MS\O_ *SD'3_L"E^BP?-+F,NNH=KZW@!2NP]9WZBC+'Z6 !&WU _6X)E:!HHR
MMH9*,#X;$UY 8\",+8CK6\D2<"DU(Q!+#WY&NAMU;#.M>S!.T?\ :+#-'(R>
MDR;L$8E1S1TW/AS1U^$C 3F1T +(R@^192-_ 'PW'L(/XB#Y$9BE:^OJ*:UL
M5RDVUO7SY!P0Q>7*Z7;I\@LRM"'14>RKAI"ODFE+1AV S-7+;\_-;*<>>>>^
MO!UC7ZT77"AS!U$ZP0^3&/?F%/J8C;\..#\>?%N'ERV/'?V;^6_X//-ILOWG
MM5_PHVE_N4+D^3[$J_G+/_V<@0_9UW\U3_\ R,Q=1U#M>_A3EDHFL[]<Z_6?
M7?"(Y5:@?/B0BHX@G89""A$4/E1(+D>O!35@D-2'6W& 08N9=2@:+G2H^MEM
MU8'2.>S!#))MTTEFCC=]W6,<59@6WD=$! .[NB?"90=@L;N"51F \RJD@>!/
MCL/8"?Q GR!R2-?=/NVVVJK O6JNK?8S9E(*N361=QU]I'9=SJI)X;,?'$6H
M%AKE9)")C@\A%DP)K<>8XJ+,COQ7\-OM.(3'GU;2JLK06M3T^M,O$M#/=K0R
MJ& 92T<DBN.2D,NX\001X'/2P3NH9(974^3+&[*=CL=B 1X'P_'FM:X$E -H
MV,#.#2 8V&UQML28#EH<@<4$E!U7,0R TD/F-LRX)"#+9>BS(<IEJ1%D-.,/
MMH=0I.-O3=9.;HRNCU+#HZ$,KJU=RK*P)#*P((()!!!!VS7W00( 001=J@@^
M!!$PW!'J(R-:S5[+=; (J=.KQRV6D_.9& JU6A,\Z?-$I*O1CP!(<6Q*($9K
MZON68L..\^YG[2$9SR+)+'#&\LTB111J6DDD=8XT4>;.[$*JCUDD 9, +$*H
M+$^  !))]@ \3FY8TGN15YBZR1JC8[NQIPUDU!HC-)LCUOG!9(?X11C4*NM#
M5EI8:37O_O\ '+1XK@]\'G!=J2L?G$GF'OM/HFSWJOW=6*-/UH^DKA^F4,G+
M@'#^@5)Y!_1(Y>&>NG)RX<'YD;A>)Y$;;[@;;D;>._EMX^686]:VV%J\K"![
M(HUNH1@F&'6,8-N-=+5R84KIA"W1%A&,%XD1PB"+--K=&&(6'QI!M"G(DEY"
M<JQ[@L5[*%Z\\4Z*[1LT,B2*LB?#C8H3QD3<!D.S*?!@#GQD=" ZLI(! 8$;
M@^1&_F#ZB/ ^K-BW;]\@Q^]5._H57N3[?]NWY$/S,>0J/V,GY<_S\F8R-J':
M\RAR-I1-9WZ5K2'[3F5L&/4#[U+CIADQP6:Z]9FQZ@S;,(T8$!YCZYF&8I8N
M*&R%MS2,)A_7&W56<539@%D[;5S+&)CR5G4",MS)*([@;;E49AZ*DB=TW*\P
MC<!YOQ/'S \]MO,@'\) ]8SV\Z3W(FB?&BK5&QTZUQ :+9O^:39,4[ A\T[6
MV2^;)D;[HP(>L;+U>:*9E^P.'F70R)"B3:XR?G?:?7[KWJOWGEPZ'6CZW,)U
M"G3Y<^0C(D*[<@A#D<2#CIR<.?!^'GSXGCMOMOOMMMOX;^6_AYYK=#_9Q3/X
M5UW^=X?)T']O#^=C_P#6,C6/L>?\S+_Z&SROW[.[K_"VQ_SQ,XG_ +>;\[)_
MZSGRK]C5_P Q%\VN??%X/K3'0OP%-B=GR++0ZQ6:L]@NS*$2D)2]++#X$JB:
MO'96YYI6W86:!5'AC6<^H]*QI5E*7'W\YX'VLWUSMS7TU3RCCDH::2#X!&83
MV6_ 8S/*&V\?K?X!EOH?U;37F/F5EF_U XH/]>(V]7I9\)VKY#\N9LR7*>=D
MRI.K;Y(DR'W%.O/OO,1W'GGG5Y4MQUUQ2EN.+SE2UJRI6<YSG/._U0!U@  !
M5E  \  %&P ]0&4J[_\ *_IM?][9%<&#.*38@T9#E$2,^2Q#@0(,=Z7-FS)+
MB68T6)%CH<?DR9#RT-,,,MK==<4E#:5*5C&8S,%!9B%5069F( 4 ;DDGP  \
M23X 9- W\!XD^  ]>2)'TIN29LQ&E8>IMES-QN3%#D:FB46T2MEK(H&J,N#T
MT5@6Y:,SVA"%DWH>!?M+,!MR6XTEAM:TQS<IBMWPVJPJ<>7>C/$*W'EP#=<M
MTN);T0W+8MX;[Y[Z<A?IA',GEPXMS\M_@[<O+Q\O+QS]VEI+<^C2PX!NO46S
M]/'3 [WP)"[2H-KU\6*"?:7H7O0<-MHD1,FCO;(TB)[;&9=C>TQWF/6^M:6A
M*M<IW4:2G;K6T1N#O6GBG17V#<6:)G"ML0>)(.Q!VV.'CDC($B/&2-P'5E)'
MM 8#PSV-V_?(,?O53OZ%5[FRM_V[?D0_,QY!H_8R?ES_ #\F:M5]?WN\1K+-
MIE+MEMATP!.M=PF5JO%CD6J5<8RY((V.R21D22R#!P66G')18FN+!82A67'T
M^7(,L\$)C6::*(S2+%"))$0RR,=ECC#$%W8D *N['V9-56;?BK-Q!9M@3LH\
M23MY >TYPU"D738)A-=H51L]WL"XLJ<@%40!6R&%0H+67ILQ(P-$FS<Q8;.,
MNRI&&/4QVL9<>6A'V^?99H8$ZD\L<,>X'.618TW/D.3D+N?4-]SZL^*K,=E4
ML?/902?#S\!FUZBBR8.[-809K#L69#VG2HLN*^VII^-)CVT8R^P\TO&%MNLN
MH6VXVK&%(6G*58QG&>2Z9#6:K @@SP$$>((,BD$'V$9#U#[!N_HEGYE\C@C^
MN$[]V2?Y9?,3_#;\IOWG)*? 7\E?W#-CD:^OL2G#-B2J3;8U -FWZR%O$BNE
MV*B8L<5A4J4!%6-V&D.1,Q8R%/RAD.8],C,^3C[*$*3G. 3P&9JXFB,Z()'@
M$B&9(R=@[1@\U0D[!B "?(YDXMQ#<6XD[!MCQ)]@/D3^#SR:[ETJ[DZZK!B[
M;!ZE=FJ)3*]%Q.L%NN6AMIUBL X67FH^)A@^;JL$4,BY?>98Q(FRV&LO.M-X
M7Z;B4YA0ZQI%B1(8-5TV>:0\8XH;U621SL3LD:2LS'8$[*"=@<R-7G4%F@F5
M1XEFC< ?C)789'FD_OAP?X.; _X>VGF\I_9"_FY_^WES6:A]BM^=K?\ =0Y%
MK##TEYF-&9=D2)#K;####:W7GWG5X;:99:;PI;KKJU)0VVA*EK6K"4XSG.,<
MB$@ DD  ;DGP  \R3Z@,FY)+FD]RL[$;U"[J;93>UWH\"6UK)=&LR=@+BE*[
M&MPZ0FFY&8L669M4F1++%=]W>@\ DL%T9R/<1(S'[Y4-<VQ:K]U!8&SUH^@"
MLAB8=;ET]UE!C(Y>$@*?"&V>^G('X%'Y[ \.)Y;$!@>.V_BI!\O+QS$7K6FQ
M-7D!HG9%$M]")&0L&R!85PKI:NR#-<)^MP,L(=!:)%R5 D<L/>P&('M Z9ZE
MWV:2[ZM?E[@LU[*L]>>*=4=HW:&1) DB[<HWXD\9%W')&V9=QN!OGQD=-@ZL
MI(W'($;CVC?S'X1X9*2]AWK3YGKOLK5EM/Z^O]5UZP;KMPJ).4#/B2C.R-D-
M)EQ2,!QF0E3D?&8DEM:ELRX2W(4IMZ(ZXRJ5J%>"U6@KV88YX)J?&6*5 Z.I
MGG\&5@0?(;'S! (((&0Z3NDUUD9E9;GHD$@C^JU3X?ZD^'D=S[<^S3PJOJDB
MD;@^#>B>_DT%K+:3OL@BN=@V&8X36%\E9]"/':V)$:PW!UK9I:_06Z?8PSKT
MB\N2X^FCH:B0I_#>T_\ 1Y-4ZE[0@]FJ-WDH$E[4 \R:Y\[,8]2'^L*-MNN2
M2MOI:LLFT=HA'\A+Y(WY?J0_A^ ?_#GUBQY#$MAF5%>9DQI++<B/(CN(>8D,
M/(2XR\R\VI3;K+K:DN-N-J4A:%)4E64YQGG+B""0000=B#X$$>8(]1&;O/D
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MTY$TB1L,B'!B,(^UZ3TF2\TRTGSQZ2UIQ_EYYM.L<EAW(5$>5W8^2JK,6)_
M "3BJ":]8#Q)AA 'X3&N?=YX\YD=TN\%W374.MS&6I-K<T+UX;;AJ]4]-J^H
MZ[%N-F-)5]PXXS-,:^ 12KN?TV6NS93(PM,I_P ^#]AT;6.V%S5I%\(N_:@=
M_)9;<AAC3V#9+$A4>0$?AY#+;J9%?3XX!_BZ47_TQCD3\: 'V\OPG/A=U/\
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M$^L[;GUDY(E@ZK>-O:-# NL1SJAV F:&JYA=BK>MD=;*G"# ;*ZB>U(M B3
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M C(;RJ5F(TMOT\O(QCCW](>LU=6U&A!1M0V:U6LQZT4@:(6+,OUP<AX>C'#
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M<;'P\CRS;-8>']XO^FW+3G7?4'LN%AWFOXJEW!3=-.V:J7*N(*#SC >V4^U
MC=6L<*$<$BS0ULR'FY&&!T(H/S&GQ69"(5G7NR=L1=XU;3G,,G5A=;@BEADX
MLA>*:)TEC8HS(Q1UY(S*VZDC)*5;T>_&"8<ALPZ9(8;[[%2"#X@$;CP(!'CE
MF]54OZH@TE:=I7C6.J>XU:NN[+(U;=KW!6GH9RTWD['0\U"D'+!8JF7+/1!K
M<F2V*$-2V0XE$F0D; BI?=PK6VINP%R*M!9M:1)#3CZ56'O92*!#MN$CCE1
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MIPS'L0J0*?DH]"-YY>CMR%.M)5]PI:<87]SY\EQ]K>SL98C6=-/*.2/QM1^
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M2>]IK5JDG5JQF_+O6D'K@D$XEB'KX(ZIOZ7'?QS.%U0.\@BG#R#9STAZ8_\
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M#<20ISVL? D1OEG4^Q5N1I;.H:7*\D<<,Q:WL)XH9!+%'959 ME(Y &59Q(
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M/X\EKW.:["6#KOV@([BM-2)4&ZW16A D>3L*CF0,6K%:ALL5$IC #95:GUN
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M4K0M.<*2I.<X5C.,XSG&>12""01L1X$'P((\P1F;,85/@@.1:3AH2&4<+10
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M3_X[?.R9QO/>XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQE4[A^R<Y^^#_\
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M*UH9R)TZ1:$TY4=.*RL)XG$98-'CZ7V([F7ZR5F72*U\*=:Q]][/U?=CS=5
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M$34S^A[KK$$B-*I\Q!@_2$! @^(P)U[-FJ]B[$FG/)J,8ZWN35OM'RK"B(M
MT$&1(*U$16X7U,:U4U";DMM3%!<::9W,M[!'-KT26E6JQX=\FK [2FP7U'43
MP>2:P7AD%0T)JL?$Q'G)!PC4!*^2+WSQ&&;H7%A:^%E5ERI.1@-B*T!J((0?
M?U>&,03I>..)%+/$4F^)F!R46((,.#,2BCC-+-/1A=?:QQ4^PQJ1233S+8%G
ME-!%=+R] :C+$T$1DCCKO_4BLL;M+&)"L8:U$K23-[>?M%UW1(XS%T2(Y'@
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M^E$>5-0TMF!ZY$N<N/ ;DRV(EW3*%:N\U?1:]MD])H59HW* $L8_1DYL/M
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MWK-#?I>'YA.:RMH?')%')<T2'CI%CGV(STO$B+7I5*DD\M>!(I++<YF4>?\
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M,6E:#.J-#7IS*ZLR-%)U%=4;@[(4D(95?T&(W"MZ)V/AFW?#*T?AN=_K$_\
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M]9(_YN/?C/\ <,7RS_P8]YU?[MF^23^+'QM%/P5 _P!9(_YN/?C/]PQ?+/\
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MN3YYUS5OP]I(0%#E?"9([8Y/L1<KM>+C6+WLNNOEM W'L-M7>L_4 9\).$2
M+DE>SGQIMX0T+38B$))(D24TP+BCKS/VV669E[OU*$>AU*E.K8IT)A%K530M
M-T9-4E$J2K,%&G"2%93)T$<QQQ[F1I*Y%V>,<:GJ\;+:C///-'/9C+4)]1MW
MFJ(493'OWHK)PX"1EY,W@H6.]F^'WV8OE(V;1WNS;QVO7VN;3I[E9M)J\>Y"
M"+]4.RE:$WX^]&=F27C@/XXM:LNT/$>;4I$#3H7+!*.^V%P%GZ?VVT"E<T^X
MO9]89J4^G6A/7BIB:,TK6@V)*4 8*HAF]R]0(N<DLB35)N4;*9>K'M=G]3L0
M6JYU,O'8CM0].5Y^#"Q#J423R;$DR1]\K P;-"5IILRD1\)'V/TLWS9JG?\
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M,Z=ZJ]'E(9:Z.?4NDW66;IWY/KL]>;IM)*FR]*..["LXYNB3O$EB(B-A#+S
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M6*]$BFU?@7[W '[@7,TJM? <(^"@? &IS'EBJ9[XCR%3;3[G::^$)5MDC/\
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MFRF25FC3N4FJN%CX[-7CV 9E$T\=#=[;"WO3[F=V58FBYN#-I:X8V+KBV4&
M)@E:.(?*R(#]FJX./8!QF[Q[A* O S=TBC:JS78LZRD2CDN;,T_;+1Z.CVZL
M-" Q0LML.[WZMV21X[DHC61:]B9H)(:C54F$T-1I+)G9($C"HD_0KUB]%.]F
M0.ZM#Q5:TT"HKP(6*F6)!(KSB8QF.28+$(PTK.23?+E-S>XXQCC&;%I_[YU_
M_BYI'](+_P Z%V/^PK7Z5_\ :CSGG;#[.J?HA^>;-99_Q37^C1_NXY1+7V38
M_/R_.-E\J_8U?\Q%\VN<G,&9\C7;%"-;(IZZN V5=M3D5G:N8Q<-?N!6K&B+
M7K$--S@B%GQ)H?[MLD2 \#+I5"4XX-GR6\*RA3C3L_3;D5"T+$U"IJ2"&S%W
M6Z)3 6G@DA28B&6%^I79Q-%Z>PD13Y[$1K<#V8>E'9GJ-U(GZU?@)-HY%D9/
MKB.O&4*8W]'<JQ'X#F-B0)I2AW :.JE>O1&=6S$6!3+=*;A52TS7X+S<4#9I
M;HTRW'KY1]3<0RZL.6PD<[)S[L(?^4>Q472.Y5DDLSTT2Q$SVZRE[-9 X+3U
MU$D1::,;O$!+%Z87ZXGPA[L*SP3*L4<[-&X6&8@12DJ0(Y25<"-CX/Z#^B3Z
M+>1I54M$;WH/7KK%KK5WP<U.=UEL<07V+3!5OFV.D&:*]9+"];*\@]" 40LB
M#.@GG;4 &!! \)6CT(/5':[9*A!<9>MEK6-&NZYVAO:CU]3AU"A+'1MR5EKW
M(K@@@%:<PO-<C+K)"*T\DTKS6('ELB>O:<$:6*A>KZ?IE:KTZCUK"/9A29I8
M7@,DAECZ@C@?BRR&5%1%2*14BZ<L*[&L$SJUXB!]FMD3>UJDYL#7D^YDM;W4
MK:Y1]NNGS'5'>.E8EE9C2*BA3+Q+9%XI]EDQG81-$4+'FE9$6<6BKKTZPQ]H
M^P\!GCBTRUW&]'4COU(ZZP&Q#%VDT;5FKLRVB"(Z%.U75@Z%I66-62-NNFL;
M2^T,BQL]N+O%=IFK3/*9!'(^DW:2R@&+P+69XI2"K )R<AF'!L\_1/$*G[RL
M%3K>RC=<'BJJ/NE3M=E?-E-9@@UHW%W*P)H1IYX&1#;+V'7-63NN8*UM*DSI
M@:2$%V)10NZO)ZQ8!<[$)H\%F?3X9Y);#U+%:N(8]0FEK:5V5ZMV("9)=/HV
M-2379ZQ"HDJS25Q'$!T8/9@[0->DABLO&$B6>*:0R-5C26YK/"N_UMDLV(ZK
M:='+N69#&LI9R>I)N\?2OB!(L>KC,+<&!L<97:NFY"S5Z791,6SR9^XG;JE<
M#%7A(MX*&S9]=LUY9GUI9T?6T(D262 V*^]$;5NQ1@U&)M+,ADGL=UDBJ=WE
M:NJZ6*GI]Y<U9F->\9Q%M$'G.RE)& SBEK_4JNMSB$CBZRO/U4$I:V9O1Z8Z
MR*):XCY^D5CV)#JI.,7H?O\ 3,:J>F;?)L8'5^D(V6-A[2E);D'$7^))V9'#
MSX58#S"8XI15V*)5IQ1Q)> Z5%>JEA)P8.]7<GNQV+3W2":8C=2>X=/D;3EW
M6$TG73S*CV9EC>.X*[V$C'2<12;K,DLHL>>X:\>ZDW&V6.#O*BTWB_>%-D1L
ML2%E>#JK$SD.I=-BC(G3[%-(BMB M,:D![=+1S^UPNLZ((V<>B2,2XAW80RK
MBX-S-1)6(D#VF(6L;!(A&?S @*=8D-K7!AK4J,U1]7DHS:MJ<VEQ-!IDVH7)
M=.@<%7AHR6)'J0NI9]FB@:.-AS?9E(#N/2-AI)8CIU([;B2VE:!+,@.XDL+$
MBS.#LNX>0,P/%=P?@CR$H<UV2LQ]6^__ *J_@KM3^0I_+IV-_MK_ .9A^<;*
M7VR_L:'YZ;YM<O!R^90\<8QQC'&,<8QQC'&,<8QQC'&,<8RC-UBV&>"ML&HE
MX-?MDP2>BU@\4%J.# EAD0Y;(4N1"IF#U&((TDN-,EBTSX*B$=ER)B9&R]ZY
M'(K+0)K-A[43SUDU.5K$,<G1DF@6TQEBCE*OTGDC#(LG!^#$-Q;;8]?I"1M)
MJ+"ZQRG3H!%(R\U20UD".R;KS56V)7D.0&VXWWS%42!;Q=)J S8-@&6R]CZR
M#A7.T!0N:X(L5IBC(S)XV,K^9A#(6 4*(E38HOVZ5B"R\B-AY>&\9Y%N/5DM
MVI*4$E:F]B9ZE>67KRP5FD8P0R3\4ZSQQE4:3@O,@ML-\F0+,D$*V)%FG6*-
M9I43I))*% DD6/DW35VW8)R;B#MN=LZV1>N^X>HK)8B.N9YC9&M;4)1<:S%V
M&<FE+YI.T6C=6HAN[::)@V&8_P#"FM+U3G86RM(#Y29_P2L@LW1&X4BMFZT(
M?ODE[LMJE>!+Z1T-0K2&K8:C"L=/5Z];2=4?2+<KP(.[6/=+N.GZNZE.]5Y8
MKI9;$-B45M:^L5)9&K,]FM*G6B%F1GL4I9;U1;L*+(3U8NZ=XLT5/+I2*\&Q
MC>)#DM=WKQ(9&QJ:W<];U-=;E50*BQBBDH-6JJS8I.JC)>?()7.O0+O91,EK
M8(\ )F-A@%D&09)LQ!C0R(YN 5$X[U/L(M&T:E^R+"V9NA)&LUBP8%U**)!'
M5G>I!*IHR32H99H)'6&)V>-R\<OJM/VC-F 35HNDT*=16*11"4U7=BTT:SRH
M186-#PCD4,[J%90KIKNX6N\U[R_ZZK'J[,JF\\Y&US712 BJ3M=MZ7VRQ!/B
MMAP[#6;;;PYJU6&FBCX"TU,!-&VL)&-P1PN#[.B%GTP]D*>VUF&PEG1QSGO1
M/WE+QU;36>"6BT-BM5EBK5[4D,U:U.CUIC"\DC\BV.X-<GWWBDC:*\>$==UZ
M35^Y6PLBSK)'+,CRR0I)'-#&5EC#A57;CI#)#Q$Y]?(5(S0S"JO%JM19 QH[
MT2 9C%ZL0Z0SXZ%6P;;X]T(.D%&^W<4X^5.REDX6O0;4U]U1*([=9C)V&2>.
MS#=B[RUFR9F*L\)BL)VO1CW:6H:B!!#V7:$10KTWO3% .FPIX.7:%HVA>NQB
M6*(1@$*P>)]#9?KJ3"9N7/5Q(7<\EK("3R4S2VG8?B#)DZL><UG+DK,[;7$W
M $57=:L *5K^'N'3U5,?!RS)V0^:M0&7JLCM.]4Y]FL-6.4ZB+[_ #$:75,5
M2YZSN/8DKJ0&H*!%IG+2Y>M?,]RZVE:I9BZ]?N AK3+J2:=3M V37 +=")DL
M]ZJ2^\=H-ZN]8GG;*W$Z=81P5Q<J1/TY.\F26,U6M3PD1B4D+U'!BZ4^3HK'
M<VE:!ZC5H2**$KG@3-K^^F;61&E+B+<><BQ1EA^%I]5F%3)5>6],*DA9+U3=
MD$,2/=ULCFQP:JW7'</96WK/::Q)+''5ZJSZ*:T<B59 .3/ :T/=Y468!(XY
M4Y&O*5ZE9H9);-3W -9AH:3&BLTW QWQ*RM,N^RK)U9.HC&(DNR-L)8P>,P=
M4BGAL)=?%&KM3!!8]!F6H[ Z]#2+Q2YQ-:KE3=O-]=X4J:(+$0YX5&E%4[X'
MFX,%OT8PJ;#>&-G#;, FP6SM9:G]'D]J:5KJUH'UR1!'5;4 J:6=<=4EBCE@
MD98_<9X7?X4J,LABA,D9CR&DW:B.%$%<RRKIZ,6F%4DW/<X%D=DD4,POJZJ/
M!64KS<*P?,34X7?FAG+.0 4^_G81:V[0;C'KL7$'38>BV_N#=2U>,":>Y;F:
M<X0#:;+5@JQ7&P<&6(JD:97P$8>Z/@5].2R_8N[#62:U2A:*KIW*&I%)#%+<
MJ]EJ<4\4MH5C:"3:K%8B-@S.LEEEGF9Q(\Q\0KK]=Y3'%8D5YK0$DSH[I#-J
M\SQND!F$)9*;1.(Q&I2$-'&%*K&.Q#KX8["$2.V8.^! R,P(O$B/KDZ&BQ1(
MX_49#DZ0QC ##Q$@*E!F501LE^18[9!.(0P<A&H4N>5J57H^MQ:(D>FOHTDC
M&6FIOPRLTLD%I0BM]?VCCE64\Y%"P5GAW:%XG5([5FPZ>^H,UM;Z* DY%>1%
M"+)"2Q'UO=V1D'%23+*K^#JZEFBCLIS0YLL<8QQC'&,V367WUX'\7]O_ *0T
M3EZ[&? U+\JG^ZUE%[9_#TW\FY^^KEK.7;*3CC&.,8XQCC&.,9!>W/UP"?N.
M;_+1^4GME\#3_P JU^Z#+OV-\]1_%4_?9RK-8#;1A;$V>7M=WKQW6IOX%_%1
M3!M14'/43W:$?C7GX1VK)B:FX_"<\N.4$>B)#?!^&RL=GV_UOM":I8ET]Z.G
MQ5JD\-^'O?NE:DM"6&YU)E:GT*W20U>[PAHY=Y9NNY$GUO;B;A$EI;%IY9XY
M*S]'NL*P\'@XH1/U)>;=;JR;.GH)TP./I;[Y17NFYM"LW&Z7*<0N7Q/E.J]I
MUQJKX&&20=%,[:6FWYBU2U68@+FCF:>HK EU4?4=N6F7 I>LG MKR>M-01:6
MEG[AV4&G6*E2HD=7W4C[15KVI=[ACE[UV:K5>5FO721'-KI.ME[6F5U>UJ(E
MK=&M9-8]'1ZSWJ.::8M-W1]+EK5>B[)T=6EFVBED9640\E,2PVY2L-8I+U)8
M1*.I L;5G;U=Y&D+TWLVY"\]J]!V>Y%*'<" @%:-4".@RJ3MN;48T"RU_(ZF
M&NT2I!=FM1$AUR[-)B7U@6F(TFPL[IM1[+]SD2F=/JR>]K6:U2.Y526>OJ<O
M;7OFF)9=Z\W4M1=G.,1L,90M=6I-)R/0, 5=6,ZM.+4Z^ZM"69X)F2.6JF@=
M"TT(66/C"^J$N(QPWD(G"\0)!M?7_KUW((;9T\4WOM#95;8UYH'KX3MQ(5:I
M1D?>MEU'9'8"5;-=6&5!LR:^6*S=<VG48;:UME5RQQKXH&RH,<65"LFQ,;6]
M;[+)INJ1Z/I^GSF]K>N1U8Y*RQ/3T^U0T1*MZ%7K]>.-;];5)=-K+/ U+K-U
M81%,89<NGZ?K#6Z;W[5F,5M/TYIF24NL]F&SJ!EKR%9>F[-7EII;E,<HL%!P
M<N@D2:D6+OHW<QZL"Q\BH'-Y[; *:?JU6Q\$=95"_P F3J,J36R>BDR@/;&N
M'9HXZ>B>@9J!L?4B'NQ#K]C&%M08.QIJ..HXM0Z1ID^XLV/ZU?LTE74XHP86
MCCFTV^$>&%MXK4+VDZA4021S>IKO6395,,EZW&=XHOK-:&P349MG#/';K<ED
MD'IPNL+<03(CQJ2M'B'6?7,$84H\P:8M/7_8Y"TQ6P-2&S16ZVZ4P)?U?%*5
M?96)T.O.VN02*ZHV4&)#)LH:TW%L/M<N(.+F]@E?L/7O/)%<62*OK5%*S&:R
MZ2Z2;;2+J+16-/*-,*RQQ:EI\L<BJY+0<4:2*&*TO:&6NJO RM+I]EI0(X59
M+PAX&J&BL[B,REFJ6D925&TF[!7>0I);OE7:.=9@!()B3%NFK1M4G18M<(V*
M+K.XU2F2+N1E@2\]ITE8].7)NQ WTD#<^;=:G.EET)?L0^&M<%8^QL]N$O,\
M0:IJ,EE&,Z0-J-6S;%.-)XD(2OJM0P3 I"B5+*+%N('?:2SZ]'#(%C5R)ZJQ
M,HC:05IHH3.S1NP+24YNHAWD9IXBS^,BKF6T!&[7E>T=XM>\@QH-3(NO;U3A
M# Z4'AZT?DC=VS)&MR=?"0;&8)RCA[4F1!TZ6,>\9(LS/.UI!=B/!CBH^/6F
M[-Q=G:E;2)HIK;7J5J5I%D:^%DTA1?CFE:"*-(8=3ZL,,47366)(;!B+.TA]
MT!JKZI-->C>. 5YX4"L@K<ENDUG1%E=B\E3@\CN&*.SQ!]E"KV%\I&6#'&,<
M8QQC'&,<8QQC'&,<8R8NO7WF*!^\[O\ .,WG:JWV-6_1X/FDSBUK[*M?I-CY
MY\KCL<[9ZQ2;K8Z52Y.Q[>"KQTM6*!#-BJU*NAZ!!D2158CV$XI(<(Z;FMLC
MT%2><PH.7_:9"5MMJ3GE30U[&MO!;MK0JS:F\5BZ\,EA:D+V2LEAH(099A"A
M+F./TWX\5\3G6())8M*@DAA-F9*$+Q5U=(C-(M=2L0DD]!"YV7DWHKON<R
M@4*5L(4/!G:F:(@QI S7GR \H_6BDN S((AGBL!3PLBZ&EN/07"$)3H^6N-F
M3'4N.XC.8$Z1QV)HX919BCFD2*=4>-;$:N5241N!(@E4!PC@.H;BP# Y.C9F
MC1Y$,3LBL\996,;%060LOHL4.Z\AZ)VW'AG1O!\0/M11](:M[(WH=K:V:ON-
MFNS6!;3\"MVFTP=4Z)[H;0V0.'3Q"3XP"/5)TAJ5BE3IXU9N4<FWD4<ALAR%
M<)P^O/V)[.7-8U'0*4FH5M1JP5#U6#6*U=M2UKLGIU"1TDZ,DS\=8U-K:I((
M5A2G+"QECGC>CKV@U6"C6U*=:TU6:6<! 5BEE%2CK5JRJ,G45%_J-00%E+M(
MTZ. C1NMG[#XH%'"W:_5&%KH@>C4"946BYL5;AA#V0=8C%K#F"Q$&'%%CBFJ
M>H"))GQ]7AVXM""'9),A!'-5LVEFO0?T>W)JE*RUZ.%KJVC'#+6>/D\$5:6*
M-)I9(H=[76EC@>PU6)Y85C1Y#8A)VDG::!)[$(KLXKM$'=)E;99'E1W9$5Y"
M(>FKR+$LSJCEF51%)M*'Z,$G=NL/9[>5(JH^H3M+U?<<RHO6XT M,6>=UD*M
M2<QKC5Z^>&6&H%XE@K+P\]4#S@J='1(BN#RA-MYQ;&N]Z\=/M#V>TBY8DM)J
MUC2ELK5BGK.D.H25B&JV)X)(+43P6%>"U )48A@\:$ &3[KO/IFIWH(EA-**
MX8C,\<JM)667<311R+)"ZR1%9(9"C#<%6;<[;V?[.LU-'6 !.&#2=B[%A(DV
M&<FV<33:Q%5 BT.79VAA4I&GCREN4&N!&UU&DX5&>M0NGV>-"(MRX4=B7#@[
M/M:]\$Z2/'!H4K(\*5Y;5AN;7$KF2.-D>*J)JL=:U;/(5I+5=GC*N2N>34Q#
M[EQLJM)J**RR-*D,0XB R<&8,KS%)FFA@\.JD,H5N0 ;K<UUXM%C":MK=OV7
M4A%[-E=;ZSN!EH$='4J&,?(=7@^^+HX,CY%V!^:Y-?48A"1<UZ(B+.Q$A.$V
MX:W942^7OZ-8)M2L5=/LRTX8[U^K"9H9+CR!.T4NBU!(PD@"!1TGED0,63FX
MCY;*U<K]K)$JQ3684G=Z]:5^$BP*I;3$OS%1QD+$^F$4D;'B"P4DBR0/Q&1@
MUW:0JR A<^7K"7V>M)DH5N=;I#,NBZ:W/V.UT.CTN),C/(NLH*[I>OC[BN*_
M$+ A.Q*5;)8XDT0(LQ-#-V$E?W.>O-(BZBO9ZO#''5GME;FJZ3H-]S:9"IJ+
M*-6G>J&5XYI:-NLLB&-"VR3M$JFTLD:,U4ZI*[//% #!2NZE640A@>L8S219
MMBKQK8@E96#-QY=8]]C^S&>S-Z!U<8_6]0]5 >YZWK]TJT\4D7P)LSN'0+J%
ME6H; =>?"FE]?*NZ&7\'O;AS99^2]%6N<W!C-0[&0T/>_4FL2+8U3M)-I,]P
M1D1K2ET[LM>IS+6D<!9HAKE@2CK\',056V0NRMKTED:E/'$ABIZ4EV. N"QL
M):UBO,C2JI]!SIT? ]/DO(DC<\1Q9[]6@B@:Y\#ZH%"U[=?735%WN(N^P34(
MT6W-J;5>X78M<#%:^,;A@< ]CR1;IZ?8D2Q\NONKCQIR)3CT%[RZ\?,=ZLRR
MSZ3KFIU*LM-X7BBTK4]2TH&>6.:0M/UJ"R"!("KK. 60J XZ_*W$]")$CNZ=
M4GF6P'5GN5*EPB-&C7:/IV2G4:3=3&2%.^XR_7#OHYV;W;K"O546.KM(LNM>
MQQ<^*=*0;'/EV+6)/J40HY@,=BL#7&A12I[]-K(#Y [TW9D1A3#OJ!ZI,['K
MW8P=G](U&>S))/<KZAH,4,@C>"-8-0C[3)<BEA?GO+'9T6$)(LFP1B".3\4]
M:=KWNG=J1Q(L<$M;4GD7DLC&2JVD- R2 +Z#1:@Y92OB0-O!=V[5M/\ WSK_
M /Q<TC^D%_YZ['_85K]*_P#M1YHNV'V=4_1#\\V0GM5W;+&M+([HN'K\AMA
MZ+FF0]IS; .H#Y#,V'B4FR3*K$G6!F*D7F<N/[MC..N3TQ&G5-1UO/-U*L--
M.K[:PUU---J?O;:<D$ET)O)Q[NEET@+=3@&ZC !.1&[  W-C;&FH:*UVM]VA
MZ(M-(M<MQ3?JF(-(!QY;<1ORV'@-SFWFU$45PNN)[<@ND(05&]Q-#I9))'$!
MW+/N=@ZI@3)G)DX3[O:,J9'//X9004W&4]G&OAX=>(-PZ?53EUC(L?#F-^J8
M0953C\,Q R ;E 6VR:_+IOMRY\&VX!2W+B=N ?9"V_P0^RD[<MAOE+K?;>T\
M(YU@47!S!\<WV5E!=@0== '2R2.F7=$;?*0YNUX,=F]"-8O0]J#J(-]M![6.
M5J7*E"<RK&Q@N\!'VRK6[.O#VBZ<R.T.@I+1>].(BFJC6M+C9--=C2EU$/IL
MEV3A-IL-A567C7/2$SZ6:;5%?3.:,H?4F2=:\9?E3[A<8-;4"=*NUI8%Y):>
M(DIO(.9C6J\.^]Z+I<I:S%;VIKI KMKDBC5QH$X%>MVEHNNNN34BKU/;6MQV
MSM:1Z]6#M@V27?D6P\,A[.D9+115H!%JK<6:78GI=CZE5.E8TZ_U>S/3.HPS
M=45M6:_KQ6S9TR_)IVH&>>&"A$HK0R-IZ]-Y*TT5FJ;6K6QKDTS<X[5?AJW+
MNKQ\#+2%;3MXHK=9;-8)%))9<F6119/-4EC>*80YG6?8#M[J[J[O_;F\J])=
MN-*=TR^ @7RNE8L1=LL=8UP/W,*%#AF0I(K40EZ-FTUEX.^Z-]X^WC TN2.'
MMP(^*_HO9C4>T6BZ9H\X%2V-5$STYXW<5H+%]]*DDDDZJ1VIJ4,)L"51)PX2
MRHLDA=O=:_J]72]0MWHR9H>YF,3QL 99(JRW415X,T*3O)TBI*\BR(Q5.(Y+
M5W%[JX$D1-8ZSG56-W5F_"HD^UIO<#XE^YTH=V:?TX2C1YB<0(4;9^-/:OG,
M4$H4F6 >O<5?&2RV9TH3&*_*W9;LGU8Y;':" 5AJ.BQRPG5-+$JU+;]GAJL;
M,AYNVG>ZNHH;L<20R#2IY$BX+*T276-:X,D6F.935U!DD[G;*&:!=3--@#Z*
MBUW.J17=S(IN1J6W*!\Y5>QW;H9<[96G=/V$Z-F62Y%A=VNFM=SB A8=5]2]
M;R,(#3Q 6KF'JR^;+VW:)$1#LLED!8K+3;!5(EE$%T%'1.&QH79B2I6L#5((
M9$KU8Y*E34-)EFC>QJ>O1O-:EELQ"P(8JNG)*U=3-!7MP6FKRQF(39(M1U=9
MY8C3D=&EF9)YZUU$=8J>G.(X42)S$7>6TR+*1'+)#)"LB/R*:]7NUW?&PQJP
M6?Z_8!2\57;$LE6BVG]O5\58+:-UGUDN6MP4LT263GTUB4?VGN&H.ER#>0I8
MYJ@A$F3J^ZP70'SS]G.QL#6(QK?67O6F)'/%JFF3R0U9+_:&I?F6*,1I;98=
M.TJT(HSUHX=2C=$G#1&7'%JNO2"-CI_!NC;9HWIW(UDF6MIDU9"[%F@#26KL
M)=@4=ZC*3&0_"6]P;\[(@$Z'O&OM07TM(M_6\_;K;3INN+Q,@U?8IW9?5 7!
MKEWK56E%GQ5L$5&Z;:*0 #UI7/$,TRVJ5-,#H927'UFEZ+H,_NQ4O:I2B%77
MH:M6REZHKV:,.G]I9'GISV%B$E:6U5TR-YA6"2FW6]"*1HU,JW?U-.X35J<[
MF;39)IHFKSE8K,EG256.>.(OPE2*:VZQF4L@@F])U#L+==>KS>MDZ<I-TV94
M9%$O9B(339*O)!GJTL?.&'2@=+[8&SY6=%Q2L8>P8A1"+TIUN'/8RB;.8RU,
M?K.MTZ=#5+=33[2W:431]WLK-#8#I)#'+L9J^T,C1L[1.T84%T;=$.Z#<:?/
M/9IP3683!.ZMU8BDD?%E=DWZ<OIJ'"AU#$GBP])ALQF?FJR9F/JWW_\ 57\%
M=J?R%/Y=.QO]M?\ S,/SC92^V7]C0_/3?-KEX.7S*'CC&.,8XQCC&.,8XQCC
M&.,8XQCC&49NI(R&!6TQ7:Z];[ *$GB0*IQB4 /(M!F##ERAE=8+E5MC!3QN
M:TP-:)$G&X$%<E,F8M,=IQ6.168XI=9L13SBK!)J<L<UEHWE6O$]IEDG,48,
MD@A0F0QQ@NX7B@+$9U^DSII-1XXS-(FG0-'$&5#*ZUD*QAV]%"[ *&;T5WW/
M@,Q5$-6.QTFH6"X5"1KZV'*R#+V:B2S RPRJ8?(C(TLO5I!\*I0@V\!GNOBW
M"PQ68!!<7,N)Y,.HQB+<B@@MVH*MI;M:&Q-%7N)%) MN%)&6*RL,P$L0F0+(
M(Y!S0-Q;Q!R9 \DD$,DT)KRO&CRP%UD,,C*"\1D3T',;$J77T6VW'@<Z^Z'O
MS<^V^OY/80W9=$U=NDS<[]36M36D$%E1=6%AVV9NK::%L@^5-BVQ9,2M=<(W
MF85D+BV)TPI^KP*P.(A&\W6[HVE:9K4=&2A<U'2HJM*T=2K32JVI12:8FHVI
M8'5&K".0"PE-8U#0"+C8>Q)',<K]>]=MZ>UA;,%6Z\UB'NDL:%:KK::M!'(I
M(FY)O$TY8[2%]XEB5D&5M+^(CV$2Z\2521-+]=UNT!=S53M%=E+):HMEX[&M
M:(WCL*Y1L$F"I"DZG]DMMB@QV71HV?7*\.LQ(BP$)RIT7?Q]AM$V"=[DM;:]
MK=2&S7G7IZG6IZ$=8T>C4;IF-+>I<JT#L1)(D\\D$:-+&J-K6[1:AN6Z"P;Z
M;I\[PRQDM5FGU'N-^Q,.0=H*>TLB@%5:.-9&8(Y([$MD;TSI#6S=W=L@+<D
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MGOWB;B:0]<X#.G31"94KF4IS2SMN8K4>8X&O'9>@O2S;[=5*YKL\K/ZT&+&
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MC&.,8XQCC&3%UZ^\Q0/WG=_G&;SM5;[&K?H\'S29Q:U]E6OTFQ\\^5Y+&+C
M)D(2--[:()B39,=,\<!"OP)B6GEHQ)A/.61AQV*]C'K&'%LM+4VI.5-HSG*<
M4&UV8U2:S9F05^$L\TB;S@'B\C,NXV\#L1N/4<OM7M/I<-6M"YL<XH(8VV@8
MCDD:JVQW\1N#L<Q_PBN7XC]S?^W /_=','O4U;V5OUA?HS/[Z])]MG]7;Z<\
M?A!</+R^(W<GEC]3'P: >7V_U?M?"CCWJ:M[*WZPOT8]]>D^VS^KM].>*CEM
M5Y>EHK<2O)25X]*LU_/DI"L+0K'G9_\ "0O&%)S^JE6,*QG&<>?/OO5U?_\
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M,TTMW4Z%>&,0Z>^[VK&E3&N[<()*]BG;,RU9C,GV'7Z\[0+'3O[V-RG*.O&
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M>HZ:\@F;3[UNBTJJ561JD\E<R*I+%0YCY!220" 2=M\W5.P+=2K;5. M5X;
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M69!5A:1-/75&A34-.EG2B^F^ZT<[PQVWEC633OZS&CJLC =,+UBL9]^[6G
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M<DNNNNK2VTTTVI:W'''%YPE#:$XRI:U9PE*<9SG.,8SGG'=1!.I7P 23>M
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MOT>+,\A<ABV^;#6^NG4&SZ\KIRLTT*SK'8KVM=BU6##/W.K5,A.9I8:O:\/
MZFHV'@ S$ZFL 1CC$(.+*&VH0MNP1IQ ?&]1@L:[VGKWIXK-J4ZA1%^C9=X:
MEBRB-;EGO0S6>C*\T26C-("\LD<)>0P,B2-RR1:;I$M>.2*%!6L&M9B59)HH
MF80I'7DCAYHL;M"(U(5%:0*HD#,HVT#7.N>B&QZS.@T ,WFH+^+ZX8R\1V]2
M #1.K!"6M:I8*Y+L,ZO0HEPB5C6DNJVV=6GF;9/K8F#&V"N6(,#%$IMZ_P!L
M:-A'NRGO0[[5\(]+MSF.Q,E^Q#.L"3NU5K&H+9JI8!K)8E=J/&6*3IX*U;0K
M$3+73ZR>[S^+7($#1(U:&2,R-&%F6*J8I3$1*T:*+&Z.G*V6MR&M05=':[H6
M< Z_K9W&J08"?%.BL0TT((/82% NVIF/-LPT($Q#:2;%2#(UYJ.^E)60]#F>
MIK5]+\T\EZ[]>GOCW2FF1H9.9NRNW5F%<LE>2:7D3#(L4@+#>-0Z;[6LU:.-
M:\'H1UOZJD;"1-N[HHX1F4!I51./UQ"ZD ^F2&V]Z/M?7DNY? "+:8$FT? 5
M6R\1&&Y;H]5';-NUQT^BPHC*KJV&3++D-^*@LH@QZ/M#T1$527\^6TV\M7OK
M5W6OWSN'(E0_>S")Q"8"W7!,3!U8Q\&^"&+ C/0M5S-W<2J9>AWG8 E>AS,9
MD$FW3(#C8@/R'F0 0<]5>X]99K(&X0;@,/UVSO4YJO3ZFF7<%EV[Z7!A*O.@
MP*O&+D7A$V99 [\PTF)[I"")+M@.S1H&#/)1?HTO4.\357JR0SUQ:,Z62E41
M&E%--81WLM%&)42O*J0\NK-*H@A22=TC;YWRKTDF699(Y3#TVBWF+BPZ1Q,J
MQ!V*,TB$OMP1"9)&6-68<I?;NM@5FJ]0*V\7%/7)FYOUYC'M,B#*1KR./EW/
M$LU%CO! [P".4A.2HYHB/D.>M6B*U(7'DI:^1:9?FKV+4=:1H:IJB=O15E-Y
MI%J\8F(EE$QB?BT2.!MNQ4%23VZT<L4+S*))A,8QXE2*X4S;N 43@'7<.RD[
M[#<@[2(VXAU"'6EH<;<0EQMQM6%H<0O&%(6A:<Y2I"DYPI*DYSA6,XSC.<9Y
M!(()!&Q'@0? @CS!&2<\^,8XQCC&;)K+[Z\#^+^W_P!(:)R]=C/@:E^53_=:
MRB]L_AZ;^3<_?5RUG+ME)QQC'&,<8QQC'&,@O;GZX!/W'-_EH_*3VR^!I_Y5
MK]T&7?L;YZC^*I^^SD,M38;\F5#8EQ7I<'U'ML5I]IR3#]J;R[&]J80O+L?V
MAK&7&/7)1ZUO&5M^DG&<\HY1PJN58*^_!BI"OQ.S<21LW$^!V)V/@<O ()(!
M!*[;@$;C?Q&X]6_JW\\J=N^]]5*5MBGO;?,NU3:SE&FM5^QC&=F!)GQ<']CT
M&B3A]@N=#CQA**A(V9;]?#W1-P,I$PCID45]DC86[/39-(I=H[>FVAI<0LZ:
M+B&>!VT^5>_PT+MQ)(*EQFE-I=/JWG$M6+J-#%+'R;X!U-Z?2H+<)N.8K1@8
M1RJ+*'NSV*\#+)/  G1-F:NI29^"NZOL/%LYAM-ZE=AJ -O$2#6KE3;\_7)
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M01MX*C ,7,2LSL.HS&255(CZC-(L:/)(SV<Y7\V>>DHF.1,0.60A((.83EN
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M&!5N$TN\VE3SAO>&K*1ML:4P&D#W,%:KJZ\GM@U.!5Q=J;+LU.R22TX<JJD
M1&-I&BZ%=T^&>YJZ5;KS:G%)5DMTZVPATC4;>F/'U5D'3LZC3AHV7L25C$;5
M=8HY!829,MW4-1KVI(X:+35U2HZRI#/+OSNU8;:OP*[-%5GDL1+$DH?HREV7
MHM&U2:]VG[XP\6"]N];+X:G6RAZG.-4 OKW9 JOUBZMZ5V99K!1JM#(1XQ@1
M*N.P@E2IQ:PF2!0+0R!"(JQQ5S2\!N199NSO8YC#2&O4X4K7=3A-Z*[1EFL4
M_=;3Z\%RPT;-%*M6C+:M101)%+=1&Z#A(F(U,>JZZ!)/[FSNTL%63N[U[*)%
M-W&S+)!$K .C364BA>1RR5V9>J.3KOMPGNQVSLLBUXJ&B0=I!1-J;"UB/O,.
M@[C<JE/GTGL#V6TQ$D6=%8;NAV]PI\?4>MI]I)Z[%K3K=V_3B%C'O#(L1KD:
M7LGV:KK6[SK$U>9]-HZB]-[NEBS:2WHF@:LXKFP:D--D;4[Z5H[T@-\4EC@<
M2,QS*FMZM*9>C126,6[-59UKW3%"T&H:E2!EZ0F>PK"I7:5JZ_U8V"TBE0!F
M7E]M^ZT:R7T'CK1G Z)=Y59IEJE:JWMBO"A"-U;SUR,LUDR%'V Y=@I6KT?4
MMK?GT@%!?"@]EJNKXJ;58S?JL:]F>RC5Z4WO@!=J:V;=9=1T?KR2G2-&OR5X
M.K)#%4EBL7-4JA+<SB:;3Q45TLL=_9U;6A+.GN9Z(G,4,IJW^FJ=]O5EDDZ:
MR23(\4%2;E#&O!+76*-$/#+".T_<U[<L6I%^NSK6O7MN,TY\W"U!N;&8])7O
M"PZU=M"+E,FM@7HS=&8!;,38'P$(2L)B7,<@,BRL2<)Q2]G>RHTIK46N W1I
MAM"%]4TKQMC2(-0%<U$0SAC<,VG]!9GE$W%!(9(F27VFJ:R;HA?3B*_>Q"9%
MIW/"$WI*W5ZS,(R! $L]0QJG#=N(5@5V[8.^.V?QBV"MU+6#->I57[$ZOHL@
M\O66U[K8B>JBS $F?OHY0P3'I5AJY=9&4,(E:N?E&* @>3&' S9!6;"%BTM'
M[-=QAL6M1,]NQH>H7%A&H:;4@CU*(S1PTI!)*UN"Q'TUDCCL0+%>YQR0RF/:
M";-/?U;O,D4541PQ:C5@,AK6II'JN(VDL+Q0021-R*L\4A>OP=)$#?7(X[&]
MQNX#S^NG?T+UE,,76V6U4X.K2V[:05KE 95+AZ]7:B]@22KU0N5DPNOV0Y$F
MR"@JL0S9.JEG81>H%2TJ?)V6[,*M\>^&O&U2M5"2>ZVD6X[%T\6O"M%#PGM5
M:_U^"%D$<MAHH[,0>*S'$L==8U<FL?<R1Q-+-R0TKT#1P#=:_5>3E'#-+];D
MD#%DB5VB<J\+.=?TKOWO*8/&/>&K34QF[WZPV]#5\T[MJJ!:K5ZYU8ZLW5.N
M*:[82@CX+HMNVC>[J$&.W0N7A1+S!)S8T&?"!2*E(S:MHW9"*&+IZA$K5*4%
M7>GJNFV9;%B?M'VDJ=_MB"*7O!K:9#H]V6&I%$[4WC1F1YA97'1OZX\C\JSD
M3V))AUZ=N)(HHM*TJ;NT)D=.EU;CWH$>9W G5V"LL9BR1JEV@[;&'=8+MF@B
M0 %<S]HJ-K)#=0[>E&*TZUJVF7BJ71T+[<]*KM4F7J;>M*%L6#TID&PB0%\;
M=S5I)" Q!L]GNS,8U'NNM)/-5@KVJL<FIZ8L5@'4;=.S4$O +/96FE/5XNAL
MCP234B!96-S(BU35G-7JZ>T:322PRLM2VSQD58)XIBG(F*(SM8I-U-V$B1V!
M]:+*-ZZ%6K?=KKUWF[U#[*!3% >M<T"*V/7[(%E#B!GJMIPKL\<.D686-GE'
MAVW9-XAV5:U27X%J9,0)OLLIER*W#[9UM&K3U$T>6A,G6U])I*$\$RND7:35
M8M/D=:\LB1B32UIO7'HAZQB=.2D,<^@S7YHYVO)9C;AIIC2S')&59]*I-:53
M*BL_&X9Q)YE90ZG8@C+^\I>;_-DUE]]>!_%_;_Z0T3EZ[&? U+\JG^ZUE%[9
M_#TW\FY^^KEK.7;*3CC&.,8XQCC&.,9!>W/UP"?N.;_+1^4GME\#3_RK7[H,
MN_8WSU'\53]]G*LUAS;ZMB;/1<HVN6M4-_ OXF9%:E65W8$GT@C^=A_&7&)Q
MFJ[%]38_944[X,2)/KPN7UFO4S<-HS5+ TSN.GFJUXZD>]^ZJV%KBDOUY>X^
MY[1L9VW@Y&WWA5XS<1#R3<Y<(C<[Q:$PKBH.AW(Q-(;!] ]X[R& C7:380](
MMNFY?9O#*E]BA79*U]GM.TW3ERN&NJ1-T]?+#;;RP -E]?AK=6-T]?)X*&7;
M2*DU4O:+)K;.X:R'JQ\L)8FCS!(\I;DZN!%-V70Y-!K=GM5M:I5JWKBZI2@J
MTS/#%=EK6-)UQ)GB)D%F*O7O^Y=B6Q#%*4DBCA\$GEWU.HIJ4NJ4H:<TU: T
M[$DTXC=ZZ317=.:-7' Q/++6[[$D4CH"KM)ORC3*G4GMGWJH6HI$4_UZV%L6
MY!#PM >>;TGNCWY8:Z3';6L9>&:]V1,MJ*A54^N@(-B88B1,.6RN#Y=>F3Y<
M>7/LMOLUV/NZH&@UNC1JRPR]5(M6TKHP31R:;7B>'J/N(Y>]S3/78LVU6Q(L
MZ(I5-3!JVNUZ9$FGV+$T;IP9Z5WJ21LEJ1Q)Q&W).C'&L@ &\L:F,L06LY5^
MR?:HSM('0S'7]NNU\AMO9%:E7\E4MJXJ$BA5>P:<DT^2**BPQN?!.6_6UWV,
M9CV6]5ZET7XP-9$*"J7$@R6+=(K]C0>SD6G378M;,\Z:90L+2CLZ;WI;EB#5
M5M++')-%&\-74*=&(UZ<]NYW'48[W!G5JHV<>I:J]I*[Z>(XVN68C8:*WT>A
M%)3,15T21EDFK3V'66>.&#O%9JY*J1-F]!;OV3)=M=M5V;KJW@]1@]"(E:O)
MFVZJK6=FV+'NY6(U,S9*^>+G5&;&+Q!?>#F882?7@,%7K@,)<F,:M4.6IH$?
M9G3)UO59M3FUHKJ,<)L^Z%>BU2-BO0G@C@Z4$G,++$\R3S/X3.%:*OG2?4FU
M>W&U>9*:4 :K.(N[2V1.PWZL<CR<Y%XDHZHT<8\8U)#RP93;9OU&BNM5I+M[
M[F[^,W71P;LK5R]0OK 006LFQ:FG;I-L9#",UP/3J+[)8(@Q^FS(U*GZWDOD
MBDDK%FC;(UM[=;13K.OUHCHZZ+%5UB70+,=FF998J]&S[EQEVE,\EJYS@>06
ME-M+ZB.-8V22N8,,U_N&FRMW]M0>:BNI1/#8"(\MB'O;! @B2&#:0)T2(6K$
MLQ<,LF:GH7N7W*WC6=*V(7I"MLAMI JO;Y-U3K7:<6H,C#'6^O[CG !SY.TQ
MXK"EWV7+U:"V*3/8IY><9'O#X4\E63(DM)UGLKV6TBQJT$FKSF73IK-5*G?]
M.:T9(M>GTI)I!'79C_4D749J,<'>HDB<.Z1V(I8L5#6=9O149%HQA+<<4QG[
MM:$(5]-CNM&I:4 ?7V-5++OT79UXJS1.C1/N7=??S9U @%0FO-NZF*B]8[@/
M-0=8:QV$T2LNP!>K>L=PHD23&FPS1@2L;L&_;HUC&KA=I^-=U:X/F(\%:EP%
M -EI6D]B]/NO'+>TS4XY=0TN$OJ&H4NG7I2:CVAJW&5D>**424:6DZBUB(@U
M._P0L^W4$T6Y=UZS KI7N5&2K<D JUK >2PM72YH%*D.ZE;%B[5$;@B?NTCA
M?@F.RIOM1V_@QKV18ZV$&HE0NU<AL0F-:[0M)HO3B&ZM\Z_M:0$$'+8^%=@I
M>IZ#J_?+1,5F, N8V^XUZ ;:LQ>L3)>AA[.=EW--&UY"]JI.Q9K^GUH8K2:1
MHMVMUWF1N[0V]3NZCHICEWFJ/2[_ #DUXK"+LGU36%$[#32!#-&H7NUJ5WA:
M]?KR]-8R.K)!3KU;X9-HYEG[M'M*\3'C=[;=J7[[=*K%Z[G!=5@;2'4FL[(*
MZ7WE-#L5\A-[0AX]H+ !D/!ZS!7#^I-)P9]BJ;:1P$)O&'<YL*57H,!PCZ'9
MGLX*52RVNPR67TY[EC3X]5T=)3,B=G)6K1S2/T:\P@U35W2"R><TNCM41EG=
MQ'\]U]5-B>(:=(L2VEABLM2O%!&S:H@E>-5ZDJ%ZE)6EB'&-+PF93&J\L9K#
ML7V\8V1K>C'M'6R50[%L>VCKC;K%K';'O<0$-[Y[:@1)-FSR5QP(("#I.N=)
MV$>@P*FQFZML40C$YD>4KQ''K4="[,&C?MPZO66Y!0JR5:T&H:;TI)8M%[,S
MR1FNO*::>6W?U:"0Q2(W>:$OH=2.>//-;4=7%FM ]&4UY+,JS2R5K7-$DO:M
M&C"4D(D<<-:E(O-&'2LIZ05HVS9KUO\ [C1]K/5:L:=>B5"N[AM(1FQQM97:
MT@;UKS&BM\V.ER)!E)83-"RW]KTFCU*S34!1@,40/U2<,L]@KMOA)F8*>B]E
MFTSO-C5 UJ;2Z\W=VU"I6GIWO=C1:]M1#TY4F0:;<N6JZ&:2:6."RLE>">J_
M#+/J&L"T8HJ>T4=R6,2"M/+'/7[C?E@)DYJ4)M000RG@B*TD3)+)',-X(/\
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MD)(B2.W)+("DS ],4IUX[\W;AP4J69<Q-\1JBSKD]2@=2N@2=7]P#]=V&?:
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M"[!6KPD;&*/CG-*F>6]2L>19FW@B](L)%8MZ'B6664,3XD22 ^#MOG!6NM?
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MEFX&J6X]61GX\A..7'EMOL-]M]AY9<JW:T5ZU>O[GL_0@BAYBT%#=*-4Y;&
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>HS2,):CQ(<5MJ/&8;3]I#3+:&T8^TE.,<^9]S__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g522368g20i14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g522368g20i14.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $" ET# 1$  A$! Q$!_\0
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M;H"_=1/-+5T*UF$$/F HC.BTYPL^*XG6TA9J1GGE7;,2-'.WKOZML/AV WF
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M11P#:.'&+6^BQ62_Q&_E.#7=LL<%E[880/.&OA-?HNE*5EE__8+BG^%G8/\
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M(M6SMZDTNPYA-VY;L62#AQ@G999%HV24SRP02QQM.S6QIA6V.PVQIMTEDG2
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MN"F6>.ZPG#%QG'4PUYF@6XEO2954.R[B"XN!DI*@ZC$%/*,@Q/P95?/?-AN
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M)L[ATTMQ+*)I.%#$5FC:0"-EQ1+-+D#2BNN0L8=T0X9"7.;$KIH@7N=>G0L
M?0K&:[8=&NO$0V+&-IX$X#']F0&5P)JY8Q-_$B4-UU&8U;$:R(&6CI*2161X
MR!$\;ZRW,YD5LZLDVQQ&2\6ZX+AZQ<%N+.>P*7<UC=V]VRM<)<)<WD\_;ND3
M*8+B#<M#%N-T$ JM-F[-+9H.$7C/PB"YBN]=O'=6\UN"L+0M#;11=H&<'>PR
M;P22;W>:C57GO 3K+:L3$1C9NQ]W3UX+UANK4Z\RDLP /)@9CN^#<).S)T3>
M)0]N)2)#W$! LXHD'"B0($99TQ3!KI9-NBUVFUE]87$EQ8V6&6:O?X7B"VT%
MO,MM%-A,5U%:JBM<M(4<7DS7!EEDEFDTN90=6J=QL_:W<*175S?7#):7UF9Y
M9HVF>+$)())R[;D)J4V\:PZ$2.-,U$9&67:\X!M./MBDIRYDVUU #_8,LW W
MT[E,6F6H VY)N$,!))M03'LP.1S"5/K2$Z82:/I._B3"2%WT@81EL35LXQ+M
M;B2V26BP8>)DL[?#6Q+@S<8RX;:RQ2P6$DV]W7!TW,,19($N'@C6%YVC!4^G
M9^R-RUP9;LQM<S7HLC.#9QWL\;QRW:1&/6)6WDCA6E:%97:18@YSK)NG^%K6
M^DC<2/P]Y*G#V%\-^IN%L1B<)CWK=36^FGA][$GCU-J(89K2I=:2$+&B:2B#
M!YABVQ;"&-T\\E<'$<>O<4BN(;E8 ESC6(X])NHV4B]Q-85N%4M(^4 $";J,
MYLO;:I'S&65983:V#PR0&8M!AEGA*;QU8<%L3(T);)%SF)E;6X(5N3)%R.>R
M-:6MG2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I66-7_]^?\ MG_R%;3#?LW]G_B5R^TG_@O_ %/^!4TM#0RQ0DMF
MY)VS5(/%<[89->]MDHX4SRMCRHWOWMKWOR<M[WY.3EORU;-9PM+*Q>7,R.3E
MH^%B>]6-:XS>1VUNBQ6Q"00H"=[F0L:@9Y-EGD.7*J?U)"=J*_.:>IJO@,'A
MR_J>BK^.[WFK7]KZ].I(3M17YS3U-. P>'+^IZ*<=WO-6O[7UZ=20G:BOSFG
MJ:<!@\.7]3T4X[O>:M?VOKTZDA.U%?G-/4TX#!X<OZGHIQW>\U:_M?7IU)"=
MJ*_.:>IIP&#PY?U/13CN]YJU_:^O3J2$[45^<T]33@,'AR_J>BG'=[S5K^U]
M>G4D)VHK\YIZFG 8/#E_4]%..[WFK7]KZ].I(3M17YS3U-. P>'+^IZ*<=WO
M-6O[7UZ=20G:BOSFGJ:<!@\.7]3T4X[O>:M?VOKTZDA.U%?G-/4TX#!X<OZG
MHIQW>\U:_M?7IU)"=J*_.:>IIP&#PY?U/13CN]YJU_:^O3J2$[45^<T]33@,
M'AR_J>BG'=[S5K^U]>G4D)VHK\YIZFG 8/#E_4]%..[WFK7]KZ].I(3M17YS
M3U-. P>'+^IZ*<=WO-6O[7UZ=20G:BOSFGJ:<!@\.7]3T4X[O>:M?VOKTZDA
M.U%?G-/4TX#!X<OZGHIQW>\U:_M?7IU)"=J*_.:>IIP&#PY?U/13CN]YJU_:
M^O3J2$[45^<T]33@,'AR_J>BG'=[S5K^U]>NY*!A%,'&?3"MN81Q5Y.5I?ON
M5P@AWOX'WOPW?<OO_L>3]WEKT6$)#'7+VHS^LY>V5>]^%4&QZ]4QC<VIWCE/
MLO)E&[Y^Z_ R_P!-=/4D)VHK\YIZFO. P>'+^IZ*GQW>\U:_M?7IU)"=J*_.
M:>IIP&#PY?U/13CN]YJU_:^O3J2$[45^<T]33@,'AR_J>BG'=[S5K^U]>G4D
M)VHK\YIZFG 8/#E_4]%..[WFK7]KZ].I(3M17YS3U-. P>'+^IZ*<=WO-6O[
M7UZ=20G:BOSFGJ:<!@\.7]3T4X[O>:M?VOKTZDA.U%?G-/4TX#!X<OZGHIQW
M>\U:_M?7IU)"=J*_.:>IIP&#PY?U/13CN]YJU_:^O3J2$[45^<T]33@,'AR_
MJ>BG'=[S5K^U]>G4D)VHK\YIZFG 8/#E_4]%..[WFK7]KZ].I(3M17YS3U-.
M P>'+^IZ*<=WO-6O[7UZ=20G:BOSFGJ:<!@\.7]3T4X[O>:M?VOKUW+0,(CG
MCC=X5R[Y%!7EY6EOPZ*:W)^!_P#P]_WO+^[R<O[M>M80J<M<O<4_6?7*&[WP
M9U!,>O7!.YM1D[I]E^L<KG[KX<L_O=RNGJ2$[45^<T]37G 8/#E_4]%3X[O>
M:M?VOKTZDA.U%?G-/4TX#!X<OZGHIQW>\U:_M?7IU)"=J*_.:>IIP&#PY?U/
M13CN]YJU_:^O3J2$[45^<T]33@,'AR_J>BG'=[S5K^U]>G4D)VHK\YIZFG 8
M/#E_4]%..[WFK7]KZ].I(3M17YS3U-. P>'+^IZ*<=WO-6O[7UZ=20G:BOSF
MGJ:<!@\.7]3T4X[O>:M?VOKUVH00(NNBCTPKCSRJ:7?<K2_>\YG;#EY.9]_D
MY>7DKU;"%F5=<HU$#ZSX3EWJB^/7J([[FU.A6;+VWET@G+W7WJZ[P@):][=*
M*^]>]OV33]S_ /XUYP&#PY?U/14ACEZ0#N;7E_2^M7YU)"=J*_.:>IIP&#PY
M?U/13CN]YJU_:^O3J2$[45^<T]33@,'AR_J>BG'=[S5K^U]>G4D)VHK\YIZF
MG 8/#E_4]%..[WFK7]KZ].I(3M17YS3U-. P>'+^IZ*<=WO-6O[7UZ=20G:B
MOSFGJ:<!@\.7]3T4X[O>:M?VOKTZDA.U%?G-/4TX#!X<OZGHIQW>\U:_M?7I
MU)"=J*_.:>IIP&#PY?U/13CN]YJU_:^O7<G PBB2ZG3"MN8QPRO;E:?KN_5Q
M3Y.7F?>Y.^Y:]%A"0QUR]KEX'PG+O5!L>O59%W-KVY89^V\FE2WA?>RKIZDA
M.U%?G-/4UYP&#PY?U/14^.[WFK7]KZ].I(3M17YS3U-. P>'+^IZ*<=WO-6O
M[7UZ=20G:BOSFGJ:<!@\.7]3T4X[O>:M?VOKTZDA.U%?G-/4TX#!X<OZGHIQ
MW>\U:_M?7IU)"=J*_.:>IIP&#PY?U/13CN]YJU_:^O3J2$[45^<T]33@,'AR
M_J>BG'=[S5K^U]>G4D)VHK\YIZFG 8/#E_4]%..[WFK7]KZ].I(3M17YS3U-
M. P>'+^IZ*<=WO-6O[7UZ[KP,)9O@OTPIR9+*(][RM.6UT\$L^7EYG]WG.3D
M_<Y/_&O> 0Z=6N7ND?6?  >]]^H#'KW64W-KF$5\_;?KBXR]W\&G_;73U)"=
MJ*_.:>IKS@,'AR_J>BI\=WO-6O[7UZ=20G:BOSFGJ:<!@\.7]3T4X[O>:M?V
MOKTZDA.U%?G-/4TX#!X<OZGHIQW>\U:_M?7IU)"=J*_.:>IIP&#PY?U/13CN
M]YJU_:^O3J2$[45^<T]33@,'AR_J>BG'=[S5K^U]>G4D)VHK\YIZFG 8/#E_
M4]%..[WFK7]KZ].I(3M17YS3U-. P>'+^IZ*<=WO-6O[7UZ[F\#".'""%GA3
M&ZRJ:5LKW:7MCSF=L>7DYGW^3EY>2O5L(695URC40/K/A.7>J$F/7L:.^YM3
MH4ME[;RY#/+W5=/4D)VHK\YIZFO. P>'+^IZ*GQW>\U:_M?7KSBV]QVZ&X?^
M.^ <%^Y'SN%-MOZ:B4_UML\@_9(@%9R<GVQH<O 91FNA@@$P*H1$2M%3:BO0
MG!AT]#DLVJCD2HKU-CL-<8GL[=8]8--<&QOIK:ZLU53*+>.VMI^$PY F309G
M$T8&I8U$B:@'"ZFXVREM<2APZXBM8S<0)+#,3*$,C221[I^W[4MH!1NX2=)R
M)%>CO4D)VHK\YIZFN6X#!X<OZGHK;<=WO-6O[7UZ=20G:BOSFGJ:<!@\.7]3
MT4X[O>:M?VOKTZDA.U%?G-/4TX#!X<OZGHIQW>\U:_M?7IU)"=J*_.:>IIP&
M#PY?U/13CN]YJU_:^O3J2$[45^<T]33@,'AR_J>BG'=[S5K^U]>G4D)VHK\Y
MIZFG 8/#E_4]%..[WFK7]KZ]7W"HV-'>$^CK/L^>Z%W_ #V3?WN;Z7WO>]XE
M;[_?Y<O+R_>MR?NUGV5K$F]TM(<]&>>GX-?>'WZTF,8G<W'!MY' -&^RT;SE
MU;K//-CX(RR^_761_;!]^6.?X[.O)/?)/SV_>-(/>(?T4?[@J'4*MI2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E3&WX$C^1X?ZP8U-?<R?F#^)'
M5,ON[?\ 3-_P\]0ZA5U*4I2E*4I2E*4I2E*4I2E*4I2E*4J8^_"I_D;#^1(5
M.3W0_,C_ (:U3![E_P!-/_%>H=0JZE*4I2E*4I2E*4I2I;#\>9?E;;^.PJ<?
MOD?YZ_O"JI_>)OT4G[AJ-G^SR_NLO]-ZA5@[@_(/[JXTKVE*4I2E*4I2E*4I
M2IK?\5(?WI#^5)5-?<R?D7]X53)[[!^<_P##:H50JZE*4I2E*4I2E*4I2E*5
M-R_:Y+\M<?Q#6I_8Q^>?W15(_P H?]#%^_-4*H5=2E*4I2E*4I2E*4I4T;^V
M#'\K;_QN%3C]\C_/7]X53<>\3?HW_N-0JA5U?"3_ $4-_P#SW:9__P!289_O
MCWE7Z*]B'^;M_P#_ .ZG_P"!P^OF.VW^<K7_ ,BG_$7%;C=Q)[MKX0ZH\&W&
M1+O^D/ZRC>CMXR1]^V'[!H)UMLDL[S_;#\$QATP?*_U__4 !]?I_@X@_TGL@
M>Q_EO\>P&#M>VEQ'#HE]SW6>[M$4>Y[K7%NH[3EEB&C6B;'9O:37N\/Q"3MN
M1+:Y<^Z^!89F/UWP(Y]U[EN7(GZ\*^(5WM*4I2E*4I2E79%_W]_BW_$5F6GV
M3_4_ZJU>)?8?[3_#JWR/[8/ORQS_ !V=8TGODGY[?O&L^#WB']%'^X*AU"K:
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I4QM^!(_D>'^L&-37W,
MGY@_B1U3+[NW_3-_P\]0ZA5U*4I2E*4I2E*4I2E*4I2E*4I2E*4J8^_"I_D;
M#^1(5.3W0_,C_AK5,'N7_33_ ,5ZAU"KJ4I2E*4I2E*4I2E*EL/QYE^5MOX[
M"IQ^^1_GK^\*JG]XF_12?N&HV?[/+^ZR_P!-ZA5@[@_(/[JXTKVE*5IT9XY-
M)A-E[NUBNQV@]>\/$./2_:DP$ZOEI36T=SC4!%;0+1->=M&*@)*8X00Z(.LQ
M+QPT;D^GI"AI!V;3<#4=XFSU_):8?=AK-5Q.>*"S@>\A2[E$US):).+8MO#
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M(YBVE\1Q;LF$@+-&B&.6KX,IEBBV;NTT4L<E,\\[VPPQM?/++*_OY7O?]5;
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MY)X,N.$6\C*(;F9-:8<$W]LNF66ZLK>[G6-H[AY&:)'EDT+"V7M$)?>W$.N
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M"288V:X43S+>M#'&BSP$6, N)M=W%*T0SC/:[H3!&&5P8$R>KVO<G8"/VM#
M'9V,4@X0YC33"\8<Y,.V#E"5Y8]XW:U9XKBQ/%X4RFRNM&(,0JQUPV-V5G*)
M0^ DFY @,[KUFQCN,<'82@2U9S"(XS<PD:#H"""LI9QK"8M8B_*.+WP:)+AK
M<7;2/JNC&1;E(I8K&22.Y9I3*QA=F@G-O&8W,B;EI=PTZH("^9HQ)N0JD0AO
M; 75[A5:$!- UJ!)'O6U*%.\";P1DFG,.+P\U Z]:G-;M7T\V3']9GXFSB<@
MD$QC3X9L2&;'F3=_(7L&U_+I''73<?JB66S8@8G.PSERZ"8!I69&XR0Q&Y-@
MD9DNFCNBMM:2W<4QFBC@F5[6XM("L:W%S!%*I:]@[:2:WD4+(9(8VW2307$&
M"PJ\.<LRPL@1VD0K-'-(&<Q12.AR@?D6.122NEV&MDEJ<9K=I&RD^(ZO/,X
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M#DN^>*,B8R2_)?1NF;*4HS:9%R#W,L$.64;)R",&0O)&>[H5V!2MC='RZ3;
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MK**B#EWB!?:TC*I#XXTBT>79MA =T'6P:KO762,/!U/),[3274%U(T9>*$O
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MN8WDCM@%BO#]=W,H')Y7=5Y0ZYD)D),CI+_2%7RNNPI2E*4J[(O^_O\ %O\
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M7$48MQ<6U_"8T,:.<WK0< B@(,Q:O%'@@BH[;M!S!LW1<J$(^!?YKIIXJY/
M@AUEG=<:RS1E+=W4[%YKFXF=AI9Y9I)&*A74 L[$D!9)%R)RTR..XS9DAAC
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MHP4V$'='Y $LQ,NCD2UBWCQ8&3*LI6Z)^Y?#W;^*1=%DD)6P-)EWMTD.#G1
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M]NMFI!%G*V4/Q2S33C=L^\#X,\,<,<8189A\"0QPV5M'';K,D*)"@6-;G(7
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MA4IN@MBB^MDGE:^;7#'"U_>OEE9\SSOCC_;OWF&67);]S&]_O6J:@Y2<AY4
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M4I2E*4I2E*4I2E*4I2E*4I2E*F-OP)'\CP_U@QJ:^YD_,'\2.J9?=V_Z9O\
MAYZAU"KJ4I2E*U'-<3)*.3/9L;=P18T)UNZ.G#9X:39#4Q.O8Q&=6ES3U1H_
M<.79Z5XN-@/W@X2Q;C!KT.!=I+%&)7%@W-;M,)26WM)EN1&]T(HXXG1G+W4T
MMVB*"H"QPY6RJSL7=9)%R1DU&/7M>LDDZ&+4L)=F8,%TQ1I S'(YEGSE)"@
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M-J^):"U2_G(/5/4F+/)P87W1,HT D:&2*STV("!G,Y0C.15PTCH8L.!!^><
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MV% I,5U;LV,38KW.E;B75U;PZ,H1".)N3ZLVQ/SG%++];1Q]K&'J1 1EK9W
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M;U_5%8S?-R5WR-- ^%B1M%,%!6*9Y@JZXOAX52'+JZE<0)E@@E93808=CW9
M;FXEO$@X8TRRQ2K+8\7[D!;%D?%(R#K[1@,)9Q-E=B9LZI>:SX)H01EC%IT,
MNF7?:LS*"L!_*!P@+I[30!EG@_@PVWH34_"EQ$=?^)08D9V9H?B"U"YT*4A&
MV,]L1*22X(Q5UV4X<I<(3D&FK17;TA8@Q?$4ZG-H>;:0^)*!QS<DH^$$U<[&
M+2^NL3P_<8<^BVOK"[%\L]J+2:.%SPA<0A8QWF]M(R[8>(1,C32ZV*A76JK:
M2&.WFUS#5)%-'N2LF\5F T&%AG'ID.0FU:3I7(? :\>JZRM;2E*4I2E*4I7:
M@NNV4LLV65;K8XYXXJH*9I*6Q4PR24QMFG?'*V*B>>:>=K7Y,\,\L,N7'*]K
MB >0C/\ +][E'^VF>7<Y*WIUSPW<61%F']S\SD^29Q(3<"%8'B!UD(4XD];/
MB@V*,VJ8XI'8Q*)QK8^L1*D7"PD9%L2XK"3R>-29\%;JZ2XQ'"E+\(323*^M
MVC5"_%UPJM*3J622.&XC"JH#-+H;=12QJY&6D%R0-!SR09 $L!OXR0H&1"ED
M;,GD"YC-E8BL5'M$;O?2B.."Y/$_*MD%-3 4"KN4.WA)Z7WR'.*0EB5,%;)*
MO$2H4$13?%6[HB"N.4;<R4>L7B6>64M]9+'(%71%;K=2%5B 54L'CWS*B]PJ
M\BZ5(5]0.:JRD5!H9=2DG4SF-<]69SE!T@D\O*HY3W,LN4BK_D_"].!<;(SP
M!M5A(7@1.>&)(S7SD(J0!PNMQ&EI18HJLGX4Q=NGQK<(=-F@@YNU$Y,$) 1*
M,TG3SP)1'B<#2) ]LT:R&!(CVCQL]P]Y'I[B9!4M'S.6;:C&JD@:Y-;MEK60
M'+6S Y@J$$39\F>9SE'WAW21RY:>DB9V4&%R1<@6D1\NZPR<D"3MX7,%'BO>
M(IW7=.E'#UZZ4Y$TL+J**JY\F&&/+^MM6U58XD"HJ1QH.15 1$4<IR R50.[
M\ K&S+'ES9B?ODD_WDU]Y/<">YS[UX/-:2S<.\99*XF8WH($K#^''-QS06*"
MVZB3P9,I\-<)*9M=H/6O]9-AC+)DO%X\Z<C)+D^-OLQ,3_./LD[4X=CEW#8X
M?##-'ASN&Q3+.29SFKP6S@@&S4]L7;4)I0'BTQKKF^H[*X1=8?"]Q<R21M<J
MI6TS[5!W1)*#W)B.0*,M"\CYMR)]$-?,*ZZE*4I2KLB_[^_Q;_B*S+3[)_J?
M]5:O$OL/]I_AUAO<^QA^IHI)IX5%D"[ .6%-5V8UP'99I]8)2,C:9%^3D),,
M"# 0RQ=,O)CQ<HS' HZQ*%W:MT666&?MO:M>WO!D=8V=IV#.)&!W4<DI14B2
M22220(8X8T1FDE9$ S:LDS"WLXY64L%BAS"E1[K0F99BJJJZM3LQ 5 S'D%6
MO)=W0R*1=[(3.;MH^&O4 C^*7R'KR!G*E8*CLI6)+*,'[T"J::0M:YMQFP-O
M1&;9)3)F5=VNE=3V*PGFF6*/(JRF19LG$9A%P;43 ,JR"-IQNP&C5P2-2+RY
M2>ZC2,NW(00ICS&H2;H3&,D$KJ$?;')BN0Y":@+<1^F&^+G)69<G-/60]ACA
M'I4JK*'!$FJ$'W@2*0/-78K5\;2\"LW\#PD;%R869BT7.;]\R;KR&%7YR @[
MJLS>VPC<A$$C\))DRM66,[QEN=TPC#.0%5B!N[<=V3X0!VDG;DG2-UVOMN;=
MJ#%K!8A0<R :BAOC5#EP":H2O%5:09,TF_>A9%=(0Y)24A"AK"9./!%F\ )D
MIJ(,0H<+G2L=(OYD'+Q1HV6D M^.;Q.'7JB0M#D(M1.<D6;JL*W#M ->=RB6
M[QW#/;B55@D29B(G5CZ+JW)0"3/7EEVK]J2[1@2'3E$3(K1@2:"9%9 -2D"F
MC^(_39<6D8$2MT7:N_ &8AN*B4U)&),VE#$\3CY"&Q]E'5STU%%1L5E;]J7B
M8TR,NRBDH=9N\$(X:S8R;"KY'*/"$(W@<O- B1&%HTE2>1I1' Z/-"K1S-&^
MJ:%=.<L8;P7ENRAED+ Z=(5)"SAPQ4QH$+R*P1R&C5ER1SGDC90W/$_HQNYZ
M(E./"BV>(_%K>.QJ7R=N2>%(@.V&Q#AW<< %&AJ1+Z^*-9]U:$KO9 E!\'TO
M6&IQT44),Y#",1(U&WT#ML][+!"55)WMF=UED1DB%RC6V]<+$;C3 ',KHC>&
M]M<\M[J/)EH21\RT8E"J45@SF)A+H7-]WG(5T D7B>W#K>-9@[%90VQ2D(Q
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M_<3^XH)::2BW%YQ>19-;;ZZ;4[I_3YYIBHEJE)7'%P/FTV'N,<L,]EJ87P<
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MHCPSP\D6>D5)/.4&3YA.&>8%![&LAK-QL#81O:9XP&?.HLYDT?,WG!,.:0>
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M$2EY))'D(554<I)/^@#,D@ FNVMYX;7"K>XN)4A@AL8))99&"HB+ A+,3_\
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M1?,UG*"N2*[=)RBHNBM@FDMFDJCAG=1-7!%=%7)//&V>*:R2E[6Q4PO?%*L
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MM.EE)QX+RWN7N8X9-3VEP;:=2K+IF$,,Y4:@-8$5Q$VI-2]MEGJ! _3.VH"
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M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*5EC5_\ WY_[9_\
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MU'?::< N.]'TT/KTX\L/"G^2S_1TZCR#Q3'SJ.^TTX!<=Z/IH?7IQY8>%/\
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MZ?=W6#XU&'H.X<_T1T^IOL7_ $-_[CBO7J=E./?;W^ZV?5ZN:)=W![LC,S&
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M8_:[6/M \SB3Z^0=L7WK/(WK7\A4HL4$:%9@5C1@#OT5)&Y7)SR4%?@'<R(
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M_9W)&VQ8AKV#9.<_!;]=+9*$KD<3@@P5=H\U38'$VY0-<VDDLE\@%\L: Q6
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MDBCDCPRSN6WK[B1 ;Z>9TCWDUNL)*LJS9[A+%O9]ZL1C'+*R]N45F5[J:(%
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g522368g29x80.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g522368g29x80.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2$.4&AO=&]S:&]P(#,N,  X0DE-! 0
M     &4< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   @  ' )0  AR<C(Y
M-#8R,1P"!0 T36EC<F]S;V9T(%=O<F0@+2!)=&5R=6T@5&AE<F%P975T:6-S
M("T@1F]R;2!3+3$N9&]C>  X0DE-!"4      ! '\3+#)851M(;SF--)#0N8
M.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
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M;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6)
M;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M        0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M            4G-L=%5N=$8C4'AL0&9\S,         *=F5C=&]R1&%T86)O
M;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2
M;'0               !4;W @56YT1B-2;'0               !38VP@56YT
M1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O
M<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M  UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M   X0DE- ^T      ! #P     $  @/      0 ".$))300F       .
M         #^    X0DE-! T       0   !X.$))3009       $    'CA"
M24T#\P      "0           0 X0DE-)Q        H  0         ".$))
M30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       !
M #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M  !P  #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@  #A"24T$"       $     $   )
M   "0      X0DE-!!X       0     .$))300:      ,U    !@
M       !L@   Q8          0                         !
M      ,6   !L@                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   !L@    !29VAT;&]N9P   Q8    &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   ;(
M4F=H=&QO;F<   ,6     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M    .$))300H       ,     C_P        .$))3001       ! 0 X0DE-
M!!0       0    $.$))300,     !9Z     0   *    !8   !X   I0
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M+\YEUM]E1)H&UHL!T/HFSU7,V^[9O/IIF2?!&_L\U^.'%*OM=ACFO:'M,M<
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MHW.:_P#T:1B#N ?-(D1L2/)J]1Z'B9#/4HHH;DM!#2^MI8\'Z55S8^B_]_\
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M &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-30 J
M"  ( 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P
M  $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD
M!     $   "\    Z  ;<U@  "<0 !MS6   )Q!!9&]B92!0:&]T;W-H;W @
M0U,V("A7:6YD;W=S*0 R,#$X.C S.C W(#$W.C,U.C$P ')R,CDT-C(Q
M   #H $  P    '__P  H ( !     $   ,6H , !     $   &R
M  8! P #     0 &   !&@ %     0   38!&P %     0   3X!*  #
M 0 "   " 0 $     0   48" @ $     0              2     $   !(
M     3A"24T#_0      "           _^$!2$U- "H    (  @!$@ #
M 0     !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M    '@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0   +P
M  #H   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I #(P,3@Z,#,Z,#<@,3<Z,S4Z,3  <G(R.30V,C$       .@ 0 #
M ?__  "@ @ $     0   Q:@ P $     0   ;(         !@$#  ,    !
M  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !  (   (!  0
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M(S)A)(&1H;'P%R5"4L$8,]$*)G+A\6+_Q  = 0$  04! 0$
M!@$$!0<( P()_\0 1A$  @(! P($! ,&! 8 ! 4% 0(#!!$ !1(&(1,B,4$'
M%%%A,G'P%2.!D:&Q"$)2P18D,]'A\25#4V(7-$1C<H(F5**2_]H # ,!  (1
M Q$ /P#[^.FFCIIHZ::.FFCIIKJYS6I^I43O_P!_[_\ GTTU&'CCU-Y371U)
M&H2/!"[>9I/%YF@L0XJ_>TQ\O_DOVP]R000Z<L58B2<@2Y+>**5)0FV0T)I
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MOLX/)G;J2:-7^3F6V>=7VD)+8W>ZR2(IKV^TO9R,<O?)TNH=]H!15W:_#@
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M)BU6(L>,.7\1N/?_ #.<^8_9<=];Z2O##):L+&JV;>#:D4!6F;@(\G'890
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MQ<XM8",78?3:>&FKH!6Z">KBZO1Z9_M_3UQJV^VFRQO!&:S=+G2))U$Y-I:
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M;U*.EN82,;A-, ?E@N59P@9O+S#JA/)N&/-@Y,=.;]%M.,H,T&\*NSK]+86
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MC!(Y,S*5&?8'&G0L.2,Q!F'L==TO\W$YV"SES-?I*:PMJUQD; "I?I "IS"
M*JP*="^PC'>-/+!%VE7W$?U'-\VR?9MMN;H:5X1B5ZPFF''PQ(Q4.P*C\/9@
M,9([D9!U(.F[,.\[QME&&[1E:1_&EC5L^+%"1*1AF4+RX\<L!@-@D:BE@N0]
MSQ7ZE:$7"8</D&QY<X=V%=8AFZJ'(@ $<7:?+6>=N+.WEK[^9@#&\CZ,&<8"
MAL;5L]@'-['T@Y+DE7P/ZL@Z7I=217XA+4-[:[:/YR3/(+L3EAEL>-X41?)
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M>QQCT]?YZDM53' @.0QXAL_4]S]R",_7[?=1\&@[V /:Q;L3<B9V<^O_ )0
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M V0RD0O']F"=X]N!E*<B\FKAC'X[+X4X))0,P)9<G')5/(>H! !U'[,;X,W
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M*-WVO:]DG@KAZKTR7:<;O.5>2&/]T%J.RQR9X^*,2*PF%M!<7]J4'(WKF:#
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M6O4YNV*M/==AW7;Z-">OLMJ+Y.O>^:E>"4ON+9C29)&1$3B>3>GKWQ.T]/\
M1O3DM"*SN6T;]LE^_>AL;S6E6S+M[U$\:!4VZ &PT<D:,[%EX@$#FH.3%CTM
M^G;B*X]/W&.@UG$_&\^AU->1R):G#9^NFG;;;RWL]BXJ*Y:-&?(^%+OVX)DG
M1&1MC2!L3&1M;T+MQLUJE07,K.M6N)U8Y F\)!+ENW+SY\WN<'OKGO=S!-<N
M&F1\N;4Y@;!4/#XSF,\03@%.)"EB!G&3C.GH@]+G&%:0XK-3\E8PQ3_N39\9
MS%RIG(WD+W]SW! ->VOEAF;*YL@KPWCO:[LL?9$;U?$Y[^WMV_B/]_7[ZM1Z
M#7$W!6P8.3'G_4ESU1H\QQ$*GV6#VOLL61TWTT3MO@+XI@SY7>3E<;)(W\,5
M$[-2N>V.WYG^7Y=LG] ::]2../4D,8AE;ZE*NR&C&:-"!N.$<_<R,0>!D$*D
M&9+3X&67P\6.>P>$=J?I8BM8GEU0'']>X]OR]/7W^VFD)Q_Q?ZKN-ZW821<G
M\&[NTU6XOMI)]SXNW.(8/-HI8W?0_6U_*6Q<\4$040,175[GL''C;(^14_6.
M#]OU^??OC^'MIK;:OE3U&\:5.;O=KQCQ#?TY>^XZQE]8X_E;7B6@ W(F_P Q
M@ K2JS=UQ*\>TFK3M0/8% $ZRL1X@TWM&-G6-O3'\OO^>/X_^]-2V>B21*O^
M&BR(WQ1&-[)Y/17>X]O_ *D8YO9?CX_2GXZI^OU^OKIKK[3$58O)8_%C&HK.
MRL<U6HY4\D7LC?QW[N1'?K5._;QZ::RV1JDGEYJO=S'HO;NQ&L:G=6KV\E\?
M-G^9/%4^5[^/5?\ ;M^OZ_\ CMIKB.-/A7/:C&I^&M>U.RJJ*G9B*W^JJB?A
M%5?W^7]AW/\ O^O^VFH>^N_-#G>GJ]U<M?#-H.,-%D.0<V<JJA-9]+H :71R
MC=YX6/6PQ5UIJB0>17_40V,L;8G$.@5L5Z]VN'>.CNIJ30I*TE&6Q7#MV2>K
M3$D$RD'L\3IRC.,9(Y Y[3#X;;G/LW6W2]Z*9H1'N44$[(1R,=JV89HSR!!1
MXV 8$'N,CWS"R>2-KY48DO91F2.9WB?\O[+[OZ"'JKV*]D2=OV<]RHOZ>_YN
MS2(&..Q\'F5P/QOW8D G!Y-]O4#Z:_2Z-9"J$D=I^ ;NH"@%B@)4=F[M@G.
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M26+V6-D%H,0^.)O@UTCUBG<Q&J]S$9YR)W57(G?L[L58,GPQ)*0<$>(S#/\
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MS)'X1EFF2.,9P8XW*K+W SX@'(]OXD=]<W;E66I96O'(9@$!E<\3X<F.1B)
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MA!4@8Y#/ AF^IRY7/M[:@]ZDTGM><./8H98XW57&.N;(&R<9L\IM]JL;$-)
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M_+]M7!#O<\;C_>14XUAHQ&QQ/,?7%G Z.!C'$G40O=TJX"C\,J&W<WH[QO\
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M8)RNND_A3\>ST73H]/[YM4-S9:[<8;5-$BNU$!SSDCP([2+G)YYD) (8-WU
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MOJ?*3V9!W/5T<PT4L37.A>CG^3D9VY0NXJV75PLT$4[PI/&#.LJJS\)%4<&
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M/?'#96-M,@Q[X',0I'$LCC#F<)!&5'/,X-[);TS;6&IU#N]BW(T<+TI(3-+
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M 'W.OBQXO@/\N 9C%/X>3V,BQL8__P#IBOL1J.FOY&]8(F0YG3/TVC)TU7R
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M7 ::W'_PS<-+S3AKG![O:9S#%7NQ$Y.Q]?R3K0;3 5&<$$2P(*T6JT>VK;&
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M6>!KBF/ZB&X;9M";-/NNWV;C<-R_9DD-U88&9_!M2RR 12,^$>)$4$\<L2N
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MQ,5XHSQ*GH/-*8#'Q_+QXCV[@E=?#L(&2-VP3#&P)SW@Q.D;=NW$O6E4'TY
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MTN5O0+D&MT1#L+F,2[1ZJ*_"N]%S'GK6>PJ[#+4%C:P[*MS$E")7R%UMA7;
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MP1*T:O&"K2+"?OVG,9$XETD+G1NGCDD:0&U$1Z,E;''(KF-<U"/,+XRCMX:
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MNR#$.%G2(@:7Z<X0<X7Z@,R. T*:00H>=131ARHF3,2:&-R^/332C[I_5/\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g522368g43z47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g522368g43z47.jpg
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M 0$! ?_  !$( 7X" P,!$0 "$0$#$0'_Q  >  $  P$!  ,! 0
M!@<("04! P0""O_$ $80  $$ P ! P("!P4&! 4#!04" P0&  $'"!$2$Q05
M"2$6(C54EK;4(R0Q-W87,G5WM[@E-D%"&#-#46$F-#A&4V)QL?_$ !T! 0$
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MW][JZ\B)A$PB81,(F$7QO7KK>M^OIO6];]-[3O\ /\OR4G>MZW_]MZWK>O\
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ML[A$4PH1>1XOZ!P>\;=901%B6R.FG/+BYQQEY+B&CA:"YW$<- #6CK@-&!T
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M1)L=<%RPC0\A(U+A9=M^G]P'3V8^N$W]O<3C]_=[!OUP"I69YP<7+I8<:WY
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M6:?*.DTVVT>JOVNI5BS/#NR>/\(>]80(HT[ AV'R"Y2,/Q(3A*))7%C'!O\
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M!?3SL+H)V#O?#(]H.Q(.RVQ:;Y:;[3BJM-=!618'&(W8EA+MPV>!X;- \_\
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M-+* >%TYH*EQF-..IGM]7<6R$_IP@+\-V_#A;M043[YV2:SMNIK>?6%MKZJ
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MC416E[_+:T:_/(KY??[%16GKGN3KPLG&B0YF[9&^6/!FO$8R-:I5.TWM$M^
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MQ#8[L<>30*[6!',B%Z.7&SDVG"3=9%E %9C$;-8! N<5'?Y=YQ]_RIUXG*M
MV7WRD7_O-N[U?^>]=AURRF+M2N6T@O6V)_+^>6VLAXD3D=?K%:+!2M9LHJW0
MBDT.P?CR["1KY-Q?V-A#1#W;8_R5K["B81,(F$3")A%DOR'ZK> E\X_Q?FPT
M](/]/U=;/9S%6:J[]F <ZYS#$.FVZRF[$P]2BV.SFK'7ZZ/+'IRH0:))*3VH
M<HHV,1K( ;D]WU\M_@H3T'C\AC*K^D]H#]KZ_P ^Y?22]Z"405RKJMVO TJ:
ML0KH.KU4NC@N5-TBT&EEY%E'O5$L_;IA>-#//,$I[5>>8FRP;;:9PC ).,Y
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MY:6KI9F\<4]/.PQRQ2-[VO8X@XP1U!! *_9;Z^MM5=27*W5,M'7T%1%5T=5
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MEHS+D>*0MW0+89NMD=@LNJ4\V-CE3DB )2_OZC[7#A_4_P!X^7>X3D_+R'1
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M4T[73L\Y5-C[2.SRMATWVM:7N&GZ]\@IK7J(QLJ=.7]XSRXJ:]T3IK6ZX/8
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MD;VR1O:',>QP>Q[3N'-<TEKFD;@@D%:VDC?$]T<K'QR,<6OCD:6/8X;%KFN
M<UP.Q! ([U]N9+!,(F$3")A$PBR9YO XMI\<[/47^BE^2/72W<CHX_I5=LCU
M2LE+GW7KM'JC1VO'X\X:_#+Q&C#^XS:)C:)J=NP9*7HDF0RYRMF>8KA'**=E
M6(8:N9U-)&)HYFPTD\I9)&6N#F'@&<@XV<-P"OSU(XH7-XS'Q.C:'M=P.:7R
M-;D.VP=]O'I@KG=5.Z]5Z]WK\.\IV.:9YJ1&7?R#X9U7FCI6?6*IT/M'*>'=
M5A]BN" 2I$0;?>;1>A52L+Y 5F1Y4<;(8L$V(UITA"E;Y^6AI:2@U VD;'4-
M=#;ZVDJ0T22T]'55U,:2'CW=!4&"205; 07#E@GU7!?E;*^26D,A+"'31/CS
MPM?(R-XD=P[![.)HY9(VP3@'"B7BGT5=D_\ @H =@O\ .?\ 'JW\U\O2J#IZ
M]$EU?I?DC6O(<4&I-)Z1;)1=2;))!<=<NA;G]!LQ1\.=2+*%V1)*?SL X#^U
MTI^7^<24D#1<(:FTM+(X6B6FM\EO<Z::GB#/TP^LY+*B>)H?&7,87-;42<>,
M+^(TPD?F%S*C<OV?,)0&M>[/K8CXRUKC@X)QE@QV1Y8WS:ETN.$J%\W8:UHA
M>;4.*6&^OW&6D<;NA^P%FH=C-DY\^74ZP4*RZZ 2J=)'5T",&5V(^W#%1VF^
MH57I$LQ?-!RY"V&-S8X!".)D,;&9C8UK1+(QK9)/5#I'N=(1EY*Y%G UN&NR
M/6<"7\6Q<2?6))P"<#?88;W+P>^]?L_)Z@"LU(HFNER#!R.-4/C0NWEFV!T@
M60()+-ZX%X^^1UDVUM<2.RB03J8>OJ3*3I=D;GK'C27TH*2*JE?'//Z,&,+N
M(FB;EP<UO#_KJ^W1]"3ALKY-O^66\3FXRR&-H<UO'DXP!*=L$Y_2BF=W=[0/
M;G ,QXY>3G2><5VZ62KJI9HS]W^LK2HO2(2AOVXZ3%1_6+USEG%>A-?618+$
M_7Z0<SK7OU*^05]Y"+&GROQK(&4]1)#'+SF,X.&3-.>+B8UYWI*JMI]BXM_3
MJ9.GK\#^*-N4;B]@<6\).?5P\8P2.DC(W]V=V-]F1@FS<_,LTPB81,(F$3")
MA$PB81,(F$3")A$PBBE=_:]\_P!5P_Y'IF4]!Y?4J#J?/Z!2O(JF$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(HS<:
M;5N@UDO3KH#@6.LGHBX14029^6-)95O2DJUO6TNQY+#J42(DR,XS+A2FFI41
M]F0TVZG]E!7UEKJX*^WU,M)64SQ)!/"[A>QPV/BUS7-);)&\.CD8YS)&N8XM
M/Y:VAI+E2S45=3QU5)4,+)H)6\3'MZCP+7-(#F/:6O8\->QS7-!'$#IU7Z%^
M&[:)4JO*C=6\6NL3I@HASFU$T,+3/=A.O+%RMZ8D*B%6X$=28]G&C9$,L/C:
MA6 =J2P.WOT';I;+VQ6TTERB_*M66J!C_P QI8#)'+3\889 "Y@DIW2.''1S
M3-D@E?S*64L=*M#5\5X[);B*JWR?F>E[G,]HH*F8,?'/P%X8YP8\QSMC:>"K
MBB<R:-O!4Q<;8E??ACYP>.AF19:G.HE#\99SK:#+<G=C$CZ;9]-RE(<:65(Q
M*^U"/,NDG'T07TO_ '!ER=,9DZ<:>8UT[5_9)=[#%!56B2JU#!(_E314U!+Z
M;3/X7.#S3P/J3)3NX2#*TM,;RQCFGB#CV[2G:G:KY+/376.FL,\;.9%+45T7
MH=0P.:TL$\[*;ESMX@1$>,/8'O:\<):.F ?J',[#[?L'1**<]_I[/L]N $_?
MZ_X>WZ(@_P"[U_\ 3T]?7-93V>[TN?2;7<:?&<\^AJ8<8ZYYD3<8[UL6"[VJ
MIQZ-<[?49Z<BMII<^7+E=E>V=K-7N _8ZS5\!:!3R=[W!.BAYL>ZE>O3>]QB
M#$F,O2D_EO?LWK>O_P 9P-PM=NND)I;K;J*XTYSQ4UPI(*N$YZYAJ8Y&;]^6
MKGK==;E:9VU=IN5=;:D8+:FW5E11SC&XX9J:2.08[L.V62[U^'WXLWGYG=<^
MW3I[WN_\0HI6< ^+W?\ ]D.I<RM-^W?YI_\  ]^G^'YI_5S5%\[ ^S"]\;_R
M#\HG?_Z]CJIJ#AZ_T4F9K:WKG_R1Z =-EMZP_B&[5K%P,_XB_.:=F/\ 3WZD
M@N''C_KK.&&YNR-C_KQX]=UF]_\ #DZ-SMYR?X[^3=SIJM+4XR$-.$A\9]>]
M^[6IY6JSHT22VK?IIUMZHOMN?[RD[]/9FNW_ (>=0Z?>Z?L^[2KS9R"7,HJQ
MU1!&\]1SZJUSQ12-.P<U]ID:[J1_:MEQ_B2TWJ-C8.T;LOLMZ!:&OKJ)M-42
MQC&#Z/27:"6:)PZM<R\1N;T![U]7Z2?B@\:_(O6:?W<'$_57,@1Q9&:ME'_M
MBL@GJ9:Y#RDZWM#\L"17Z^GS)<7O2=X?F/XF='_^<MMGUS11;&6!E+/.6#NB
M90OLUTD>0,B26AJ3_P!8)V67Y;^%K6G_ ).YWG05=+N(:B2KIX&O/?*^O9>[
M3'&#_4R*OIA_T%HW'IB/Q.X5;G-!>Z\&Z+S0KK^S=W$;W,5M2=ZTM]8>S1*B
M0BLI5O7O;:>).H3_ +NW5;TG/TTGXEH;=,RCUQH74.G*K^EW*:922,!SS27.
M*TU$3 >K6OJ'-'0O.R_+6?A=GN4#JW0>OM-ZGI/ZF"5PA&#NUC:VUS7BFE>1
MG#G,I6$]0T9*U91?-GQ@Z#\+0GK5=$SG?;K[?<-RJ;(0ZK_!C3UD8'#I+V]^
MB4Z@SI25JWI"%*5^6;1L?;/V9W_@;2ZKM]),[ ]'NYEL\@>>C ^XLIZ>5Y.
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MF&(6Y,:>C19"/5]N/&E]PT!VC4VFKG57>@+;A21TI@NE.YM13DTSSSVOB>^
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M?O9O^(#?]?A,#V_$_P I]@B?O9O^(#?]?A,#V_$_RGV")^]F_P"(#?\ 7X3
M]OQ/\I]@B?O9O^(#?]?A,#V_$_RGV")^]F_X@-_U^$P/;\3_ "GV")^]F_X@
M-_U^$P/;\3_*?8(G[V;_ (@-_P!?A,#V_$_RGV")^]F_X@-_U^$P/;\3_*?8
M(G[V;_B W_7X3 ]OQ/\ *?8(G[V;_B W_7X3 ]OQ/\I]@B?O9O\ B W_ %^$
MP/;\3_*?8(G[V;_B W_7X3 ]OQ/\I]@B?O9O^(#?]?A,#V_$_P I]@B?O9O^
M(#?]?A,#V_$_RGV")^]F_P"(#?\ 7X3 ]OQ/\I]@B?O9O^(#?]?A,#V_$_RG
MV")^]F_X@-_U^$P/;\3_ "GV")^]F_X@-_U^$P/;\3_*?8(G[V;_ (@-_P!?
MA,#V_$_RGV")^]F_X@-_U^$P/;\3_*?8(G[V;_B W_7X3 ]OQ/\ *?8(G[V;
M_B W_7X3 ]OQ/\I]@B?O9O\ B W_ %^$P/;\3_*?8(G[V;_B W_7X3 ]OQ/\
MI]@B?O9O^(#?]?A,#V_$_P I]@B?O9O^(#?]?A,#V_$_RGV")^]F_P"(#?\
M7X3 ]OQ/\I]@B?O9O^(#?]?A,#V_$_RGV")^]F_X@-_U^$P/;\3_ "OPSZ:!
M*-;8)LS2+&_76V9Y4I+:WK?^.MMR);B/S_\ 7\OSSZ1S30NXH99(G?\ 5&]S
M'?%I!7SD@AF;PRQLE;_TR-#V_!V0L(>0'X;?)^TV2);J^?+<N-;CL1#: 8Z*
M5$&V8WZK$E8Z3*@KA%4,[U&5,8F*CO,M,[>@./H6^[VJGU):JNWP6O6FC=,=
MH-%0SR55I;JRV45WFM=1+PF1U)+<J2OX(WN8UQ8QC),C E#<-;UV2QWBWU\]
MRT7K+5'9_65T$=-=':3NM=9XKG!%Q<L5<=MJZ$R/8'N:'/D>S&_+XLN.J>,<
M!HW#.?B.=TQVP:%C5/RI4Z2=(-SS!::O3A N0U >AP]2I2](3[(T5EEB.TQ&
M:;TVRG.(O=YJ+[7NKJB*FI@(H::EHZ*%M/1T-%31B*FHZ2!OJQ001M#6-'?D
M]ZY*SVB"S40I(9:FI>Z6:IJJRLF?/65U94R&6IK*N9QXI9YY'%SWNWQ@;X5J
M?8(G[V;_ (@-_P!?G$+E,#V_$_RGV")^]F_X@-_U^$P/;\3_ "GV")^]F_X@
M-_U^$P/;\3_*_3$%L0W=NM/DG%;1M'MEE24UKTWO6][TS+E/-:7KVZ]%Z1[T
MZ]=:5K2E:V3'G\2?FO2PJF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(HG<ZB)NX1=?L#LO=>D/M.G!T::^/9.#V$N+4'
M)RHCC$O[/(D?3O$XC$EAHI%CK%$OJ1$TC!E.B*@_%WGVJ%'ZWNM_7#N0V7IC
MAKC-6ESIL^,"JC=4K(PW. _<'Y+XVK6N\P;/8ZP*CN_;- IL P-;9C&M,HI[
MO'&_^_MQC*@_;N\OO=:HR*IA$PB81,(F$3")A%SE\]^X4:!RCMG*=]:I](M
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M4%E\_=[C6IYNND:2ZW$L;][C+5?:S8>91#DBCMUR3T 4H"@M[20264*8._L
M/N/?^^56[OFUS[H_-.#]:H9'J #GW6.V\"IU9ME:$<>MH^X(ZR?T$@56P+>M
MMG16A.S*E5GI<>%H;U?GY%A3.@X^2I#CI,;D>?CW?[>["]ZE>??*[ET$70W:
M+UFHQS5X\DN9C+U:A-&12Y70/%,P>&=9JZ-U[H-AMJ7H\*L'[" -.5-%7,B!
M<EA)V/8-(!+(01\ ?<=Q\Q\5,^ ^8-%\B[3^C--I/2@K4GA?'_(X+9;;!I42
MNV/E'>5V=OEIP.X"O-A,?66-5)N6G@Y,,-) OT<D_I!'%[)UW1DA&/E[^_X?
MX6L\*)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB819N*^
M-P<IY5U/RSW>+?$ME0XC=>"0:6PS5ETB73K]<:5>ST^<F177;2JPZL7/:L["
MF1;-%@1X4.3#4,>U-?=V5SL1XD'X9_DJC.?_ (>E&YJ4!VRN]3Z8[T.K>0GD
M7Y%5N[%6:*])AG?*TL9.]NH9 ,/J L,7YM93)AHM %2(C=C!DZ_694"U)T*4
MU**EQ/P Q[!C'R44OGX7?';A43E&#],[#0*_>> =X\=^IZJTKG,HETRK^15V
ML'3>C6<Y-M7.K$T%O!#I%PN-PT4I\.NBMS+24'J"?:F!$,80.P<X&001UVQT
M'7IXK0 3Q3'@3WD)9(G4N@/E?(ZR<NL]R<GP.>R8T.3RVGTFA,B8(Y-):&S*
M[>JC18(3H08S$(LEH9BPM!'*XW.BH@%,^SIGQ_GN_P Y7FP_"WFH;Q,OWA_4
M3EMY]SR_#.M#ON5 DBJX4H[78;19[<;'\W&I%2ZQ4ZM72%JG"J=36PDVNB:K
M&@UZ=#+1]37IQ,[Y._3KWX\?JJZ'_A]U^&3)EY'<NLDYACR@Y-Y;3TRA''X,
M-?3^2<CHW&AP^/!K_,0L:#3+!6.=UAPV"A-QY$:7 1NNE :'IVII,^P=,=_C
MGQ[O\Y0U^'U7GK04O-,[OVKFUU1Y%VWR5H]AK#?*YZZ%:^E4]^D]5JL0=:N:
M6 ;:Z'T,3,D/% EXC6&4'(Q@A&KD@DT,Q(=)GV!7C0O&L;1>XGN]*Z1T.WVR
MS\5Y_P 2.QK>]5YD(D(YW<^DW\;:'7!-9#2XMF)V;K-S=(Q1;P^F0ACXD'6*
MC71(6#%00G(QX$GX@#Z#ZJGNV^ =-[/:NR'T=>Z]S<1Y"0>2H['4:/OFTH+:
M#_$RP^=0[B/?O7.[D4K5C;%BA5:/*$36A!X*$ )E"43ASLR<0'IL#CI]@J2C
MO!_FPTC-9;L]V?HDCR*+>6$/G3\@#]C$]V.RB%@*64:2C@F+ R%>Z.4G]B8K
M>R2F(?3Y;Q*-+;J^F*BP3/RQ]^[90K7X=G,43I!N)=;B(LI?M7C_ -ZN!P )
MY^!U?^B^.DM<^L6>X@AE/CUF7:KU,4V_UVW"0X6P7;Z,5&C3  \*(A029_8$
M=_0^_N[OKNO'/>' ;C(ESLU0OEWL-NXC??,_REI]=L4NG":Y8>B^2H:^';;6
MK(4'<]*DQU-&%[6735Y P?,,A8[\=TSNXZ@ZA2RN<G'CPM]PP!\@LH_@Q].J
M/5JF<+\?NE[L'-:Y2*Q5;(.ZWQ'Q\Y9>&+3"?VY4W@AGQ_B1(=DK+$/?0%%&
M;@E<Z,3*BYH5J,X0LBI9'==\9.^V<?ONNYF%BF$3")A$PB81,(F$3")A$PB8
41,(F$3")A$PB81,(F$3")A%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g522368g47p15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g522368g47p15.jpg
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MA/\ &%;T=,N^]D[#]3KI/45;R<$MM$IH&R[!(E,"8, =+LHD2?FQ7UAAC4.
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MIGIXUEIUQZOML-..I#1=4-Z=/ZHPN1%QR#)$(1;X#=:-T9!:BUP0>L\;@'(
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MIB"EPR $L"HVCF>T9V@U]?JMM*E5K8=)G2B54MPM@R#FS@QNNSGH4CPL)Q.
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MMPK8$J2T1U+V736K:;UI]=_5P=D[EU-?7J&"K.BZ[%U [K>ZA[W'V=N*SO\
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M)FW<C$,!<[,B0IR)V@\P<?@+HPT#U$]>W7_:=_:7&[ 2.D]+HRH$+.BPLB9
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M@M(VGHEC:HMYW8EQN0"ILT\M4Z4!'UN:#V'3-ADF7Y(;98Z=.H1NOGVK)8K
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MLBK#+),L<X,3QR\2)GB6.2*1W5)8V:76(O!QO8LN["1R,RKDKEE52R^$"N&
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M<CL%!()954E<$%<, =P*@;@16+@=;&@["$K1RB$[SL]NV0[*7$B]8:IV7>[
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M20-;VMW<6T;M=6O%FX#QA]D0EW221K-"9HXU+(7(V_!R;(PW*RK'X+!WC1V
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M3W$JIFU93&PBN">5Q(DP99FB'A11N#'Q-KR!U3AO.:.1T"1LJJ3X8.1N3'Q
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MW'EO/O>/\ZR0CA-C"<(S'9D)CN9=<0IQ6I>WBW2PJL93A-=,<D'/6+F2< 8
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M5:M6I&[LEUL];@>UJ_:2"ZE?:W3 6NFKE6YU3-#7K&$(4ZIU"+/UT257,8+
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M$>S() 9#+G<,C(992O:"I\(9(%2G3^IMPA]W;7WEMZUZ_GSMC:PTSK8)2->
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M^HY]"<2/[8GX2^NO'8/<?,:D$)^\CZZ5JL4:6:"&CM<L9&-YFD*6^5JD.RP
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M:))69(E2'L-H1E#3KRW684="$X2Q#C)5A"&F\8PI2?&+[<^#A L3C/B_OF@
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MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2M6]\=+H3>Y\*?*6HJ
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M89]?QQS]B/.:</R^C_G3UNNH>^19/D89]?QQS]B/.:</R^C_ )UL<_U%Z$M
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MKCJ]O8.S6,-MQGZM%;I!D</:-L/4YO\ +0TA_P")6[_EY;N?I7L%?XU^B/\
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MN(2H<1IZ;0=4GU6*_FF6S"P:@UK;M8W#WEK)"EG92F2*[>&VZR#/-,ID6")
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MM6G+78GC$"<)8CN18K&&Y;LQ+V%,-Y2K.<,PWD>#G/\ @]CF<]GY\8Y_2A7
M '.OY3,A))Y5"NXFT^V@#X\C]V\SO'E]'KK&P^3T^JG<3:?;0!\>1^[>-X\O
MH]=-A\GI]5.XFT^V@#X\C]V\;QY?1ZZ;#Y/3ZJ=Q-I]M 'QY'[MXWCR^CUTV
M'R>GU4[B;3[: /CR/W;QO'E]'KIL/D]/JIW$VGVT ?'D?NWC>/+Z/738?)Z?
M53N)M/MH ^/(_=O&\>7T>NFP^3T^JG<3:?;0!\>1^[>-X\OH]=-A\GI]5.XF
MT^V@#X\C]V\;QY?1ZZ;#Y/3ZJ=Q-I]M 'QY'[MXWCR^CUTV'R>GU4[B;3[:
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MI _=0E?\AND<>]9A).Z#1VH[A5Q=(56NJW0 86#KVTGELA[Y6['I8ILXI;9
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M.<CXB88>7XV1R-)C-A=1<$T=9MP^Z50+YZMXMR^@M0;!V?*,DJ-D."HCD'7
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MQKR@8SVXHU/QG]W%9"XS_+B%S/M%HG\CZ5^;[3^QJ!Z0:^>1UO5R/+J5Z?\
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MD>4Q]VUTNQE1Y)%A@VS6\"%;2.0%[A9RK2$,CI&O .]D29\-X,;$8-+WUX"
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M>,,RX=Y8!1\+D6E^G/G&:E'9D/V98EJ.^MN1U"S7DTP4_P 9721&CY[0)E9
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M;E?+2$17K""./>B!G9 #L81E2K,6(#;2"_,?&&.8Y+CYFZ9VZ* %1UIVUKP
M#U47I!:XB[)6[2XJDNR;CL;NOGG!2M73"):.?-7NXE\AF(AEV"(ML-JY"HBH
M;8@(%Y:-(C16MQ))=),D+1R1#C8AM^LJC]:"J8T@A3>60%XFX+L#O<8I "&E
M15C*%@RGP?"DX9(V9()=B1SP&\(<@!W03_68;AF8(/%"BB@-CL.MYHMYKITJ
M8T<Z&,:[KMLIL &:2$0U13%B)ZZ%V45"@8I%RL)Z-&+-F#%E,()1D&CQLC/Q
MRSQQW*L#J,S,'2XDBF9T+DSK&EPT3LW'BCC)0HD:;0-R1X.P ,R8^!4#!174
M X(1F*!A\5B<')8YK"4!ZF,3&_"8'M3MLV*E4G(0<0U@W+0=M.O;/0Z'4Y]7
M'2\2=;-O:YN5C A Q(95( D5);RAB"^&&O#]D/IN.UL6D<T^]A<XV17$4\\J
MRL,7&+B&.1W5I69@>;!V#5D7&?+(R+@&,<V1D12H_@_ 9@H(4 =V!BYHMWZE
M@-"2UBF:V)$8%,Q$!;/P>U49+$J50S3U_9[MBXDXN3;2>N;!3F3)2)1"QT76
MY0&-(L]08L9"<7,:AATYY\\6X56FS);;+E$6:>,6YZRCIB);B*7AJ9U1Y%<B
M*4QJJ)<&N%3XJ$A<+)N0DJAWXC(;P]A7)";@"OA+N))UO#=,VT+%&K,NOPQ-
M@1:ZD_;1L$ =$&+&Q&0,LL^'$*4^'.7;!>24FL2@\(I."L@GRDT5$:)N/$X+
M<CH/J-M&9!(SQ\*41,TD;I&6+1J2DI'"?:)0Q57+A5<E0$;&N()#MVX;<NX
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MY&^J'_\ :/1?]B7/^.DN;,'8WWQ_553]O\W_ !->?/+ZA3BE3.OZ_MEI'^=
M8UF7#R:'5QM;I8- =DFRKT=B -A12)")+G2'ERF,JQ#8?0PVO+\A33+;CB,%
M@#@GQ$]A[!Y>P4K(YU/L/TF&U!JLRI5@,PI9$1#@2AQ!@I!@MS79DH>2@S)
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M>5HRXFL5B0)KK;LB:ZV,0Y/FJD.L:&#GK]EXMP.HJ1(1V/*IN")9/_XLH>3
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MCZ]54P\$(*A5AH!)8?E++#YX!,[RPA*E+[(T[!MXY9I<N*S"'(;E&$.Y<?\
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MUDD$V'O98[DQ^$1:Q1V\LC1HL;,'CC:9BQWK@ E0%).'=@7 V\HP4W<AQ"7
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MN=9/55_\D&Q?[:4;_BV>?/'[H_\ Q87W^EM(_P!Y-?2/[EG_ !N:=_H;6_\
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MBR&O=K7@L;VV-)RQDJ10"FKX(T+#(#[W34@VIS5X)O$B;D2T2(Z(<5V(%?\
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M]X]E0D;9&[@9*J6 [\"J&5U3KIL&0SLR@W5N8"BD\V6P"P-8KXALK'I-YV5
M#1*X2V;8#D62_4*/*;>FS"+H=LJ2".ODH8Z>4=KN[[6<9@;:> K(5X<;22NY
M4S0VS.9%MHT($TPP  Y17PI95#UF;;R96Y9R0% SM=\8+D_%0\^S..8!.) -
MW8F5F^&+%JN?"M])V[7=-5JO(ETF=:)I&UT#7%OB*?L;=D>K8>&ZJ_3'W%/'
MX;RQ$1EAD9+L<^&%(0:RQP$CNE:*:TDO)9,3"(+%<7$1Q'PA([#@ 8$; .22
MZQJSJXGQBT9W+((PN4+9948<]V!\;/;V#LSRJ#A.JL,?#$S!K3-PG^B6PK36
M2;0:/0SLP+>Q5RN=7I0" )3<7RQZW&(P$5"DFZA',5J"=LT9F+8G0PRX$JI<
M^ELCHB7D*\6"*1-YG17@:&*6:1G,(2.%"[L$F*2%(CF,.T*RQ$X()X9.'8'&
MPX<,P48W9+':.:Y +<F(#8R@/J]!%#9" FFVXB-C&J)$G%AD6L-Q*?#OD350
M^!%/>.N[Y4X5B6G9*4$VP8*/*&CQI@?(#J, V/26#Z2ZHK<:)6*3E58RDS&
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M7>-R[B"?%C.,XR/^]MVXYRJOIQ2G%*<4IQ2G%*<4K5-[?EJ';4V)3I%)(&Q
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M',6+80\ 0R[Y?@;B%W9W#.+IUEG.X-O#-(H9'WF1, B0MEC$S.7++A?#1P,
M@&,%4\6#@$@C ![L<JI4F3(&B1 P7FR214M.EDR9&:\N1,GD)[[DJ;-ER'<J
M<?DRI+KC[[SBE+==<6M><J5G/-Q55%5$4*B*%55& JJ,*H Y    #Q"JB222
M3DDDD]Y/,FNCR58KV ]00_SM_1W_ +0;1_Y%;1YY+IU_@IJW_@M?]^M:Z.D_
M_$+?[\G^QDJLO5E?\Z+UL_[[37_#A?-GHA_@SHW^9K_ZWJ&I?]>N?\I_]HKS
M4B1G9LJ-#9\'QTN0S&:\+/@I\:^XEIOPE=F?!3X2\=N>S/9CV>SGHR0 2>P
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M(D0DNU 7+8<'5N(F&(%Q8X48,'0ZA:Z4NW;*B<,$1E+V13'N4)(T9$V4:55
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M@S1$HN<T,@.7FUHFD7!>58)MP(JK5A^6L=E"L3D1T.*B92K$C#?9GL!IRK,
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MLVTG6EDAE=NLC@.\;(9&6'J^]&F"G/P[HC.Y1-NQ$HX3;3'O'#(8 ;/" ;.
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MM42%E@,QP9%DN5:X?**5E7?EN(=J.#8P.<JJ\@  #(2P+[?$50[!S/@G'BK
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MWC)[SYS3 [AYA3NXH_N;'_R/?6\9/>?.:8'</,*=W%']S8_^1[ZWC)[SYS3
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#*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g522368g73n73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g522368g73n73.jpg
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MQ&O%NY+E9L<=>%@O&GI< )A6S6,LW/2)XHXK%>W)$8 YY-C70Q]7=F#%NKS
M#94)^<MVUM<I>M,D?(I+(Z \VW??G._+V&P'+MOYGW) "_48=W,TD<,/?-9*
M++?:%%&'T3IIU\@DAQ+3##+2*,I;KSSJTMMMHQE2UJ2E.,YSC'5SGP_THH+&
MC(  22;MP  =R2>MY <+ORM>_*+_ +M/Y>'6N$NE.ZS"3M)V'S?YLZYNT(N
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MMOEWRFRA&<\A]RYSE"<YSG8MI_/XQ_\ 4^N),WB7XAB:4#6^J@!(X &<R.P
M8@ ?Z1[..T\7A-X8&.,GP_T>240DG3^,[DJ-S_T;@DW%G3G-7D]JM6T@N9FS
M*2$]8Y>"C(V3L=WE7)!B(:!P]*)+&L@B&F5GD&1^&?CNJ2Y'N.9<SAS"$7IX
M=Z6\6/$'3AU%%XJ:@Q,37[-.O7L7\O9:=*JPA[(ECOQA5,SRP!.1B# S<WK
M#7;Q0U?X,^&FJ!IB;P=TWFIDQU2]9LUL?A:JUWMM.4JF&3'2EW6".&<OU$!6
MPJ\HY2S8KRCU?W N,%3&O\IRAV%>*4N1'BI.7K>PKVP77RS591'N34;($M^Q
M'R#_ *!CGC%ELH/6R&5@9TL'Y4=XAZ=\:O#W&IFK'B%G,OB3.E:>U0SF926E
M),>6!K=>:0<D,[[1)-'+*@F9(I.1I8>I*^&.IO 3Q,RLN!J^&6G\)FA7DM5J
MF1P&#DBOQ0CFL+3L01GGL5TWFD@DBB<P*\T1D6*;I83P*W)R1W%RFUG5;#O#
M;,Y5@R)>SV>,D;W9#8TN*KD,=(,B2(;\@XP4$?+HBXXAA]"F76S,H<2I.<IS
M$^#6J==ZH\1<!CKVKM2W,=$]K(9"O/F;\T$M:C5FG6.>)YRDD4UH5X'1P582
M[,"-QQ,^.NC_  YTAX7ZDRF/T3I6EE)HZF,QEFO@\=!8AM9&Y#7>6O,E</%-
M!4-JQ&Z$.K0@J0>X,KS:UMS>V'1X+'!ODC0./E^@GYHR99V)JB'V-![!;(#%
M1!PSLW*M3#E%8CBV3'B9*/J-E*/^:RG+0S8*D&]%\-8PU>9_EK'3WX'"!#7M
M/7>#8GG<(O()RP( 5I8PO*>YYNW,^PEAU'H\RQ,-]^>,.&]PW._+M[PK;[^7
M;A"F4^HI[N41)R,45R"IJRHPXN/)4+I3290RGPB'!GE#DLTE3)#&7&E9:?:4
MIMYO*7$*RE6,]7BN@-*.JN*$VS*&&]RX#LPW&X,W8]^X]G"R<M>';J+V_P#=
MQ_R\->Z?T5WOMGZCU?LN6[G>J:3+["UW2[S(THSA/K"5)J1]LK<;/$UDN6;,
MCTR!,$\>N+).;C0T$O"K>0*RE>&TU=;O:,K6[-=--VID@L30K,,S942K%(R"
M0)RMRAPO,!S-L#YGB;CCR+HCFY&I=%8J:Z'E+ 'EWW&^V^V^W E>Y[S#[]/;
M#F*29?>4&L]GZJV.X;'U+:E/X_ZJC8]-DC6?E'5&T0LG1WB*[8% >4K%-8/D
MX^;BV37XV1>*B9H*,:]-XG0^I$F$&-LUK5?9I:LU^TS=-CLLL;K,!)'S>JWJ
MJR,0&4!D9L*Y8R=,KS3(Z/N%=8D W'X+ KZK;=QW((WV)V(#,8=:YI;3X'Z=
M$J?(&O:=Y@6+5>IK/=]LV+3]9O$*U<CJ]$SM]@\:^]R"KL:.=)DEP;$@S'$Y
MB FE$L0[QJD+9KAI,/6SELRT)+>)CM6HX:L=N2!S"LCI _7]>1BJA7*EASMV
M+A?.6 L/6CY91'.41F<QAAS$ L.7L!W[>W;XGOPECR=[W/>7XK<@=M<=KSR5
MUI.6S4-RDZ;-3%5TQJ VO2A,?E"VSHM\S7H)N&"1GF75#FABFAO*<#,8:)8=
M1BX<;HS2&4H5<A!CK*16X5F1);EM9%#?@L!89=P01NK%2-B"01Q 39&_!*\3
M2H6C8J2L:$';W>J/X]QY<&]X5D]];FOP]U_RHJG<!TOK^1V:/;3*IKB[<6==
M984#7+;/U($Z5N,+6I!\(:>?@'I,50U.D%LQA8CZ4%>YC&4S,#1.&RUC&2X&
MY.M8Q"6Q#D[&_-)$DK*L+R*"4YPIWF&[ ^7$C7^4K$"S"S&A?F*HT*^QBHW8
M#MOMO\T]N!"77O\ _=_X7<@+SH_DL)I._7#5MH<KEVJ5GUS'10Y*$MCFCGP%
MBUF?35Y"G84P&:KDPX.:,_'2(!S\6^AQ8F6R'0ND\Q0@NXXW((;,74AEBL,Q
M!W(*R1V5F]:-PR2(""&5@&_"XP&R=^O*T<W39D;9E* ?'L4Y>Q!!![]B#PX%
MVU.X%0.Y'QFBM_TJO&TF7 L4E0]D4"0D&I=^F7V$!BI0Z-$F6A@4SD*=$3D-
M-0DQ]OCW"09) Y@(4D(<(Q4VHL#/I[)-0FD69&C6>O.JE!- [.JL4);D<,CH
MZ<S ,NX9E*DSM.TMN$2J"I!*NA._*PV)&_M!!!!V'8]P#N +WO3[<[JG"BH7
MOEWH'EWJP+CL+9J/!-:3EM&4/-SHZ+"Q$U=M<3;K'%6Y[869"TI(G)/YK]=*
MC!)=]N/CWHV']$LNCJNF,S+!B;^*M'(&.=_3$NS]&;IEY?7BC>(5^6+9%Y1(
M&* LP9^,/(27:ZM/%.G2YE'3,:\R[[#LQYN;=NY\MM^W8< 6XC=YKO7\S>1N
MK>,^J^0FOQKMM.<*C )*>TGJ!B#@XV(AI*RV2PS#H>OC#/MT!6H66F"6A!2"
MR4!_%$9=)?9;4\Y72&CL/C[.2M4+!AJH&98[ELN[.ZQ1QH#.!S22.B D@#FW
M) !/$;!D,A8E2%)4YG.P)C38  DD[*3L ">'>N).L.5^LJC/B\MN44'R=NDQ
M)A&0LI6]*572\-3(Q@+V2X082MG&NVA9ARE&+FI1$<ZVTA@4>,8PE]XBF,K9
MQ=F5#BL8^-A16#K)<EN/,Q.X<F15Z6P]7D4L#W)8]@&&!)T4]>83,2-B(Q&%
M&WEV)YN_M.WT<"G[PUI[MO&6I[8Y<<4>4.K1>.]#BJS+3>CYC2U((O=,AVQX
M&NV&;B;C98.U-WQ#]A(+M,@.<14W8>%,=CHL.5<B6U2#1I*+2N2EJXK*8VT<
MA.TJI=2Y,()GW>2-&BCDBZ&T8$2E1+SNH9BO/ZN%?:]"KSPS)TE )C,:\RCL
M"0QYN;OZQ^;L#L =N]-NV7L?OU]Q/5[>^C^9NK-!:2DYF5@ZI9)OC1JN[VR[
M/0)KD9.2M;J =;K,>NNQLN,=!KE9.VQKQ$U&R(@D>^R&Z5B7U'7T-@+)HKB+
M5ZZJ*\L:9&U#%")%YD225I)&ZC(5?E6)@$926!.W'A3?)6TZIL1Q1DD*3"C,
MVW8D+LHV![;EAW![<;@[P^U.[[P*U[,<H]0\RM<V_1#-JJM8E*&=QTUE"W*@
MIGQAH6+D_NTI&VQBZ!2EC85]W*237RH\^>#;C8!<.T^J,Q-)5=)YR=,9;Q%B
M*]TI95G7(67AGZ9+LO*K1&%EC/JC:0,J$L_.1S?=][U9#-'.C1\RJ4,2!EW&
MP.YWYMSY^6V_8;>2]%][_G>4UG97JA<]W5B'L0L36)DN->T=I?+XHEMK$/;H
M=!&/T-CVR%PL['ND,_G++RULY4KP\LOL&A=(V8Q+#2E>,M(@87;FQ,4CQ/M]
M^\N=& /M'?B+;*7T/*TB@[ [=./\(!A^#[B.'TN ^\IKDKPJXM[VM!H\E;]F
M:0U]8KO("""@"FWM=?##O)(P +3(0 [UM$F7&0!&6APFU)&9;0VTE.*/SM),
M=F<G2B4I#6NV(X%)+%8.H3 "S$LQ$13=B26\SW/#+5D,U>&1CNSQH6/8;ML
MW8=AZV_;V>7&?<H>16ON)G'_ &KR)V@<@*FZKJ4A9#6?>;8+FY%&$B5ZJQ*G
M<90N<MM@)C*U"-+QX.2DH(EW*&O-:?#&X^?*WZN/K+S36I5C4[;A%\Y)6V_
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M&':;99;0A"4XHR22261Y97:221F>21V+.[L269F))9F)))))).YX9@ H"J
M   !L !Y #A-7ZMO=WXX@\< #/Z<[ W=:@//_P /MU$H!GMXS_Y[+9\UX_\
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M8S2-5P\; <T%8[&2YRGW^K*"05(%9=^6=QQXSDW[8JJ?]'KD26&'D[^R/?\
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M -XLM_5\'W/?##\P-$_W8P?]#PY1K4PJ1US0) XE\PTZDU4PLLIUP@DHHJ"
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M_'/M^J&WDWLKN(Q.K(X]!$5Q\TO3JF<(T\EYL:YW8B2V-./J\592V0]7+#2
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MU\(<CF2220^;NSG_ &F)_P"_AY#M64']:<LZO+O,^\%KFJV>[DX4GU:]_P"
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MJ=.U?L1U:<$EBQ*P5(HUYF/O)]BHOF[L0B#=F8 $\9\DB1(9)&"(O<L?+_\
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MA>)K+R<IYIRTCAF4AF#  LSL7+';:1K5C7!7KS2KLH42L&"!=^R]AL#N!MY
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M;1"BHC\2)_SGU80A"8UG#ORGLX0E.&5KSA.,>F-HENQ+CUR-O:E"M,7;/78
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MRH-SO"6*^2M2=26!B=ME Y0JCSV4<W\223[2>*@?]"7W5/\ <KVK_P 13O\
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MW81ZU'5F'K6EJ3-33)(T ^JM?$(OT$Q8'&<129QJQQ89S$#\E,H:P<MP04C
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6Q.C@XG1P<3HX.)T<'$Z.#B='!Q__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
